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Abstract 
Photodynamic Therapy (PDT) and Photochemical Internalisation (PCI) are both 
light-based therapies which can be used for the focal treatment of cancer. Both PDT 
and PCI require the combination of photosensitisers, light and molecular oxygen to 
induce photooxidative reactions that damage biomolecules. However, while PDT 
employs a photosensitiser as the sole therapeutic agent, PCI combines low-dose PDT 
with another therapeutic agent to enable the improved delivery of this agent to its 
intended subcellular targets. The overall aim of this study was to investigate PDT and 
PCI for prostate cancer in both in vitro and in vivo tumour models. 
In the PCI procedures, the ribosome inactivating protein type 1 saporin was 
used as a model chemotherapy agent. We have concluded an enhancement in cell 
killing in prostate carcinoma cells after PCI compared to PDT in 2-dimensional models, 
i.e. 80% cell death, compared to 32% killing after PDT. Similar observations resulted 
from qualitative observations in the 3-dimensional model. Moreover, conjugation of a 
photosensitiser to cell penetrating peptides (TAT or Antp), resulted in a similar 
difference in cytotoxicity after PCI and PDT using lower concentrations of the 
conjugates - 76% and 14% respectively. These data confirm the synergistic effect of 
drug and photosensitiser in PCI. 
Three different clinically relevant photosensitisers were used in vivo in a 
subcutaneous rat model. Vascular-targeted PDT resulted in the most efficient 
treatment, and photosensitisers targeting a cellular effect, showed a better outcome 
with shorter drug-light intervals. The analysis of tumour samples through 
immunohistochemistry and molecular analysis revealed an innate inflammatory 
response that led to an adaptive immune response. A highly suppressive tumour 
microenvironment was suggested by the infiltration of regulatory T cells (FoxP3+), up-
regulation of PD-L1 and down-regulation of cytolytic proteins (i.e. Perforin). Moreover, 
the beneficial effect of using immunoadjuvants (cyclophosphamide) was investigated. 
Light based therapies could play an important role in prostate cancer treatment both 
eradicating tumours and generating long-term immune protection against secondary 
tumour deposits.  
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1.1 Introduction to the prostate  
The prostate is a gland in male individuals located above the pelvic floor, below the 
bladder and in front of the rectum, with the urethra running transversely through its 
central region (from bladder to penis), see Figure 1. A healthy normal prostate weights 
18g approximately and measures 3 cm (length) x 4 cm (width) x 2 cm (depth) (Wein et 
al., 2012).  
 
Figure 1. Anatomy of the male urinary system.  
(A) Midsagittal section of the male reproductive and urinary system. (B) Detailed representation of the 
prostate gland and surrounding organs. Images taken from [(Gray, 1918)] 
The prostate is composed of connective tissue and smooth muscle fibres and can be 
divided in four clearly defined parts: 
 Anterior region: rich in muscle fibres with no glandular structures. 
 Peripheral region: main component of the gland, around 70% of the 
prostate belongs to this region. It is the zone where most cancers are 
developed. 
 Central region: located surrounding the transition region (25% of the 
entire structure), it is the zone where the ejaculatory duct is found. 10% 
of the cancers are found in this region. 
 Transition region: located in the inner part of the gland, composed of two 
lobules directly surrounding the urethra between the upper section of 
this structure and the bladder. This is the smallest part, corresponding to 
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5% of the whole structure. 25% of prostate cancers will be localised in 
this region. 
The main function of this gland is the production of the fluid component of semen. As 
such, prostatic gland cells continuously secrete a protein- and mineral- rich thin fluid 
which is responsible for the maintenance and correct functioning of the sperm. A role in 
urine flow regulation has also been described for the prostate: its muscle fibres 
surrounding the urethra are controlled by the involuntary nervous system and therefore 
regulate the urine flow (Chapple and Steers, 2011). 
Several pathological conditions have been described in the prostate, namely prostatitis, 
benign prostatic hypertrophy and prostate cancer. 
Prostatitis can be an acute or chronic condition, sometimes associated with bacteria in 
the urine (acute or chronic prostatitis) and sometimes not. It can be difficult to diagnose 
and difficult to treat, and there can be significant overlap with chronic pelvic pain 
syndrome. On the other hand, benign prostatic hypertrophy is characterised by the 
abnormal growth of cellular components of the prostate, due to an imbalance between 
proliferation and apoptosis. It is mostly related to ageing and the presence of 
androgens. 
1.2 Prostate cancer  
Prostate cancer is the fourth most common cancer, second most frequent in men and 
fifth cause of cancer-based deaths worldwide (WHO, 2012).  
In 2012, 1.1 million men were diagnosed with this type of cancer, accounting for 15% of 
the overall cancer diagnosed in men that same year. In 2016 only in the U.S. over 
180,000 new cases are estimated (10.7% on the overall cancer diagnosis) (National 
Cancer Institute, 2016). In the UK, around 330,000 suffer currently from this disease 
and yearly diagnosis are already above 47,000 new cases, implying 130 diagnoses per 
day (PCUK, 2016). Moreover, it has been hypothesised that it will be the most common 
cancer by 2030 (CRUK, 2016). It has also been anticipated that prostate cancer will be 
diagnosed in 14% men throughout their lifetime. A higher incidence is generally found 
in developed countries, probably due to the existence of more advanced diagnostic 
capacities. 
Background and Introduction 
 
 
21 
Over 307,000 deaths worldwide in 2012 (6.6% deaths in men) and 26,000 in the U.S. 
in 2016 were documented. Fortunately, prostate cancer survival is high: 94%, 85% and 
84%, at year 1, 5 or 10 after diagnosis correspondingly. In fact, in the U.S. 5-year 
survival involves nowadays 98.9% of the cases (CRUK, 2016; National Cancer 
Institute, 2016; WHO, 2012) 
1.2.1 Aetiology and risk factors 
Prostate cancer is a multifactorial disease, much influenced by endocrine, genetic and 
environmental factors. Incidence is considerably associated with family history, race 
and age. In addition, androgens play a major role in prostate cancer development and 
maintenance. Prostate cells are very sensitive to the presence of these hormones 
(mainly dihydrotestosterone and testosterone). 
Age is a key influencer, with 75% of diagnosed cases occurring in patients over 65. 
Regarding ethnical and geographical distribution, the greatest incidence of prostate 
cancer has been recorded in African-American men, while China and Japan suffer the 
least cases, possibly based on lifestyle and genetic factors. Family history also 
enhances the probability of developing prostate cancer, 1.5 to 5-fold higher likelihood 
depending on the degree of relatedness and number of family cases. In addition, 
lifestyle appears to be a secondary factor in the increase of the risk to develop prostate 
cancer. For instance, while red meat and fat have been associated with an increased 
risk; the consumption of vegetables, vitamin E, vitamin D, selenium, etc. are thought to 
be linked to a reduced probability (Castiñeiras Fernandez, 2007; Provencio Pulla, 
2011).  
1.2.2 PSA and Prostate Cancer diagnosis 
Generally, prostate cancer is an asymptomatic disease. Only when tumours reach 
advanced stages are the symptoms detectable.   
Early diagnosis is based on the combination of rectal examination, prostate specific 
antigen (PSA) levels, imaging studies and eventually the pathological examination of a 
tissue biopsy. PSA has revolutionised prostate cancer diagnostics and follow-up over 
the last two decades. It is a glycoprotein belonging to the kallikrein family of proteins 
Background and Introduction 
 
 
22 
(serine proteases), secreted almost exclusively by the prostatic epithelial cells. It is 
considered an organ-specific marker, yet not tumour-specific since an increase of this 
marker has also been noted in several benign conditions. The “normal” cut offs of PSA 
are much debated with the latest PCUK guidelines suggesting referral of men with a 
PSA over 2.5 ng/ml. In given radical treatment, the PSA reduces dramatically, and PSA 
kinetics post intervention of tumours has become a good prognosis indicator 
(Castiñeiras Fernandez, 2007)  
1.2.3 Gleason score 
Among all prostate cancer subtypes, adenocarcinomas represent 95% of the total 
number of cases, most localised in peripheral regions. Other less frequent subtypes 
can be detected including carcino-sarcoma, transitional carcinoma, or sarcoma 
amongst others (Grignon, 2004).  
Gleason scoring is nowadays the most widely accepted system to conduct 
histopathology grading of prostate cancer. This system was developed first in 1960-
1970s (Gleason, 1992) and modified recently in 2005. It is based on the cellular 
distribution and architectural patterns within a prostatic tumour.  
 
Figure 2. Gleason grading system for Prostate Cancer.  
Graphical illustration (left) showing the scoring system (1-5) and description (right) as developed by Dr. 
Gleason [(Gleason, 1992)]. 
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Different patterns are given different values 1-5 and then the two most common 
Gleason scores are reported providing a Gleason sum or score (see Figure 2 for a 
detailed description). 
 Grade 1: Uniform glands, with reduced stroma. No infiltration observed. 
 Grade 2: Similar to grade 1. Glands exhibit slightly larger size and shape 
disparity, with a greater amount of stroma between cells.  
 Grade 3: tumour infiltration within and between non neoplastic glands. Glands 
exhibit a smaller size than in previous grades. 
 Grade 4: stroma infiltration between normal glands. Main difference with grade 
3 is the fusion between glands. 
 Grade 5: tumour infiltration creating diffuse stages. Glands are no longer 
noticeable. 
 
Table 1. New Gleason scoring system and associated prognosis.  
Table taken from [(Matoso and Epstein, 2016)] 
The Gleason grade assigned to a particular prostate cancer case relates to its growth 
rate and prognosis although the view about this relationship has evolved since its 
development (Matoso and Epstein, 2016). Accordingly, higher Gleason grade refers to 
less differentiated, more advanced tumours and worse prognosis. Briefly, nowadays 
Gleason grade 1 and 2 are considered normal prostate epithelial tissue and have been 
removed from the scoring system; 6 is the lowest score possible; although tumours 
presenting Gleason score 3+4 and 4+3 are both treated as 7 in relation to treatment, 
they differ in their prognosis; a slight improvement in prognosis has been noted in 
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Gleason 8 cancers compared to 9-10, and there is no substantial difference between 9 
and 10. A new grading system using grade groups 1-5 has been proposed, where the 
lowest grade group (1) corresponds to Gleason 3+3, and grade group 5 encompasses 
Gleason sum 9 and 10 (Matoso and Epstein, 2016).  
1.2.4 TNM staging system 
In addition to Gleason scoring, prostate cancer is classified based on the TNM scoring 
of malignant tumours developed initially by Pierre Denoix (Harmer et al., 1970), and 
maintained and modified by Union for International Cancer Control (UICC) and the 
American Joint Committee on Cancer (AJCC). This classification implies an alpha-
numerical coding system that described the stages of an initially solid tumour. 
Accordingly: T – refers to the size of the original tumour and the potential invasion of 
nearby tissues; N – refers to involved lymph nodes located close by; M – refers to the 
existence of metastatic tumour deposits. In prostate cancer TNM staging is as follows: 
T – Primary Tumour 
TX Primary tumour cannot be assessed 
T0 No evidence of primary tumour 
T1 
T1a 
T1b 
T1c 
Clinically apparent tumour neither palpable nor visible by imaging 
Tumour incidental histological finding in ≤5% of tissue resected 
Tumour incidental histological finding in ≥5% of tissue resected 
Tumour identified by needle biopsy (e.g. because of elevated PSA) 
T2 
T2a 
T2b 
T2c 
Tumour confined within prostate 
Tumour involves ≤one-half of one lobe 
Tumour involves >one-half of one lobe 
Tumour involves both lobes 
T3 
T3a 
T3b 
Tumour extends through the prostate capsule 
Extracapsular extension (unilateral or bilateral) 
Tumour invades seminal vesicle(s) 
T4 
Tumour is fixed or invades adjacent structures other than seminal 
vesicles such as external sphincter, rectum, bladder, levator muscles, 
and/or pelvic wall 
N – Regional Lymph Nodes 
NX Regional lymph nodes were not assessed 
N0 No regional lymph node metastasis 
N1 Metastasis in regional lymph node(s) 
M – Distant Metastasis 
M0 No distant metastasis 
M1 Distant metastasis 
M1a 
M1b 
M1c 
Non-regional lymph node(s) 
Bone(s) 
Other site(s) with or without bone disease 
Table 2. TNM staging of Prostate Cancer.   
Table adapted from the 2010 revision of American Joint Committee on Cancer (AJCC) for the classification 
of prostate cancer tumours [(Cheng et al., 2012)]  
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1.2.5 Currently available treatments for Prostate Cancer 
Prostate cancer treatment will vary based on the tumour staging combining Gleason 
grade, TNM stage and PSA levels. Among the available alternatives, surgical removal 
of the prostate (prostatectomy), chemotherapy, radiotherapy (both external beam 
radiotherapy and brachytherapy) and hormonal treatment are the most widely applied 
therapies (Castiñeiras Fernandez, 2007; Provencio Pulla, 2011).  
 Radical prostatectomy involves the complete removal of the prostate and 
seminal vesicles, being a suitable approach for healthy young patients (below 
70) suffering from localised prostate cancer. Frequently, this surgical procedure 
results in some degree of urinary incontinence and erectile dysfunction. Partial 
surgical removal of the prostate (exclusively focusing on affected regions) still 
remains a challenge given the usual peripheral localisation of tumours in the 
gland. Recently, the partial removal of tumours located in the anterior region of 
the prostate has been successfully achieved, reducing the above-mentioned 
side effects, e.g. erectile function was maintained in 83% of the cases 3 months 
after treatment as opposed to 54-90% measured 12 months after radical 
prostatectomy (Villers et al., 2016). 
 Radiotherapy is a suitable strategy for localised and locally advanced prostate 
cancer. It can be administered as treatment itself or adjuvant to surgery, should 
there be affected marginal regions such as seminal vesicles or extracapsular 
extension. In addition, there seems to be a direct relationship between the 
efficacy of radiotherapy and the dose of radiation given. Currently administered 
doses are ≥ 70 Gy over a 6-7 week period. Among side effects, radiotherapy 
causes urinary and bowel toxicity and sexual dysfunction. 
 Low dose brachytherapy consists of the administration of radioactive material 
seeds within the parenchyma of the prostate, resulting in high radiation doses 
within the prostate (around 145 Gy doses) while minimising the radiation of 
surrounding tissues. It is only indicated in patients with a positive prognosis (low 
Gleason and TNM scoring and PSA levels below 10 ng/ml). Despite the 
localised application of radioactivity, brachytherapy often results in rectal and 
genitourinary toxicity. 
 Hormone therapy is mainly based on the administration of anti-androgens and 
blockers of the Luteinising Hormone (LH) to achieve hormone deprivation and 
consequently inhibit neoplastic cell growth. This approach is generally followed 
in patients with advanced metastatic lesions as well as adjuvant treatment to 
high risk patients and post-radiotherapy. Generally, side effects include weight 
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gain, higher risk of thrombosis, loss of libido, osteoporosis, fluid retention and 
hot flushes. In addition, tumour response to hormonal treatment is limited to a 
relatively short period of time (24-36 months), after which tumours progressively 
develop independence to the absence of hormones, and PSA levels increase 
continuously, in the end resulting in the deterioration of patients and eventually 
irreversible death.   
 Chemotherapy is the gold standard for metastatic prostate cancer. The most 
common chemotherapeutics for prostate cancer are docetaxel (Taxotere), 
cabazitaxel (Jevtana) and mitoxantrone (Novantrone)  
1.2.5.1 Focal treatment of prostate cancer and 
active surveillance  
Side effects associated with current prostate cancer treatments (i.e. incontinence, 
rectal toxicity, sexual dysfunction, etc.) have led to the investigation and development 
of different strategies to reduce such undesired effects. For example, active 
surveillance is becoming every day a more frequent alternative for low risk prostate 
cancer patients, thus avoiding complications related to treatment. Several clinical trials 
are being conducted these days worldwide, in which some participating men have 
already surpassed the 10 and 15 year time point, indicating the potential of this 
strategy in eligible patients (Tosoian et al., 2016). On the other hand, the delay in 
treatment during active surveillance could result in missing the most adequate 
therapeutic window, in addition to the concern developed in patients knowing the 
existence of a non-treated tumour (Lindner et al., 2010). 
Focal treatment of prostate cancer is becoming a widely used alternative nowadays. It 
involves the combination of minimally invasive image-guided systems with ablative 
techniques directly applied to diseased regions of the prostate while minimising 
damage to surrounding healthy tissues, reducing adverse side toxicity and systemic 
effects (Bozzini et al., 2013b). These alternatives have to be deliverable to the prostate 
and capable of destroying tumour cells. Some of these are (Bozzini et al., 2013b; 
Lindner et al., 2010): 
 Cryotherapy is the direct application of very low temperatures followed by 
thawing to the prostate. This will cause direct tumour cell death as well as 
trigger inflammation. Early application of this technique resulted in high 
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morbidity but it has improved nowadays thanks to the development of 
transrectal ultrasonography and needles introduced through the perineum 
which allow the visualisation of the process. Additional improvements involve 
the use of argon-based cryoprobes (miniature cryoneedles) or probes 
monitoring temperature throughout the process. An overall analysis of the 
temperature in the prostate and surroundings would improve tumour destruction 
and avoid side damage to tissues close by such as nerves or the rectum. 
 High-intensity focused ultrasound (HIFU) implies the administration of sound 
waves at a high frequency (0.8-3.5 MHz) combined with power > 5 W/cm2. This 
way tumour will be destroyed in two manners: the focal application of 
ultrasound will result in heat (>60ºC), denaturising biological molecules such as 
proteins, then causing necrosis; cavitation in tissue will occur as a result of 
rarefaction and compression cycles. The procedure is performed using an 
ultrasound probe inserted into the rectum.  
 
Figure 3. Graphical representation of focal therapies for prostate cancer treatment.  
(A) Cryotherapy, (B) High-Intensity Focused Ultrasound – HIFU; (C) Focal Laser Ablation (FLA); (D) 
Photodynamic Therapy – PDT 
 Focal Laser Ablation – FLA consists of the application of a laser fibre through 
the perineum aided by transrectal ultrasound imaging or in-bore MR imaging, 
delivering an excess heat directly into the prostate. Prior to the administration of 
high temperatures, MRI or TRUS will determine the optimum positioning of the 
laser fibre in the diseased prostatic tissue, and temperature will be monitored 
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throughout using probes, minimising side damage. FLA has low morbidity in 
patients: mild haematuria or perineal discomfort in some cases, not affecting 
urinary tract or sexual functions.  
 Photodynamic Therapy, which is a major focus of the present document and will 
be further reviewed in sections below.  
Importantly, during the application of focal therapies for prostate cancer treatment it is 
crucial to take into consideration that this cancer is usually multifocal, hence the use of 
these site-specific focalised treatments could be questioned. However, the 
hypothesised existence of an “index lesion” supports the need for focal therapy even in 
more advanced, extended prostate cancer cases. “Index lesion” implies that the 
greatest tumour component in the prostate is responsible for disease progression 
outside the prostate, and eventually metastatic spreading. This is supported by studies 
reporting a monoclonal, single-cell origin in other metastatic cancers. Based on this, 
the identification of the index lesion and treatment concentration around this single-
focus origin will control the progression of the remaining diseases foci. Challenges 
currently reside in developing potent techniques to identify the leading lesion (i.e. 
biomarkers) (Lindner et al., 2010). 
1.3 History of light-based therapy 
The use of light in therapeutic applications dates 1400 BC in India, as described in the 
sacred Hindu text Atharva Veda for curative purposes to treat pathologies such as 
vitiligo combining plant extracts (i.e. Eclipta prostate, Curcuma longa, Citrullus 
colocynthis) and sunlight (Fitzpatrick and Pathak, 1959).  
Indeed, medical reports in the 18th century described on several occasions the 
treatment of different diseases based on energy coming from sunlight (Giese, 1964; 
Rollier, 1927; Russell and Russell, 1927). Among these, a cancerous mass on the lip 
was cured with a sunbath in 1735  (Giese, 1964), skin ulcers in 1774 (Russell and 
Russell, 1927), wound healing and tumour destruction in 1776 (Rollier, 1927), or even 
non superficial disorders such as rickets (Giese, 1964).  
It was not until 1877 that the use of sunlight to kill bacteria was discovered when 
comparing the turbidity of sugar solutions placed either in the shade or exposed to light 
(Downes and Blunt, 1877). Not only treatment but also prevention of rickets was 
already hypothesised with sun baths (Palm, 1890, 1888). Later on, it was speculated 
Background and Introduction 
 
 
29 
that rays coming from the sun or other light sources such as an electric arc lamp could 
stimulate tissues. Accordingly, red-light was used to address the treatment of skin 
conditions such as exanthemata of eruptive diseases, i.e. small-pox (Bie, 1899). Dr. 
Finsen hypothesised the capacity of light to aggravate pre-existing inflammation 
lesions. He then took advantage of this for bactericidal applications, as stated in 
Remarks on Finsen's Phototherapy “As the "chemical" (blue, violet, and ultraviolet) light 
are capable of causing an inflammation (erythema of the healthy skin), it might be 
assumed that they […] equally be capable of aggravating pre-existing inflammations 
the method consists local superficial bacterial skin diseases by the concentrated 
chemical rays of light” (Bie, 1899). Within a short period of time, sunlight was first used 
in 1902 to heal wounds followed by cavities and foci caused by tuberculosis (“Light 
treatment in surgery. By Dr. O. Bernhard (St. Moritz). Translated by R. King Brown, 
B.A., M.D., D.Ph., Medical Officer of Health, Bermondsey: Lecturer in Public Health, 
Guy’s Hospital Medical School. Medium 8vo. Pp. 307, illustrated. 1926. London: E,” 
1927). Rollier then established an important distinction between “hot-air bath” and 
“sunbath” and developed a way to irradiate the body with sunlight. The term 
heliotherapy then started to be used and gained popularity (Rollier, 1927). 
In 1900, Photodynamic Therapy (PDT) was discovered by Raab, a medical student 
who observed that the combination of acridine red and light during a thunderstorm 
killed the paramecium Infusoria (Raab, 1900). It was initially speculated that this 
cytotoxicity was due to the transfer of energy from light to the compound in a similar 
manner to plant photosynthesis. Soon after this, the use of photosensitisers in humans 
was first reported (Prime, 1900). In his studies, Prime noticed the development of 
dermatitis in light-exposed skin during the oral treatment of epilepsy using eosin 
(fluorescein-derived dye). Founded on the above, a combination of topically 
administered eosin and white light was used clinically for the first time as a therapy for 
skin tumours (von Tappeiner and Jesionek, 1903). The need for oxygenated conditions 
was then described (von Tappeiner and Jodlbauer, 1904) and the concept of 
“photodynamic action” was introduced in 1907 (von Tappeiner and Jodlbauer, 1907). In 
spite of their great contribution to the development of PDT, J. Dougherty was pioneer in 
the application of PDT in medicine and thus often considered father of the this 
therapeutic approach (Dougherty et al., 1979; Weishaupt et al., 1976).  The idea of low-
level lasers therapy was conceived by Mester during his observations on increased 
skin healing and hair regrowth (Mester et al., 1971, 1968a, 1968b). PDT was then 
addressed to treat other skin disorders, such as vitiligo and psoriasis (Parrish et al., 
1976, 1974). 
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1.4 Photodynamic Therapy – PDT 
Photodynamic Therapy (PDT) involves the administration of photosensitive compounds 
- photosensitisers (PS) in the presence of light and oxygen. PS exist in a ground stable 
singlet state in which their electrons are spin paired and found in low-energy orbitals. If 
these are exposed to light at the specific wavelength where maximal absorption of the 
PS is found, they absorb photon energy: the electron found in the highest occupied 
molecular orbital (HOMO) will be excited to the lowest unoccupied molecular orbital 
(LUMO) (Huang and Hamblin, 2014). When this process occurs, PS reach an unstable 
excited state (1PS*). In PDT, this high-energy state will rapidly lose energy in the form 
of heat, light and more importantly, exhibiting “intersystem crossing”: the spin of the 
excited electron will be reversed and lead to a different excited triplet state (3PS*). This 
triplet state has lower energy but longer lifetime than the singlet state (Huang and 
Hamblin, 2014).  
 
Figure 4. Jablonksi diagram.  
Schematic representation of the excitation of photosensitisers, showing the transition between singlet and 
triple states and the consequent energy transfer and formation of reactive oxygen species (ROS). Figure 
taken from [(Agostinis et al., 2011)] 
From this point, the excited electron will slowly correct its spin orientation to then relax 
back to the initial singlet state, or either reacts with molecules present in the 
environment through photooxidative reactions. Selection rules determine that 
interactions between triple-triplet are spin-allowed, while triplet-singlet are not. 
Consequently, 3PS* will most probably transfer energy via different reactions to 
molecular oxygen (O2), since only a minority of environmental molecules are naturally 
found in a ground triplet (Huang and Hamblin, 2014).  
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 Type 1 reactions: the excited PS transfers an electron leading to the 
formation of superoxide anion (O2
-) then resulting in hydroxyl radical 
(OH) and hydrogen peroxide (H2O2) among other free radicals. 
 Type 2 reactions: the excited PS transfers energy to O2. Environmental 
oxygen in its ground state is a triplet molecule with its two most external 
orbitals unpaired and spin parallel. Type 2 processes will alter the spin 
of one of the furthermost electron and displace it into the orbital of the 
other unpaired electron. As a consequence, the resulting orbital will 
contain two electrons of opposite spin. This is a highly reactive species 
known as singlet oxygen (1O2); however, it is not a “radical” due to the 
pairing of all electronic spins. As a result of its electronic instability, 1O2 
effect is restricted by its short lifetime (~10-320 ns), thus its diffusion will 
be limited to around 10-55 nm in cells, only affecting cellular structures 
located close enough for short periods of time (Agostinis et al., 2011).  
 
Figure 5. Detail of excitation of photosensitisers.  
The excitation of photosensitisers from the ground stable state to the triplet excited state leads to the 
formation of singlet oxygen (1O2) during the interaction with molecular oxygen present in the environment.  
The generated reactive oxygen species (ROS) cause oxidation of cellular structures 
compromising their integrity and inducing several molecular changes. Proteins are 
considered major PDT targets due to their abundance and high rate constants in 
reactions with singlet oxygen and other ROS released in the process. These are also 
differences based on the aminoacid composition of each protein and location of these 
susceptible components, causing distinctive damage to residues in the protein’s side 
chains. The prime targets in protein photooxidative modification are cysteine, 
methionine, tyrosine, histidine and tryptophan. In addition to modifying aminoacid 
residues, covalent cross-linking, PS-protein photo-binding may result in the formation 
of molecular aggregates. Overall, proteins may lose their biological activity (catalytic in 
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the case of enzymes, cell signalling, etc.) (Benov, 2015). Similarly, lipids are also 
targets of PDT-induced damage Highly abundant unsaturated fatty acids in 
biomembranes (i.e. membranous organelles and cellular membrane), make these a 
target for peroxidation reactions that may even conclude in the formation of radicals 
capable of initiating free-radical chain reactions which exponentially expand the 
process, affecting other biological molecules and even altering metabolic and signalling 
functions. The high solubility of oxygen in lipids makes this damage specially relevant, 
given the oxygen demand for these oxido-reduction reactions to happen (Benov, 2015).  
Furthermore, an important PDT-induced cellular damage is DNA oxidation, entailing for 
instance base modification or DNA nicks. The low ionisation potential of guanine 
makes this base particularly susceptible, producing guanine cation radical that can then 
react with residues in proteins such as lysine, serine and arginine causing DNA-protein 
cross-links. In spite of this, it has not been reported that PDT-based DNA mutation 
could be the source of additional mutations that will unleash the formation of secondary 
tumours (Benov, 2015).   
1.4.1 Cell death mechanisms after PDT 
Extensive studies on programmed cell death mechanisms were conducted by John 
Sulston, Sydney Brenner, and H. Robert Horvitz during the investigation of the genetic 
regulation surrounding organogenesis and cell growth in C. elegans (Hedgecock et al., 
1983; Sulston et al., 1983). Since then, cell death pathways have been further studied 
on many occasions, for instance in relation to different cancer treatments.  
Three main cell death routes are involved in PDT damage: apoptosis, necrosis and 
autophagy. Apoptosis is generally accepted as an active “programmed cell death”, a 
series of events resulting in cell-induced suicide through which cells will experience 
condensation and fragmentation of the nucleus, and cleavage of DNA resulting in 
internucleosomal fragments and final formation of apoptotic bodies within an intact 
plasma membrane. These apoptotic cells will be recognised by phagocytic cells, 
generally avoiding inflammation. Conversely, necrosis is the consequence of an ATP-
deficiency which is not compatible with cell endurance. The outcome of this will be 
cytoplasm vacuolation, membrane disruption as well as release of pro-inflammatory 
molecules and thus an inflammatory response in the cell environment (Edinger and 
Thompson, 2004).  Finally, autophagy is a survival mechanism followed by cells to 
degrade and recycle cellular components under certain conditions such as nutrient 
limitation (Agostinis et al., 2011; Edinger and Thompson, 2004). The engagement of 
PDT in these three cell death pathways will be commented below. 
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Apoptosis 
Apoptosis was first described by Willey et al (Kerr et al., 1972) and is now accepted as 
the major cell death pathway acting in PDT. This can occur via permeabilisation of 
mitochondria outer membrane (MOMP) governed by proteins belonging to the Bcl-2 
family and in a p-53 independent manner. MOMP can be triggered by mitochondria-
associated PS acting on Bcl proteins bound to the mitochondrial membrane, such as 
Bcl-227-29; or else leakage of cathepsins from lysosomes owing to lysosomal 
membrane damage (Agostinis et al., 2011). Thereupon, pro-apoptotic signals and 
molecules can be released, caspase activators (cytochrome c, Smac/DIABLO), 
apoptosis-inducing factor (AIF) among others. Blockage of caspase pathway will delay 
cellular damage by PDT or alternatively result in necrotic damage.  
In addition, PDT has been related to an increment in intracellular calcium levels 
inducing the influx through ion channels, releasing internal storage in mitochondria and 
the endoplasmic reticulum (ER) or via exchange mechanisms (Castano et al., 2005). 
This calcium increase could activate proteases such as calpains (calcium-dependent 
cysteine proteases) which are also involved in phototoxicity propagation (Agostinis et 
al., 2011).  
Necrosis 
The basic mechanisms by which necrotic phototoxicity happens are not clear. That 
said, it is known that the activation of receptor interacting protein 1 kinase, ROS 
excessive formation, lysosomal damage and Ca2+ overburden result in necrotic cell 
death. In line with this, in the event of mitochondrial permeability transition, caused by a 
severe damage to their inner membrane, as well as the mentioned Ca2+ overburden 
could shift from apoptotic to necrotic damage (Agostinis et al., 2011).  
Furthermore, it has been recently described that signal transduction pathways may be 
engaged in necrotic cell death. These suppose mechanisms of cells to receive external 
signals and respond accordingly. Among the most important are the mitogen-activated 
protein kinase (MAPK) signalling pathways, comprising p38 kinases, ERK 1/2, and c-
Jun N-terminal kinases/stress-activated protein kinases (JNK/SAPK). Upon PDT 
treatment, JNK can be activated via exposure of cells to tumour necrosis factor-α (TNF-
α) and interleukin 1 (IL-1) (Castano et al., 2005). 
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Autophagy 
To a lesser extent oxidative stress is known to trigger autophagy. As a matter of fact, 
PDT damage could act as inducer of the autophagic pathway to secure cell viability 
(Agostinis et al., 2011). PDT phototoxicity involves several other biological components 
and processes such as transcription factors, biological structures participating in cell 
adhesion, cytokines, stress-signalling molecules, hypoxia, angiogenesis, etc. (Castano 
et al., 2005) 
 In brief, PDT treatment conditions such as physicochemical properties of PS, 
subcellular location, PS and oxygen concentration, light wavelength as well as dosage, 
will be determinant in the occurring cell death pathway (Mroz et al., 2011b). On this 
basis, there are several probable scenarios. Mitochondria-localised PS will most likely 
result in apoptosis under certain levels of oxidative stress; whereas lysosome-targeted 
PS will prevent or at least setback apoptotic cell death in favour of necrotic cell death. 
Necrosis is likely to emerge as a consequence of endoplasmic reticulum/Golgi 
membrane targeting. Generally, the amount, site and type of ROS produced will dictate 
the oxidative damage caused. Overall moderate levels of stress on the cellular 
membrane will trigger apoptosis; yet if these were extensive necrosis would be 
unleashed, disrupting its overall integrity (Benov, 2015). Following this same line of 
argument, sublethal photooxidative stress results in apoptotic cell death; however, if 
this is severe, ATP production will be impaired and necrotic cell death pathway will be 
forced. It has been recently suggested that apoptotic cell death may be favoured by 
very low light fluences, additionally minimising adverse effects, and reducing 
associated morbidity, yet at the same time improving tumour control and maintaining 
therapeutic efficacy (Benov, 2015).  
1.4.2 Photosensitisers in PDT 
Despite initial studies involved dyes such as acridine orange or eosin, PDT studies 
were greatly propelled with the discovery of porphyrins. These are water-soluble 
aromatic macrocycles composed of four pyrrole rings (closed structures built with one 
nitrogen and four carbon atoms) linked through methane groups (−CH=). Featured by a 
characteristic red-purple colour they can be found within biological structures i.e. 
protoporphyrin in haemoglobin. 
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The first PS studied in depth was hematoporphyrin, derived from the acid hydrolysis of 
haemoglobin, after which iron is removed from the heme group (von Scherer, 1841). 
Initial examination of hematoporphyrin preparations revealed a rather impure solution 
which was proved to be more efficient in therapeutic applications than the pure 
compound itself (hematoporphyrin stereoisomers, hematoporphyrin vinyl 
deuteroporphyrin isomers, and protoporphyrin – later known as hematoporphyrin 
derivative, HpD, Photofrin®) (Huang and Hamblin, 2014). Moreover, the interaction of 
hematoporphyrin with neoplastic tissue was first observed during the studies carried 
out in 1924 by Policard (Policard, 1924). Dougherty carried out a clinical trial using this 
PS combined with red light in a wide range of cancers including recurrent colon 
carcinoma, metastatic prostatic carcinoma, metastatic breast carcinoma, metastatic 
squamous cell carcinoma of the skin, metastatic angiosarcoma, metastatic endometrial 
carcinoma and metastatic chondrosarcoma in 1978 (Dougherty et al., 1978), proving 
HdP-mediated PDT to be an efficient anticancer approach in tumours that did not 
respond to other treatments.  
Photosensitiser Structure λ (nm) Cancer type 
Porfimer sodium (HPD) Porphyrin 630 
Lung, oesophagus, bile duct, bladder, brain, 
ovarian 
ALA 
Porphyrin 
precursor 
635 Skin, bladder, brain, oesophagus 
ALA esters 
Porphyrin 
precursor 
635 Skin, bladder 
Temoporfin (Foscan, 
mTHPC) 
Chlorin 652 Head and neck, lung, brain, skin, bile duct 
Verteporfin Chlorin 690 Ophthalmic, pancreatic, skin 
HPPD Chlorin 665 Head and neck, oesophagus, lung 
SnEt2 (Purlytin) Chlorin 660 Skin, breast 
Talaporfin (LS11, MACE, 
NPe6) 
Chlorin 660 Liver, colon, brain 
Ce6-PVP (Fotolon), Ce6 
derivatives (Radachlorin, 
Photodithazine) 
Chlorin 660 Nasopharyngeal, sarcoma, brain 
Silicon phtalocyanine (Pc4) Phtalocyanine 675 Cutaneous T-cell lymphoma 
Padoporfin (TOOKAD) Bacteriochlorin 762 Prostate 
Motexafin lutetium (Lutex) Texaphyrin 732 Breast 
Table 3. Clinically approved photosensitisers for PDT.  
Table adapted from [(Castano et al., 2004)] 
The discovery of porphyrins as PS together with the principle behind porphyria 
(disorders that emerge due to the accumulation of natural constituents of porphyrins in 
the body) sowed the idea of endogenous PS production. In line with this, the 
combination of exogenous 5-aminolevulinic acid (5-ALA) administration (basic 
component found in biological porphyrins) and red light, successfully resulted in the 
synthesis of porphyrin derivatives (uroporphyrin and protoporphyrin IX) (Malik and 
Lugaci, 1987). Since then several photosensitisers have been approved by medical 
Background and Introduction 
 
 
36 
regulatory agencies worldwide: Photofrin (1993 in Canada, 1994 in Japan, 1998 
FDA), 5-ALA (1999 FDA), Visudyne (verteporfin formulation – 2000 FDA, more than 
(Huang and Hamblin, 2014). See summary table below (Table 3).There has always 
been a great interest in the modification and optimisation of PS (Boyle and Dolphin, 
1996), which might be crucial for the future of PDT. Along these lines, second 
generation PS were designed with the ultimate objective of maximising photooxidative 
damage to finally eradicate tumour masses whilst minimising side damage caused to 
surrounding healthy tissues. Such is the case of Pc4 (silicon (iv) phtalocyanine), 
benzoporphyrins (i.e. Visudyne), porphycenes, chlorins (i.e. Termoporfin) and 
metalated derivatives. These second generation PS exhibit absorption at longer 
wavelengths than first generation PS. Moreover, third generation PS are nowadays 
being developed to be excited well into the red and highly selective.  
Most PS used share a basic tetrapyrrole structure and ideally fulfil a series of 
requirements: 
 Purity. Rather than impure mixtures as is the case of Photofrin, new 
photosensitisers are designed to be pure solutions of single PS, enabling this 
way a tight quality control.  
 
 Absorption peak 600-800 nm (red to deep red). The aromatic nature of most PS 
leads to small energy differences between HOMO and LOMO orbitals, and in 
most cases visible and near infrared light are used for their excitation (Huang 
and Hamblin, 2014). Longer wavelengths are less energetic and thus 
insufficient to excite oxygen from its ground triplet to the excited singlet state in 
order to produce ROS characteristic of PDT (Agostinis et al., 2011; Juzeniene 
et al., 2006). Red light is preferred over the more energetic blue “counterpart” 
due to the greater penetration of this light on the grounds of the optical 
properties of tissues (“optical window”). Briefly, red light is able to penetrate up 
to 3 mm into tissue as opposed to blue light, penetrating < 1 mm into tissue 
(Master et al., 2013). Endogenous chromophores found in biological molecules 
such as collagen, water, proteins, melanin and haemoglobin will absorb light 
themselves within the blue region of the spectrum (Figure 6A), leading to light 
scattering, limiting penetration and thereby affecting photosensitisers’ capacity 
to induce phototoxicity (Agostinis et al., 2011; Allison and Sibata, 2010; Benov, 
2015; Huang and Hamblin, 2014). For the above reasons, chlorins, 
bacteriochlorins and phthalocyanines are often chosen for PDT in cancer 
treatment (see Figure 6B).  
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 Reduced aggregation. Most PS contain aromatic rings within their structures, 
which limit their solubility in aqueous environments and result in aggregation 
under physiological conditions. PS should exhibit low aggregation profiles to 
avoid affecting energy transfer processes occurring during photochemical 
treatment (quantum yields of ROS production) (Boyle and Dolphin, 1996).  
 
Figure 6. Therapeutic window for clinical use and main groups of photosensitisers used in PDT.  
(A) High absorbance of biological molecules is observed at wavelengths under 600 nm (i.e. haemoglobin 
shown in red) and above 800 nm (i.e. water shown green). Therefore, clinically relevant photosensitisers 
must exhibit adequate absorption levels 600-800 nm; picture taken from [(Castano et al., 2004)]. (B) 
Representation of the most relevant PS used in a clinical setting: porphyrin, chlorin, bacteriochlorin, 
phtalocyanine; picture taken from [(Benov, 2015)]. 
 Rapid biodistribution and clearance from the system. Photosensitisers have a 
major disadvantage: photosensitivity. This was already noticed with the first 
photosensitiser used for cancer treatment, HdP, remaining within patients for a 
long time (up to even 8 weeks), who in turn had to avoid sun exposure to avoid 
skin phototoxicity (Agostinis et al., 2011; Castano et al., 2004). In line with this, 
PS dark toxicity should be as low as possible (Allison and Sibata, 2010).  
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Relative fast metabolism and elimination of PS would avoid undesired toxicities. 
However, a balance is required between the persistence of PS within the body, 
and the amount of time needed for these to be biodistributed (specifically into 
tumours). In line with this, drug light intervals (DLI) tend to be long to enable PS 
diffusion to tissues; yet, the benefit of shorter DLI have been reported due to 
their effect in vasculature, which will be addressed in the following sections 
(Agostinis et al., 2011; Castano et al., 2004).  
 
 Preferred accumulation in tumour cells. This is closely related to the above, 
generally the aim is to reduce presence in the skin in favour of a greater PS 
burden in the tumour mass.  The first demonstration of specific retention of PS 
by cancer cells dates back to 1924 (Policard, 1924). Since then, this has been 
observed in many occasions (Agostinis et al., 2011; Penjweini et al., 2014; 
Zhang et al., 2015). It has been hypothesised that the reason behind this 
phenomenon is an “enhanced permeability and retention” (EPR) effect 
(Agostinis et al., 2011). This is based on the combination of two factors: on the 
one hand a passive extravasation of drugs from the vasculature into the tumour 
mass due to the leaky nature of recently formed immature blood vessels in 
tumours; and the poor lymphatic drainage of these on the other hand, which 
results in the retention of drugs within malignant cells for a longer period of time 
(Greish, 2010).  An increase in the hydrophobic features of PS or else the 
modification of these to add amphiphilicity can improve tumour selectivity 
remarkably, reducing levels of PS found in the skin (Jori, 1996). This tumour-
selectivity can be further enhanced by designing PS targeted against molecules 
specifically located or overexpressed in malignant cells.  Some of these 
strategies include binding PS covalently to antibodies, peptides and proteins 
(EGFR -endothelial growth factor receptor-, insulin, transferrin…), folic acid, 
carbohydrates, etc.  (Agostinis et al., 2011; Pereira et al., 2015). This will be 
further reviewed later chapters. 
 
 Additional desirable features of PS include low manufacturing costs and stability 
for mid- to long-term storage (Agostinis et al., 2011). 
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1.4.3 Therapeutic application of PDT 
PDT is considered a minimally invasive treatment with low side effects and good 
cosmetic outcome. Consequently it is widely used for dermatological purposes both in 
cancerous and non cancerous lesions. Among these, non-melanoma skin cancer, acne 
vulgaris, psoriasis vulgaris, cutaneous T-cell lymphoma, disseminated actinic 
porokeratosis, localised scleroderma, vulvar lichen sclerosus, photorejuvenation, 
hidradenitis suppurativa. In addition to dermatological applications, there are also non 
dermatological uses such as anal and vulvar carcinoma, Barrett’s oesophagus (Taub, 
2007). Due to PDT’s major effect on vasculature, it has been used to address choroidal 
neovascularisation (CNV). Among these, the most relevant is the classic use for age-
related macular degeneration treatment; other uses include secondary to pathological 
myopia, central serous chorioretinopathy and choroidal haemangioma (Battaglia Parodi 
et al., 2016).  
The development of the antimicrobial potential of PDT experienced difficulties with the 
discovery of antibiotics to treat infections caused by pathogens such as bacteria, 
fungus, protozoa, helminths, etc. It has slowly taken up from 1970s and is experiencing 
nowadays a rapid growth due to the rise of antibiotic resistance as an alternative 
antimicrobial therapy (Kharkwal et al., 2011). In these cases, it can be sometimes 
known as photodynamic inactivation (PDI), photoactivated disinfection (PAD) or 
photodynamic antimicrobial chemotherapy (PACT). Multiple clinical applications for 
infectious purposes involve the administration of 5-ALA topically or else the ALA-methyl 
ester, methyl aminolevulinate (MAL), in turn resulting in the excess accumulation of 
PPIX (Protoporphyrin IX) in cells. Other antimicrobial applications of PDT include viral 
lesions and dentistry and more recently it is being studied in clinical trials for 
Helicobacter pylori infection, brain abscesses and leg ulcers (Kharkwal et al., 2011). 
Moreover, beyond clinical applications, PDT is being used for water sterilisation and 
surface disinfection (Benov, 2015). 
Despite the variety of applications of PDT, it was initially developed for tumour imaging 
and treatment, and to day, it remains to be its main application. In line with the above, 
several PDT-based effects have been described in cancer treatment: 
 Direct cytotoxicity, as reported above in 1.4.1 Cell death mechanisms after 
PDT.  
 Vascular shutdown. In addition to a direct effect in cell death, PDT’s effect on 
vasculature (i.e. clinical application in macular degeneration) can be exploited in 
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cancer treatment. As a matter of fact, tumour growth is largely dependent on 
the existence of blood supply mechanisms. This has been addressed previously 
through the use of anti-angiogenic agents blocking the formation of new vessels 
in tumours; yet the elimination of already existing vasculature remained 
unaddressed. PDT has demonstrated a great capacity to affect tumour 
vasculature. In short, PDT-PS can accumulate in endothelial cells or else 
associate to the walls of blood vessels severely damaging the lumen of blood 
vessels and triggering physiological processes such as thrombogenesis, 
aggregation of platelets, constriction of vessels, increasing permeability, etc. 
Consequently, blood flow is blocked, casing tissue haemorrhage and overall 
causing ischemic death (Huang et al., 2008). This is supported by several 
studies, for example complete ischaemia upon irradiation was determined 
during indocyanine green-based PDT treatment to melanoma tumours (Abels, 
2004).  
Moreover, PDT has shown potential addressing multidrug resistance (MDR), which has 
become a major obstacle in cancer treatment nowadays (Gottesman, 2002). MDR can 
has different origins in each case, although there are two major hypotheses, both of 
which affect drugs before these can pursue their biological activity. First, the 
overexpression of energy dependent transporters (P-glycoprotein efflux pumps) mainly 
belonging to the ATP-binding cassette (ABC) family of proteins. Second, the 
degradation of drugs in mature lysosomes. 
1.4.3.1 PDT in cancer treatment – Preclinical 
studies 
In addition to its application in a clinical context as will be commented below, 
PDT has been studied for several types of cancers in pre-clinical investigations both in 
vitro and in vivo. For instance, breast cancer cell lines (MCF7) and their Adriamycin-
resistant counterpart were subjected to Chlorin e6 (Ce6)-mediated PDT (H. Wang et 
al., 2016). In this study, PDT effectively affected viability of both cell types, also finding 
a direct relationship between PS/light dose and cytotoxicity. However, Adriamycin-
sensitive cells appeared to be more affected by PDT than resistant cells. Interestingly, 
despite both cell types showed a similar PS intake, sensitive cells exhibited a higher 
production of ROS, suggesting that the underlying mechanisms which confer 
resistance to Adriamycin could likewise lead to emerging mechanisms against 
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oxidative stress. This same study also concluded different cell death mechanisms in 
both cell lines, specifically apoptosis or autophagy in sensitive and resistant cells 
respectively (H. Wang et al., 2016). In a different investigation, in vitro and in vivo 
breast cancer models looked into the PDT effect of sinoporphyrin sodium (DVDMS) 
(Xiaobing Wang et al., 2015). Specifically, a significant increase in the production of 
ROS was observed in vitro in a light-dose dependent manner. Moreover, PDT-treated 
mice did not only show a delay in tumour growth but also an inhibition of the formation 
of metastatic nodules in the lung, consequently enhancing survival of these animals 
(Xiaobing Wang et al., 2015).   
Osteosarcoma cells have been likewise exposed to ALA-PDT, verifying the 
accumulation of PpIX 4 hr after the administration of ALA as well as a light-dependent 
cell death. Even the lowest PS concentration (0.5 mM) led to a substantial reduction of 
cell viability under 3 J/cm2 light (White et al., 2016). Similarly, liposomal ALA-PDT was 
recently investigated for melanoma treatment, concluding a more significant cell death, 
enhancement in the accumulation of ROS intracellularly and reduction of mitochondrial 
potential, than free 5-ALA (Lin et al., 2016). This serves as a first glimpse on how the 
adequate design of PS formulations can enhance therapeutic outcome.  
Recent investigations of PDT for prostate cancer involved the use of the 
photosensitiser Pc413 targeted against prostate-specific membrane antigen (PSMA). In 
vitro, PSMA-expressing PC3 cells showed an increased uptake of the PS conjugate 
compared to non PSMA expressing cells, which then lead to a greater PDT-induced 
toxicity. Imaging of in vivo samples showed major presence in PSMA+ tumour cells as 
opposed to other tissues as well as a strong growth delay after a single dose of the 
targeted conjugate (X. Wang et al., 2016).  
1.4.3.2 PDT in cancer treatment – Clinical studies 
Skin cancers are common targets for PDT treatment clinically due to the accessibility 
and easy application of both photosensitisers and light (Huang, 2005). For instance, 
topical PDT was recently investigated in extramammary Paget’s disease using 5-ALA 
as PS (Gao et al., 2015). In this study, patients were grouped in two cohorts, either 
treated with PDT alone or a combination of PDT and surgery. In the former group, 4-6 
sessions were necessary to achieve complete tumour regression. Among the study’s 
findings, a higher recurrence rate was observed in the PDT group, which was thought 
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to be due to the limitations in light penetration, possibly not completely eradicating 
tumour cells located in deeper regions (Gao et al., 2015). In a different trial, patients 
suffering from facial nodular basal cell carcinomas were subjected methyl 
aminolaevulinate (MAL)-PDT, comparing conventional PDT to ablative fractional 
illumination. Overall, despite ablative fractional laser PDT still requires optimisation, 
resulting in a higher cure rate (100% vs 88%) as well as a delay in recurrence with the 
new PDT approach under investigation (Haak et al., 2015). 
Brain tumours have also been PDT-treated on several occasions (Huang, 2005). Along 
these lines, 27 patients suffering from parenchymal brain malignant tumours were 
treated with talaporfin sodium as an adjuvant treatment to surgery. At least 91% 
progression free survival was observed, even achieving 100% rate when tumours were 
identified as glioblastoma (Muragaki et al., 2013). On it side, PDT has also shown 
potential to address breast cancer chest wall progression in patients where previous 
treatments had been unsuccessful. Although a larger cohort is needed to reach more 
conclusive findings, at least a partial response was observed in 5/9 patients, 
additionally verifying apoptotic cell death through histological observation of tumour 
samples (Morrison et al., 2014). 
In addition, PDT treatment of intractable advanced lung cancer has been recently 
assessed in combination with chemotherapeutics to address airway stenosis. 
Throughout this study, an improvement in the production of sputum and pneumonia 
were found as soon as 1 week after light treatment. The early blockage of bleeding 
post PDT was attributed to the effect of PDT on microvasculature. Moreover, a control 
on the growth of bronchially localised tumours was concluded after PDT, while 
systemic chemotherapy had a positive effect in survival of patients (Kimura et al., 
2015). 
1.4.3.2.1 PDT in Prostate Cancer 
Importantly, PDT has also been applied clinically for prostate cancer (see PS used 
clinically in prostate cancer in Table 4) (Arumainayagam et al., 2010; Moore et al., 
2011, 2009).  
During the application of PDT in the prostate, it is important to design the arrangement 
of fibres and source used for light delivery so as to ensure the appropriate illumination 
of the gland and succeed in the treatment. Accordingly, a feasibility study measuring 
optical properties (diffusion of different light fluences) prior and post administration of 
LuTex-PDT to patients was conducted in 2005. Light penetration was confirmed 
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between 0.1-1.1 cm, which was in fact smaller than determined previously in pre 
clinical studies in the canine prostate. Importantly, differences between patients 
suggested prostate-based differences and the need of real-time dosimetry to determine 
light fluences during specific treatments (Zhu et al., 2005a). Light distribution, 
oxygenation of tissues and drug concentration were further investigated in the same 
phase I clinical trial. Briefly, the authors concluded that variation of light fluence, as 
previously reported, was caused by disparities in the optical properties throughout the 
prostate tissue (i.e. photosensitiser accumulation, light distribution and oxygenation) 
(Zhu et al., 2005b).  
In 2006 mTHPC was used to treat 6 patients suffering from localised prostate cancer, 
observing a reduction in PSA as soon as after 8 sessions of light delivery. Moreover, 
tumour biopsies showed inflammation and fibrotic formation 2 months after treatment. 
The lack of PDT-induced irreversible necrosis, i.e. to connective tissue, resulted in a 
positive outcome regarding uretho-fistulas, sexual function or continence. Although co-
morbidity was reported by some patients, it resolved spontaneously in almost every 
case, with the exception of patients previously exposed to radiotherapy. This study also 
concluded no cumulative toxicity after the repeated sessions (Moore et al., 2006). 
Target Photosensitiser 
Drug-light 
interval 
Tissue 
Haematoporphyrin derivative 48 hours 
Porfimer sodium (Photofrin) 72 hours 
mTHPC (Temoporfin) 72 hours 
5-ALA 4 hours 
Vasculature 
Motexafin Lutetium (LuTex) 3/6/24 hours 
Padoporfin (Tookad® WST-09) 10 minutes 
Padeliporfin (Tookad® WST-11) 10 minutes 
Table 4. Photosensitisers used clinically in prostate cancer PDT.  
Table adapted from [(Arumainayagam et al., 2010)] 
More recently, TOOKAD® Soluble was used in 85 patients enrolled in a Phase II 
multicentre study (Azzouzi et al., 2013). 74% of the patients had negative biopsies 6 
months after treatment, which was significantly different (p < 0.0001) to previously 
reported studies. As soon as 7 days after, vascular targeted PDT resulted in necrosis in 
78% of prostate tissue. Overall, it was concluded that TOOKAD-PDT was safe and 
tolerated by patients, showing early efficacy for site-specific prostate cancer treatment 
(Azzouzi et al., 2013). Similar conclusions were drawn from the joint analysis of 3 
clinical studies with this same photosensitiser including 117 men. A total of 68.4% of 
negative biopsies was determined 6 months after PDT and mean 76.5% of prostatic 
necrosis 7 days after light. Adverse effects (mild to moderate) were noted in almost 
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every patient, including dysuria, erectile dysfunction, haematuria, perineal pain, 
mictourinition urgency and urinary retention. Therefore, despite the focal application of 
PDT, co-morbidity is still detectable (Azzouzi et al., 2015). Recently, a TOOKAD 
Soluble dose escalation study conducted in the US concluded 4 mg/kg and 200 J/cm 
are the optimal doses (TOOKAD Soluble and light respectively) to be used clinically 
(Taneja et al., 2016).  
1.4.3.2.2 Clinical limitations of PDT  
In spite of the great benefits of PDT as a focal treatment of cancer, several limitations 
have been identified, some of which have already been briefly mentioned above.  
The main disadvantage of PDT is related to the capacity of light to penetrate tissues 
(Agostinis et al., 2011). As stated previously, penetration of red light is limited to 3 mm, 
which could result in tissue damage up to 1 cm, restricting the application of PDT to 
tumours located superficially (i.e. skin) or else easily accessible through laser-fibre 
illumination (i.e. colorectal, oesophageal). Besides, severe skin photosensitivity, as 
reported with various photosensitisers, is another major drawback of this therapeutic 
application, and upon administration of photosensitisers patients need to be protected 
from a direct exposure to light for several days (Castano et al., 2004; Moore et al., 
2006). 
Moreover, light dispersion can occur during illumination, damaging surrounding tissues 
which have been equally exposed to systemically administered PS (Arumainayagam et 
al., 2010). On the other hand, this site-specificity, will be a limitation for PDT treatment 
of more advanced metastatic lesions, which nowadays imply a major challenge. More 
recently, the potential of PDT in the elucidation of an immune response has been 
reported (Garg et al., 2010), opening the possibilities of PDT as regards metastasis. 
This will be further reviewed in the following chapters.  
As regards PDT in prostate cancer specifically, variability in the positioning of fibres 
and shape of the prostate between imaging during treatment planning and the 
treatment itself carried out at a later time point, could result in inefficient light delivery. 
This could be enhanced by real-time monitoring (Arumainayagam et al., 2010). 
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1.5 Photochemical Internalisation – PCI 
Chemotherapy has become nowadays a gold standard treatment for most types of 
advanced cancers. However, it is associated with undesirable side effects and 
resistance to several chemotherapy drugs has been reported during the application of 
anti-cancer treatments (MDR). Moreover, chemotherapeutics can have difficulties 
reaching their biological targets: endosomes bearing chemotherapy compounds can 
fuse with catalytic lysosomes and this will eventually result in the degradation of the 
chemotherapy drugs before they have exerted their biological activity. (Gottesman, 
2002; Zahreddine and Borden, 2013).  
On the other hand, a large volume of knowledge has emerged regarding cellular 
targets for different therapeutic approaches, which together with the improvement of 
production technologies, have resulted in a great increase of the number of 
macromolecular drugs available (immunoconjugates, toxins, antibodies, growth factors 
for targeting, peptides, ribozymes, siRNA, peptide nucleic acids) (Høgset et al., 2004). 
For instance macromolecular chemotherapy drugs that result in higher specificity than 
their smaller counterparts. In line with this, there are several macromolecular drugs 
approved for clinical use currently that exhibit different specificities:  CD33-targeted 
immunoconjugate (Mylotarg), HER2-targeted antibody (Herceptin), (EGFR)-targeted 
antibody (Cetuximab), IL-2 modified diphtheria toxin fusion protein (Ontak) (Berg et al., 
2006). 
Albeit this progress, cellular uptake of these therapeutic compounds may be an issue 
to consider. First, small molecules generally diffuse easily through cellular membranes; 
however, there are exceptions in which cell membranes may pose a difficulty in terms 
of internalisation of low molecular weight particles, as noted with hydrophilic molecules 
(Høgset et al., 2004; Martinez de Pinillos Bayona et al., 2016). Second, larger 
compounds are internalised by cells through endocytosis, in which the molecule at 
issue interacts with the external cell membrane and is engulfed, leading to the 
formation of cytosolic vesicles or endosomes. Moreover, there are several lipid 
membranes drugs will encounter and need to go through: the external cell membrane, 
endolysosomal membranes or even the nuclear membrane in the case of nuclear 
agents acting in the nucleus. Thus, physicochemical properties are a limiting factor for 
the different compounds to exert their cytotoxic effect within tumour cells (Adigbli and 
MacRobert, 2012; Norum et al., 2009d). Even if a particular drug is very efficient in a 
cell-free environment, its capacity to exert toxicity within a cellular system can be 
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limited. Consequently, despite many compounds could potentially become therapeutic 
agents, it may not occur when used alone.  
Based on all the above, several different drug delivery systems (DDS), for example 
Photochemical Internalisation (PCI), are being studied to enhance drugs’ cytotoxicity, 
assisting the delivery of biologically active agents to their intracellular targets and in the 
end enhance the therapeutic outcome. Importantly, the lack of toxicity in the absence of 
a suitable DDS and provided that cytotoxicity is triggered only where required, results 
in site-specific treatments (Berg et al., 1999; Høgset et al., 2004; Martinez de Pinillos 
Bayona et al., 2016). 
PCI was developed by Berg & co-workers in 1999 (Berg et al., 1999), emerging 
as a further development of PDT. Despite the shared features between PDT and PCI, 
these two treatments differ in key aspects. Unlike PDT, PCI is a site-specific DDS 
based on the use of low dose PDT in combination with therapeutic agents where PS 
are not a therapeutic compound on their own (Adigbli and MacRobert, 2012; Martinez 
de Pinillos Bayona et al., 2016; Wang et al., 2013). In this respect, there are a wide 
range of compounds and molecules with different nature and size, susceptive of PCI-
based delivery (DNA, peptides, oligonucleotides, genes, immunoconjugates…), turning 
PCI into a very versatile tool. 
PCI requires the administration of sub-lethal doses of light and PS, limiting the PDT 
effect and being the delivered therapeutic agent the main responsible for the curative 
outcome. Specifically, during a standard PCI approach, the photosensitiser and the 
therapeutic compound at issue are administered and desirably uptaken by cells 
through endocytosis. PS designed for PCI are amphiphilic molecules whose 
hydrophobic domains remain within the endosomal or lysosomal lipid membranes 
during internalisation, while their hydrophilic motifs face the matrix of the vesicles and 
impede the complete penetration through cellular membranes (Arentsen et al., 2014). 
On the other hand, drugs in PCI should locate inside these endocytic vesicles, 
featuring hydrophilic properties, hence being trapped inside the matrix (Martinez de 
Pinillos Bayona et al., 2016). Upon illumination, excitation of PS located in the 
endo/lysosomal membranes, far from affecting the external cell membrane and 
inducing cell death, they will lead to the disruption of cytosolic vesicles carrying the 
therapeutic molecules, and consequently enable their transport to cellular targets. A 
crucial requisite in PCI is therefore the localisation of PS in endo/lysosomal 
membranes (Martinez de Pinillos Bayona et al., 2016; Selbo et al., 2010), ensuring 
photochemical damage on these rather than on the cell membrane. 
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Figure 7. Schematic representation of PDT vs. PCI.  
(A) Detail of endolysosomal disruption during light exposure. (B) Graphic display of the underlying 
differences between PDT and PCI. Image taken from [(Martinez de Pinillos Bayona et al., 2016)] 
Initially, PCI was developed to enhance the delivery of macromolecular drugs which, 
due to their high molecular weight, had difficulties traversing cellular membranes and 
escaping from endocytic vesicles, as is the case of some chemotherapy drugs (Berg et 
al., 2006). However, PCI has also achieved an efficient intracellular delivery of low-
molecular weight compounds, such as Bleomycin (MW 1400), which is unable to 
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penetrate cellular membranes efficiently, thereby accumulating in endosomes. 
Therefore, both large and low molecular weight molecules could be eligible for PCI-
based delivery (Berg et al., 2006). 
1.5.1 Photosensitisers in PCI 
The above-stated requirements of PS used in PDT can be equally applied to PCI. One 
important distinctive feature is the prerequisite for the localisation of these in 
membranes within endosomes or lysosomes. (Lim et al., 2012). This can be achieved 
by the presence of a limited number of carboxyl-groups in photosensitisers, which due 
to their high pKa enable cell membrane penetration. Otherwise, these could be replaced 
with sulfonate groups. Yet, in this case, more than one group is necessary to avoid 
penetration through cell membrane due to the low pKa of these groups, which impedes 
protonation even in the acid environment of lysosomes. This pair of sulfonate groups 
will be responsible for the adsorptive endocytosis of photosensitisers. In addition, 
cellular membranes act in a protective manner with ROS, rendering longer lifetime and 
thereby greater toxicity (Berg et al., 2011) 
As with PDT, when facing clinical application, PS in PCI should not cause dark toxicity 
in the host and exhibit desirable pharmacokinetics such as being rapidly uptaken 
mainly by tumour tissues and a fast clearance from the body (Berg et al., 1999; Bozzini 
et al., 2012; Cunderlíková et al., 2001; Dietze et al., 2003; Friberg et al., 2003; Pass, 
1993; Prasmickaite et al., 2002; Sibata et al., 2001; Weyergang et al., 2011, 2006). 
Likewise, tissue penetration is also a major issue to consider when performing 
photochemical treatment.  
AlPcS2a (aluminium phthalocyanine) has been widely used for in vivo PCI due to 
structural reasons: a main porphyrin macrocycle enhancing the absorption in the far-
red region of the spectrum (peak at 670 nm), together with two sulfonate groups 
conferring amphiphilicity (Berg and Moan, 1994; Selbo et al., 2002). Recently, TPCS2a 
(sulfonated chlorin-based photosensitiser - Amphinex®) was developed (Berg et al., 
2011). It is featured by the more efficient and reliable production compared to AlPcS2a.  
TPCS2a has optimal photobiological and photophysical features for PCI (Wang et al., 
2013). For example, the enhanced photobleaching rate would benefit patients by 
reducing skin toxicity (Berg et al., 2011). Moreover, due to the above-mentioned 
reproducibility and purity during the manufacturing process as well as the high 
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absorption of this PS within the therapeutic window (600-800 nm), TPCS2a was 
proposed in 2011 for the first time, as a clinically suitable PS. Importantly, TPCS2a has 
been recently used in the first-in-man dose-escalating phase I/II study of PCI in 
combination with the antibiotic bleomycin for the treatment of cutaneous and 
subcutaneous malignancies either local recurrent, metastatic or advance for patients 
who had no success with other forms of treatments –ClinicalTrials.gov, NCT00993512 
(Sultan et al., 2016). The successful outcome of this study has led to a larger phase II 
trial among several European centres. TPCS2a has also been combined with 
gemcitabine for the treatment of inoperable advanced cholangiocarcinomas – 
ClinicalTrials.gov identifier: NCT01900158 (Martinez de Pinillos Bayona et al., 2016).  
In vitro, light absorption by PS will remain unaffected, thus compounds with low 
absorption in the optical window such as porphyrins can be used. Accordingly, TPPS2a 
(meso-tetraphenylporphin disulfonate), has been proved extensively to be efficient as a 
photosensitiser in vitro (Berg and Moan, 1994; Fretz et al., 2007; Lilletvedt et al., 2011). 
 
Figure 8. Photosensitisers used in PCI.  
AlPcS2a, TPCS2a (Amphinex®) and TPPS2a are three photosensitisers commonly used for PCI. 
1.5.2 PCI modalities 
The PCI procedure previously described corresponds to the traditional “light after” 
treatment. More recently, “light before” PCI has been described (Prasmickaite et al., 
2002). Briefly, as opposed to “light-after” PCI, during a “light before” approach, light is 
applied before the administration of the therapeutic agent.  
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 Light after. Both photosensitiser and therapeutic drug are administered before 
illumination. They will both be endocytosed and localised in the endolysosomal 
membrane or matrix respectively. When excitation of PS occurs, the 
endolysosome will be disrupted and its content will be discharged into the 
cytosol, enabling the access to its target (see Figure 9A) 
 Light before. Light-activation of PS will be triggered prior to the administration of 
the drug at issue. It has been hypothesised that after PS incorporation within 
endosomes and illumination, cytosolic vesicles present in the cell are disrupted 
(Prasmickaite et al., 2002), so that upon administration of the second 
therapeutic agent, newly formed endosomes containing the drugs will fuse with 
already disrupted endosomes, releasing the drug content (see Figure 9B). 
Further study of this more novel PCI proposal needs to be conducted to better 
determine the adequacy of either.  
 
Figure 9. Schematic representation of the different PCI strategies: Light-After vs. Light-Before.  
(A)Light-after PCI: light delivery occurs after co-administration of the chemotherapeutic drug and the 
photosensitiser. (B)Light-before PCI: the administration of photosensitiser is followed by the application of 
light and prior to the administration of the chemotherapeutic drug.  
The higher efficiency of either approach seems to be dependent on the particular 
nature of the therapeutic compound that will be delivered, its sensitivity to PS-induced 
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photochemical toxicity (Prasmickaite et al., 2002; Weyergang et al., 2011). It is 
therefore likely that molecules and compounds less resistant to ROS species will suffer 
more damage when administered before PS light excitation, especially when located 
close enough to be affected by 1O2. This could be applied to oligonucleotides, genes 
and other DNA sequences (Prasmickaite et al., 2002). Additionally, light before PCI has 
also been successful in vivo, i.e. for the treatment of subcutaneous colon 
adenocarcinoma tumours combining AlPcS2a and gelonin (Berg et al., 2006). From a 
clinical setting, light-before may also be an advantage, since light treatment could be 
performed at the same time as drug administration (Prasmickaite et al., 2002). 
Additional examples will be given in the following sections. 
1.5.3 Therapeutic application of PCI 
The use of PCI has been mainly investigated for cancer treatment with different 
macromolecules, nanoformulations, etc. However, as a DDS, it has is also an effective 
system to delivery several nucleic acids. Most of these are uptaken by cells through 
endocytosis, after which the release from cytosolic endosomes into the cytoplasm or 
else transport into the nuclear compartment, where these will perform their activity, 
remains to be a major challenge (Selbo et al., 2010). 
For example, PCI has been previously used in combination with oligonucleotides (i.e. 
ribozymes, antisense DNA, peptide nucleic acids, siRNA). Along these lines, 
phorodiamidate morpholino oligomers (therapeutic oligonucleotide) were recently used 
in PCI bound to Ce6 and combined with dendrimer structures. Despite the previously 
described difficulties in endosomal escape of PMO, after PCI PMO resulted in an 20% 
cell death. Moreover, when compared to the widely used transfection agent 
Lipofectamine, PCI induced a greater expression of eGFP, concluding an effective 
release from endosomes and entry into the nucleus of the PMO of interest (Yuan et al., 
2015). In a different study, PCI together with tetraglucosylated polyethilenimine were 
used to transfer p53 into pharynx carcinoma cells exhibiting a mutated version of p53. 
PCI did not only increase the efficiency of transfection but was also able to maintain the 
expression of the transgene in 10% cells for 144 hr after delivery. In the end, an 
increased cell death (up to 50%) induced by p53 was observed in these mutant cells 
(Ndoye et al., 2004). 
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1.5.3.1 PCI advantages over PDT 
Despite the shared features between PDT and PCI, we believe that an optimised PCI 
strategy has several advantages over PDT. In the first place, the lower dose of both 
photosensitiser and light fluence used in PCI will potentially reduce skin sensitivity and 
side phototoxicity as reported for PDT.  
Additional advantages of the former are: 
 Greater effect in tumour vasculature: 
Vascular shutdown has been often described as an important event occurring post 
PDT (Pizova et al., 2012; Selbo et al., 2010; Weyergang et al., 2011). Likewise, PCI is 
equally capable of affecting vascular structures. For example, a vascular shutdown was 
observed at a later timepoint for PCI, hypothesising that the combination of PS and 
bleomycin in this case resulted in a more subtle damage to endothelial cells possibly 
due to the lower light fluence employed (Norum et al., 2009b). Moreover, tumour 
oxygenation needed for singlet oxygen formation would have occurred for a longer 
period of time during PCI, resulting overall in greater tumour eradication (Norum et al., 
2009b). Endothelial cells as such, namely fibrosarcoma and human umbilical vein 
endothelial cells (HUVECs), were further considered as direct targets of PCI in the 
studies conducted by Vikdal et al. combining saporin with either TPPS2a or AlPcS2a 
(Vikdal et al., 2013). A more efficient uptake of PS was confirmed in HUVEC cells, 
being localised in endosomal organelles. Interestingly, a higher dose of saporin was 
required to achieve a comparable PCI effect between endothelial and cancer cells (100 
nM and 10 nM respectively) and a higher efficiency of the PS was likewise shown in 
cancer cells. The authors of the study hypothesised that disparities in traffic pathways 
between cell types were the cause of the above observations (Vikdal et al., 2013). 
Overall, this sheds light to the importance of endothelial cells during light-based 
therapies and potential vascular shut down within the context of tumours in vivo. 
 Enhanced damage to the tumour periphery: 
Distinct areas within a tumour are involved differently in tumour growth and 
development. More specifically, cells exhibiting slower proliferative capacity are more 
common in the central region of tumours, while peripheral cells usually proliferate at a 
higher pace. This was observed for example in the study carried out on a human 
glioma in vitro model (Mathews et al., 2012). Through cell monolayer and spheroid 
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toxicity observations, not only was PCI capable of inducing synergy between PDT and 
bleomycin, but also whereas PDT had a major effect in the tumour’s central region, PCI 
exerted a major effect in the quickly proliferating periphery. This led not only to the 
temporary delay in tumour’s growth but their complete  eradication (Mathews et al., 
2012). Similar results were obtained when combining PCI of bleomycin with other 
treatments such as external-beam radiotherapy (Norum et al., 2009a) or marginal 
surgery (Norum et al., 2009c). In the former, PCI treatment before ionizing radiation, 
led to a 13-day further delay of tumour growth opposite to radiation on its own (Norum 
et al., 2009a). Hence, the major destruction of tumours post-PCI could be explained by 
the combination of radiation - acting on the inner tumour mass, and PCI - affecting a 
large region of the tumour periphery. In addition, this enabled the reduction of the 
overall dose of radiation applied. Furthermore, during PCI delivery of bleomycin to the 
existing tumour bed after tumour resection in a fibrosarcoma in vivo, PCI resulted in up 
to a 17-day delay of tumour growth. However, PDT on its own did not improve the 
results observed after resection. Moreover, recurrence took 3 times longer after PCI 
compared to PDT when surgery had not been completely successful (Norum et al., 
2009c). In a different study, the same group confirmed higher efficacy of PCI towards 
periphery cells through magnetic resonance imaging (MRI) measuring perfusion based 
on vascular shutdown. In this case, two hours after either PDT or PCI, the access of 
MRI agents to the centre of the tumour was blocked, whereas high levels of perfusion 
were observed in the periphery revealing a smaller area of viable peripheral tumour 
tissue post-PCI on the treated animals through histological observation (Norum et al., 
2009b). Importantly, the greater cell killing in this highly proliferating area was 
associated to the delivery of bleomycin in the tumour parenchyma. Dietze et al. 
determined deeper necrosis after PCI than PDT: up to 7 mm and 4 mm from the skin 
surface respectively (Dietze et al., 2005). Importantly, achieving a greater depth 
penetration is particularly relevant in solid tumours. 
 Overcoming MDR:   
In several cases PCI been able to overcome resistance to several chemotherapy 
agents, enhancing the biological effect of these to an even greater extent in resistant 
subclones than parental sensitive cells. This has been successfully performed with 
doxorubicin- and mitoxantrone- resistant cells for instance. Both of these drugs are 
weak bases which are unable to penetrate membranes in their protonated form: 
diffusion of these into lysosomes results in their protonation and sequestration, hence 
causing drug resistance. Moreover, highly acidic organelles have been reported in cells 
exhibiting a drug resistance phenotype (Altan et al., 1998). In 2006, Lou et al. proved 
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the possibility of overcoming doxorubicin resistance caused by endosomal entrapment 
of the drug in MCF-7 breast cancer cell lines, promoting transport of the drug to cell 
nuclei, where it is expected to exert its cytotoxic effect (Lou et al., 2006). Cell viability 
measured on MCF-7 parental cells after PCI showed additive effects between 
photosensitiser-based photooxidative damage and chemotherapy-based damage; yet, 
synergistic effects were seen in the doxorubicin-resistant counterpart together with an 
8-fold decrease in LD50 (>20 M to 2.5 µM). Based on doxorubicin’s delivery “light-
before” and “light-after”, PCI was more efficient when drug accumulation in cytosolic 
vesicles was avoided as opposed to relocation after accumulation (Lou et al., 2006). 
Similarly, PCI was also capable of triggering cell killing in mitoxantrone-resistant cells in 
a dose-dependent manner, i.e. combining the PS hypericin and mitoxantrone as shown 
by Adigbli et al. on both breast and bladder cancer cells (Adigbli et al., 2007). Again, up 
to 13% higher reduction in cell viability was seen in resistant cells compared to parental 
sensitive. Also, this enhanced cell killing after PCI was not due to changes in P-
glycoprotein (Pgp, drug-excreting efflux pump) expression in resistant cells. 
Surprisingly, when breast cancer cells were exposed to PDT using low doses of PS, 
some proliferation was seen, possibly due to activation of cell pathways under cell 
stress which are able to propagate cell proliferation (Adigbli et al., 2007). This 
recurrence was not observed in the bladder cancer model used, suggesting the 
induction of proliferative signals after PDT could happen at a later time, correlating with 
the described recurrence in bladder cancer patients after a primary PDT procedure 
(Yavari et al., 2011). More recently, Olsen et al. (Elisabeth Olsen et al., 2013) 
concluded based on studies performed on uterine sarcoma cells, that upon 
doxorubicin’s integration in the DNA structure it can induce ROS formation as well as 
expression of ROS scavengers as a consequence of cellular adaptation to the 
environment (Elisabeth Olsen et al., 2013). It is suggested that the release of 
chemotherapeutic drugs located in cytosolic vesicles after exposure to light in PCI, 
occurs before their capture by ROS scavengers. ROS scavenger overexpression, 
together with the attenuation of p-38 death signal in the MES/Dx5 resistant cell line, 
clarifies the origin of PDT (TPPS2a used as photosensitiser) and doxorubicin 
resistance. P-gps were also studied as a consequence of their participation in drug 
resistance (Gottesman, 2002); however, high PS uptake was seen even under 
exposure to P-gp inhibitors (Elisabeth Olsen et al., 2013).  
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Aims of the thesis 
Based on the potential PDT has shown already clinically as a focal therapy, the main 
aim of this thesis is to evaluate the potential of light-based therapies (PDT and PCI) for 
prostate cancer, specifically advanced, aggressive, and highly metastatic.  
Despite the success PDT has shown in tumour eradication in clinical trials for prostate 
cancer treatment, there are still some limitations as regards co-morbidity induced by 
side phototoxicity. Therefore, in addition to the investigation of PDT, we will also 
examine the capacities of the PDT-derived drug delivery system PCI as therapy for 
prostate cancer. Both these therapies are difficult to optimise due to the number of 
influencing variables, especially PCI. Taking this into consideration, we hypothesise 
that should a PCI approach be optimally designed, it could result in an improvement 
over PDT regarding both therapeutic outcome and adverse side effects.  
During this project, we aimed to conduct experiments in vitro which could serve as a 
basis for further investigations in vivo. Several goals were established, each of which is 
covered in a different chapter of the present thesis.  
The first objective was to investigate both PDT and PCI in our prostate cancer model in 
vitro. This involved rat cells (MatLyLu) as basis for later in vivo studies, and a human 
cell line (PC3) to compare and assess translation to human disease. Moreover, we 
aimed to evaluate the effect of different photosensitisers, differing in their nature, hence 
physico-chemical properties: AlPcS2a, TPPS2a, TPCS2a, BPD-MA. These studies aimed 
to investigate the cytotoxicity exerted by each treatment as well as the underlying 
mechanism behind both therapies. In addition, founded on the false positive rate 
frequently noted when drug testing in 2-dimensional studies, we aimed to additionally 
conduct equivalent studies in 3-dimensions to validate 2D observations and potentially 
reduce the number of animal experiments required in future PDT/PCI work. 
The second objective was to evaluate the benefits of targeted PDT and PCI strategies 
could provide regarding site-specificity and further reduction of side phototoxicity, with 
important implications in a clinical setting (i.e. decreased skin sensitivity). To conduct 
this study, conjugates composed of the photosensitiser TPP covalently bound to 
different cell penetrating peptides (TAT, Antp) were tested in vitro against human 
prostate cancer cells. Additionally, CXCR4 - highly expressed receptor in prostate 
cancer, was the subject of a more specific targeting of these compounds via the vMIP-
II moiety.  
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The third objective was to transfer in vitro findings to experiments conducted in 
Copenhagen rats. So as to determine the most suitable DLI in these subjects as well 
as bioavailability of the PS drug, a pharmacokinetic analysis was conducted before 
initiating light-based treatment on tumours. For the performance of light-treatments, 
different PS exhibiting a varied suitability for PDT and PCI were used. For instance, 
hydrophobic BPD-MA was used following a vascular targeted PDT approach, while 
amphiphilic TPCS2a and AlPcS2a were either used for PDT or combined with saporin in 
PCI. The overall aim of these studies was to evaluate therapeutic outcome, which we 
carried out through tumour growth monitoring, tumour cell death and survival of animal 
subjects.  
The final objective of this thesis was to determine whether PDT and PCI were eliciting 
an immune response in our advanced prostate cancer model. In line with this, we 
rechallenged previously cured rats with a second injection of tumour cells, observing 
whether these individuals were capable of rejecting the rechallenge. In addition, to 
further measure the effect of these treatments at a molecular level, we have analysed 
the expression of different genes involved related to the immune system and have also 
pursued IHC stains to perform a similar evaluation at the protein level.  
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Chapter 2 In vitro studies of PDT and PCI in 
Prostate Cancer  
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2.1 Introduction  
Both photodynamic therapy and photochemical internalisation have been successfully 
applied in multiple in vitro cancer studies as already discussed in Background and 
Introduction. Most published PCI studies in cancer treatment focus on the delivery of 
macromolecular agents although some other smaller drugs have also been assayed 
(Martinez de Pinillos Bayona et al., 2016). These could be grouped into the following 
categories: glycopeptide antibiotics and anthracyclines, macromolecular drug delivery 
vehicles and macromolecular toxins (Martinez de Pinillos Bayona et al., 2016).  
Bleomycin is a hydrophilic glycopeptide (1.4 kDa) that has been widely reported in 
published PCI studies and is currently subject of PCI clinical trials as commented 
previously. This drug’s potential to induce pneumonitis has been demonstrated, 
eventually resulting in lung fibrosis (Berg et al., 2005). Consequently, there is a need to 
reduce drug dosage as well as the number of repeated administrations without 
compromising the efficacy, all of which could be potentially overcome by PCI. For 
instance, an efficient delivery of bleomycin resulted in complete tumour eradication in 
60% of the animals used in the study carried out by Berg et al. in 2005 in combination 
with AlPcS2a for the treatment of colorectal adenocarcinoma (Berg et al., 2005). In a 
more recent publication by the same group, Amphinex-based bleomycin delivery 
(combination currently used in clinical trials), was able to delay tumour growth further 
than that seen in the PDT group using m-THPC (Foscan®), even at the lowest light 
fluence tested (Berg et al., 2011). Bleomycin has also shown potential in several 
human and non human cancer models in vitro; in bladder cancer for instance, at least 
an additive effect between the PS and the drug was seen (Arentsen et al., 2014). It was 
also compared to other chemotherapeutic agents not as cytotoxic, suggesting 
bleomycin’s physico-chemical features are ideal for PCI. 
Despite the fact that large molecules are more commonly used in PCI, anthracycline 
drugs of smaller size such as doxorubicin (0.5 kDa) and mitoxantrone (0.4 kDa) have 
also been used in several PCI studies (Adigbli et al., 2007; Lai et al., 2007; Lou et al., 
2006). The former acts intercalating DNA and is associated to deadly cardiac damage; 
the latter was developed as a doxorubicin analogue in an attempt to reduce side 
cardiotoxicity. Some studies with both of these drugs have been reported in the 
Background and Introduction. 
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As noted in above, PCI is a multifactorial process whose optimisation is not straight 
forward and involves the consideration of several entangled variables. There are no 
available publications addressing this matter as such, given the additional role the 
diverse biological systems play in the process as well. Therefore, different variables will 
be evaluated in our prostate cancer model in vitro in the following sections. 
2.1.1 Photochemical Internalisation of Ribosome Inactivating 
Proteins  
Ribosome inactivating proteins (RIPs), are enzymatic toxins widely distributed among 
plants with N-glycosidase activity (EC 3.2.2.22). RIPs cleave a specific adenine residue 
located in tetranycleotide G(A4324)GA within a sequence in the rRNA in the 28S 
ribosomal subunit part of the 60S subunit of the rat ribosome. This will irreversibly 
affect the interaction between ribosomes and the elongation factor 2 during translation 
of mRNA in protein synthesis resulting in cell death (Polito et al., 2013). This rRNA 
sequence is considered to be universally conserved throughout eukaryotic species 
(Puri et al., 2012; Schrot et al., 2015; Walsh et al., 2013).  Additionally, some RIPs can 
act on other substrates such as mRNA, tRNA, DNA and poly(A), or even poly(ADP-
ribosyl)ated proteins (Polito et al., 2013). A guanine cleavage has also been sometimes 
reported and thus, these proteins are sometimes considered polynucleotide adenosine 
glycosidases i.e. PAP from Phytolacca americana, which can also cleave guanine on 
Escherichia coli rRNA (Schrot et al., 2015).  
Two main types of RIPs have been described: 
 Type 1: composed of a single chain A responsible for the enzymatic activity of 
these protein toxins.  
 Type 2: consisting of 2 polypeptide chains A and B linked by a disulphide 
bridge. The latter is a lectin peptide capable of binding to galactosyl residue 
found on the surface of animal cells, therefore enabling the entry of chain A 
inside the cytosol and hence acting on their target organelles.  
 Type 3: only described in maize (b-32) and barley (JIP60), these consist of a N-
terminal domain with catalytic activity and a C-terminal with unknown function. 
They are synthesised as ProRIPs that undergo processing to form an active 
toxin (Schrot et al., 2015).  
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Figure 10. Structural differences between Ribosome Inactivating Proteins (RIPs).  
RIP type 1 are composed of a single A chain responsible for the enzymatic activity. RIP type 2 are 
composed of two peptides: chain A and chain B. This last peptide is a lectin-type protein assisting the 
entry of proteins into cells.   
Structural differences between RIPs type 1 and 2 explain the differences in toxicity 
exerted by both. On the one hand, RIPs type 2 are very potent toxins (the best known 
is ricin). On the other hand, the lack of lectin-type B chain renders RIPs type 1 less 
toxic within a cellular environment, despite the great efficiency these have 
demonstrated in cell-free systems or when modified via conjugation to cell-binding 
molecules. Ricin has been reported to enter mammalian cells through endocytosis and 
reach the endoplasmic reticulum (ER) via retrograde transport through the Golgi 
complex. It will then reach its subcellular target exploiting ER-associated degradation 
route (Vago et al., 2005). 
Due to cell uptake-associated difficulties, PCI has been used on several occasions as a 
delivery vehicle for RIPs. For instance, RIPs type 1 such as gelonin and saporin, have 
been combined with photosensitisers in different cell lines and cancer models (Berg et 
al., 1999; Dietze et al., 2005, 2003; Prasmickaite et al., 2002; Selbo et al., 2000a). In its 
early stages, PCI studies were carried out in cervical carcinoma cells combining 
gelonin and TPPS2a or AlPcS2a, observing a greater 200-fold increase in cell death 
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after PCI as opposed to either treatment on its own as well as synergy between PS and 
the toxin (Berg et al., 1999). It is important to take into account the integrity of the 
therapeutic agent, which could be compromised by the PCI protocol followed as 
already mentioned. It was seen in the study conducted by Selbo et al. that gelonin 
could be affected by the acidic lysosomal environment if PCI was delayed and upon 
illumination the drug was released from these organelles rather than earlier 
endosomes, consequently eliciting a reduction in cell death  (Selbo et al., 2000a). This 
was further confirmed by the significant enhancement in cytotoxicity when delivering 
light before administering gelonin. It seems that vesicle disruption prior to gelonin 
administration avoids damage to the toxin in the endocytic environment, hence result in 
a faster delivery time (Prasmickaite et al., 2002).  
In a different study, Dietze et al. (Dietze et al., 2003)  selected different cells derived 
from human synovial sarcoma tumours as a model for their study. Again, 
photochemically delivered gelonin was more efficient than PDT regardless of the 
differences of uptake rates or traffic pathways between cell lines, being able to reduce 
light dose four times the amount required to reduce cell viability by 80% (Dietze et al., 
2003). In a later study (Dietze et al., 2005), the same group completely eradicated 
sarcoma induced in mice in 50% of PCI treated animals, and showed tumour regrowth 
after 20 days in the remaining 50% significantly delaying the end point of the study 
compared to PDT or non-treated groups (Dietze et al., 2005).  
Saporin is a monomeric protein belonging to RIPs type 1 family of proteins which has 
been as well subjected to PCI and is focus of the present thesis in different prostate 
cancer models. It is a multigene family of proteins comprising more than 9 isoforms 
which differ in biological and chemico-physical properties. Yet, all of them have a 
similar molecular weight around 30 kDa, being saporin-S6 the most representative 
(Polito et al., 2013). Its mechanism of entry into cells has not been clearly elucidated to 
date. In a similar way to other RIPs type 1, passive entry of saporin through 
mechanisms such as pinocytosis was initially proposed, its uptake was suggested to 
happen in a non-specific manner. However, the existence of specific receptors 
emerged due to resistance to saporin found in some cell lines together with the higher 
sensitivity found in some organs. There is discrepancy between studies claiming 
uptake of saporin occurs through receptor-mediated endocytosis through the α2-
macroglobulin receptor (low-density lipoprotein receptor-related protein, LRP) or either 
mechanisms independent of specific binding sites i.e. non-coated vesicles (Polito et al., 
2013). Upon cell endocytosis of biologically active saporin, it needs to reach cytosolic 
ribosomes. Several pathways have been described in different cell lines, concluding 
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that saporin could reach various intracellular compartments, even possibly by more 
than one pathway (Polito et al., 2013). Cytotoxicity induced by saporin has been 
evaluated both in vitro and in vivo. In the latter, necrotic damage in spleen, liver and 
kidney has been found. As for in vitro studies, saporin-based cytotoxicity has been 
related in the first place to protein synthesis inhibition; besides, nucleic acid 
depurination has also been reported. There is evidence of apoptotic death based on 
fragmentation of chromatin, formation of apoptotic bodies, cellular hypodiploicity and 
caspase activation in cells exposed to saporin. Other cell death pathways have been 
described, i.e. autophagy or necrosis. In fact, triggering of autophagy could result in cell 
death due to atrophy or else activate necrosis or apoptosis. Saporin has sometimes 
been found in the nucleus, indicating possible DNA damage in addition to its RIP 
function. Overall, apoptosis appears to be the major cell death route but cell fate may 
vary in different cell lines (Polito et al., 2013). 
2.1.2 Three Dimensional (3D) tumour models 
Efficiency and reliability of studies performed in two dimensions is being increasingly 
questioned, since culturing cells in a monolayer environment is far from resembling the 
natural 3D environment of cell growth. Publications throughout the literature have 
already proven three dimensional culture to improve the outcome of several studies, 
more accurately mimicking the natural setting (Antoni et al., 2015). Cells growing in 
monolayers will lack contact with other cells in most of their dimensions, being only 
connected to other “neighbour” cells in the edges, as opposed to conforming multi-
dimensional structures similar to the biological environment. This will eliminate naturally 
existing communication and intercellular contact, affecting different aspects of cell 
behaviour: metabolism, physiology or even phenotypical features. Overall, this may 
affect the outcome of research based on 2D cell culture, leading to misinterpretation, 
misleading results or unreal conclusions, as has been reviewed previously (Nyga et al., 
2011). 
Within organisms, cells undergo a series of interactions, communication, transport and 
signals between them as well as with elements present in the extracellular matrix 
surrounding them. Therefore, it is essential that cell culture environments preserve this 
spatial distribution and cell polarisation so as to enhance cellular performance (viability, 
proliferation, response to the surrounding environment, metabolism, morphology, 
phenotype maintenance, communication with neighbour cells, protein and gene 
expression, etc.). There is evidence of 3D culturing of cells resulting in an improvement 
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on several cell functions, including the above (Bono et al., 2016; Li et al., 2010; 
Toivonen et al., 2016). Furthermore, they will have greater lifespan due to the longer 
periods of time required to reach confluence, which enables conducting longer studies 
important in longer-term drug effect. In line with this, is has been reported that 2D 
studies may overestimate toxicity exerted by drugs in vitro which then result ineffective 
in vivo (Antoni et al., 2015). 
Moreover, there is a growing interest nowadays to develop new platforms towards the 
Replacement, Reduction, and Refinement (3Rs). The use of biomimetic 3D culturing 
may permit more reliable drug screening thereby reducing the need for animal 
experimentation, at the same time maintaining the cellular model needed to study the 
mechanism of PDT and PCI.   
In a cancer setting, growth rate and metabolic profile are altered in monolayer cultures, 
also showing greater sensitivity to therapeutic approaches than in the 3D counterpart. 
The latter would more accurately recreate lower growth rates, nutrient and supply, 
waste removal, etc., which in the end result in a genotype and protein expression which 
more closely resemble to naturally occurring.  
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2.2 Aims 
The main aims of the present chapter are as follows: 
 Compare the outcome resulting from PDT and PCI in vitro  
 Establish optimal parameters for maximal tumour kill during PCI in prostate 
cancer in vitro  
 Elucidate the mechanistic processes underlying PCI in prostate cancer 
A significant part of the present thesis involved the observation of the therapeutic effect 
using cell viability assays. Accordingly, the first few sections reported below will look 
into the optimisation of PCI treatment, while also comparing the outcome to that of 
PDT. Different experimental settings were examined, assessing the influence of 
different variables participating in photochemical internalisation such as light dose, drug 
light interval, photosensitiser and drug dosage.  
Both rat and human prostate cancer cells have been exposed to PDT and PCI in vitro. 
A number of different photosensitisers (TPPS2a, TPCS2a, BPD-MA, AlPcS2a) were 
investigated for either PDT or else combined with saporin when undergoing PCI. Both 
light-based treatments were performed in conventional two dimensional and more 
novel and biologically relevant three dimensional models as a more definitive 
confirmation of the therapeutic effect these treatments would have in biological 
systems. Investigations performed in both platforms will be detailed below. 
Experiments performed in the rat prostate cancer model (MatLyLu cells) will serve as 
basis for later on described in vivo experiments; while the human counterpart (PC3 
cells) will shed light into the applicability of light treatments, PCI in particular, for its 
clinical application.  
The last sections of the present chapter will investigate the underlying mechanism 
behind PDT and PCI. Photosensitiser and saporin subcellular localisation were 
examined before and after exposure of light, tailored to each particular photosensitiser.  
In vitro studies of PDT and PCI in prostate cancer 
 
 
65 
2.3 Materials & Methods 
Cell work 
Both PDT and PCI-based experiments were performed on two prostate cancer cell 
lines, PC3 and MatLyLu (MLL) of human and rat origin respectively.  
PC3 cells, kindly donated by Professor John Masters (Prostate Cancer Research 
Centre, UCL), are a widely used prostate cancer model for studies in vitro. They were 
originally derived from bone metastases of a prostatic grade IV adenocarcinoma in a 
62-year old male Caucasian. They do not express androgen receptor (AR) nor 
prostate-specific antigen (PSA), and thus are featured as androgen independent cells 
as well as an aggressive form of prostate cancer. With frequency, they are employed to 
depict castration-resistant tumours.  
MLL cells, purchased from ECACC (catalogue no. 94101454), were derived from a rat 
adult malignant prostate carcinoma, initially obtained from a 22-month old Copenhagen 
rat. Development of this cell line was carried out growing it in gradually increasing 
doxorubicin doses, justifying the multidrug resistance phenotype reported in the 
literature. They are anaplastic and androgen independant, also highly aggressive and 
with potentially causing metastases in the lung (Kager et al., 1992; Wenger et al., 
1984). 
Both cell lines were growth in RPMI 1640 medium containing L-glutamine (Gibco, 
Invitrogen), further supplemented with 1% penicillin-streptomycin (5,000 U/ml, 
Invitrogen) and 10% fetal bovine serum (Life Technologies). In the case of MLL, media 
was additionally supplemented with 250 nM Dexamethasone (suitable for cell culture, 
Sigma-Aldrich). Cells were kept in culture at 37°C in a 5% CO2 humidified atmosphere. 
Media was changed two times a week and cells were subcultured when reaching 
confluence (usually twice a week) using 1X trypsin (0.5% trypsin-EDTA, Gibco®, 
Invitrogen). PC3 cells were used at passage 25-45, MatLyLu cells were used at 
passage 6-15. 
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Chemicals and photosensitisers  
Saporin was purchased from Sigma Aldrich (S9896). Lyophilized powder was dissolved 
in PBS and stored at 4°C, experimental concentrations were obtained diluting a 1 µM 
solution in cell media to obtain desirable concentrations. 
Saporin-Alexa-Fluor488® conjugate was obtained following a modified protocol from a 
Molecular probes labelling kit. A saporin solution (Sigma Aldrich, S9896) was eluted 
with a pH 9.24 carbonate buffer (9 ml 0.1 M NaHCO3 + 1 ml 0.1 M Na2CO3) to a 2.5 
mg/ml final concentration. Parallel, an Alexa-Fluor488® (ThermoFisher Scientific) 
solution was prepared in DMSO to a final 4.29 mg/ml concentration. 2 ml of the saporin 
solution were combined with 222 µL of the dye solution and kept for 1 hr on overhead 
rotation. This solution was finally eluted in a PD10 column (GE Healthcare) which had 
been previously equilibrated with PBS, and 2.5 ml were recovered. The concentration 
of this solution was determined by UV-visible absorbance measurements. 
TPPS2a, meso-tetraphenyl porphyrin disulphonate, was purchased from Frontier 
Scientific. The stock solution was prepared by dissolving the powder in DMSO, then 
diluted in PBS and the the resulting aliquots were stored at -20°C. Working TPPS2a 
solutions were kept at 4°C and experimental concentrations were obtained diluting a 10 
µg/ml solution in cell media to reach desirable concentrations. 
TPCS2a, meso-tetraphenyl chlorin disulphonate (Amphinex®) was kindly donated by 
PCI Biotech AS, Oslo, Norway. The 30 mg/ml stock was initially diluted in PBS, storing 
the resulting aliquots at -20°C. Working Amphinex® solutions were kept at 4°C and 
experimental concentrations were obtained diluting a 10 µg/ml solution in cell media to 
reach desirable concentrations. 
BPD-MA, benzoporphyrin derivative monoacid ring A (Visudyne, verteporfin for 
injection) was purchased from Novartis. 15 mg of lyophilised were dissolved in 1 ml 5% 
dextrose and keep stored at -80C. Working BPD solutions were kept at 4C and 
experimental concentrations were obtained diluting a 10 µg/ml solution in cell media to 
obtain desirable concentrations. 
AlPcS2a, aluminium phthalocyanine disulfonate, was purchased from Frontier Scientific. 
The stock solution was prepared by dissolving powder in sodium hydroxide, and 
neutralising with 0.1 M hydrochloric acid to a 1-2 mg/ml final concentration. Working 
AlPcS2a solutions were kept at 4°C and experimental concentrations were obtained 
diluting a 10 µg/ml solution in cell media to reach desirable concentrations. 
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Light source  
Different devices were used to tailor light treatment to each photosensitiser: 
 LumiSource® (PCI Biotech, Norway) was used to excite cells exposed 
to TPPS2a and TPCS2a in vitro. It consists of four fluorescence tubes 
emitting light uniformly in the spectral region 375-450 nm at a constant 
power of 7 mW/cm2. 
 
 LumaCare lamp LC-122 (LumaCare, USA) was used to excite cells 
exposed to AlPcS2a in vitro. A fibreoptic probe was attached to the lamp 
emitting in the spectra region 660-710 nm, power around 7.96 mW/cm2  
 
 Omnilux Clear-U LED device was used to excite cells exposed to 
BPD-MA in vitro, emitting in the spectra region 400-440 nm at, power 
around 12.7 mW/cm2. 
 
 
 
 
 
PS spectral measurements 
Different photosensitiser solutions were prepared in methanol to a final concentration 
ranging 1-15 µM. Absorption spectra were measured using a spectrophotometer 
(Lambda 5, Perkin-Elmer, Beaconsfield, UK) with 1 cm pathlength quartz cuvettes. 
Fluorescence emission spectra were measured using a LS50B Perkin-Elmer 
spectrofluorimeter (Perkin-Elmer, Beaconsfield, UK). Setting absorption at 420 nm for 
TPPS2a, TPCS2a, BPD-MA; or 600 nm for AlPcS2a. 
 
LumiSource®                             LumaCare            Omnilux Clear-U 
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TPPS2a / TPCS2a (Amphinex) uptake  
PC3 and MLL cells were seeded on 96-well plates at 10000 cells/well or 1000 cells/well 
respectively. Cells were allowed to grow for 24 hr before administering increasing 
doses of either photosensitiser solutions prepared in cell media during 24 hr. Plates 
were then washed once with PBS and replaced with fresh RPMI no-phenol red. 
Fluorescence emission was immediately measured using a LS50B Perkin-Elmer 
spectrofluorimeter (Perkin-Elmer, Beaconsfield, UK), with excitation and emission at 
420 nm and 650 nm respectively (10 nm bandwidths) and a 515 nm longpass filter to 
remove any scattered excitation light.  
AlPcS2a / BPD-MA (Visudyne ®) uptake 
MLL cells were seeded on 24-well plates at 3000 cells/well. Cells were allowed to grow 
for 24 hr before administering 0.4 g/ml of either BPD-MA or AlPcS2a prepared in cell 
media during 8 hr and 24 hr. Plates were then washed once with PBS and replaced 
with fresh RPMI no-phenol red. A BD FACSAria 1 (Becton Dickinson, USA) flow 
cytometer was used to quantify fluorescence emission. BPD-MA was excited using a 
407 nm laser and emission was measured 530/30 nm; AlPcS2a was excited using a 
633 nm laser and emission was set at 660/20 nm.  
Drug-dose response curves 
PC3 and MLL cells were seeded on 96-well plates at densities ranging from 5000-
10000-cells/well or 600-1000 cells/well respectively depending on when cell viability 
measurements were conducted (24 to 48/96 hr after hypothetical performance of light 
treatment). These values were selected based on optimal cell count in control groups 
within MTT detection limits. Cells were allowed to grow for 24 hr before exposing them 
to increasing doses of either photosensitiser or saporin solutions prepared in cell media 
during 24 hr. Plates were then washed once with PBS and fresh media was added. 
After a 4 hr-cell recovery period (chase period), plates involving treatment with 
photosensitisers belonging to “light” groups, were illuminated. This chase period also 
enables translocation of PS from the external cellular membrane to a subcellular level. 
Cell viability was measured at different time points. In those wells where viability was 
measured later than 48 hr after light treatment, culture medium was replaced once 
more to avoid starvation-based cell death. Plates were kept in a 37°C humidified 
atmosphere containing 5% CO2 at all times, those involving photosensitisers were 
wrapped in foil and corresponding experimental procedures were carried out protected 
from light to avoid unintended excitation of photosensitisers.  
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PDT & PCI (combination) experiments 
PC3 and MLL cells were seeded onto 96-well plates at densities ranging from 5000-
10000 cells/well or 600-1000 cells/well respectively depending on when cell viability 
measurements were conducted (24 to 48/96 hr after light treatment). Cells were 
allowed to grow for 24 hr before undergoing either “light-after” or “light-before” PCI 
procedures: 
a)  “Light-after” PCI. Cells were exposed to sublethal doses of photosensitisers 
alone or in combination with saporin prepared in cell media during 24 hr. Plates 
were then washed once with PBS and fresh media was added. After a 4 hr-cell 
recovery period (chase period), plates belonging to “light” groups were 
illuminated. 
 
b) “Light-before” PCI. Cells were exposed to sublethal doses of photosensitisers 
alone during 24 hr. Plates were then washed once with PBS and fresh media 
was added. After a 4 hr-cell recovery period (chase period), plates belonging to 
“light” groups were illuminated and saporin was administered immediately after 
light. 24 hr after administration of saporin, drug was washed off once with PBS, 
and fresh media was added. 
 
Hereafter cell viability was measured at different time points. In those wells were 
viability was measured later than 48 hr after hypothetical performance of light 
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treatment, culture media was replaced on an additional occasion to avoid starvation-
based cell death. Plates were kept in a 37°C humidified atmosphere containing 5% 
CO2 at all times, wrapped in aluminium foil and experimental procedures were carried 
out protected from light to avoid unintended excitation of photosensitisers.  
Analysis of cell viability in two dimensional models 
MTT was used to observe cytotoxicity in 2D experiments. MTT assay [3-(4, 5-
dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide)] directly assesses cellular 
metabolic activity and is very frequently used as an indirect measurement of cell 
number or viability. MTT is a yellow tetrazolium salt that can be reduced by 
dehydrogenase enzymatic activity present in metabolically active cells, generating 
NADH and NADPH. This results in the formation of purple formazan intracellular 
crystals which can be solubilised with organics solvents such as dimethyl sulfoxide 
(DMSO); subsequent solution that can be spectrophotometrically quantified. 
Background absorbance levels of this reagent are negligible in the absence of cells. 
When performing the MTT assay, cell media was removed from the wells and replaced 
with 100 µl of a 1 mg/ml MTT (Sigma-Aldrich) solution prepared in cell media. Plates 
were then placed at 37°C in a 5% CO2 humidified atmosphere during 1 hr 30 min. After 
this incubation period, the content was removed from the wells and replaced with 100 
µl DMSO (Sigma-Aldrich) to dissolve the purple crystals. An ELX800 absorbance plate 
reader (BioTek Instruments, Inc., Bedfordshire, UK) was then used to measure the 
absorbance of each well at 570 nm. 
Subcellular localisation of TPPS2a and TPCS2a 
PC3 and MLL cells were seeded onto glass bottom dishes FluoroDish (World 
Precision Instruments, Inc.) at 9000 cell/dish and 2000 cell/dish respectively. Cells 
were allowed to grow for 24 hr before administering photosensitiser solutions in cell 
media (0.4 g/ml). 24 hr post administration, dishes were washed once with PBS and 
fresh no phenol red RPMI 1640 Media, (Gibco®, Invitrogen) was added. After a 4 hr-
cell recovery period, dishes were excited “on-stage”. Intracellular localisation before 
and after excitation, and light-based redistribution of photosensitisers were assessed 
using an Olympus IMT-2 epi-fluorescence microscope with a low power (2 mW) 405 
nm blue diode laser coupled to a liquid light guide. A PIXIS 512 charge-coupled device 
(CCD) camera (Princeton Instruments) was attached to the microscope, using 20X 
magnification objective and 250 x 250-micron scale. A 660 nm bandpass detection filter 
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was used. Pre-excitation fluorescence images were recorded with 1 s exposure, 
insufficient time to activate TPPS2a or TPCS2a. Later images were taken at different 
times through additional illumination. Image analysis was performed Image J software. 
Plates were kept in a 37°C humidified atmosphere containing 5% CO2 at all times, 
wrapped in aluminium foil and experimental procedures were carried out protected 
from light to avoid unintended excitation of photosensitisers.  
Subcellular localisation of BPD-MA and AlPcS2a and cell death assessment after light 
MLL cells were seeded onto glass bottom dishes at 4000 cell/dish. Cells were allowed 
to grow for 24 hr before administering photosensitiser solutions in cell media (2 g/ml). 
24 hr post administration, dishes were washed once with PBS and fresh media was 
added. After a 4 hr-cell recovery period, dishes underwent light treatment at 1 J fluence 
rate. Subcellular localisation of photosensitisers was observed using an inverted 
Olympus Fluoview 1000 confocal laser-scanning microscope (40X magnification 
objective) 2 hr, 24 hr and 48 hr after light treatment. Images were obtained setting 
BPD-MA excitation at 405 nm and emission 655-755 nm; AlPcS2a was excited using a 
635 nm laser and emission was set at 668 nm. Additionally, cell death was evaluated 
using propidium iodide (PI, Sigma-Aldrich) 1 mg/ml in PBS. PI is a fluorescent stain for 
nucleic acids, excluded from viable cells due to cell membrane integrity (excitation 559 
nm, emission 612 nm). Prior to imaging cell dishes, cell media was replaced with a 
1:100 PI solution and incubated during 15 minutes before washing 3 times in PBS, then 
replacing it with fresh phenol-free RPMI 1640 media. Image analysis was performed 
with Fluoview FV1000 (Olympus). 
Plates were kept in a 37°C humidified atmosphere containing 5% CO2 at all times, 
wrapped in aluminium foil and experimental procedures were carried out protected 
from light to avoid unintended excitation of photosensitisers.  
Subcellular localisation of saporin-Alexa-Fluor488® conjugate 
PC3 and MLL cells were seeded onto glass bottom dishes FluoroDish (World 
Precision Instruments, Inc.) at 9000 cell/dish and 2000 cell/dish respectively. Cells 
were allowed to grow for 24 hr before co-administering TPPS2a or TPCS2a (0.4 g/ml) 
with saporin-Alexa-Fluor488® (400 nM) in solutions prepared in cell media. 24 hr post 
administration, dishes were washed once with PBS and fresh no phenol red RPMI 
1640 Media, (Gibco®, Invitrogen) was added. Additionally, cells were incubated with 75 
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nM LysoTracker® Red DND-99 (ThermoFisher Scientific) prepared in no phenol red 
media during 30 minutes and then washed once in PBS immediately before imaging. 
After a 4 hr-cell recovery period, images of subcellular localisation of the conjugate 
saporin-Alexa-Fluor488® and LysoTracker® Red DND-99 were taken using an 
inverted Olympus Fluoview 1000 confocal laser-scanning microscope, using 488 nm 
and 559 nm lasers respectively. Fluorescence images were recorded prior to irradiating 
with a 405 nm laser, known to activate TPPS2a or TPCS2a, during 10 seconds; later 
images were taken at different times through “on-stage” excitation of photosensitisers. 
Image analysis was performed with Fluoview FV1000 (Olympus). Cells were kept in a 
37°C humidified atmosphere containing 5% CO2 at all times, wrapped in aluminium foil 
and experimental procedures were carried out protected from light to avoid unintended 
excitation of photosensitisers. 
Fabrication of 3D collagen hydrogels 
Type I rat tail collagen (2 mg/ml in 0.6% acetic acid; First Link, UK) was the basic 
component of the 3D hydrogels. 80% v/v collagen was mixed with 10% v/v Minimum 
Essential Medium (MEM) 10X (Sigma-Aldrich). Soluble collagen polymerises when pH 
reaches values above 7; therefore, commercially available collagen is sold as acid 
solutions and has to be neutralised prior to seeding cells. To neutralise the collagen 
prepared mixture, 1:10 and 1:100 dilutions of a 46-51% v/v sodium hydroxide solution 
(Fisher Chemical) were used. In parallel, a PC3 10% v/v cell suspension containing 
4000 cells/100 l gel solution was prepared. Finally, the neutralised mixture was added 
to the cell suspension. 100 l of the final solution was added to single wells in a 96-well 
plate. Plates were kept in a 37°C humidified atmosphere containing 5% CO2 for 5 
minutes until solidification of collagen gels before adding cell media into the wells and 
re placing the plates in a 37°C humidified atmosphere containing 5% CO2. 
Analysis of cell viability in three dimensional models 
Dead/Live staining was performed through the LIVE/DEAD® Cell Imaging Kit (488/570, 
Thermofisher Scientific) on 3D hydrogels. The kit is based on two fluorescent dyes: on 
the one hand, calcein AM, which can be converted by intracellular esterases present in 
viable cells into an intensely green fluorescent calcein. On the other hand, the 
impairment of dead cells’ membrane enables the entry of the red fluorescent 
component propidium iodide-based.  
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To perform this dead/live assay, cell media was removed from the wells and gels were 
incubated with the dead/live dyes for 15 minutes, then washed three times in PBS and 
imaged using an Olympus Fluoview 1000 confocal laser-scanning microscope. The 
nature of collagen gels resulted in entrapment of the red fluorescent dye in spite of the 
washing steps, causing high background in the images. In addition, there was 
overlapping in the excitation and emission of fluorescence of PI and PS (TPPS2a and 
TPCS2a employed), hampering the distinction of both compounds. Therefore, only the 
calcein green channel was imaged (excitation 495 nm, emission 515 nm), which was 
combined with transmitted light to evaluate cell viability. Image analysis was performed 
with Fluoview FV1000 (Olympus).  
Statistical analysis 
Statistical analysis was performed using GraphPad prism 6. Two-way ANOVA followed 
by Bonferroni post hoc multiple comparison was used.  Data is displayed as mean with 
error bars +/- SEM; significance level of p < 0.05 (*p = 0.05 to 0.01; **p = 0.01 to 0.001; 
***p = 0.001 to 0.0001)  
All experiments were carried out in triplicate. Specifically, in MTT cell viability assays, 
each data point was the result of experiments carried out in triplicate and each of these 
repeats was the average of 8-16 wells. 
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2.4 Results 
2.4.1 Photosensitiser spectra 
In order to tailor light treatments to specifically excite each photosensitiser, solutions of 
all the compounds used throughout the project were prepared in methanol and both 
absorption and emission spectra were measured.  
 
Figure 11.  Absorption and emission spectra of TPPS2a, TPCS2a, BPD-MA, AlPcS2a in methanol (1-15 
M).  
Emission spectra were taken exciting TPPS2a, TPCS2a and BPD-MA at 420 nm and AlPcS2a at 600 nm; 
cut-off filters set at 515 nm. Graphs in the right corner of each PS correspond to the emission peaks in the 
red. 
Both the porphyrin- (TPPS2a and BPD-MA) and chlorin- (TPCS2a) based 
photosensitisers showed an absorption peak at around 420 nm, corresponding to the 
peak of the Soret absorption band. Absorption in the red region of the spectra were 
also found in all of the above, being particularly noticeable in TPCS2a (Amphinex®) and 
BPD-MA at 650 nm and 690 nm respectively. Conversely, the phtalocyanine-based 
photosensitiser (AlPcS2a) showed an absorption peak at around 670 nm as well as an 
additional prominent peak in the ultraviolet region of the spectrum, approximately at 
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350 nm. All four TPPS2a, TPCS2a, BPD-MA and AlPcS2a exhibited fluorescence 
emission peaks in the red spectra.  TPPS2a, TPCS2a, BPD-MA showed emission peaks 
at 654 nm, 655 nm and 672 nm when exciting at 420 nm; while AlPcS2a’s emission 
peak was found at 692 nm exciting at a higher wavelength, 600 nm (Figure 11).  
2.4.2 TPPS2a and TPCS2a uptake in prostate cancer cells 
The uptake of TPPS2a and TPCS2a was measured in both rat and human prostate 
cancer cell lines (MatLyLu and PC3 respectively), related to the overall emission of 
fluorescence by PS. Specifically, solutions of both photosensitisers were prepared at 
different concentrations ranging 0.2 – 0.8 g/ml and following a 24 hr incubation, 
uptake was measured. Figure 2 shows a comparison of the uptake of both 
photosensitisers at the different concentrations in PC3 and MatLyLu. 
 
Figure 12. Uptake of TPPS2a and TPCS2a in rat and human prostate cancer cells (MatLyLu and PC3 
respectively).  
Cells were incubated for 24 hr with 0.2, 0.4 and 0.8 g/ml photosensitiser solutions, then washed and 
media was replaced with no phenol red media. Uptake was related to photosensitiser fluorescence 
intensity. Data is displayed as mean with error bars +/- SEM; two-way ANOVA followed by Bonferroni post 
hoc multiple comparison was used, significance level of p < 0.05. 
In both cell lines a concentration dependency was seen, being retention higher in PC3 
cells in all cases. A significant increase (p < 0.001) in the uptake of both TPPS2a and 
TPCS2a in PC3 cells was found between 0.2 g/ml and 0.8 g/ml, which was also seen 
in MatLyLu cells when measuring uptake of Amphinex. This photosensitiser also 
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exhibited the greatest differences between both cell lines. Fluorescence of Amphinex 
was nearly 2-fold higher than TPPS2a in both cell lines at 0.8 g/ml (Figure 12). 
2.4.3 Saporin dose-response curves 
As discussed previously, PCI aims to enhance the delivery of drugs, which will 
translate in an improvement of drug-based cytotoxicity. Therefore, in order to determine 
the optimal doses required for PCI combination experiments, it is essential to first 
determine the most adequate dosage of each drug independently (both photosensitiser 
and drug to be delivered). To accomplish this, a range of saporin, TPPS2a and TPCS2a 
doses were assayed in both PC3 and MLL cells to establish subthreshold values of all 
independently (see section below for photosensitiser dose response study).  
 
Figure 13. Saporin cytotoxicity in PC3 and MatLyLu cells.  
Both cell lines were incubated with saporin solutions ranging 0-60 nM during 24 hr, drugs were then 
washed off and cell viability was measured 24 hr and 96 hr after light treatment in later PCI combination 
experiments. Data is displayed as mean with error bars +/- SEM; two-way ANOVA followed by Bonferroni 
post hoc multiple comparison was used, significance level of p < 0.05. 
Saporin did not result in significant cytotoxicity in the 0-60 nM range assayed in PC3 
cells compared to the control group. Unlike the human prostate cancer model, the rat 
counterpart exhibited higher sensitivity to the RIP type 1. Even the lowest dose tested 
(2 nM) measured only 24 hr after drug removal, resulted in 25% cell death. There was 
a direct dependency between drug dose and cytotoxicity observing a plateau when cell 
viability was reduced to 40% of control cells (Figure 13). 
These saporin drug-response curves served as basis to establish drug doses required 
in PCI combination experiments. Founded on the higher sensitivity seen in MatLyLu 
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cells when measuring cell viability just 24 hr after the “hypothetical” performance of 
light treatment, even the lowest dose assayed (2 nM) would result in higher cell death 
than the required threshold. Conversely, the human counterpart seemed to be more 
robust and not affected as much by the RIP type 1 toxin, regardless of the dose used. 
Therefore, 20 pM and 2 nM were the chosen doses to combine with photosensitisers in 
PCI in MatLyLu (further reduced from the lowest 2 nM dose examined in Figure 13 to 
achieve subthreshold toxicity) and PC3 cells respectively.   
2.4.4 PDT effect in dose-response curves 
Photosensitiser dosage was also evaluated in rat and human cells incubating these 
with different solutions of TPPS2a and TPCS2a, and then exposing the system to light to 
establish an adequate “low-dose” PDT effect (see Figure 14 and Figure 15). A 3-minute 
illumination (1.26 J light fluence rate using the Lumisource lamp) was chosen as a start 
point based on previous studies carried out within the research group.  
A direct relationship between photosensitiser dose and cytotoxicity was observed with 
both compounds under investigation in human prostate cancer cells (PC3 cells, Figure 
14), which further increased when cell viability was measured at a later time point after 
light (Figure 14B, Figure 14D). 24 hr after light, significant cell killing was found only at 
the highest TPCS2a dose tested (0.8 g/ml), where only 41% +/- 8 cells would remain 
viable (Figure 14C). Under these same circumstances, 68% +/- 8 cells remained viable 
when exposed to TPPS2a-based PDT (Figure 14A). If measured 96 hr after light 
treatment, these cell viability values decreased to 55% +/- 11 and 21% +/- 13 for 
TPPS2a- and TPCS2a- PDT respectively (Figure 14B, Figure 14D).  
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Figure 14. Evaluation of PDT effect in PC3 cells.  
Cells were incubated with either TPPS2a (A, B) or TPCS2a (C, D) solutions ranging 0-0.8 g/ml during 24 
hr, drugs were then washed off and a 4 hr chase period was allowed before illumination. Cell viability was 
measured 24 hr and 96 hr after light treatment. Data is displayed as mean with error bars +/- SEM; two-
way ANOVA followed by Bonferroni post hoc multiple comparison was used, differences between dark 
control and light groups are shown; significance level of p < 0.05.  
A correlation between photosensitiser doses and cell death was also found in rat 
prostate cancer cells (MatLyLu cells, Figure 15). Similar to the saporin dose-response 
curves, these cells appeared to be more sensitive to PDT than the human counterpart. 
A significant reduction in cell viability was found from 0.2 g/ml TPPS2a, which resulted 
in 55% +/- 8 viable cells only 24 hr after light (Figure 15A); viability values for TPCS2a-
PDT at this point were 83% ± 13 (Figure 15B).  
No dark toxicity was found regardless of the photosensitiser dose neither in the human 
nor rat model.  
PCI aims to benefit from low dose PDT. In line with this, and based on the above 
results, 0.2 and 0.4 g/ml were the subthreshold doses chosen (resulting in below 50% 
cell death when exposed to PDT alone) for both photosensitisers in later experiments 
combining photosensitisers with saporin (PCI).  
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Figure 15. Evaluation of PDT effect in MatLyLu cells.  
Cells were incubated with either TPPS2a (A) or TPCS2a (B) solutions ranging 0-0.8 g/ml during 24 hr, 
drugs were then washed off and a 4 hr chase period was allowed before illumination. Cell viability was 
measured 24 hr after light treatment. Data is displayed as mean with error bars +/- SEM; two-way ANOVA 
followed by Bonferroni post hoc multiple comparison was used, differences between dark control and light 
groups are shown; significance level of p < 0.05. 
2.4.5 PCI combination experiments 
Successful performance of PCI requires a challenging optimisation of the treatment 
due to the amount of variables influencing and involved in the therapeutic outcome. 
Several experimental conditions were assayed using PC3 and MatLyLu cells to 
establish he optimal PCI procedure, which would result in maximal cell kill. Some of the 
variables that will be reported below are illumination (fluence rate), interval between 
drug removal and light-excitation (drug light interval, DLI) or performance of a “light-
before” approach.  
2.4.5.1 Light dose 
Taking 1.26 J (equivalent to 3 minutes of light, using the Lumisource lamp) as a 
starting illumination time, different light doses were tested in PCI experiments. A clear 
PCI effect was found 24 hr after exposure to light being this nearly 2-fold more 
cytotoxic that PDT in PC3 cells (Figure 16A, Figure 16C). Briefly, cell viability was 
further reduced 29% and 9% combining TPPS2a (0.2 and 0.4 g/ml respectively) with 
saporin (Figure 16A). As for Amphinex (TPCS2a), combination with saporin resulted in a 
further 35% and 31% reduction in cell viability (0.2 and 0.4 g/ml TPCS2a doses 
C
on
tr
ol 0.
1
0.
2
0.
4
0.
6
0.
8
0
20
40
60
80
100
120
140
Concentration 
(mg/ml)
C
e
ll
 v
ia
b
il
it
y
 (
%
 c
o
n
tr
o
l)
 
24 hr
Dark
Light 1.26 J (3 minutes)
****
****
****
***
C
on
tr
ol 0.
1
0.
2
0.
4
0.
6
0.
8
0
20
40
60
80
100
120
140
Concentration 
(mg/ml)
C
e
ll
 v
ia
b
il
it
y
 (
%
 c
o
n
tr
o
l)
 
24 hr
Dark
Light 1.26 J (3 minutes)
TPPS2a in MLL cells TPCS2a in MLL cells
(p < 0.05)
A B
In vitro studies of PDT and PCI in prostate cancer 
 
 
80 
respectively) (Figure 16C). Overall, a maximum 1.6-fold greater cytotoxicity was seen 
after PCI. 
 
Figure 16. Assessment of PDT/PCI effect in PC3 cells after light (1.26 J, 3 minutes).  
Cells were incubated with either 0.2 or 0.4 g/ml solutions of TPPS2a (A, B) or TPCS2a (C, D), alone or in 
combination with saporin 2 nM for 24 hr. Drugs were then washed off and a 4 hr chase period was allowed 
before illumination. Cell viability was measured 24 hr and 96 hr after light treatment. Data is displayed as 
mean with error bars +/- SEM; two-way ANOVA followed by Bonferroni post hoc multiple comparison was 
used, differences between dark control and light groups are shown; significance level of p < 0.05. 
The latest time point tested after light (96 hr) for cell death of PC3 cells, showed the 
greatest PCI effect in both photosensitisers. TPPS2a-PCI resulted in at least 3-fold 
higher cell killing than the PDT equivalent at both 0.2 and 0.4 g/ml photosentiser 
doses (Figure 16B). This was slightly higher for TPCS2a-PCI (compared to TPPS2a), 
which resulted in a 3.5-fold higher cell death for the lowest photosensitiser dose (0.2 
g/ml) (Figure 16D). The mean viability after PDT was 67% and after TPCS2a-PCI (96 
hr and 0.2 g/ml) was 19%, corresponding to a ratio of 3.5 increase in cell killing with 
PCI vs PDT. As indicated in Figure 13 and Table 5, saporin had a negligible effect on 
this ratio, since cytotoxicity induced by saporin alone was less than 10%. Hence, cell 
death in PCI did not correspond to a mere addition, but synergy between saporin and 
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PDT. If the PCI effect had been merely additive (i.e. PDT + addition of saporin), then 
then the observed ratio between PDT and PCI would have been close to 1. 
 
Figure 17. PDT/PCI effect in PC3 cells 96 hr after different light doses.  
Cells were incubated with either 0.2 or 0.4 g/ml solutions of TPPS2a (A) or TPCS2a (B), alone or in 
combination with saporin 2 nM for 24 hr. Drugs were then washed off and a 4 hr chase period was allowed 
before illumination. Cell viability was measured 96 hr after light treatment. Data is displayed as mean with 
error bars +/- SEM; two-way ANOVA followed by Bonferroni post hoc multiple comparison was used, 
differences between light groups are shown; significance level of p < 0.05. 
Figure 17 displays a comparison of PDT and PCI effect in PC3 cells 96 hr after three 
different light doses (0.63 J, 1.26 J and 1.68 J). A significant increase in cell death was 
found when light fluence was doubled from 0.63 to 1.26 J in all TPPS2a cases (Figure 
17A). However, a substantial difference was only found using TPCS2a as 
photosensitiser in the 0.4 g/ml PDT group. In addition, light doses higher than 1.26 J 
did not seem to significantly affect cell viability of PC3 cells at the doses and 
experimental conditions tested. 
Likewise, a comparison of cell viability of MatLyLu cells after PDT and PCI 
using different light doses was performed (Figure 18). Given the relevance of 
Amphinex in the in vivo studies (see Chapter 4), TPPS2a was not further investigated 
in vitro in the rat prostate cancer model (MatLyLu).  
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Figure 18. PDT/PCI effect in MatLyLu cells 24 hr and 48 hr after different light doses.  
Cells were incubated with either a 0.2 g/ml (A, B) or 0.4 g/ml (C, D) solution of TPCS2a, alone or in 
combination with saporin 20 pM for 24 hr. Drugs were then washed off and a 4 hr chase period was 
allowed before illumination. Cell viability was measured 24 hr or 48 hr after light treatment. Data is 
displayed as mean with error bars +/- SEM; two-way ANOVA followed by Bonferroni post hoc multiple 
comparison was used, differences between dark control and light groups are shown; significance level of p 
< 0.05. 
This study carried out on MatLyLu cells also showed an enhancement in cell death 
after PCI in all cases (Figure 18). The highest light dose tested (2.1 J) led to the 
smallest differences in cell death after PDT and PCI in nearly all cases: 6% (24 hr after 
light for 0.4 g/ml), 13% and 12% (48 hr after light for 0.2 g/ml and 0.4 g/ml 
respectively). Yet, 28% resulted from the 24 hr measurements using 0.2 g/ml TPCS2a 
(Figure 19A). A relatively similar cell killing efficacy was observed in cells treated with 
1.26 J at both photosensitiser doses: 17% and 18% (24 hr after light for 0.2 g/ml and 
0.4 g/ml respectively), or else 14% and 21% (48 hr after light for 0.2 g/ml and 0.4 
g/ml respectively) reduction in viable cells. The lowest % of viable cells was seen after 
48 hr combining TPCS2a 0.4 g/ml and saporin 20 pM following a PCI approach, 
treatment which led to 86% cell death (Figure 18D, Figure 19B) 
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The direct comparison of cell killing between both light treatment groups revealed 
significant differences between the lowest and highest dose tested for both PDT and 
PCI and both 24 hr and 48 hr after light in MatLyLu cells (Figure 19). Cell viability 
measurements after the highest light dose led to the greatest therapeutic outcome of 
light treatments, especially at the later time point, 48 hr after light. (Figure 19B)  
 
Figure 19. Comparison of light groups after PDT/PCI in MatLyLu cells.  
Cells were incubated with either a 0.2 g/ml or 0.4 g/ml solution of TPCS2a, alone or in combination with 
saporin 20 pM for 24 hr. Drugs were then washed off and a 4 hr chase period was allowed before 
illumination. Cell viability was measured 24 hr (A) or 48 hr (B) after light treatment. Data is displayed as 
mean with error bars +/- SEM; two-way ANOVA followed by Bonferroni post hoc multiple comparison was 
used, differences between light doses are shown; significance level of p < 0.05. 
2.4.5.2 Drug-light interval (DLI) 
The time window allowed between drug removal and light (DLI) is thought to be 
particularly important in vitro after PCI (indicated as chase period throughout the 
present chapter). During this time, internalisation of photosensitisers from the external 
cell membrane into cytosolic endo/lysosomal membranes is enabled in order to 
achieve a photo-oxidative effect at a subcellular level. Founded on this, the therapeutic 
effect resulting from different DLIs was evaluated in PC3 (Figure 20, Figure 21) and 
MatLyLu (Figure 22) cells and results are subsequently reported below.    
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Figure 20. Comparison in PDT/PCI effect with/without chase period before light in PC3 cells.  
Cells were incubated with either 0.2 or 0.4 g/ml solutions of TPPS2a (A, B) or TPCS2a (C, D), alone or in 
combination with saporin 2 nM for 24 hr. Drugs were then washed off and either a 0 hr or 4 hr chase 
period was allowed before illumination (1.26J). Cell viability was measured 24 hr after light treatment. Data 
is displayed as mean; two-way ANOVA followed by Bonferroni post hoc multiple comparison was used, 
differences between drug light interval groups are shown; significance level of p < 0.05. 
As shown in Figure 20, the performance of light treatment immediately after drug 
removal (0 hr chase/drug light interval) resulted in no differences in cell viability 
compared to the 4 hr DLI in PC3 cells except for TPCS2a 0.4 g/ml (Figure 20D). In this 
case, the combination of photosensitiser and saporin did not further enhance cell death 
and PCI effect was not different to that of PDT 24 hr after light in the 0 hr DLI group. 
Further investigation of this in PC3 cells 72 hr after light is shown in Figure 21. In both 
cases, similar cell viability resulted from 0.4 g/ml of either photosensitiser after PDT 
and PCI (see Figure 21A for TPPS2a, Figure 21B for TPCS2a). Briefly, 29% +/- 13 and 
6% +/- 6 cells were viable after TPPS2a (PDT and PCI respectively); while 12% +/- 8 
and 10% +/- 6 were the viability values for TPCS2a (PDT and PCI respectively). In the 
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lowest photosensitiser dose (0.2 g/ml), an enhancement in cell viability was found with 
PCI. 
 
Figure 21. Comparison in PDT/PCI effect without chase period before light in PC3 cells.  
Cells were incubated with either 0.2 or 0.4 g/ml solutions of TPPS2a (A) or TPCS2a (B), alone or in 
combination with saporin 2 nM for 24 hr. Drugs were then washed off and immediately subject to light 
treatment (1.26 J). Cell viability was measured 72 hr after light treatment. Data is displayed as mean with 
error bars +/- SEM; two-way ANOVA followed by Bonferroni post hoc multiple comparison was used, 
differences between dark control and light groups are shown; significance level of p < 0.05. 
On their side, despite the fact that no significant differences between DLI groups were 
seen in MatLyLu cells, there was a general trend to reduce cell death when increasing 
the length of the chase period; being cytotoxicity more noteworthy post PCI than PDT 
of TPCS2a (Figure 22). 
 
Figure 22. Comparison in PDT/PCI effect after 
4 hr or 6 hr chase period in MatLyLu cells.  
Cells were incubated with either 0.2 g/ml 
solutions of TPCS2a alone or in combination with 
saporin 20 pM for 24 hr. Drugs were then washed 
off and either a 4 hr or 6 hr chase period was 
allowed before illumination (1.26 J). Cell viability 
was measured 24 hr and 48 hr after light 
treatment. Data is displayed as mean; two-way 
ANOVA followed by Bonferroni post hoc multiple 
comparison was used; significance level of p < 
0.05. 
 
C
on
tr
ol
S
ap
or
in
 2
 n
M
TP
PS
2a
 0
.2
 µ
g/
m
l
TP
PS
2a
/S
ap
or
in
 0
.2
 µ
g/
m
l /
 2
 n
M
TP
PS
2a
 0
.4
 µ
g/
m
l
TP
PS
2a
/S
ap
or
in
 0
.4
 µ
g/
m
l /
 2
 n
M
0
20
40
60
80
100
120
Drug combination
C
e
ll
 v
ia
b
il
it
y
 (
%
 c
o
n
tr
o
l)
 
72 hr
Dark
Light 1.26 J (3 minutes)
** **
*
C
on
tr
ol
S
ap
or
in
 2
 n
M
TP
C
S 2
a
 0
.2
 µ
g/
m
l
TP
C
S 2
a
/S
ap
or
in
 0
.2
 µ
g/
m
l /
 2
 n
M
TP
C
S 2
a
 0
.4
 µ
g/
m
l
TP
C
S 2
a
/S
ap
or
in
 0
.4
 µ
g/
m
l /
 2
 n
M
0
20
40
60
80
100
120
Drug combination
C
e
ll
 v
ia
b
il
it
y
 (
%
 c
o
n
tr
o
l)
 
72 hr
Dark
Light 1.26 J (3 minutes)
**
****
********
TPPS2a TPCS2a (Amphinexâ) 
(p < 0.05)
A B
In vitro studies of PDT and PCI in prostate cancer 
 
 
86 
2.4.5.3 Light-before PCI 
A brief study into the “light-before” PCI procedure was performed on PC3 cells, as 
shown in Figure 23.  
Differences in cell death after “light-before” PCI resulted in 3% - 11% between PDT and 
PCI. In these cases, PCI did not result in a significant enhancement of the therapeutic 
outcome, not even when cell viability was measured 96 hr after light. In addition, in the 
best case, cell viability was reduced to 67% (Figure 23D), and in all groups 
investigated, cell death remained within 13% (for TPCS2a, PDT 24 hr after light – Figure 
23C) and 34% (for TPCS2a, PCI 96 hr after light – Figure 23D), which was only slightly 
over 1-fold greater post PCI than PDT (Figure 23). PDT only resulted in significant cell 
death 24 hr after light in cells treated with TPPS2a (Figure 23A); while cell killing was 
still significant in all PCI light groups. 
 
Figure 23. “Light-before” PDT/PCI effect in PC3 cells.  
Cells were incubated with 0.2 g/ml solutions of either TPPS2a (A) or TPCS2a (B) during 24 hr. 
Photosensitiser solutions were then washed off and a 4 hr chase period was allowed before illumination. A 
solution of saporin 2 nM was administered immediately after illumination for 24 hr. After this period, drug 
solutions were removed and cell viability was measured 24 hr and 96 hr after light treatment (1.26 J). Data 
is displayed as mean with error bars +/- SEM; two-way ANOVA followed by Bonferroni post hoc multiple 
comparison was used, differences between dark control and light groups are shown; significance level of p 
< 0.05 
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Table 5. Summary of cell viability after PDT/PCI in PC3 cells. 
 TPCS2a- and TPPS2a- based PDT and PCI 24 hr and 96 hr after delivery 
of light. Shown both light after and light before results under different 
drug-light interval and light conditions. 
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Table 6. Summary of cell viability after PDT/PCI in MatLyLu cells. TPCS2a-, BPD-MA-, and AlPcS2a- based PDT and PCI 24 hr and 48 hr after delivery of light.  
Shown light after results under different drug-light interval and light conditions. 
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2.4.6 Subcellular localisation of TPPS2a and TPCS2a in PC3 
and MatLyLu cells before and after light treatment  
An efficient PCI procedure has the following basic requirements: 
1. Endolysosomal localisation of photosensitisers and the therapeutic agent to be 
delivered. Fluorescent properties of photosensitisers enable this observation. 
However, a much higher resolution is needed to prove specific localisation 
within the membranes. 
2. Light-induced release from these endolysosomes: consistent with 
endolysosomal disintegration due to photooxidative damage which then 
releases the drug content. Again, intrinsic fluorescence of photosensitisers can 
show this with dispersion of fluorescence into the cytosol upon light exposure. 
In our study, in order to observe the subcellular localisation of photosentisers at the 
moment of exposure to light and better comprehend the occurring PDT effect, cells 
were incubated with photosensitiser solutions following the same protocol as performed 
for cell viability measurements reported in the previous sections. Observations of initial 
localisation of TPPS2a and TPCS2a were achieved through illumination for short periods 
of time (1 second) which are insufficient to excite the compounds and trigger the 
characteristic photo-oxidative reactions (as displayed in Figure 24A for TPCS2a in 
MatLyLu cells and Figure 24B for TPPS2a in PC3 cells). Specifically, at this initial stage 
of illumination, both photosensitisers were seen conforming discrete granules in the 
cytoplasm (highlighted with red arrows in Figure 24A, Figure 24B). As cells were being 
illuminated, these cytosolic granules started fading in a time dependent manner. 10 
minutes after light treatment, fluorescence had been redistributed throughout the whole 
cellular structure, as shown in Figure 24C, Figure 24D. Changes in cell morphology 
after light were also seen; these were evident in PC3 cells, which seemed to have 
adopted a rounded morphology as light treatment was performed (Figure 24D).  
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Figure 24. TPCS2a and TPPS2a localisation and redistribution after light treatment in MatLylu and 
PC3 cells respectively.  
Cells were incubated with 0.4 g/ml solutions of either TPCS2a (MatLyLu cells) or TPPS2a (PC3 cells) 
during 24 hr. Photosensitiser solutions were then washed off and a 4 hr chase period was allowed before 
illumination “on stage” using a low power (2 mW) 405 nm blue diode laser coupled to a liquid light guide. 
Micrographs were taken at a different time during exposure to light. Red arrows indicate PS cytosolic 
granules. Scale bars shown as 50 m. 
2.4.7 Subcellular localisation of the conjugate saporin-Alexa-
Fluor488® before and after excitation of 
photosensitisers  
So as to better understand the subcellular mechanism of PCI in the prostate cancer 
cells used in the study, we aimed to determine the location of saporin-Alexa-Fluor488® 
at a subcellular level, as performed with TPCS2a and TPPS2a.  
Alike above-reported for photosensitisers, saporin appeared in both the human (PC3) 
and rat (MatLyLu) cell lines as discrete cytosolic granules. Moreover, incubation with 
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lysotracker red (specific lysosomal dye), resulted in colocalisation with the saporin 
conjugate (Figure 25).  
 
Figure 25. Saporin-Alexa-Fluor488® conjugate localisation in MatLyLu and PC3 cells respectively.  
Cells were incubated with a solution of Saporin-Alexa-Fluor488® (400 nM) during 24 hr, then washed, 
allowing cells to recover for 4 hours. Additionally, cells were incubated with a 75 nM solution of 
LysoTracker® Red DND-99. Imaging was performed using a 488 nm (for saporin-Alexa-Fluor488®) and 
559 nm laser (for lysotracker red). Scale bars shown as 20 m (MatLyLu cells) and 50 m (PC3 cells). 
TPPS2a and TPCS2a absorb light at 405 nm (see spectra in Figure 11), thus exposure 
of both compounds to light of this wavelength would result in their excitation. 
Subcellular distribution of saporin-Alexa-Fluor488® remained unaltered in PC3 cells if 
these were exposed to a 405 nm laser followed by micrograph capturing, as displayed 
in Figure 26.  
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Figure 26. Saporin-Alexa-Fluor488® conjugate in PC3 cells before and after illumination with a 405 
nm laser.  
Cells were incubated with a solution of Saporin-Alexa-Fluor488® (400 nM) during 24 hr, then washed, 
allowing cells to recover for 4 hours. Imaging was performed using a 488 nm laser before (A, C) and 5 
minutes after (B, D) a 10 seconds “on-stage” excitation with a 405 nm laser. Scale bars shown as 50 m. 
We then aimed to investigate possible changes in subcellular localisation of saporin 
occurring during PCI. Therefore, saporin-Alexa-Fluor488® and photosensitiser 
solutions were co-administered in PC3 (Figure 27 and Figure 28) and MatLyLu (Figure 
29) cells following the same protocol as for the above cell viability assays. Accordingly, 
if PC3 cells were imaged before illuminating the cells with a 405 nm blue laser, saporin 
remained forming green fluorescent cytosolic granules (Figure 27A) as was shown in 
Figure 26 in the absence of PS. Yet, if cells were imaged after illumination with 405 nm 
light, the cytosolic vesicles in which saporin was initially located, were dispersed 
throughout the cytosol (Figure 27B, Figure 27C) similarly to the fading of 
photosensitiser’s fluorescence after illumination shown previously (Figure 24). As 
highlighted with red arrows in a single cell in Figure 27, overall fluorescence “glow” (B, 
C) remained after dispersion of the initial discrete fluorescent granules (A).  
This same fluorescence dispersion and cytosolic redistribution of the conjugate is 
represented in a single cell in Figure 28.  
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Figure 27. Saporin-Alexa-Fluor488® conjugate in PC3 cells co-administered with TPPS2a before and 
after illumination with a 405 nm laser.  
Cells were incubated with Saporin-Alexa-Fluor488® (400 nM) and TPPS2a (0.4 g/ml) during 24 hr, then 
washed and allowed to recover for 4 hours. Imaging was performed using a 488 nm laser before (A), 1 
minute after (B) and 5 minute after (C) a 10-seconds “on-stage” excitation with a 405 nm laser. Red arrows 
indicate Saporin-Alexa-Fluor488® cytosolic granules. Scale bars shown as 50 m. 
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Figure 28. Saporin-Alexa-Fluor488® conjugate in PC3 cells (single cell detail) co-administered with 
TPPS2a before and after illumination with a 405 nm laser.  
Cells were incubated with Saporin-Alexa-Fluor488® (400 nM) and TPPS2a (0.4 g/ml) during 24 hr, then 
washed and allowed to recover for 4 hours. Imaging was performed using a 488 nm laser before (A), 
immediately after (B) and 1.5 minute after (C) a 10-seconds “on-stage” excitation with a 405 nm laser. 
Scale bars shown as 50 m. 
Similar experiments were performed in rat prostate cancer cells (MatLyLu) exposed to 
a combination of saporin-Alexa-Fluor488® and TPCS2a following the same drug-
combination PCI protocol performed in the human counterpart (Figure 27 and Figure 
28). As shown in Figure 29, emission of green fluorescence by saporin-Alexa-
Fluor488® was also subject to a time dependant dispersion and redistribution (Figure 
29B, Figure 29C). However, this was evident longer after illumination was initiated in 
this cell line, as shown 10 minutes after 405 nm light irradiation (Figure 29C) opposite 
to 1.5- (Figure 28C) and 5- minutes after 405 nm light irradiation in PC3 cells (Figure 
27C). 
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Figure 29. Saporin-Alexa-Fluor488® conjugate in MatLyLu cells co-administered with TPCS2a 
before and after illumination with a 405 nm laser.  
Cells were incubated with Saporin-Alexa-Fluor488® (400 nM) and TPCS2a (0.4 g/ml) during 24 hr, then 
washed and allowed to recover for 4 hours. Imaging was performed using a 488 nm laser before (A), 1 
minute after (B) and 10 minute after (C) a 10-seconds “on-stage” excitation with a 405 nm laser. Red circle 
indicates Saporin-Alexa-Fluor488® cytosolic granules. Scale bars shown as 20 m. 
2.4.8 PDT and PCI in 3D collagen hydrogels using TPPS2a as 
photosensitiser 
The above shown images and viability assays were performed in traditional 2D 
platforms such as cell culture plastic plates and dishes. 
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Following the 3Rs principle (Refinement, Reduction, Replacement), aiming to mimic 
more closely the natural environment cells are found in, and thus gain reliability of our 
results, we performed light treatment (both PDT and PCI) to PC3 cells seeded into 
collagen hydrogels.  
 
Figure 30. PDT/PCI in PC3 cells seeded onto 3D collagen gels.  
Images showing fluorescence of calcein in viable cells. Cells were incubated with either 0.2 g/ml solutions 
of TPCS2a (A, B, C, D, I, K) or TPPS2a (E, F, G, H) alone, in combination with saporin 2 nM (C, D, I, K, G, 
H), or exposed to saporin alone (L) for 24 hr. Drugs were then washed off and a 4 hr chase period was 
allowed before illumination. Micrographs were taken 96 hr after light treatment. (I) and (K) are zoomed 
images of (B) and (D) respectively. Scale bars shown as 50 m. 
Cell viability of PC3 cells was affected by both light treatments PCI and PDT 96 hours 
after light with both photosensitisers (TPCS2a and TPPS2a). This was reflected by the 
lower cell density of these groups after 5 minutes light (Figure 30B, Figure 30D, Figure 
30F, Figure 30H) compared to dark (Figure 30A, Figure 30C, Figure 30E, Figure 30G). 
Combination of photosensitisers with saporin appeared to result in a lower cell density 
even under dark conditions (Fig. 20C, 20G) in comparison to cells exposed to 
photosensitisers alone in the dark (Figure 30A, Figure 30E). Like cell viability 
measurements reported above, cytotoxicity in 3D gels after PCI (Figure 30D, Figure 
30H) seemed to be greater that exerted by PDT (Figure 30B, 20F). In addition, PC3 
cells were morphologically affected after both PDT and PCI (see details Figure 30I, 
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Figure 30K), were they adopted a more “round” shape as opposed to their 
characteristic elongated phenotype.  
2.4.9    BPD-MA & AlPcS2a in MatLyLu cells 
Due to the relevance for in vivo studies reported in Chapter 4, a brief investigation into 
PDT and PCI effect in MatLyLu using BPD-MA and AlPcS2a as photosensitisers was 
performed (prior step to in vivo experiments). Based on optimal photosensitiser doses 
established in previously-commented experiments, a single 0.4 g/ml concentration of 
either BPD-MA and AlPcS2a was investigated in the sections described below.  
2.4.9.1 BPD-MA and AlPcS2a uptake in rat prostate 
cancer cells (MatLyLu cells) 
As reported above with TPPS2a and TPCS2a, an initial experiment involved measuring 
photosensitiser uptake in rat prostate cancer cells. Both BPD-MA and AlPcS2a were 
administered to MatLyLu cells to measure uptake of these after two different incubation 
periods (8 hr and 24 hr). In this case, a direct relationship was found between uptake 
and length of incubation with both photosensitisers with significant differences between 
time points (see Figure 31). Higher uptake of AlPcS2a than BPD-MA was seen both 
after 8 hr and 24 hr incubation.  
 
Figure 31. Uptake of BPD-MA and AlPcS2a in 
rat prostate cancer cells (MatLyLu).  
Cells were incubated for 8 hr and 24 hr to 
photosensitiser solutions at 0.4 g/ml, then 
washed and media was replaced with no phenol 
red media. Uptake was related to 
photosensitiser fluorescence intensity. Data is 
displayed as mean with error bars +/- SEM; two-
way ANOVA followed by Bonferroni post hoc 
multiple comparison was used, significance level 
of p < 0.05. 
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2.4.9.2 Assessment of cell viability after light 
treatment and subcellular localisation of BPD-
MA and AlPcS2a in MatLyLu cells  
Different light doses were investigated to establish the optimal in vitro treatment of 
these cells with both compounds. Cell viability 24 hr after light was measured, as 
displayed in Figure 32.  
A direct correlation was confirmed once more between light dose and reduction in cell 
death for both PDT and PCI in the compounds here discussed, exhibiting significant 
differences in cell viability compared to the non-treated group. The lowest light fluence 
tested [0.25 J and 0.5 J with BPD-MA (Omnilux Clear-U™ light source) and AlPcS2a 
(LumaCare™ light source) respectively] rendered the greatest difference in cell viability 
between PDT and PCI for both photosensitisers, 21% and 50% for BPD-MA (Figure 
32A) and AlPcS2a (Figure 32B); this was even more pronounced in the phtalocyanine-
based photosensitiser (Figure 32B). Cytotoxicity after 1 J light was similar in both light 
treatments and photosensitisers exhibited the greatest cell killing, 87% - 73%. As with 
the previously tested photosensitisers, no dark toxicity was found in any case.  
 
Figure 32. PDT/PCI effect in MatLyLu cells 24 hr after different light doses.  
Cells were incubated with either 0.4 g/ml solution of BPD-MA (A) or AlPcS2a (B), alone or in combination 
with saporin 20 pM for 24 hr. Drugs were then washed off and a 4 hr chase period was allowed before 
illumination. Cell viability was measured 24 hr after light treatment. Data is displayed as mean with error 
bars +/- SEM; two-way ANOVA followed by Bonferroni post hoc multiple comparison was used, differences 
between dark control and light groups are shown; significance level of p < 0.05. 
BPD and AlPcS2a cytotoxicity after PDT-light treatment was further evaluated through 
fluorescence imaging after exposure to light and staining with propidium iodide 
(membrane impermeant fluorescent dye which is only able to stain cells with an 
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impaired cellular membrane). As displayed in the red channel (BPD-MA), the 
photosensitiser was initially located in the cell cytosol (Figure 33A) and was 
progressively dispersed throughout the whole cell, entering the nucleus by 48 hr after 
light (Figure 33C). Cell death and more specifically, its time-dependency were 
confirmed (Figure 33D, Figure 33E). 24 hr after light, PI staining of cells was already 
detected; yet it significantly increased, resulting in very bright fluorescence 48 hr after 
light (Figure 33E). In addition, cellular damage was evident as soon as 2 hr after light, 
detailed in Figure 33H.   
 
Figure 33. BPD-MA localisation and cytotoxicity in MatLylu cells.  
Cells were incubated with 0.4 g/ml BPD-MA during 24 hr, solutions were then washed off and a 4 hr 
chase period was allowed before illumination. Additionally, cells were incubated with a 1:100 solution of 
propidium iodide prior to imaging. Micrographs were taken 2 hr, 24 hr and 48 hr after light using a 405 nm 
(for BPD-MA) and 559 nm laser (for propidium iodide). Scale bars shown as 50 m. 
As for the assessment of fluorescence after AlPcS2a-based PDT in rat prostate cancer 
(Figure 34), contrary to the subcellular more disperse pattern seen with BPD-MA 
(Figure 33A), AlPcS2a distributed in a similar way to the above-shown TPPS2a and 
TPCS2a (Figure 24). Discrete granules were found throughout the cytosol (Figure 34A). 
PI staining was not as clear as seen above with BPD-MA PDT, cells seemed to be 
gradually affected when imaged at later time points (Figure 34D, Figure 34E). Cell 
integrity was maintained even 48 hr after light as opposed to BPD-MA PDT (Figure 
33H) 
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Figure 34. AlPcS2a localisation and cytotoxicity in MatLylu cells.  
Cells were incubated with 0.4 g/ml AlPcS2a during 24 hr, solutions were then washed off and a 4 hr chase 
period was allowed before illumination. Additionally, cells were incubated with 1:100 solution of propidium 
iodide prior to imaging. Micrographs were taken 2 hr, 24 hr and 48 hr after light using a 405 nm (for 
AlPcS2a) and 559 nm laser (for propidium iodide). Scale bars shown as 50 m. 
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2.5 Discussion  
Briefly, the aims of this first chapter were to assess PDT and PCI in vitro as 
potential prostate cancer treatments and compare the therapeutic outcome resulting 
from each of these light-based therapies.  
The absorbance of light (photons) and consequent dissipation of different forms of 
energy (heat, light, chemical energy) is the foundation of both therapies investigated in 
the present thesis. Hence, an initial verification of the absorbance and fluorescence 
emission of each of the photosensitisers used was measured, as shown in the spectra 
displayed in Figure 11. These proved the eligibility of TPPS2a, TPCS2a, BPD-MA and 
AlPcS2a as photosensitive compounds, and thus we moved onto measuring the 
likelihood of having a positive therapeutic outcome in prostate cancer eradication.  
The prostate cancer cell models used throughout the study, PC3 for human and 
MatLyLu as the rat counterpart, share common features such as androgen 
independency or metastatic potential, characteristics of advanced human prostate 
cancer. Despite their similarities, they both exhibited differences such as growth rate 
and pattern. In line with this, MatLyLu’s doubling rate has been previously described as 
substantially faster that other models (Isaacs et al., 1981). This was confirmed in our 
experiments, observing a significantly faster growth of these than PC3 cells, which 
could also be the reflection of a faster metabolic rate.  
Moreover, Kouvroukoglou et al. hypothesised the production of autocrine factors by 
MatLyLu cells. In their studies, they observed growth of these cells in the absence of 
serum, or a modification in their metabolism as an adjustment to inhibition of glycolysis 
or mitochondrial respiration (Kouvroukoglou et al., 1998). The differences in growth 
between cell lines were the reason for the use of different cell seeding densities of 
each during the experiments. Moreover, rat prostate cancer cells tended to grow 
forming clumps of cells at low confluence (possibly related to their high metastatic 
potential), which was not observed in the human prostate cancer model.  
Photosensitiser uptake in PC3 and MatLyLu was directly related to emission of 
fluorescence in cells previously incubated with photosensitiser solutions. No 
fluorescence was detected in control cells, showing that autofluorescence was 
negligible. Based on the observations, a direct correlation between photosensitiser 
dosage and uptake, or between duration of incubation with photosensitisers and uptake 
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(displayed in Figure 12 and Figure 31 respectively) was demonstrated for TPPS2a, 
TPCS2a, BPD-MA and AlPcS2a in the above prostate cancer cells (the two last 
compounds were evaluated as a direct basis for in vivo experiments). In addition, the 
lack of any sign of saturation (i.e. tending towards a plateau) in the curves suggests 
non-receptor mediated uptake of the compounds under our experimental conditions. 
The 2-fold greater fluorescence emission of TPCS2a compared to the porphyrin 
analogue at the most (Figure 12), could be the result of a higher uptake of this PS in 
both cell lines. However as discussed previously, differences in fluorescence quantum 
yields between both photosensitisers (Lilletvedt et al., 2011, 2010; Wang et al., 2013), 
could be responsible for the differences found; therefore, a higher uptake of this 
photosensitiser cannot be concluded neither in PC3 nor MatLyLu cells. Likewise, no 
conclusion can be drawn in spite of the greater fluorescence emission in MatLyLu 
incubated with AlPcS2a than BPD-MA (Figure 31). The comparison of different 
photosensitisers would require chemical extraction measurements. Moreover, 
differences in cell number at the time of PS uptake measurement may also explain the 
significant differences found in the uptake of TPPS2a and TPCS2a between cancer cell 
lines (Figure 12). The aim of the PS uptake studies was to verify the internalisation of 
PS in PC3 and MatLyLu cells under relevant experimental conditions (as established 
for later experiments).  
We proceeded next to determine suitable drug doses (of both photosensitisers 
and saporin), which would result in under 50% cytotoxicity when administered alone. 
As a principle, PCI uses low dose PDT directed against organelles at a subcellular 
level and aims to deliver drugs and enhance the therapeutic outcome exerted by PDT- 
or drug- alone. Therefore, the objective is to combine subthreshold cytotoxicity levels of 
both treatments when administered independently. 
The lack of cytotoxicity observed in PC3 cells upon exposure to saporin (Figure 
13), even at the highest dose tested (60 nM), confirmed the inability of this RIP type 1 
to reach cytosolic ribosomes because of the lack of the chain B reported in the 
literature (Polito et al., 2013). On the other hand, the higher sensitivity to saporin seen 
in MatLyLu cells even when assaying 2 nM (25% cell death as shown in Figure 13), 
could be explained by the combination of several internalisation mechanisms involved 
in these cells together with a higher metabolic rate (suggested by their greater growth 
rate). Due to this greater toxicity caused by saporin in the rat model, PCI combination 
experiments performed in these cells required lower saporin doses (20 pM). Uptake of 
saporin in MatLyLu could occur independently to the type B chain, involved in the entry 
of RIP type II, i.e. ricin.  
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No general internalisation mechanism has been defined for saporin yet and it is 
still not clear how this RIP is uptaken by different cell types or even organs. Different 
cellular uptake mechanisms and traffic pathways have been described (Polito et al., 
2013). For instance, pinocytosis was suggested in human trophoblasts due to the high 
sensitivity these presented (Battelli et al., 1992); receptor mediated endocytosis via an 
2-macrogloblin receptor (low-density lipoprotein receptor) was the most likely 
hypothesis in lymphoma cells (Cavallaro et al., 1995), yet this was rejected in CHO 
cells (Bagga et al., 2003); non-receptor mediated endocytosis and localisation in non-
coated vesicles in HeLa cells (Bolognesi et al., 2012).  
As for PDT effect (described in Figure 14 and Figure 15), 0.2 and 0.4 g/ml were 
selected as optimal doses for later PCI experiments in both cell lines based on the 
large cell death resulting from illumination of cells exposed to the highest PS doses 
(0.6 and 0.8 g/ml) and light, which was even further accentuated when measurement 
of cell viability was performed at a later time point (96 hr for PC3 cells). This greater 
PDT effect found at higher PS doses is related to the non-saturation in the uptake of 
PS determined in initial uptake experiments. A greater PDT effect was observed with 
TPCS2a in PC3 cells. However, TPPS2a was the PS in MatLyLu cells causing greater 
cytotoxicity (Figure 14).  
Both PS could be following different metabolic pathways within MatLyLu and PC3 cells 
and thus result in different photooxidative rates causing greater or lesser PDT-based 
killing of these. Different cancer cells show different susceptibility to ROS-based 
damage. Along these lines, cells develop different mechanisms to coordinate and 
balance their redox, i.e. varying local concentration of these oxidative species or 
expressing ROS scavenging proteins as a protection mechanism (Liou and Storz, 
2010). As could be expected, mitochondria has been reported to have an important 
role in ROS balance, being a key organelle in ATP production (Okon and Zou, 2015). 
Taking all the above into consideration, differences between both cancer cell lines and 
PSs employed throughout the chapter could be caused by disparities in antioxidant 
enzymes levels, mitochondrial activity (this can also be directly related to metabolic 
rates). 
As mentioned in Background and Introduction, light absorption by PS will not be 
affected in vitro, unlike in vivo where haemoglobin and other chromophores are 
present, and compounds with low absorption in the red region of the spectra are still 
active using blue light excitation. Conversely, this is a critical requisite for PS in vivo, 
since 600-800 nm is the optical window considered suitable for tissue light penetration.  
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On this basis, and regardless of the better outcome exhibited by TPPS2a, subsequent 
experiments in MatLyLu cells (basis for the in vivo model reported in Chapter 4) were 
only performed using photosensitisers more suitable for in vivo experiments. These 
must have relatively intense absorption peaks in the red, such as TPCS2a, AlPcS2a and 
BPD-MA. Experiments with TPPS2a were also performed in PC3 cells as a model 
compound and a proof of concept of both PDT and PCI in prostate cancer.  
The successful performance of PCI faces a challenging optimisation process due to the 
delicate balance between PDT and PCI. Photosensitiser dose, drug dose, light dose, 
drug light interval, measurement of cell viability time points are variables involved in 
tilting this balance towards one treatment or another. Accordingly, taking the pre-
determined subthreshold doses of PS and saporin as the starting point, different 
experimental conditions were assayed.  
The first PCI combination experiments displayed in Figure 16 served as initial proof of 
the higher efficiency that could be achieved with PCI over low dose PDT (1.26 J for 
both treatment groups) in human prostate cancer cells (PC3): up to 3.5-fold higher cell 
death was observed 96 hr after light treatment combining TPCS2a 0.2 µg/ml and 
saporin 2 nM (Figure 16 D). Differences in PDT effect were found between both PS 
doses tested, with greater cell death at the highest dose (as seen in PS dose response 
curves, Figure 14 and Figure 15). Despite PDT differences, negligible differences were 
found in PCI-based toxicity between 0.2 g/ml and 0.4 g/ml when comparing each 
time point (24 hr and 96 hr) independently. This indicates that after PCI, the therapeutic 
effect relies to a large extent on the drug being delivered (saporin in the present case), 
giving less weight to photooxidative damage itself.  
In addition, the effect was enhanced even more when cell death was measured 96 hr 
after light as opposed to 24 hr (2.8-fold larger). This could indicate slower cell death 
pathways post PCI, possibly requiring time-dependant intracellular signalling. Perhaps, 
saporin could have been transported from cell to cell through communication channels 
directly into the cytosol of adjacent cells, affecting those that had not been directly 
affected by either PS or saporin. Transport between tumour cells comprising cell-cell or 
cell-stroma interaction via gap junctions, integrins, cadherins, etc. has been studied in 
several occasions (Brücher and Jamall, 2014), aiming to exploit these in the 
development of anti-tumour treatments. A recently discovered example of intercellular 
traffic structures are tunnelling nanotubes (membrane bridges), which were detected in 
several cancer cell types and whose function was to ease the transfer of organelles 
and material of varied nature between tumour cells (Burtey et al., 2015).  
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As for MatLyLu cells, viability was only measured up to 48 hr after light exposure. This 
was due to the rapid growth of this prostate cancer model: viability levels in control 
groups were found outside MTT’s reliable detection limits and the cytotoxic effect of 
treatments performed could have been masked by regrowth of unaffected cells. 
Looking at the results after the same light dose (1.26 J) discussed above for PC3 
human cells, a PCI effect was also confirmed in the rat counterpart (Figure 18), 
although not as noteworthy. It is possible that PCI using TPPS2a as PS would have led 
to a greater enhancement in cell viability than PDT, yet it will not be relevant in the 
translation to an in vivo environment as discussed. As regards TPCS2a, outcome of the 
treatment was relative to the dosage contrary to PC3, where the same PCI effect was 
seen regardless of PS dose, hence the similarities in cell viability differences between 
PDT and PCI in MatLyLu (Figure 18).  
Further investigation into light dose, positions it as a driving factor in the 
outcome of PDT and PCI (results displayed in Figure 16, Figure 17, Figure 18, Figure 
19, Figure 32). Accordingly, significant differences in cell death were found between 
the above discussed irradiating light at 1.26 J and lower light doses in PC3 cells (see 
results after 0.63 J in Figure 17) in both PDT and PCI. However, no benefits in the 
therapeutic outcome were demonstrated in PC3 cells if the light dose was increased to 
1.68 J, for either light treatment neither using TPPS2a nor TPCS2a (Figure 17). In this 
regard, viability values after PCI could have been restricted by the MTT’s detection 
limits, since these were already below 20% (96 hr after light). Regarding PDT, cell 
death might have reached a plateau (within the range of light doses tested), being 
necessary to further increase light fluence in order to reflect changes in cell viability. 
This was not relevant to the objectives set for the present chapter and thus was not 
further investigated.  
A similar effect was noted in MatLyLu cells when boosting the light dose to 2.1 J 
(Figure 18 and Figure 19 - light groups’ detail). Although cell viability was significantly 
reduced in all light groups compared to the control cells (i.e. 86% cell death seen after 
TPPS2a 0.4 g/ml and saporin 20 pM), in most cases the smallest differences between 
PDT and PCI were observed at 2.1 J (Figure 18), especially at the higher PS dose (0.4 
g/ml). Nonetheless, statistically significant differences were detected between both 
light doses at the latest cell viability measurement (48 hr post light), possibly because 
cell killing at 24 hr did not yet reach values below MTT’s detection limits (as reported in 
PC3 cells) and reductions could be further noted.  
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Similar studies carried out on HN5, squamous cell carcinoma cells also concluded a 
significant enhancement in cell killing upon photochemical delivery of saporin using the 
same light source specified for the present study (Wang et al., 2012). Specifically, cell 
death was increased at least by a factor of 7.3 compared to saporin-alone or PDT after 
a 3-minute illumination. Yet, saporin dose used then was at least 500-fold higher. 
The last important variable we took into consideration in our “light-after” PCI 
experiments was the interval allowed between drug removal and illumination (DLI). A 4 
hr DLI (chase period) has been reported in traditional PCI in vitro approaches (Selbo et 
al., 2000a; Wang et al., 2012; Weyergang et al., 2006). This has been described to be 
essential to achieve subcellular photooxidation required for PCI rather than a mainly a 
PDT effect, stemming from cell membrane damage. Nonetheless, we wanted to 
observe its relevance during PCI treatment of prostate cancer cells and the effect of 
different DLI (Figure 20, Figure 21, Figure 22). 24 hr after light, TPPS2a-PDT in PC3 
cells did not seem to be affected by the 4 hr DLI, and non-significant differences were 
observed in PCI groups (Figure 20A, Figure 20B). This could suggest a little 
contribution of PDT. In addition, greater differences might be expected if measured at 
later time points (i.e. 96 hr after light) based on the gradual and delayed death seen 
after PCI. On the other hand, DLI could be dependent on the specific PS used, i.e. a 
more prominent PCI effect using TPPS2a might have been obtained as early as 24 hr 
after light using longer DLI in order to minimise PDT-based cell death. As for the 
chlorin-based PS 24 hr after light treatment, only at the higher TPCS2a dose assayed, 
were significant differences found in the PDT group when allowing a chase period 
rather than illuminating immediately after drug removal (Figure 20D). In this particular 
case, PCI effect was similar to PDT in the no-DLI group: it is likely that the high PDT 
effect was responsible in this case for all cell killing.  Viability measurements carried out 
72 hr after light (Figure 21) revealed differences between PDT and PCI for both PS 
used at 0.2 g/ml, being the outcome similar with the higher PS dose (again, the 
increase of PS concentration at this time point is weighted too heavily towards PDT). 
With respect to TPPS2a, this serves as an additional confirmation of the delayed death 
post PCI whilst limiting PDT at acceptable levels.  
The large PDT-induced toxicity and smaller differences between PDT and PCI seen 48 
hr after treatment in MatLyLu (Figure 18) compared to 96 hr in PC3 cells (Figure 16), 
took us to investigate whether an increase in DLI in this model would enhance the 
outcome of PCI treatment (Figure 22). An extension of DLI from 4 hr to 6 hr did not only 
not enhance PCI, but in fact bridged the gap in cell death resulting from both light 
treatments. Contrary to what would have been expected initially, longer DLI may result 
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in the greater breakdown of PS, rendering less active molecules available to be subject 
to the photooxidative process.    
Overall, we conclude that when it comes to DLI, the elected combination of PS dose 
and DLI will determine the balance between PDT and PCI induced cell death. Higher 
doses will require longer DLI to internalise PS molecules and avoid tilting the balance 
towards PDT; yet, this PDT effect using lower PS doses might already be sub lethal 
and negligible even when no chase period is allowed. Consequently, PCI would be 
responsible for the effect observed.  
Some authors have demonstrated an enhancement of PCI following “light-
before” approaches, particularly, when delivering drugs or agents with higher sensitivity 
to ROS species. For instance, Prasmickaite et al. substantially enhanced gelonin´s 
cytotoxicity using “light-before” PCI compared to that observed in the “light-after” 
approach (Prasmickaite et al., 2002). In their study, the most probable mechanism 
behind “light-before” was discussed: a direct entry into the cell cytosol was rejected 
based on the participation of endosomal vesicles; passive diffusion was also rejected 
due to the fast pace at which events occurred. Thereupon, it was hypothesised that 
endosomal vesicles partially damaged by the activation of the photosensitisers, yet still 
intact, -then fused with intact vesicles formed post-light treatment which had more 
recently endocytosed the drug molecules, thus rapidly releasing these into the cell 
cytosol (Prasmickaite et al., 2002) (see schematic representation of “light-before” PCI 
in Figure 9). Following this line of thought, and based on the similar nature of saporin to 
gelonin (RIPs type 1), we looked into the delivery of saporin in PC3 cells following a 
“light-before” PCI protocol. In these experiments, only a modest increase in cell killing 
after PCI was achieved regardless of the PS used or the time point at which cell 
viability was measured (Figure 23). Based on our observations, we hypothesise that 
the endocytic transport in PC3 cells is different to the malignant melanoma cells (THX) 
used in other “light-before” PCI studies (Prasmickaite et al., 2002). A slower fusion of 
PS-disrupted endosomal vesicles with newly formed saporin-containing endosomes 
could be involved, hence if the latter vesicles were not ruptured and saporin-containing 
endosomes matured to lysosomes, this RIP type 1 would trapped in the 
endo/lysosomes and in the end degraded. In the present thesis, the “light-after” 
strategy resulted in significant enhancement of cell death and “light-before” was 
rejected as an alternative approach.  
Based on all the experimental conditions above-discussed, we concluded 1.26 
J as the optimal light dose for the mentioned PS and saporin doses in PC3 cells, 
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reaching maximal therapeutic effect 96 hr after light, potentially resulting in 100% 
tumour-cell death. A similar conclusion could be drawn for MatLyLu cells. Given the 
trend in the increase of cell death overtime after PCI, we hypothesise that had it been 
possible to extended viability experiments to 96 hr after light, no differences would 
have been found between 1.26 J and the highest 2.1 J light dose assayed, keeping 
PDT effect at subthreshold levels in favour of a PCI effect. DLI is dependent on both 
PS employed and light dose. However, as a general rule we could consider that the 
same cytotoxicity could result from higher PS doses with longer DLI with and vice 
versa; yet, specific norms apply to different cell lines (i.e. PC3 vs. MatLyLu). A 
progressive cell killing has been verified after PCI, therefore, there should be not need 
to increase PS or light dose in order to maximise cell death, and the same therapeutic 
effect could be observed over time using subthreshold dosages.  
Finally, the use of a “light-before” protocol did not result in any beneficial effect over the 
more conventional “light-after” PCI for our PS and saporin, thus it was not further 
considered.   
These optimal conditions were additionally assayed in PC3 cells seeded onto three 
dimensional collagen gels and cell death was assessed qualitatively 96 hr after light 
(Figure 30). A live/dead assay was used to measure cell viability in these experiments: 
as described above in the materials & methods section, but only the calcein channel 
was imaged reliably owing to the high background signal affecting the propidium iodide 
channel. Cell density was affected after all light treatments (PDT/PCI using TPPS2a or 
TPCS2a), showing a strong phototoxicity effect after both PDT (Figure 30B, Figure 30F) 
and PCI (Figure 30D, Figure 30H), in a similar manner to findings from 2D viability 
assays. Although differences between PDT and PCI could be detected, they were not 
as clear as concluded in 2D upon 1.26 J light exposure (Figure 16). Further work would 
have been required using Alamar Blue for example, had time permitted. Given the 
greater complexity of 3D gels, a higher light dose was used in these experiments to 
ensure light delivery throughout the whole structure, which might have weighted the 
results towards a bigger PDT effect. A recent evaluation of light dosimetry in 3D 
spheroid ovarian cancer models after PDT (Rizvi et al., 2013), found maximal tumour 
cell killing when using BPD and high light fluence.  
Similarly to our 2D study, no dark toxicity was found (Figure 30A, Figure 30C, Figure 
30E, Figure 30G). Not only dead cells were observed after treating with both PS tested, 
but those cells that remained viable had acquired round morphology, losing their 
characteristic elongated shape (shown in details Figure 30I, Figure 30K post PDT and 
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PCI respectively). This could be an indicative of cell detachment prior to death or else 
due to impact caused to existing interactions between cells and the collagen matrix, or 
even disruption of collagen hydrogels’ structure. However, the consistency of collagen 
hydrogels remained constant throughout, which leads to think this last hypothesis is not 
very likely. Against 2D assays findings, a lower number of cells was seen in saporin-
treated groups both alone (Figure 30L) as well as combined with PS under no light 
(Figure 30C, Figure 30G). The comparison of micrographs of the mentioned saporin-
affected gels, and those subject to PCI, suggest that this RIP has a cytostatic effect in 
PC3 cells unless photochemically delivered, where cytotoxicity is demonstrated. 
Throughout our study, similar conclusions were drawn in 2D and 3D platforms but for 
the cytostatic effect exerted by saporin found in PC3 cells in the 3D models. The spatial 
distribution of cells in the latter might maximise the contact area between PC3 and the 
RIP type 1 concerned, consequently increasing uptake of the drug. Potentially, an 
increase in the available amount of saporin in the environment could lead to an 
increase in the number of molecules of saporin being released from endosomes into 
the cell cytosol. Furthermore, we did not conclude an overestimation of the therapeutic 
effect in 2D viability assays as compared to 3D as stated by other authors previously 
(Antoni et al., 2015). 
 Towards the second half of the results sections (3.4.7., 3.4.8., 3.4.9.) we 
reported the investigation of the subcellular mechanisms behind PDT and PCI. Figures 
14, 23 and 24 serve as an additional visual confirmation of the uptake of TPPS2a and 
TPCS2a (Fig. 14), BPD-MA (Figure 33) and AlPcS2a (Figure 34). The existence of 
adjacent disulphonate groups in TPPS2a, TPCS2a, AlPcS2a confers amphiphilicity to 
these compounds, thus making them more suitable for PCI experiments; in contrast, 
BPD-MA is a traditional PDT PS, mainly inducing a vascular PDT effect (Fingar et al., 
1999; Kim et al., 2014). Structural differences of used PSs could explain the different 
distribution patterns within cells found in initial fluorescence images: discrete cytosolic 
granules for TPPS2a, TPCS2a, AlPcS2a (Figure 24, Figure 34), vs. cytosolic dispersion 
for BPD-MA (Figure 33). These subcellular localisation and redistribution findings 
below-discussed are supported by previous studies such as the ones carried out by 
Wang et al. using TPCS2a in head and neck cancer cells (Wang et al., 2013), AlPcS2a 
and TPPS2a in HUVECs and HT1080 cells (Vikdal et al., 2013) or in BL2-G-E6 cells 
(Berg et al., 1999).  
In PC3 and MatLyLu cells, TPPS2a and TPCS2a granules redistribute and relocate 
throughout the cytosol overtime (Figure 24). This suggests initial localisation of PSs in 
cellular membranes within cytosolic endo/lysosomes (Figure 24A, Figure 24B); yet, the 
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exposure to light of an adequate wavelength (405 nm) excites the compounds, 
disrupting the endolysosomal membranes they are docked in, consequently dispersing 
fluorescence (Figure 24C, Figure 24D). As for AlPcS2a, 1 J light was insufficient to 
observe fluorescence redistribution, but some PDT-based cell death was confirmed 
with the entry of PI in cells from 48 hr (Figure 34). Similar observations resulted from 
the incubation of rat prostate cancer cells with BPD-MA (Figure 33), although PI 
suggested cell death from 24 hr images this was even more significantly noted 48 hr 
after light. Moreover, the cell structure was affected as early as 2 hr after PDT (Figure 
33H). The smaller impact in cell viability found in cells after AlPcS2a alone as opposed 
to BPD-MA confirms the greater suitability of BPD-MA to PDT; while a reduced PDT 
effect (PCI feature) was observed with AlPcS2a. 
Localisation of the conjugate saporin-Alexa-Fluor488® within cells was also studied 
due to the relevance of saporin in the PCI combination experiments (Figure 25, Figure 
26, Figure 27, Figure 28, Figure 29). Colocalisation with lysotracker red in both human 
and rat prostate cancer cells indicates uptake through endocytosis. Correlation of this 
observation with saporin’s limited toxicity when administered to PC3 cells in 2D 
experiments confirms the hypothesis of its entrapment in cytosolic vesicles, thus being 
unable to reach cytosolic ribosomes. However, saporin was able to affect MatLyLu 
cells in 2D as well as PC3 cells in 3D assays to some extent. In these cases, some 
molecules of saporin might experience a different entry into the cells, possibly passive 
diffusion. Confocal images of MatLyLu cells in Figure 15 showed some scattered 
cytosolic fluorescence on top of the granular pattern, which could be a possible 
verification of the above mentioned.  Illumination of cells treated only with the conjugate 
saporin-Alexa-Fluor488® during 10 seconds using a 405 nm laser did not affect the 
granular pattern of green fluorescence as concluded when comparing images taken 
before and after light (Figure 26). Yet, when PC3 and MatLyLu cells had been initially 
incubated with a combination of the conjugate saporin-Alexa-Fluor488® and 
photosensitiser (TPPS2a and TPCS2a respectively) and illuminated with the same 405 
nm laser during 10 seconds, the pattern of fluorescence before and after light was 
affected (Figure 27, Figure 28, Figure 29). This can be interpreted as a disruption of the 
vesicles containing the fluorescent conjugate caused by the excitation of 
photosensitisers after light of an adequate wavelength, which concludes with the 
dispersion of fluorescent granules throughout the cell cytoplasm (Figure 27C, Figure 
28C, Figure 29C), as reported by Wang et al. (Wang et al., 2013). A similar 
redistribution of gelonin was found combined with AlPcS2a (Selbo et al., 2000a).  
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Moreover, cell integrity seemed to be compromised in the bright field images taken 5 
(Figure 27C) and 10 (Figure 29C) minutes after illumination of PC3 or MatLyLu cells 
respectively, indicated by the adoption of a round shape probably due to cell 
detachment from plates. The faster effect observed in human than rat prostate cancer 
cells could correlate with the more relevant enhancement of cell death post PCI 
measured in viability assays (Figure 16 and Figure 18). 
Extrapolating these in vitro observations to an in vivo context, the performed 
investigation serves as proof of principle that PCI can result in a positive therapeutic 
outcome, which can exceed that of PDT, being developed for prostate cancer clinically 
(Azzouzi et al., 2013, 2015; Kawczyk-Krupka et al., 2015b; Moore et al., 2009). PCI 
should therefore be capable of causing more efficient tumour eradication, with a lower 
PS dose thereby minimising side phototoxicity.  
In summary, 0.2 µg/ml of either TPCS2a or TPPS2a combined with saporin 10 
nM and exposed to 1.26 J light, resulted in an optimal therapeutic effect in PC3 cells. 
On their side, MatLyLu light-based treatments exhibited a fine performance combining 
a 0.4 µg/ml photosentitiser solution and saporin 20 pM during a 1.26 J illumination. 
Based on the above presented results, we conclude the need to tailor 
treatments to specific cancer types based on differences seen in therapeutic outcome 
after light treatments in the different cell lines use. 
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Chapter 3 Enhancement of PDT and PCI using 
targeted strategies 
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3.1 Introduction  
One of the main advantages of photodynamic therapy and consequently photochemical 
internalisation, is the minimal toxicity associated with photosensitisers unless exposed 
to light. Generally, PS are hydrophobic molecules, and therefore it is challenging to 
select deliverable formulations of these. Some of the ones used currently consist of 
organic (i.e. dextrose) or lipid-based (i.e. Cremophor) excipients which can in turn 
cause an unpredictable biodistribution of the compounds.  Even if PSs accumulate in 
healthy tissues, side toxicity is minimised (this occurs in most cancer treatments, i.e. 
chemotherapy), since no therapeutic effect will be achieved unless PSs are excited 
with a particular wavelength of light (see schematic PDT in Figure 35). Hence, great 
specificity can be reached and more importantly, even if repeated treatments are 
needed (Master et al., 2013).  
Founded on the two basic components involved in PDT (light and PS), it is possible to 
enhance selectivity of treatments in a dual manner: enhancing accumulation of PS in 
tumour tissue or else improving irradiation-specificity. Nowadays there is constant 
development and improvement of fibre-optic laser technology to enhance the focalised 
delivery of light; yet, side phototoxicity is still currently reported. For instance, although 
optical fibres were used, genitourinary side effects were found in motexafin lutetium-
based PDT for the treatment of locally recurrent prostate cancer (Verigos et al., 2006).  
 
Figure 35. Schematic representation of PDT for cancer treatment.  
During a PDT approach, systemic administration and distribution of PSs is followed by the application of 
light of a specific wavelength known to excite the PS used.  
Passive tumour targeting of PS has been explained through “EPR effect”, as stated in 
Background and Introduction. Whilst passive targeting is non-specific, active targeting 
of treatment to tumours can be achieved. Ideally, molecular targets to direct treatments 
against tumours should play differential roles in cancer and healthy cells. Some of the 
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most relevant changes in malignant cells include transformations at a genetic level and 
related pathways. However, a more frequent approach to develop targeted strategies 
implies phenotypic disparities between cancer and normal cells, some of which might 
correlate with underlying genetic transformations. Some of these are for example 
changes in protein expression levels (Andrews et al., 2010). In line with this, moieties 
used in targeted strategies generally bind molecules that are exclusively expressed or 
whose expression has been significantly increased in diseased cells, in some 
occasions even combined in multiple targeting strategies, some of which will be 
reported down below (Huang and Oliff, 2001).  
The most commonly used approaches involve the use of antibody-antigen- and 
receptor-mediated- targeting. The use of monoclonal antibodies can ease drug uptake; 
yet, it can also result in a decreased biological activity, reduction of stability of the 
compounds or internalisation difficulties due to the associated increase in size. As for 
receptor-mediated approaches, low-density lipoproteins, growth factors (i.e. insulin-like 
growth factor –IGF–, transferrin, endothelial growth factor –EGF–, folate), albumin or 
nuclear localisation signals (NLSs) among others have shown great affinity for 
corresponding receptors in cancer cells. This strategy can be hampered if receptors 
are not just expressed in tumours but also unwanted locations (e.g. metabolically active 
tissues express EGFR, receptor that is highly expressed in tumours). In this case, the 
receptor expression ratio between tumour and normal cells will determine the 
effectiveness of the targeting.  
In line with the biodistribution and localisation of PS in target tissues, it is largely 
important to consider the correlation between the physicochemical properties, 
structural features of the photosensitiser compounds and their bioavailability (Boyle 
and Dolphin, 1996). For instance, hydrophobic PS need to be administered in an 
adequate vehicle due to lack of solubility in water, whose nature will determine the 
interaction with biological proteins and significantly affect the concentration of PS in 
tumour tissue. In line with this, the aggregation of hydrophobic photosensitisers within 
the lipidic tumour microenvironment exerts a major effect. On the other hand, 
hydrophilic PS generally lack a delivery vehicle and in this case, PS design will play a 
major role (i.e. charged PS tend to have a greater interaction with tissues in a pH-
independent manner) (Boyle and Dolphin, 1996).  
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3.1.1 Targeted PDT and PCI 
The most successful approaches in targeted PDT involve physical conjugation of 
photosensitisers to antigens or receptors found on tumour surfaces. As regards 
targeted strategies in PCI, additional targeting subjects arise from the combination of 
two different therapeutic agents: both targeted PS-conjugates and biologically active 
drugs-conjugates can be designed. As a matter of fact, since its development, PCI has 
been used to enable the delivery of large macromolecular drugs that experience 
difficulties penetrating cellular membranes due to their large size, i.e. immunotoxins, 
which have an important role in targeted strategies.   
An important consideration in these approaches involves the contemplation of tumour-
specific molecules not only in the parenchyma but also in the stromal tissue. In line with 
this, a more effective targeted therapeutic strategy might involve the previous 
molecular characterisation of the tumour structure under investigation. This would 
enable a major focus on the former, identifying markers with a more important role in 
the aggressiveness of a tumours mass (Hamoudi et al., 2010). 
Following the above, several targeted PDT and PCI studies have been performed to 
date in vivo and in vitro, some of which will be reviewed below.   
Folate receptor 
One upregulated molecule on many human malignancies is folate receptor 
(glycosylphosphatidylinositol anchored cell surface receptor). Its expression is limited in 
healthy tissues and it is frequently associated to highly aggressive types of cancers. In 
particular, folate receptor’s up-regulation has been verified in 90% of ovarian tumours 
as well as other cancer types including kidney, endometrial, mesothelioma, breast, 
brain and myeloid leukaemia (Parker et al., 2005). Yet, cancers of the prostate, 
bladder, liver, lymphomas and sarcomas present normal levels of folate receptor.  
Expression of this receptor happens in normal tissues within lungs, choroid plexus, 
kidneys and placenta and is restricted to the apical surface of polarised epithelia 
(Zwicke et al., 2012). Folic acid is a small, non-immunogenic ligand, stable over a 
broad range of temperatures and pHs, capable of recognising the folate receptor. For 
all the above, it is broadly used in targeted strategies. It has been used in several 
occasions in PDT in combination with albumin as a carrier vehicle. Albumin is subject 
to EPR effect owing to its size and can be metabolised by activated cells as a source of 
amino acids and energy, which is increased in malignant cells due to their high 
Enhancement of PDT and PCI  using targeted strategies 
 
 
116 
proliferative activity (Neumann et al., 2010). In the recent study carried out by Butzbach 
et al. using polar -carboline derivatives bound to folate-tagged albumin as 
photosensitisers, the phototoxicity caused by the conjugates was demonstrated. It 
required cellular uptake of the conjugates and was lysosomal dependent. It was 
concluded that PS coupling to folate-albumin could become a new strategy to avoid 
undesired side phototoxicity to cells lacking active folate endocytosis (Butzbach et al., 
2016).  
Transferrin receptor 
Transferrin receptors are iron binding proteins found ubiquitously expressed in most 
human tissues at low levels but several fold highly overexpressed in tumour cells, and 
whose levels can also be related to tumour stage and progression. They are located in 
cell membranes and uptake occurs in a clathrin/dynamin dependent manner (Daniels 
et al., 2012). Based on the need of iron in cancer cell proliferation, transferrin is another 
frequently employed molecule for targeted treatments, PDT among others. Specifically, 
transferrin-haematoporphyrin (Tf-Hp) resulted in at least 6-fold higher phototoxicity 
compared to the untargeted counterpart, observing different sensitivity in the different 
cell lines assayed. This was probably due to dissimilarities between lipid bilayers in cell 
membranes, which could have influenced penetration and binding of Hp. In addition, a 
faster cell death was found with targeted compounds in addition to the enhanced 
specificity (Laptev et al., 2006). In a different study, no improvement was found in 
intracellular uptake or phototoxicity using transferrin-bound PEGylated Foscan-loaded 
liposomes for PDT treatment of oesophageal cancer cells in vitro. It was hypothesised 
that membrane destabilisation could have resulted in Foscan leakage from the Tf-
vehicles (Paszko et al., 2013), indicating the importance of the optimal preparation of 
formulations.  
EGFR receptor 
Epidermal growth factor receptors (EGFR) are cell surface molecules belonging to the 
tyrosine kinase family of proteins with abnormal expression in malignant cells. Like the 
molecules reported above, EGFR is associated to survival and prognosis. Targeting 
EGFR has been achieved using both monoclonal antibodies (mAbs) and tyrosine 
kinase inhibitors (TKIs). Cetuximab and panitumumab are the two most advanced 
mAbs recognising the extracellular domain of EGFR molecules. On their side, TKIs act 
on the intracellular domains of the receptor inhibiting signalling cascades initiated by 
tyrosine kinase (Yewale et al., 2013). EGFR plays an essential role in regulation of 
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proliferation, differentiation and survival, hence its up-regulation in malignant cells. 
Besides, several ligands can bind to the receptor such as: endothelial growth factor 
(EGF), transforming growth factor alpha (TGF-), heparin-binding EGF, epigen, 
betacellulin, amphiregulin, epiregulin, neuregulin-2, etc., expanding the possibilities to 
target this receptor. Recently, the second generation PS phtalocyanine Pc4 was 
formulated within micelles and bound to the GE11 ligand (known to bind to the 
receptor) so as to target EGFR (Master et al., 2012). An enhanced uptake of the 
modified PS was observed in human epidermoid carcinoma cells within just 2 hours. 
Dispersion of fluorescence was also observed overtime appearing in a punctuated 
manner at the 6 hr time point and being homogeneously spread throughout the cytosol 
at 24 hr Non targeted micelles were also able to enter the cell cytosol, yet, this was 
time and concentration dependant, suggesting receptor-mediated endocytosis occurs 
at an earlier time point. Regarding PDT effect induced by targeted formulation of PS, 
significant differences in cell death were observed at the lowest PS concentrations, 
while no differences were detected at the highest doses. This is indicative that lower 
doses could be employed for targeted-PS (Master et al., 2012). A recent study 
performed in vivo PDT using nanobody-conjugated PS specifically recognising EGFR. 
This conjugate was the only one assayed causing necrosis in 90% of the tumours, 
confirming its potential in PDT for head and neck cancer treatment (van Driel et al., 
2016).   
EGFR has also been targeted in PCI approaches on several occasions. For instance, 
very high cytotoxicity was observed combining EGF-saporin with TPCS2a, using drug 
doses as low as 1 pM in a EGFR+/ABCG2+ population of human breast cancer cells. 
ABCG2 is an efflux pump largely responsible for multidrug resistance in malignant 
cells. Accordingly, it was concluded that PCI photosensitisers could escape recognition 
by such pumps and overcome the multidrug resistance shown in numerous cancer 
treatments (Selbo et al., 2012). Comparatively, EGF-saporin was able to induce 
cytotoxicity at 2pM in ovarian cancer cells, while no cell killing was observed up to 
10pM in a breast cancer model. No differences were found after PCI on uterus 
sarcoma and breast cancer EGFR¯ control cells between targeted and non-targeted 
saporin (Weyergang et al., 2006). A similar therapeutic outcome resulted from the 
conjugation of saporin to Cetuximab. Negligible cytotoxicity resulted from untargeted 
saporin as opposed to the enhanced cell killing exhibited by the targeted conjugate in 
colorectal and prostate cancer cell lines. Minor effects observed were considered to be 
due to non-mediated receptor endocytosis of the drug (Yip et al., 2006). 
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Human Epidermal Growth Factor receptor (HER2) 
HER2 (Erb2, c-erbB2, HER2/neu) belongs to the family of epidermal growth factor 
receptors, but due to its relevant role among other proteins of ErbB family, its 
participation in targeted strategies will be independently reviewed. HER2 is involved in 
cell growth, differentiation, survival; and its overexpression and up-regulation have 
been associated with the malignant transformation of cells, being directly related to a 
poor prognosis in ovarian, gastric, prostate and breast cancer among others (Tai et al., 
2010). The anti-HER2 antibody clinically available Herceptin (trastuzumab) led to a 
major advance in breast cancer treatment. Conjugation of saporin with this antibody 
resulted in an enhanced PCI effect when approaching with a light-after procedure (see 
Chapter 2 for a detailed description of light –before/–after PCI). On the other hand, 
light-before altered the integrity of the receptor and consequently reduced cytotoxicity 
(Berstad et al., 2012). In a study performed with gelonin targeting HER2 in cell lines 
with varied HER2 expression, it was concluded that sensitivity of malignant cells to 
drugs has to be taken into consideration in addition to toxin uptake levels (Bull-Hansen 
et al., 2014). Recently, a photosensitiser was also modified to target HER-2 
oesophageal carcinoma cells (Pye et al., 2016). Specifically, a fragment of trastuzumab 
was covalently bound to a near infrared dye and chlorin (main photosensitive 
component). This structure was investigated as a theranostic platform used for both 
fluorescence cell-labelling of HER-2 tumour cells and PDT, concluding a successful 
binding to the target cells in addition to an effective PDT effect (Pye et al., 2016).  
Endothelial glycoprotein-2 
EGP-2, also known as Ep-CAM, is an epithelium specific marker highly expressed in 
human carcinomas (McLaughlin et al., 2004). Epitopes in EGP-2 molecules can be 
recognised by monoclonal antibodies such as MOC-31, then endocytosed by target 
cells. This specificity has been exploited in PCI studies, i.e. designing MOC31-gelonin 
immunotoxins and combining it with different photosensitisers. The same effect was 
observed with both targeted and untargeted toxin in cells exhibiting low EGP2 
expression; yet, EGP-2+ small cell lung carcinoma cells were significantly more 
affected by MOC31-gelonin than free toxin (Selbo et al., 2000b). In vivo, promising 
results were observed in mice bearing human colorectal tumours treated with MOC31-
gelonin and AlPcS2a. Tumours were completely eradicated in 6 out of 9 animals (Selbo 
et al., 2001).  
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CD133 
There is growing interest nowadays in directing treatments against progenitor cells in 
cancer, which are thought to sustain proliferation and survival of tumour masses. In line 
with this, CD133 is a surface molecule described in cancer stem cells, indicator of 
aggressive tumours with high proliferative and tumour-formation capacity, highly 
resistant to treatments, in turn resulting in low prognosis (Ren et al., 2013). 
Targeting CD133 in PCI has enabled the reduction of drug doses very notably. For 
instance, CD133-saporin nearly completely eliminated colorectal cells (highly 
expressing CD133) in vitro using femtomolar drug doses. In this case, saporin alone 
resulted in similar cell death to that of PDT. Moreover, viability of PDT-resistant 
pancreatic cancer cells with lower expression of CD133 than the colorectal cell line in 
the same study was reduced to 10% after PCI (Bostad et al., 2013).  
3.1.2 CXCR4 receptor and cancer: focus on prostate 
tumours 
CXCR4 is a chemokine receptor belonging to the G-protein-coupled family of 
receptors, with an important role in haematopoiesis, immunity and organogenesis 
among others. Changes in its expression have been observed in diseases including 
cancer. Specifically, dysregulation of this receptor has been observed in metastasis, 
resulting in enhanced signalling. An additional role as correceptor for the entry of HIV 
has been confirmed. Stromal cell-derived factor 1 (SDF-1) also known as C-X-X motif 
chemokine 12 (CXCL12) selectively binds to CXCR4 (Furusato et al., 2010). The 
expression of CXCR4 in normal healthy tissues is uncommon and its expression in 
cancer could be hypoxia-induced: hypoxia during tumour progression triggers the 
production of hypoxia-inducible factor 1 (HIF-1) which is associated to the expression 
of CXCR4 among others. Vascular endothelial growth factor (VEGF) or nuclear factor 
kappa  (NFK) could also be participants in the increased expression of CXCR4.  
The stem cell origin of cancer has been demonstrated in different types of cancer, 
including prostate tumours. In line with this, surface markers CD133 and CD44 have 
been recognised as stem cell markers and have been identified in cell populations 
within the prostate gland epithelia. These cells exhibit a highly upregulated expression 
of CXCR4, as shown in the stem cell subset isolated from the human prostate cancer 
cell lines PC3 and DU145 (Dubrovska et al., 2012). CXCR4 is also expressed in 
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normal stem cells in the prostate and it is hypothesised that cancer stem cells might 
derive from prostatic stem cells (Dubrovska et al., 2012; Singh et al., 2004).   
Participation of SDF-1 in stem cell homing has been reported; consequently, 
expression of CXCR4 in cancer suggests a participation in metastasis to organs with 
SDF-1 expression such as lymph nodes, lungs, liver and bones. In addition, bone 
metastases which is a characteristic in prostate cancer patients, might occur in an 
organ-specific manner founded on the CXCR4-SDF-1 axis reported above. In greater 
detail, tumours require host cells to ensure survival and proliferation, participating in the 
creation of niches within tumour masses that protect cancer stem cells from various 
external stresses. These participating cells might also be involved in the generation of 
distant premetastatic niches that will in the end ease tumour migration. Among these 
cells, mesenchymal stem cells (MSCs) were recently identified as an implicated cell 
type, recruited by different cytokines. MSCs can differentiate into cancer-associated 
fibroblasts (CAF), in charge of creating cytokine networks necessary for migration and 
progression of cancer. Prostate tumours recruit MSCs; precisely, within tumours, 
CXCL16 interacts with CXCR6 expressed by MSCs, which later differentiate into CFAs 
and secrete CXC12, responsible for the promotion of the epithelial-to-mesenchymal 
transition (EMT) of malignant cells (Jung et al., 2013). The interaction between CXCR4 
and CXC12 induces the activation and signalling of tumour-associated integrin, which 
enhances adhesion in circulating cells; besides, it also triggers the expression of 
metalloproteinases (i.e. MMP-2) involved in degradation of cell invasion barriers as is 
the case of the extracellular matrix (Singh et al., 2004; Zhang et al., 2008).  
Expression of CXCR4 has been verified in PC3 human prostate cancer cells on several 
occasions (Dubrovska et al., 2012; Hatse et al., 2002; Singh et al., 2004; Zhang et al., 
2008). 
3.1.2.1 vMIP-II selectively binds CXCR4 
vMIP-II (viral macrophage inflammatory protein II), also known as vCCL2 (viral CC 
motif chemokine) is a chemokine expressed by human herpesvirus 8, that alters the 
chemokine network in the host to successfully carry out the infection cycle and escape 
from the protection conferred by the immune system (Szpakowska and Chevigne, 
2016). A high affinity interaction between vMIP-II and CC and CXC chemokine 
receptors has been described: these host chemokine receptors are used by HIV-1 as 
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coreceptors to enter cells, the most relevant being CXCR4 and CCR5. Specifically, the 
N-terminal of this protein is thought to be responsible for such interaction (LiWang et 
al., 1999). In human target cells, viral entry is in fact inhibited by chemokines binding to 
CXCR4 such as SDF-1. 
Since its discovery, vMIP-II has been modified to promote receptor-selectivity. 
Following these lines, a peptide derived from the N-terminal of the protein was 
developed, confirming its interaction with CXCR4 but not CCR5. The relevance of the 
chosen fraction of vMIP-II protein has been confirmed, clarifying existing differences in 
binding between vMIP-II and CCR5 or CXCR4. Critical residues within the sequence of 
the vMIP-II peptide have also been identified, most of which are positively charged 
(Luo et al., 2000).  
 
 
Figure 36. HIV vMIP-II.  
NMR structure of the anti-HIV chemokine vMIP-II and sequence of aminoacids 1-21 binding CXCR4. 
Image adapted from the Protein Data Bank. 
3.1.2.2 AMD3100 as CXCR4 inhibitor 
AMD3100 (Plerixafor) is a bicyclam, non-peptide antagonist of CXCR4, originally 
designed as an anti-HIV molecule through inhibition of viral replication. In this context, 
although gp120 glycoprotein (located in the viral envelope) seemed to be its target of 
action, this was only an indirect target; while CXCR4 coreceptor was found to be a 
direct target. Initial trials carried out with plerixafor unexpectedly increased the levels of 
CD34+ cells (hematopoietic stem cells) in peripheral blood: blockage of the interaction 
CXCR4-SDF-1 mobilised these stem cells, preventing their homing in the bone 
marrow. 
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Figure 37. AMD3100, octahydrochloride hydrate.  
Structure of AMD3100 (Plerixafor), CXCR4-selective inhibitor. 
As for the inhibition now concerning (AMD3100-CXCR4), binding to CXCR4 receptor 
has been reported to be highly specific and concentration dependent, showing no 
interaction with other chemokine receptors such as CXCRX1, CXCR2, CXCR3, CCR1, 
CCR2, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, CCR9 (Hatse et al., 2002). 
Agonistic effects of AMD3100 were rejected based on the lack of cell migration and 
intracellular calcium mobilisation induced in the same study. In a different study, 
AMD3100 displayed an inhibitory effect on the interaction between a derivative of the 
vMIP-II protein above reported and CXCR4 (Yang et al., 2014). 
3.1.3 Cell-penetrating peptides 
In addition to the above reported specificity conferred by proteins and molecules 
present in tumours at higher levels, or even exclusively expressed in malignant cells, a 
very common targeting strategy nowadays involves the use of cell penetrating 
peptides, which have proven to significantly enhance intracellular delivery.  
The hydrophobic nature of the external cell membrane protects cells from the 
surrounding environment, limiting access to the cellular interior to molecules of small 
size. However, available drugs are increasingly large these days, posing major 
limitations to their entry into cells. Cell-penetrating peptides (CPPs) have been 
frequently used as delivery vehicles for large molecular weight drugs (Madani et al., 
2011).  
CPPs, also known as Trojan peptides, membrane translocating sequences or protein 
transduction domains, are short peptide sequences (< 40 amino acids long), partially 
hydrophobic, water-soluble and characterised by the presence of positively charged 
residues at physiological pH (necessary to interact with negatively charged residues 
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within the lipid bilayer). CPPs are capable of penetrating cellular membranes while also 
carrying a wide range of biologically active cargoes efficiently (i.e. polymers, liposomes, 
low molecular weight drugs, nucleic acids, nanoparticles, etc.). They can successfully 
achieve this even at low micromolar concentrations (transport is generally dose-
dependent) and in the absence of chiral receptors, while maintaining the integrity of cell 
membranes. The sequence and structure of these CPPs can be modified in order to 
enhance the delivery of biologically active drugs. For instance, replacement of lysine 
residues with ornithine confers protection to cellular degradation, modification of the 
peptides to cyclic peptides or dendrimers improves the delivery efficiency (Copolovici et 
al., 2014).  
CPP-mediated delivery is generally non-specific and thus cell-specific peptides can be 
included to increase specificity. The mechanisms behind membrane penetration have 
not been completely elucidated, yet, there is supporting evidence of it occurring via 
energy-independent processes or endocytosis. This last mechanism seems to be the 
most likely for low-CPP concentrations (Madani et al., 2011; Schwarze et al., 2000).   
Among all CPPs discovered to date, HIV-1 TAT and penetratin (Antp) exhibit the 
greatest protein-transduction efficiency.  
3.1.3.1 TAT peptide 
Discovered in 1988, HIV TAT transactivating factor served as a basis to develop CPPs. 
TAT peptide currently used as CPP is the truncated version of a protein found in 
human HIV-1 virus, and is essential in viral replication (Bayer et al., 1995; Watson and 
Edwards, 1999). 
TAT peptide has been used on numerous occasions to enhance the outcome of PDT 
studies. For instance, TAT-conjugated gold nanostars showed significantly increased 
accumulation and photosensitisation in breast cancer cells in vitro, whereas no 
therapeutic benefit was observed with the non targeted counterpart (Fales et al., 2013). 
In a different study, no presence of the PS AlPcS2a was demonstrated in KB and HeLa 
cells unless targeted with TAT. In addition, experiments carried out at 4C showed 
some uptake in both cell lines, which was significantly increased when higher 
temperatures were used. This indicates that despite passive diffusion is responsible for 
some of the PS-TAT conjugate’s uptake, most of it occurs through endocytosis (Zhao 
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et al., 2011). Initial in vitro experiments in PC3 cells and later in vivo biodistribution 
studies confirmed higher tumour-selectivity of porphyrin-TAT compounds in a prostate 
cancer mouse model as opposed to non targeted mTHPC and hematoporphyrin 
derivative. Significant phototoxicity was also verified, and dark toxicity was minimised 
using the targeted conjugate (Sehgal et al., 2008). 
Furthermore, TAT peptide has also been employed in a targeted-PCI study (Wang et 
al., 2012). In this case, TAT-TPP did not only exhibit an enhanced uptake and light-
toxicity (even at low concentrations) in head and neck cancer cells compared to free 
TPPS2a, but restriction of subcellular localisation to endo/lysosomal compartments was 
concluded (key requisite in PCI approaches). This was confirmed in fluorescence 
microscopy as well as spectroscopic analysis of the compounds, where a red shift in 
the emission of fluorescence was attributed to binding of the compound to lysosomal 
membranes (Wang et al., 2012).   
 
Figure 38. HIV-1 TAT protein.  
NMR structure of HIV-1 TAT protein and sequence of aminoacids of TAT peptide used as CPP. Image 
adapted from the Protein Data Bank. 
3.1.3.2 Penetratin peptide 
Homeoproteins are trans-activating factors with the intrinsic capacity to bind DNA 
through their homeodomain. Homeodomains are highly conserved across species and 
consist of three -helices, the third of which is particularly relevant in target DNA 
sequence recognition. Penetratin is a peptide of the homeodomain found in the third 
helix of Drosophila Antennapaedia transcription factor (Dupont et al., 2011).  
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Alike TAT peptide, membrane penetration of penetratin is not completely inhibited at 
low temperatures, confirming endocytosis plays a major role but internalisation can 
also follow an energy-independent route (Derossi et al., 1994; Dixon et al., 2007). 
Additionally, this internalisation is not completely unspecific, as confirmed by the lack of 
internalisation exhibited by truncated versions of the peptide (Derossi et al., 1994).    
 
Figure 39. Antennapedia Penetratin.  
NMR structure of the third helix of Antennapedia homeodomain and sequence of aminoacids of Antp 
peptide used as CPP. Image adapted from the Protein Data Bank. 
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3.2 Aims 
Chapter 3 focuses on the potential enhancement of PDT and PCI in prostate cancer 
following targeted approaches in vitro. Therefore, the main aim of the present chapter 
was to compare therapeutic outcomes resulting from targeted and non targeted light-
based therapies.  
In order to enhance light-treatments in our prostate cancer model, three different 
photosensitiser conjugates were examined. All of these consist of a main 
photosensitive component (TPP-) bound to either cell penetrating peptides alone (TAT, 
Antp) or conforming a targeting chimaera (vMIP-II-TAT).  
Following a similar outline as Chapter 2, the first couple of sections reported assessed 
the potential benefit targeting strategies offer through measurement of cell viability after 
PDT and PCI treatments. The optimal parameters determined in Chapter 2 served as 
basis for the experimental procedures carried out in the present chapter. PCI 
procedures require the initial determination of PS-conjugate doses yielding 
subthreshold PDT. These assessments of cell viability were followed by the 
observation of the biological mechanisms behind targeted PS-derivatives in PDT and 
PCI through the observation of their subcellular localisation.  
Should CPP-derived strategies produce better results, we hypothesise that side 
phototoxicity after PDT and, hence, PCI, could be significantly reduced or even avoided 
by using lower drug doses (photosensitiser or a combination of photosensitiser and 
biologically active drug), whilst maintaining the tumour-eradication capacity of both 
PDT and PCI treatments.  
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3.3 Materials & Methods 
Cell work 
Both targeted- PDT and PCI experiments were performed on PC3 human cancer cells 
(see detailed description in Chapter 2, Materials & Methods section).  
Synthesis of TAT-TPP, Antp-TPP, vMIP-II-TAT-TPP conjugates 
Synthesis of targeted conjugates was carried out by Dr. Ruggero Dondi from the 
Department of Pharmacy and Pharmacology, University of Bath. Three different TPP 
(tetraphenylporphyrin)-based compounds were conjugated via click chemistry. 
Targeting peptides were previously prepared through solid phase peptide synthesis 
according to the Fmoc strategy (see Appendix for detailed description of the synthesis 
of conjugates) 
Three conjugates were designed: TAT- (48-57) and Antp- derivatives as well as a 
vMIP-II-TAT (48-57) chimaera (CPP and CXCR4 targeted). The structure of TPP-
derivatives is displayed in Figure 40. TAT-TPP consists of the TAT protein (residues 
48-57) linked to tetraphenylporphyrin through a linker, attaching one of the porphyrin’s 
phenyl ring to TAT peptide (Figure 40A). Antp-TPP is composed of penetratin peptide 
linked to one of the tetraphenylporphyrin’s phenyl rings (Figure 40B). Finally, vMIP-II-
TAT is a chimaeric conjugate combining two distinct targeting moieties: N-terminal 
sequence of vMIP-II peptide directly linked to TAT protein (residues 48-57), which is 
bound to one of the tetraphenylporphyrin’s phenyl rings (Figure 40C).  
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Figure 40. Structure of TAT-TPP (A), Antp-TPP (B), vMIP-II-TAT-TPP (C) conjugates.  
Molecular weight 2770.47877, 2058.02929, 4134.14609 (g/mol) respectively. The red box indicates TPP in 
the compounds. 
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Chemicals and photosensitisers solutions 
Saporin (see detailed description in Chapter 2, Materials & Methods section). 
Saporin-Alexa-Fluor488® conjugate (see detailed description in Chapter 2, Materials & 
Methods section). 
TPPS2a (see detailed description in Chapter 2, Materials & Methods section). 
TPP-conjugates were dissolved in water, storing the aliquots at 4°C. Experimental 
concentrations were obtained diluting a 10 nM solution in cell media to reach desirable 
concentrations. 
AMD3100 was purchased from Sigma (A5602). The stock solution was prepared by 
dissolving the powder in distilled water at 10 mg/ml. Dilutions were then prepared in 
PBS and the resulting aliquots were stored at 4°C. Experimental solutions were 
obtained further diluting in cell media to reach desirable concentrations.  
Light source  
LumiSource® (PCI Biotech, Norway) was used to excite cells exposed to TPP-
conjugates and TPPS2a in vitro (see detailed description in Chapter 2, Materials & 
Methods section). 
PS spectral measurements 
Different photosensitiser solutions were prepared in methanol to a final 8 µM 
concentration. The same procedure reported in Chapter 2 was then followed (see 
detailed description in Chapter 2, Materials & Methods section).  
TPP-conjugates uptake  
The same procedure reported in Chapter 2 for TPPS2a / TPCS2a uptake in PC3 cells 
was followed (see detailed description in Chapter 2, Materials & Methods section).  
PDT-dose response curves 
The same procedure reported in Chapter 2 for PS dose-response curves in PC3 cells 
was followed (see detailed description in Chapter 2, Materials & Methods section).  
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PDT & PCI (combination) experiments 
The same procedure reported in Chapter 2 for “light-after” PCI was followed combining 
saporin and TPP-conjugates in PC3 cells (see detailed description in Chapter 2, 
Materials & Methods section).  
AMD3100 inhibition experiments 
PC3 cells were seeded on 96-well plates at 8000 cells/well. Cells were allowed to grow 
for 24 hr before administering solutions of AMD3100 ranging 0.01 – 25 g/ml prepared 
in cell media. Different procedures were then followed: 
 1 hr after incubation with AMD3100 plates were washed once with PBS and 
solutions combining TPP-conjugates 12 – 200 nM and AMD3100 at 25 and 50 
g/ml prepared in cell media were administered, incubating cells for 24 hr.  
 1 hr after incubation with AMD3100 plates were washed once with PBS and 
solutions combining TPP-conjugates at 50 nM and AMD3100 at 0.01 – 25 g/ml 
prepared in cell media were administered, incubating cells for 24 hr.  
 24 hr after incubation with AMD3100 plates were washed once with PBS and 
solutions combining TPP-conjugates at 50 nM and AMD3100 at 0.01 – 25 g/ml 
prepared in cell media were administered, incubating cells for 24 hr.  
Hereafter, plates were washed once with PBS and wells were replaced with fresh 
media. After a 4 hr-cell recovery period, plates belonging to “light” groups were 
illuminated. Cell viability was measured 48 hr after light treatment. Plates were kept in 
a 37°C humidified atmosphere containing 5% CO2 at all times, those involving 
photosensitisers were wrapped in foil and corresponding experimental procedures 
were carried out protected from light to avoid unintended excitation of photosensitisers. 
Analysis of cell viability in two dimensional models 
MTT was used to observe cytotoxicity in 2D experiments (see detailed description in 
Chapter 2, Materials & Methods section) 
Subcellular localisation of TAT-TPP, Antp-TPP, vMIP-II-TAT-TPP 
The same procedure reported in Chapter 2 for subcellular localisation of TPPS2a / 
TPCS2a in PC3 cells was followed (see detailed description in Chapter 2, Materials & 
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Methods section). In this case, a 400 nM solution of the TPP-conjugates was 
administered to PC3 cells. The same excitation wavelength and imaging settings 
described in Chapter 2 were used to acquire micrographs of the conjugates under 
study.  
Subcellular localisation of saporin-Alexa-Fluor488® conjugate 
The same procedure reported in Chapter 2 for subcellular localisation of saporin-Alexa-
Fluor488® in PC3 cells was followed (see detailed description in Chapter 2, Materials & 
Methods section). In this case, a 100 nM solution of the TAT-TPP was co-administered 
to PC3 cells. The same excitation wavelength and imaging settings described in 
Chapter 2 were used to acquire micrographs of the conjugates under study. 
Statistical analysis 
Statistical analysis was performed using GraphPad prism 6. Two-way ANOVA followed 
by Bonferroni post hoc multiple comparison was used.  Data is displayed as mean with 
error bars +/- SEM; significance level of p < 0.05 (*p = 0.05 to 0.01; **p = 0.01 to 0.001; 
***p = 0.001 to 0.0001)  
In MTT cell viability assays, each data point was the result of experiments carried out in 
triplicate and each of these repeats was the average of 8-16 wells. All experiments 
were carried out in triplicate but for AMD3100 inhibition pilot study, where data points 
are a single average of 8-16 wells.  
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3.4 Results 
3.4.1 Photosensitiser spectra 
Every PDT and PCI treatment requires an initial spectroscopic study of PS to 
determine the optimal excitation wavelength and maximise photooxidation. Following 
these lines, as performed with the photosensitisers reported in Chapter 2, absorption 
and emission spectra of all the TPP conjugates were measured (Figure 41). 
 
Figure 41. Absorption and emission spectra of TAT-TPP (A), Antp-TPP (B) and vMIP-II-TAT-TAPP 
(C) in methanol (8 µM). 
Emission spectra were taken exciting the TPP-conjugates at 420 nm, cut-off filter set at 515 nm. 
All TPP-conjugates exhibited a similar spectrum, showing an absorption peak at 
around 414 nm. A weaker absorption around 520 nm was also found in all three 
conjugates. All fluorescence emission peaks were found in the red region of the 
spectra (around 650 nm).   
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3.4.2 TPP-conjugate uptake in prostate cancer cells 
Again, as performed with photosensitisers in Chapter 2, emission of fluorescence in 
PC3 cells was measured after incubating these with increasing concentrations of the 
TPP-derived photosensitisers (12-80 nM), then related to the cellular uptake of the 
conjugates. A linear relationship between intensity of fluorescence and PS dose was 
found in all three compounds. Moreover, no plateau was seen (see Fig. 8). 
Uptake of TPP bound to Antp (represented by green squares) was significantly higher 
compared to that exhibited by vMIP-II-TAT (represented by red triangles) at the highest 
dose tested (800 nM). 
 
Figure 42. Uptake of TAT-TPP, Antp-TPP and vMIP-II-TAT-TPP in PC3 cells.  
Cells were incubated for 24 hr with PS solutions ranging 12-800 nM, then washed and media was replaced 
with no phenol red media. Uptake was related to PS fluorescence intensity. Data is displayed as mean 
with error bars +/- SEM; two-way ANOVA followed by Bonferroni post hoc multiple comparison was used, 
significance level of p<0.05 
Despite differences in uptake were not significant in the rest of the cases, the greatest 
fluorescence was exhibited by cells incubated with Antp-TPP followed by TAT-TPP and 
vMIP-II-TAT-TPP.  
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3.4.3 PDT effect in dose-response curves 
Based on the optimal conditions established in Chapter 2 which resulted in maximal 
cell killing following 1.26 J (3 minutes) and 24 hr DLI light treatment, human prostate 
cancer cells were incubated with increasing doses of the TPP-based photosensitisers 
to determine the most suitable doses of the new PS conjugates.  
 
Figure 43. Evaluation of TPP-based PS PDT effect in PC3 cells.  
Cells were incubated with either TAT-TPP (A, B), Antp-TPP (C, D) or vMIP-II-TAT-TPP (E, F) solutions 
ranging 12-800 nM during 24 hr, drugs were then washed off and a 4 hr chase period was allowed before 
illumination. Cell viability was measured 24 hr and 96 hr after light treatment. Data is displayed as mean 
with error bars +/- SEM; two-way ANOVA followed by Bonferroni post hoc multiple comparison was used, 
differences between dark control and light groups are shown; significance level of p < 0.05. 
Enhancement of PDT and PCI  using targeted strategies 
 
 
135 
The aim of PCI experiments reported in the following sections was to enhance cell 
death by combining treatments (PDT and a biologically active drug, saporin in this 
case) that would otherwise result in a subthreshold outcome when administered alone, 
hence, different doses of the PS-conjugates were assayed in PDT approaches to 
determine the optimal doses for later PCI experiments. 
Measurements 24 hr after light showed a gradual increase in cell death as doses 
increased and a significant effect was only found at higher doses, from 100 nM for 
TAT-TPP, 200 nM for Antp-TPP and 400 nM for the vMIP-II-TAT-TPP chimaera. 
Specifically, 32% was the highest cell death found after PDT with TAT-TPP (Figure 
43A), 54% when using Antp-TPP (Figure 43B), and 41% with vMIP-II-TAT-TPP (Figure 
43C). All doses assayed for all three PS compounds resulted in significant cell killing 
96 hr after light and a plateau in cell death was found from 100 nM under the assayed 
conditions (Figure 43B, Figure 43D, Figure 43F). This plateau resulted in 40%-50% 
viable cells with TAT-TPP (Figure 43B) or Antp-TPP (Figure 43 D) and around 60% 
when using vMIP-II-TAT-TPP (Figure 43F). In addition, no dark toxicity was noted at 
the assayed concentrations of PS.  
On this basis, given the high PDT effect observed at the later time point (96 hr) with the 
higher doses chosen, 12 nM, 25 nM and 50 nM were selected to be combined with 2 
nM saporin in PCI experiments, as will be displayed in the sections below.     
3.4.4 PCI combination experiments 
Following the main aim of the present chapter, to evaluate the possible enhancement 
in therapeutic outcome arising from the use of CPP-based PS, viability of PC3 cells 
was measured when PDT- and PCI- treated with TPPS2a or CPP-derivatives, alone or 
in combination with saporin respectively.  
Viability of PC3 cells was significantly affected by nearly all combinations of TPP-
conjugates or TPPS2a and saporin (PCI), regardless of the compound and time point of 
assessment of cell death (Figure 44). Yet, viability had to be measured 96 hr after light 
to observe a significant therapeutic outcome after PDT (Figure 44B, Figure 44D, Figure 
44F, Figure 44H).  
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Figure 44. Assessment of PDT/PCI effect of TPP-conjugates in PC3 cells.  
Cells were incubated with either 12, 25 or 50 nM solutions of TAT-TPP (A, B), Antp-TPP (C, D), vMIP-II-
TAT-TPP (E, F) or TPPS2a (G, H), alone or in combination with saporin 2 nM for 24 hr. Drugs were then 
washed off and a 4 hr chase period was allowed before illumination. Cell viability was measured 24 hr and 
96 hr after light treatment. Data is displayed as mean with error bars +/- SEM; two-way ANOVA followed 
by Bonferroni post hoc multiple comparison was used, differences between dark control and light groups 
are shown; significance level of p < 0.05. 
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A similar effect was found 24 hr after both light treatments with all PS (Figure 44A, 
Figure 44C, Figure 44E, Figure 44G), regardless of the presence of CPP or targeting 
moieties in TAT-TPP, Antp-TPP and vMIP-II-TAT-TPP. Briefly, in these cases, cell 
death after PDT remained between 0.71% (12 nM Antp-TPP, Figure 44C) and 16.16% 
(50 nM TAT-TPP, Figure 44A); while PCI resulted in ranges of cell death between 
32.81% (12 nM TPPS2a, Figure 44G) and 57.57% (50 nM Antp-TPP, Figure 44D). Yet, 
differences between compounds became more pronounced over time post illumination. 
For instance, while the largest PCI effect increased cell killing up to 85.09% (TAT-TPP, 
Figure 44B), 88.86% (Antp-TPP, Figure 44D) and 87.41% (vMIP-II-TAT-TPP, Figure 
44F) for the TPP-conjugates, 57.22% was the greatest cell death when PCI-treating 
prostate cancer cells in vitro with TPPS2a at the same concentration (50 nM in all PS 
cases). When comparing the outcome after PDT and PCI in these same scenario (96 
hr post light), 2.27-fold, 3.55-fold, 4.65-fold and 5.5-fold greater efficiency in cell death 
were found post PCI for TPPS2a, TAT-TPP, vMIP-II-TAT-TPP and Antp-TPP 
respectively. Light groups 96 hr after illumination are shown in Figure 45, revealing 
significant differences in cell death between PCI treatment of cells with TPP-conjugates 
or TPPS2a. 
 
Figure 45. Comparison of light groups 96 hr.  
after PDT/PCI effect of TPP-conjugates and TPPS2a in PC3 cells. Cells were incubated with 12 nM 
solutions of TAT-TPP, Antp-TPP, vMIP-II-TAT-TPP or TPPS2a alone or in combination with saporin 2 nM 
for 24 hr. Drugs were then washed off and a 4 hr chase period was allowed before illumination. Cell 
viability was measured 96 hr after light treatment. Data is displayed as mean with error bars +/- SEM; two-
way ANOVA followed by Bonferroni post hoc multiple comparison was used, differences between PDT and 
PCI groups are shown; significance level of p < 0.05. 
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Table 7. Summary of cell viability after targeted-PDT/PCI in PC3 cells.  
TAT-TPP, vMIP-II-TAT-TPP, Antp-TPP and TPPS2a based PDT and PCI 24 hr and 96 hr after delivery of light. Shown light after results under different drug-light interval and light 
conditions. 
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3.4.5 AMD3100 inhibition pilot study 
Prior to assessing the inhibitory effect of AMD3100, we evaluated the capacity of the 
inhibitor itself to affect cell viability when using doses known to cause effective 
blockage of CXCR4 receptor, as reported in the literature (Hatse et al., 2002; 
Rosenkilde et al., 2004). As displayed in Figure 46, AMD3100 alone caused no 
significant killing to PC3 cells at neither of the two concentrations tested. 
 
Figure 46. AMD3100 effect in PC3 cells.  
Cells were incubated with solutions of AMD3100 at 25 and 50 g/ml 
prepared in cell media during 24 hr. Plates were then washed once 
with PBS and cell viability was measured 48 hr after. Data is displayed 
as mean with error bars +/- SEM; two-way ANOVA followed by 
Bonferroni post hoc multiple comparison was used. 
 
 
 
Based on the combination of vMIP-II and TAT in the vMIP-II-TAT-TPP chimaera and 
founded on the specific CXCR4-inhibition reported by AMD3100 in the literature, we 
hypothesised that the use of this inhibitor with vMIP-II-TAT-TPP would prevent vMIP-II 
from recognising CXCR4. Blockage of the vMIP-II component would result in a similar 
effect to that of TAT-TPP after light treatment. Following this line of thought, we aimed 
to compare the effect of AMD3100 on TAT-TPP and vMIP-II-TAT-TPP. PC3 cells were 
incubated during 1 hour with AMD3100 solutions at 25 and 50 g/ml, which were 
replaced with solutions combining PS and AMD3100, then carrying out light treatment 
like reported in 3.4.3 and 3.4.4. In this case, cell killing 48 hr after light was only 
significantly affected with 50 g/ml AMD3100 and a high concentration of vMIP-II-TAT-
TPP (100 nM), as displayed in Figure 47B. On the other hand, a significant reduction in 
cell viability was noted in all TAT-TPP cases when combined with the highest 
AMD3100 dose assayed (Figure 47A). 
Enhancement of PDT and PCI  using targeted strategies 
 
 
140 
 
Figure 47. Comparison of PDT effect of TAT-TPP or vMIP-II-TAT-TPP with AMD3100 in PC3 cells 
(2.1 J, 5 minutes light).  
Cells were incubated with solutions of AMD3100 at 25 and 50 g/ml prepared in cell media. After a 1-hr 
incubation plates were washed with PBS and solutions combining AMD3100 and TAT-TPP (A) or vMIP-II-
TAT-TPP (B) ranging 12-200 nM were administered for 24 hr. Drugs were then washed off and a 4 hr 
chase period was allowed before illumination (2.1 J, 5 minutes). Cell viability was measured 48 hr after 
light treatment. Data is displayed as mean with error bars +/- SEM; two-way ANOVA followed by 
Bonferroni post hoc multiple comparison was used, differences between groups w/wo AMD3100 are 
shown; significance level of p < 0.05. 
Due to the effect seen on TAT-TPP-treated cells previously incubated with AMD3100, 
all three TPP-conjugates were next assessed in PC3 cells to evaluate how the resulting 
PDT effect would be affected when pre-exposed to AMD3100. Based on the above 
shown results, we considered that 50 nM was a high enough PS dose to cause 
noticeable cell death 48 hr after light (time point chosen for the present study). In this 
specific scenario, no variations were found in the presence or absence of AMD3100 at 
any dose examined with neither of the TPP-conjugates (see Figure 48).  
We next considered whether cell death after light had not been large enough to reveal 
differences in viability upon exposure to AMD3100 and whether a possible inhibition 
was being masked. Therefore, in order to maximise potential differences resulting from 
the use of the inhibitory compound, a 5-minute illumination was performed. In addition, 
incubation with AMD3100 was increased from 1 hour to 24 hour following the same 
logic.  
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Figure 48. Comparison of PDT effect of TPP-conjugates with AMD3100 in PC3 cells (1.26 J, 3 
minutes light).  
Cells were incubated with solutions of AMD3100 ranging 0.01 – 25 g/ml prepared in cell media. After 1 hr 
incubation, plates were washed with PBS and solutions of TAT-TPP (A), Antp-TPP (B) or vMIP-II-TAT-TPP 
(C) at 50 nM were administered for 24 hr. Drugs were then washed off and a 4 hr chase period was 
allowed before illumination (1.26 J, 3 minutes). Cell viability was measured 48 hr after light treatment. Data 
is displayed as mean with error bars +/- SEM; two-way ANOVA followed by Bonferroni post hoc multiple 
comparison was used. 
Cell death was also assessed in cells pre-incubated with AMD3100 during 24 hr, then 
exposed to TPP-conjugates and illuminated for 5 minutes (Figure 49). Under these 
conditions, a significant reduction in cell viability was found up to 10 g/ml in the TAT-
TPP and Antp-TPP groups (Figure 49D and Figure 49E respectively), and up to 1 
g/ml in the vMIP-II-TAT-TPP treated cells (Figure 49F). Hereafter, there seemed to be 
a trend to increase cell viability at higher AMD3100 doses although no significant 
differences were seen.  
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Figure 49. Comparison of PDT effect of TPP-conjugates with AMD3100 in PC3 cells (2.1 J, 5 
minutes light).  
Cells were incubated with solutions of AMD3100 ranging 0.01 – 25 g/ml prepared in cell media. After a 
24-hr incubation plates were washed with PBS and solutions combining AMD3100 and either TAT-TPP 
(A), Antp-TPP (B) or vMIP-II-TAT-TPP (C) at 50 nM were administered for 24 hr. Drugs were then washed 
off and a 4 hr chase period was allowed before illumination (2.1 J, 5 minutes). Cell viability was measured 
48 hr after light treatment. Data is displayed as mean with error bars +/- SEM; two-way ANOVA followed 
by Bonferroni post hoc multiple comparison was used, differences between groups w/wo AMD3100 are 
shown; significance level of p < 0.05. 
3.4.6 Subcellular localisation of TAT-TPP, Antp-TPP and 
vMIP-II-TAT-TPP in PC3 cells before and after light 
treatment  
So as to observe the intracellular localisation of the TPP-conjugates and determine the 
suitability for PCI, fluorescence micrographs of PC3 cells incubated with PS solutions 
were taken, like reported in Chapter 2 for TPPS2a and TPCS2a.  
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Figure 50. Localisation and redistribution of TPP-conjugates after light treatment in PC3 cells.  
Cells were incubated with 400 nM solutions of either TAT-TPP, Antp-TPP, vMIP-II-TAT-TPP during 24 hr. 
Photosensitiser solutions were then washed off and a 4 hr chase period was allowed before illumination 
“on stage” using a low power (2 mW) 405 nm blue diode laser coupled to a liquid light guide. Micrographs 
were taken at a different time during exposure to light. Scale bars shown as 50 m. 
All three TAT-TPP, Antp-TPP and vMIP-II-TAT-TPP exhibited a granular intracellular 
distribution before light excitation of the compounds, as detailed with red arrows in 
Figure 50A, Figure 50C, Figure 50E for each conjugate respectively. Cytosolic vesicles 
in which TPP-based photosensitisers appeared initially were dispersed overtime after 
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illumination of cells, as shown in micrographs taken at 1, 3 and 10 minutes (see detail 
in Figure 50B, Figure 50D, Figure 50F). 
No apparent changes in cell morphology could be seen, even at the latest time point 
imaged (10 minutes), with neither of the compounds assayed under the specific 
experimental conditions (Figure 50B, Figure 50D, Figure 50F).  
3.4.7 Subcellular localisation of the conjugate saporin-Alexa-
Fluor488® before and after light excitation of TAT-TPP 
Interaction of the TPP-conjugates with saporin in the presence of light is decisive 
during PCI. Hence, fluorescence-based observations were performed in PC3 cells 
where TPP-based photosensitisers had been previously coadministered with saporin-
Alexa-Fluor488® to determine the localisation of the conjugate in the presence of light 
– similarly to above-noted in 2.4.7 Subcellular localisation of the conjugate saporin-
Alexa-Fluor488® before and after excitation of photosensitisers. 
 
Figure 51. Saporin-Alexa-Fluor488® conjugate in PC3 cells co-administered with TAT-TPP before 
and after illumination with a 405 nm laser.  
Cells were incubated with a solution of Saporin-Alexa-Fluor488® (400 nM) during 24 hr, then washed, 
allowing cells to recover for 4 hours. Imaging was performed using a 488 nm laser before (A), and 3 and 8 
minutes after (B) a 10 seconds “on-stage” excitation with a 405 nm laser. Scale bars shown as 50 m. 
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In this case, a 405 nm laser resulted in the excitation of the compounds; concluded by 
the spectroscopic study of the compounds described in section 3.4.1. As displayed in 
Figure 51 (see detail A), saporin was initially located conforming cytosolic granules and 
experimented dispersion, as suggested by the scattering of green fluorescence over 
time after illumination with the 405 nm laser (Figure 51B). Moreover, no qualitatively 
noticeable changes in cell morphology were detected.  
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3.5 Discussion  
Based on the reported benefits of CPPs, three different conjugates TAT-TPP, 
Antp-TPP and vMIP-II-TAT-TPP have been considered in the present thesis to 
enhance the uptake of tetraphenyl porphyrin (TPP), and in turn its photooxidative-
toxicity in prostate cancer treatment. Some of the most common targeting strategies 
have been reviewed in the introduction, which have also been applied in PDT and PCI. 
CXCR4 receptor was the molecule targeted in the investigations reported in the 
present chapter due to its known expression in PC3 cells used throughout the thesis, 
and specifically its relation to cancer stem cells and metastasis. The experiments 
reported in the above sections were designed to evaluate the benefits targeted 
strategies would have in PDT and PCI for prostate cancer treatment and were only 
performed on the human prostate cancer model (PC3).  
The first steps followed with the CPP-based photosensitisers studied in the 
present chapter involved their spectroscopic evaluation. TPP is the photosensitive 
component of the conjugates used in our study. It is a porphyrin based photosensitiser, 
nature which was reflected in the intense Soret band (420 nm) followed by the lower 
intensity four Q bands (500-650 nm) shown in the absorption spectra in Figure 41 
(Kempa et al., 2015). No absorption resulted from illumination at longer wavelengths, 
i.e. in the red region of the electromagnetic spectra coinciding with the therapeutic 
window. For this reason, TPP is not a clinically applied photosensitiser in the 
photodynamic therapy field, yet, it is widely used as standard to determine optimal 
properties of photosensitive compounds (Kempa et al., 2015). All CPP-conjugates 
displayed identical absorption and emission, which suggests the the CPP and vMIP-II 
domains are not affecting the physicochemical properties of these and should then lead 
to at least an equally efficient photooxidation of the compounds during PDT. In relation 
to this, previous studies have reported in the literature that the presence of TAT- does 
not affect TPP’s singlet oxygen yield in methanol (Tanielian and Wolff, 1995; Wang et 
al., 2012). Moreover, the common nature of both TPP and TPPS2a, justifies the 
correlation between the spectra shown in Figure 41 and the one described for TPPS2a 
displayed in Chapter 2. For this same reason, we would not expect significant 
variations between singlet oxygen yield of TPPS2a and TPP; thus we consider 
differences described between PS compounds will be dependent on the presence of 
CPPs. 
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We next analysed uptake of the compounds after a 24-hour incubation in PC3 cells. As 
shown in Figure 42, a dose-related increase in drug uptake was observed in all three 
compounds. In order to compare uptake rates of the three conjugates, we assumed 
that the presence of one or another CPP moiety would not alter the spectroscopic 
properties of these compounds, hence, all conjugates would be identical in their 
physicochemical properties. Taking this as basis, Antp resulted in the greatest uptake 
among the TPP-based PSs, which was significantly different to that exhibited by vMIP-
II-TAT-TPP by nearly 1.5-fold at the highest 800 nM dose tested. This might indicate 
that the presence of vMIP-II could be competing with TAT to enter cells or else 
increasing specificity in the uptake, thus limiting passive entry or non receptor mediated 
endocytosis and consequently reducing the overall internalisation. Antp seemed to be 
more efficient in enhancing the delivery of TPP inside cells than the TAT counterpart, 
although non significant differences were found. Duchardt et al. evaluated different 
endocytic pathways for CPPs, suggesting differences in the fractions of arginine side 
chains between TAT and Antp explained differences in delivery efficiency. The authors 
described a greater uptake of Antp below a critical concentration threshold (10 µM) 
from which TAT followed non-endocytic pathways, and thus increasing its uptake very 
significantly (Duchardt et al., 2007). This concentration is 12.5-fold higher than the 
highest concentration assayed in our investigations (800 nM). In a different study, a 
TAT-TPP conjugate was investigated in human squamous carcinoma cells (Wang et 
al., 2012). A dose and time dependent enhancement in the uptake of PS was observed 
when conjugating molecules to TAT. Additionally, the implication of the endocytic route 
during the internalisation of the TAT conjugate was confirmed in the experiments 
carried out at 4C, which significantly reduced uptake of PS, also correlating to the 
observations found with TPPS2a (Wang et al., 2012) . 
Correlation was found between uptake experiments and PDT 24 hr after illumination. 
For instance, focusing on the largest PS dose tested (800 nM) and a 3-minute 
illumination as shown in Figure 43, Antp-TPP showed the greatest therapeutic effect 
upon PDT treatment, rendering 46.68% viable cells (Figure 43C), notably larger than 
the other two compounds. A 66.22% (Figure 43A) and 59.69% (Figure 43E) cell 
viability resulted from TAT-TPP and vMIP-II-TAT-TPP respectively. This supports the 
hypothesis that either an increase in the specificity of TPP-conjugates or competition 
between moieties during receptor recognition (which vMIP-II is responsible for), would 
affect uptake and thus limit PDT’s photooxidative effect. If cell viability was measured 
at a later time point, i.e. 96 hr post illumination as shown in Figure 43B, Figure 43D and 
Figure 43F, concentrations above 100 nM did not seem to result in any further 
enhancement of cell death with any of the conjugates. This suggests that the entry of 
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all three compounds (CPP-mediated) in PC3 cells would happen in a receptor-
mediated manner, hence a large concentration of the conjugates leads to saturation 
and limits the therapeutic effect. A similar saturation plateau has been described in 
previous studies involving CPP-delivery (Hällbrink et al., 2001).  
When compared to free photosensitiser used in Chapter 2, initial doses selected for 
CPP-TPP were reduced from 0.1-0.8 g/ml (assayed with TPPS2a and TPCS2a, as 
displayed in Figure 16 and Figure 17) down to 12-800 nM (equivalent to 0.01-0.64 
g/ml) shown in Figure 43. The lowest concentration tested in the former, 0.1 g/ml did 
not result in significant reduction of cell viability in neither of the models previously 
commented (MatLyLu or PC3 cells) neither with TPPS2a nor TPCS2a alone 24 hr after 
exposure to light treatment in PDT; whereas noticeable cell damage was observed with 
TPP-conjugates at 100 nM, which is equivalent to 0.08 g/ml TPPS2a. In addition, the 
plateau earlier described for PDT at the higher doses of CPP-PS, was not detected 96 
hr after light treatment using 10-fold larger concentrations of the non CPP-PS (0.8 
g/ml) in Chapter 2. This indicated that despite the enhancement of therapeutic 
outcome post PDT at low doses, cell death could be limited at larger concentrations, 
potentially due to a receptor-mediated internalisation of the compounds which CPPs 
are responsible for.  A similar enhancement in phototoxicity was shown conjugating the 
fluorophore carboxytetramethylrhodamine (TMR) to TAT, compared to the lack of 
cytotoxicity was exerted by it alone (Srinivasan et al., 2011). This was explained 
through the interaction of the CPP-PS with cellular membranes and consequent 
disruption of endosomes upon irradiation. 
As performed in Chapter 2, based on the PDT observations, the lower 
concentrations of the range tested (only resulting in subthreshold toxicity) were 
combined with saporin to enhance the delivery of this type 1 RIP through PCI. 24 hr 
after light, viability measurements correlated with uptake (Figure 42) and PDT dose-
response assays (Figure 43): Antp-TPP resulted in a more noticeable cell death after 
PCI from 12 nM compared to killing exerted by TAT-TPP and vMIP-II-TAT-TPP. Yet, all 
three conjugates tested in PCI combination experiments successfully enhanced 
delivery of saporin and thus enabled its biological activity at concentrations which did 
not cause PDT effect when using PS alone as displayed in Figure 44A, Figure 44C and 
Figure 44E. This effect was even more pronounced 96 hr after light (Figure 44B, Figure 
44D and Figure 44F), like reported for TPPS2a and TPCS2a in Chapter 2. Interestingly, 
PCI results of cell death 96 hr after light combining CPP-conjugates at 12 nM and 
saporin were inversely proportional to previously reported cytotoxicity levels: vMIP-II-
TAT-TPP was the one exhibiting the most substantial cell killing (76.27% death), 
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followed by TAT-TPP (60.5%) and Antp-TPP (38%). Based on this, vMIP-II might be 
involved in an additional manner in the cytosolic delivery of saporin, for instance 
interacting with the RIP type I differently to the other two conjugates assayed, in turn 
favouring its biological activity further. Perhaps, endocytosis of saporin in PC3 cells 
occurs via a specific receptor to some extent, explaining the greater efficacy of vMIP-II-
TAT-TPP in this case. This higher efficiency of vMIP-II-TAT-TPP was not seen 
however at higher concentrations of the PS-conjugates. In these circumstances, cell 
viability was reduced to maximal levels (close to MTT detection limits), overcoming the 
saturation of receptors involved in the uptake of PS-conjugates, which restricts PDT-
based cell death at high CPP-PS dose. Along these lines, 50 nM CPP-PS and saporin 
resulted in cell viability values as low as 14.91%  1.69, 11.14%  5.47 and 12.59%  
5.08 for TAT-TPP, Antp-TPP and vMIP-II-TAT-TPP respectively when combined with 
saporin. Consequently, differences between photosensitisers might be imperceptible.   
As for the comparison between CPP-compounds and free PS in PCI, observations 24 
hours after light were similar in all cases (Figure 44A, Figure 44C, Figure 44E vs Figure 
44G). Measurements 96 hr after light showed minor variations in the free PS compared 
to the results 24 hr after light (Figure 44H), while significant differences in phototoxicity 
from 24 hr to 96 hr originated from the CPP-compounds (Figure 44B, Figure 44D, 
Figure 44F). At this last time point, cell death was up to 3.8-fold greater in CPP-
conjugates than free PS (50 nM). As could be concluded from the light-only groups 
shown in Figure 45, the presence of the CPP components in PS used in PCI could 
result in a significant enhancement in therapeutic outcome while keeping both PS and 
biologically active drug at subthreshold levels. Overall, we concluded the CPP 
component of the PS-conjugates did not impede PCI-delivery of saporin, but in fact 
promoted it, further enhancing phototoxicity of that resulting from free photosensitisers 
as shown in vitro. A similar enhancement in cell killing was observed by Wang et al. in 
HN5 cells combining TAT-TPP and the same RIP reported in our studies as opposed to 
TAT-TPP alone, which served as verification of the potential of TAT-TPP conjugates for 
PCI (Wang et al., 2012).  
This was followed by the evaluation of the interaction between vMIP-II and 
CXCR4 receptor through the use of the inhibitor AMD3100, founded on the previously 
stated specific inhibition of such receptor (Hatse et al., 2002). It was first demonstrated 
that AMD3100 on its own and under the same experimental conditions described for 
PDT and PCI experiments, did not affect viability of PC3 cells at doses where inhibition 
had been described (see Figure 46). Previous studies on PC3 cells had confirmed the 
expression of CXCR4 in the surface of the cell membrane and its relevance in the 
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maintenance of tumour progenitor cells, tumorigenicity and migratory capacity 
(Dubrovska et al., 2012; Zhang et al., 2008). Founded on the above, blockage of the 
interaction between vMIP-II and CXCR4 in PC3 cells would impede the entry of the 
conjugate into these in a vMIP-II-mediated manner. Accordingly, the resulting PDT 
effect would occur independently to vMIP-II, altering the cytotoxic outcome.  
With the working hypothesis being that vMIP-II interacts with CXCR4, initial inhibition 
experiments involved the incubation of cells with AMD3100 alone during 1 hr followed 
by the combination of both inhibitor and vMIP-II-TAT-TPP or TAT-TPP. The latter was 
used based on the shared TAT-TPP structure. The initial incubation of cells with 
AMD3100 alone was intended to ensure blockage of the specific receptor prior to 
enabling recognition of CXCR4 by vMIP-II, hence ensuring inhibition. Opposite to what 
was expected, differences in phototoxicity were more noticeable with the TAT-TPP 
compound than vMIP-II-TAT-TPP 48 hr after a 5-minute illumination, suggesting 
AMD3100 was also affecting the shared TAT-TPP components. In the former, a 
significant reduction of cell viability resulted from a first incubation with AMD3100 (50 
g/ml) compared to lower concentrations or absence AMD3100 at all PS doses tested 
(Figure 47A). As for the vMIP-II-TAT-TPP groups, variations in cell death were only 
found combining the inhibitor at 50 g/ml  with 100 nM of the TPP-conjugate (Figure 
47B).  
A structural analysis of CXCR4 has previously revealed strong negative charges in its 
N-terminal, and the interaction with its natural ligand (i.e. CXCL12) has been explained 
mostly through electrostatic interactions between these and positively charged side 
chains (Xu et al., 2013). In our investigations, based on the positively charged residues 
in the CPP peptides, an interaction between TAT and the receptor might also have 
occurred, as suggested by earlier studies in which a chemokine-like region was 
described (Xiao et al., 2000). This would justify the differences above-described in the 
TAT-TPP-treated cells when pre-incubated with AMD3100. In line with this, rather than 
inhibiting the uptake of PS, AMD3100 at high doses could be sensitising PC3 cells to 
photooxidation by the conjugates. In relation to this, a strong binding to CXCR4 has 
been reported for both AMD3100 (Rosenkilde et al., 2004) and vMIP-II (LiWang et al., 
1999; Szpakowska and Chevigne, 2016; Zhou et al., 2000). It is possible therefore that 
the competition between vMIP-II and AMD3100, could be alleviating the sensitisation 
instigated by the inhibitor, explaining the lesser significant effect. Likewise, prostate 
cancer cells have been sensitised to docexatel treatment with this same inhibitory 
compound (Domanska et al., 2012).  
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In order to evaluate how all three conjugates would be affected and determine whether 
the AMD3100-inhibition could be enhanced, a study was carried out pre-incubating 
cells with the inhibitory molecule alone during 24 hr (as opposed to 1 hr), prior to the 
coadministration of AMD3100 and all three TPP-conjugates. PS were tested at 50 nM 
based on the consideration that this dose would cause noticeable cell death 48 hr after 
light (previously observed in Figure 43 and Figure 44); thus, an effect caused by 
AMD3100 would result in detectable differences in cell viability. Furthermore, light dose 
was reduced to 3 minutes, in case an excessive PDT effect had masked AMD3100’s 
effect after the longer 5-minute illumination. Moreover, a range of AMD3100 
concentrations (0.01-25 g/ml) were assayed in Figure 48 to investigate a broader 
scope of experimental conditions. Nonetheless, no remarkable effects on cell viability 
were found in any case (Figure 48).  
One last experiment was carried out in the inhibition pilot study currently 
discussed, which involved a 24 hr incubation with AMD3100 alone (0.01-25 g/ml) prior 
to exposure to PS at 50 nM and AMD3100 followed by a 5-minute illumination. In all 
cases observed, there was a general trend to reduce cell viability at lower inhibitor 
concentrations, which then recovered to initial values as AMD3100 concentrations 
increased. Again, in the presence of AMD3100, cell killing was increased, as shown in 
Figure 47. Larger differences resulted from longer incubations (24 hr), which suggested 
AMD3100 effect is time- and dose- dependent, regardless of the CPP-conjugate 
evaluated. Specifically, increasing the pre-exposure to the inhibitor from 1 hr (Figure 
47) to 24 hr (Figure 49) reduced the concentrations required to observe significant 
differences (10 g/ml as opposed to 50 g/ml).   
In conclusion, we hypothesise the following possible scenarios: 
 Low concentrations of AMD3100 (below 25 g/ml) could be competing with 
CPPs during receptor recognition but were insufficient to inhibit the entry of PS. 
In fact, despite AMD3100 alone does not exert cytotoxicity, PS-conjugates 
could be interacting with the inhibitor, triggering AMD3100-induced cell death 
(i.e. assisting uptake by cells in a similar process to PCI).  
 High concentrations of AMD3100 (25 g/ml) could surpass the competition with 
CPPs to bind CXCR4, resulting in an increase in cell viability as a consequence 
of the inhibitory outcome. Conversely, the recovery of cell viability could be due 
to an adaptation of cells to the inhibitor AMD3100, which would then lose the 
potential to cause cell death.  
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 Concentrations of AMD3100 over a critical threshold (above 50 g/ml) could 
sensitise cells to PDT effect, hence maximising cytotoxicity. 
 The association of TPP with vMIP-II-TAT could be causing steric hindrance that 
would impede a more specific interaction between vMIP-II and the CXCR4 
receptor. Therefore, AMD3100 would not cause any additional significant effect 
during CXCR4 recognition compared to the other PS conjugates.  
The last sections of the present chapter (3.4.6, 3.4.7) describe studies carried 
out to determine the subcellular localisation of all CPP-compounds, similarly to the 
studies reported in Chapter 2 with TPPS2a and TPCS2a. All three compounds TAT-TPP, 
Antp-TPP and vMIP-II-TAT-TPP resulted in a similar cytosolic pattern to that of the 
previously assayed PS as shown in the fluorescence micrographs in Figure 50 (Figure 
24). Again, this indicated that these PS would be initially found in cytosolic vesicles, 
very likely docked in endolysosomal membranes, as described in the study carried out 
by Wang et al. where colocalisation with lysosomal dyes confirmed the above-
statement (Wang et al., 2012). As opposed to TPPS2a and TPCS2a, TPP lacks the two 
adjacent sulphonate groups which confer amphiphilic properties, hence making the PS 
more adequate for PCI (Wang et al., 2013). However, the presence of CPPs could be 
compensating this lack, resulting in a similar outcome. In addition, exposure to light of a 
specific wavelength as determined in the initial absorption spectra (Figure 41), resulted 
in dispersion throughout the cytosol (10  minutes after light, displayed in Figure 50B, 
Figure 50D, Figure 50F) of the granular fluorescence pattern described after 1 s 
illumination (Figure 50A, Figure 50C, Figure 50E). This served as an additional visual 
confirmation that CPP components were not interfering with the photooxidative 
potential of TPP, which acquired an excited state and disrupted endo/lysosomal 
vesicles during PCI procedures. The equivalent study described in Chapter 2 revealed 
morphologic changes in cells after light treatment. In the present study, no significant 
changes were found despite the fact that the photooxidative effect represented by 
dispersion of fluorescence would in turn lead to a reduction of cell viability as displayed 
in Figure 43 and Figure 44. We think this was due to a more discrete and subtle 
photooxidative damage exerted in this case, affecting cells at a subcellular level rather 
than having a whole-cell effect. This could be justified by the slightly higher PS 
concentration used in Chapter 2: 516 nM (equivalent of 0.4 µg/ml) TPPS2a/TPCS2a 
compared to 400 nM CPP-PS used for the experiments now concerning.  
Considering that both fluorescence yield and CPP : TPP ratio were the same in 
all three CPP-TPP conjugates, we qualitatively compared the uptake of PS through the 
observation of the fluorescence intensity in Figure 50. Accordingly, the greatest 
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fluorescence resulted from Antp-TPP-exposed PC3 cells, which correlated with the 
uptake graphs shown in Figure 42. No major variations were found between the other 
two TPP-conjugates in the fluorescence images (Figure 50).  
As for the assessment of the interaction of the CPP-conjugates with saporin to 
determine suitability of the compounds in PCI (shown in Figure 51), a similar behaviour 
to that described for TPPS2a and TPCS2a in Chapter 2 was revealed. The fluorescent 
conjugate saporin-Alexa-Fluor488 formed cytosolic granules prior to illumination with 
the 405 nm laser, noted as endo/lysosomes in Chapter 2 (Figure 26). Combination of 
fluorescently labelled saporin with TAT-TPP under the specific light conditions resulted 
in cytoplasmic dispersion of green fluorescence. This observation together with the 
earlier described granular pattern of fluorescence of the conjugates alone supports the 
hypothesis that the CPP-conjugates under investigation were located in 
endo/lysosomal-membranes and would release their content (labelled saporin in this 
case) when photochemically disrupted. Likewise, this served as verification of the 
mechanics behind the commented viability assays after PCI delivery of saporin using 
the present CPP-TPP combinations and supports conclusions drawn in Chapter 2. 
Despite this last experiment was only performed on TAT-TPP, the same observations 
could be extended to Antp-TPP due to the common structure and nature of the 
compounds. Overall, there is no reason to conclude vMIP-II would alter the process 
and result in different findings to that of TAT-TPP and Antp-TPP. 
To conclude, we hypothesise that under our experimental conditions, TAT and 
Antp bound to the PS cargo were internalised by PC3 cells through endocytosis 
(receptor-mediated at several levels depending on the conjugate used), and were 
capable of releasing drugs also endocytosed but trapped in endosomes (i.e. saporin). 
Therefore, we conclude these compounds are suitable candidates for PCI treatment. 
We have verified that the use of CPP and targeting moieties enhance the previously 
reported outcome of PCI, widening the gap already existing between PDT and PCI. 
Moreover, PS whose physicochemical features are not as appropriate for PCI as they 
are for PDT (i.e. not amphipathic), could be used for both irrespectively if conjugated to 
CPPs. In addition, we conclude that it needs to be predetermined whether maximal cell 
death or specificity are preferentially pursued, since the further increase of specificity 
via additional targeting moieties such as vMIP-II might have a detrimental effect on cell 
killing due to a lower amount of drugs being internalised, especially if there is 
competition between moieties. As for the use of vMIP-II to target PC3 cells in PDT/PCI, 
we cannot conclude an exclusive interaction with CXCR4, as suggested by the findings 
of our study. In addition, observations upon administration of the inhibitor AMD3100 
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supported previous reports indicating that CPPs with positively charged residues may 
be responsible for targeted delivery to some extent (binding to receptors present in 
tumour cells) in addition to their intrinsic capacity to act as delivery agents. 
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Chapter 4 In vivo studies of PDT and PCI in 
Prostate Cancer 
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4.1 Introduction  
In vivo studies enable a more realistic evaluation of treatment and drug development 
than the in vitro counterpart. Specifically, in cancer treatment as in any other disease, 
cell lines do not recapitulate every aspect involved in the different disorders nor living 
organisms. There is a major systemic component missed in vitro and this is particularly 
important in cancer i.e. regarding cellular interactions during the metastatic and 
oncogenic progression (Cunningham and You, 2015).  
Mice models are the most widespread in vivo model currently due to the large genetic 
knowledge available, the rather inexpensive cost compared to other models, as well as 
the easy generation of disease models with specifically tailored features. In prostate 
cancer however, rat and canine models have led to important discoveries on prostatic 
lesions. In addition, the larger size of these species facilitates the performance of 
experiments on an organ of reduced size as is the prostate’s case. However, the 
development of prostate cancer models still faces a major challenge: the lack of an 
animal model capable of reproducing the characteristic metastasis to bone experienced 
by prostate cancer patients (Cunningham and You, 2015). 
4.1.1 Dunning R3337 prostate adenocarcinoma model 
Androgenic hormones have a major role in prostate and prostatic tumours’ growth. This 
is an important feature of the model chosen in our study of prostate cancer treatment, 
whose use in vitro has been commented in Chapter 2 and will be studied in vivo in the 
present chapter.  
The dunning R3327 adenocarcinoma of the prostate initially originated in 1961 from the 
dorsal prostatic lobe of a 22-month old Copenhagen rat, and its later serial 
transplantation into hybrid offspring from female Fischer and male Copenhagen rats 
enabled the characterisation of different related sublines, sharing several common 
features with human prostate cancer (Isaacs et al., 1978). The R3327-H subline was 
the first one to be developed from this model. It took several months to develop 
androgen insensitivity and in the end, these cells were indifferent to hormone-specific 
endocrine treatment. This led to the generation of additional cell lines such as R3327-
HI, R3327-AT and R3327-G (Isaacs et al., 1978; Kager et al., 1992). All cell lines 
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generated from the original R3327 Dunning model are described in Figure 52 and 
Table 8. This prostate cancer model covers a range of the different ways in which 
prostate cancer can appear in humans, for instance both androgen -dependent or -
independent. Its potential use both in vitro and in vivo makes it especially useful for 
prostate cancer investigations. In vivo models based on the implantation of cells or 
xenografts have an additional advantage over chemically or genetically generated 
tumour animal models: the greater controllability of tumour growth and hence 
reproducibility between individuals.  
 
Figure 52. Dunning R3327-derived prostate adenocarcinoma sublines.  
Schematic representation of different cell lines obtained from the initial R3327 rat prostate 
adenocarcinoma. [(Isaacs et al., 1986)] 
Furthermore, Dunning R3327-derived cell lines have also been used previously for 
PDT strategies in prostate cancer investigations (Bozzini et al., 2013a; Momma et al., 
1998). For instance, R3327-AT2 was used to evaluate the use of 5-ALA PDT in 
hypoxic tumours following continuous or fractionated illumination. In their study, a sub-
optimal PDT was concluded, observing no reproducibility between light treatments.  
The authors suggested these hypoxic conditions in the tumour were responsible for the 
outcome of the treatment, given the essential oxygen requirements during PDT 
(Bozzini et al., 2013a). Momma et al. reported for the first time in 1998 the combination 
of PDT and surgery in the treatment of orthotopic prostatic tumours (Momma et al., 
1998). In this specific study, MatLyLu cells were used to generate tumours in 
Copenhagen rat’s prostate and BPD-MA was used as photosensitiser to treat the 
tumour bed upon surgical removal of tumours. An improvement in the rate of local 
recurrence and metastasis was concluded in this study combining prostatectomy and 
adjuvant PDT (Momma et al., 1998). In a different study R3327-AT6 tumours were 
treated with interstitially applied light and haematoporphyrin esters, showing consistent 
In vivo studies of PDT and PCI in Prostate Cancer  
 
 
158 
damage of the structure of tumours, also finding a direct relationship between PDT 
damage and light dose (Lee et al., 1996). The authors of this study additionally 
confirmed an exclusive PDT effect, being the therapeutic outcome completely 
independent to hyperthermia, which is frequently associated to PDT treatment.  
Subline name Properties 
R3327-H 
 Well differentiated 
 Heterogeneous: combination of both androgen-dependent and independent 
cells 
 Slow growing: tumour volume doubling time around 20 days 
R3327-HI-S 
 Generated growing R3327-H in castrated male rats 
 Androgen-independent 
R3327-AT-1 
 Generated passaging R3327-H in intact male rats 
 Fast growing 
 Anaplastic 
 Rarely metastatic 
MAT-LyLu 
 Generated after serial passages of R3327-AT-1 
 Fast growing 
 Anaplastic 
 Highly metastatic to lungs and lymph nodes 
MAT-Lu 
 Generated after serial passages of R3327-AT-1 
 Fast growing 
 Anaplastic 
 Highly metastatic to lungs 
R3327-AT-2 
 Generated passaging R3327-H 
 Fast growing 
 Anaplastic 
 Low rate of distant metastasis 
R3327-HI-M 
 Generated by continuous passaging of R3327-HI-S in castrated male rats 
 Faster growth than precursor sub line 
 Less degree of differentiation 
R3327-HI-F 
 Generated by continuous passaging of R3327-HI-M 
 Faster growth than precursor sub line 
 Less degree of differentiation 
 Histologically it is not completely anaplastic 
R3327-AT3 
 Generated by a specific passage of R3327-HI-F 
 Completely anaplastic 
R3327-AT6 
 Longer doubling time: this enables good vascularisation and limits self 
necrosis 
Table 8. Summary of cell lines established from the Dunning R3327 prostate adenocarcinoma 
model.  
Highlighted in bold are MatLyLu cells, chosen for our study (Glowa et al., 2013; Isaacs et al., 1986) 
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4.1.2 BPD-MA as photosensitiser  
Verteporfin (BPD-MA) was originally developed as photosensitiser against age-related 
macular degeneration. However, its success as a photosensitiser has resulted in 
further use in a wide range of studies, cancer treatment among others (Ayaru et al., 
2007; Fingar et al., 1999; Momma et al., 1998; Schmidt et al., 1999).  
In vivo, BPD-MA has been successfully used in “vascular-targeted PDT”, a novel 
concept which is featured by short drug light intervals ranging 0-30 minutes after 
administration of the photosensitiser, ensuring the compound is located in vascular 
structures. This intends to affect fundamentally microvasculature with the subsequent 
increase in permeability and constriction of vessels. In the end, a dramatic damage to 
tissues and vascular collapse is pursued (Kawczyk-Krupka et al., 2015a).  
For instance, BPD-MA has been used in PDT applications for glioma treatment. The 
selectivity of this photosensitiser for tumour was confirmed in tumour-bearing mice, 
despite showing differences in tumours directly implanted in the brain or 
subcutaneously. Encapsulation of BPD in liposomes enhances tumour-delivery, yet, 
the existence of a blood-brain barrier poses a major hurdle and could protect from the 
accumulation of photosensitiser in normal brain tissue, while still being present in the 
intracerebral tumour (Schmidt et al., 1999). This study also carried out both BPD and 
LED-light dose escalation in a dog model, confirming neurotoxicity above 150J/cm2, 
which even led to one PDT-related death due to haemorrhagic necrosis and severe 
oedema in the brain stem (Schmidt et al., 1999). In pancreatic cancer studies, BPD-MA 
was rapidly cleared from circulation as well as completely eliminated from animal 
subjects (within 5-6 hr). In this same investigation, a 15-min drug light interval 
successfully caused necrosis to all tissues examined. Specifically, around 3-mm of 
pancreatic tumour tissue was affected upon exposure to light. Importantly, these 
investigations established suitable settings to achieve necrosis in pancreas at safe 
levels.  
More recently BPD-MA has been subject of several combinatorial therapeutic studies. 
Along these lines, an enhancement in the outcome of PDT exerted by BPD-MA was 
found when animal subjects bearing non-small cell lung carcinomas were pretreated 
with erlotinib (EGFR inhibitor), in spite of the lack of effect when only exposed to this 
small-molecule inhibitor (Gallagher-Colombo et al., 2015). In fact, the authors 
concluded a synergistic effect rather than additive. Moreover, the reinforcement of 
PDT-based vascular damage was hypothesised, possibly caused by endothelial 
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damage: inhibition of EGFR could reduce proliferation as well as favour apoptosis of 
endothelial cells. In addition, this pre-treatment with elotinib could potentiate uptake of 
BPD-MA by tumour cells (Gallagher-Colombo et al., 2015). In a different study, BPD-
MA was encapsulated in liposomes together with an anti-VEGF antibody 
(bevacizumab) for pancreatic cancer treatment. The surface of these liposomes had 
been in addition functionalised with positively charged molecules which can interact 
with negatively charged molecules that are frequently overexpressed in the surface of 
tumour cells such as glycosaminoglycans (GAG) or heparin sulphate. An extensive 
necrosis of tumours was found 3-4 days after light treatment, leading to complete cure 
of 33% of the animals (Tangutoori et al., 2016). 
4.1.3 TPCS2a as photosensitiser  
As described in the Background and Introduction, TPCS2a (Amphinex®) is a recently 
developed photosensitiser highly suitable for PCI due to the presence of two adjacent 
sulfonate groups, which confer amphiphilicity to the photosensitive compound. As 
briefly stated previously, this PS exhibits improved properties to previously reported 
PCI-based photosensitisers: the preparation of the former does not result in the 
formation of unwanted sulfonated isomers as occurring with the phtalocyanine-based 
AlPcS2a, thereby avoiding an additional purification step (Wang et al., 2013).  
TPCS2a combined with the antibiotic bleomycin was used in a PCI study aiming to 
assess the therapeutic outcome of an aggressive colon carcinoma tumour model (Berg 
et al., 2011). Results concluded an important delay in tumour growth, which was also 
similar to that seen in tumours treated with AlPcS2a and bleomycin (at least 11 days). 
Moreover, the delay seen after TPCS2a alone following PDT (72-hr DLI) was only 1.9 
days. An interesting observation was concluded using this PS: a minimum light dose 
(10 J/cm2) was required to observe tumour growth delay, and there was a direct 
correlation between light dose and growth delay. This suggested PCI might require a 
minimum light threshold (Berg et al., 2011).  
In the first-in-man PCI study with TPCS2a and bleomycin (Sultan et al., 2016), patients 
were grouped in 3-patient cohorts receiving either 0.25 mg/kg, 0.5 mg/kg, 1 mg/kg or 
1.5 mg/kg. Based on previous investigations in animal models, 4 days was the chosen 
drug light interval in this specific study before illuminating the tumour area with a 652 
nm laser. No treatment-related deaths occurred throughout the study and all PCI-based 
adverse effects were either systemic related to skin photosensitivity or else localised 
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due to inflammation. Different measures have been determined to control the former, 
such as sunlight protection during a 3-month period followed by a progressive 
exposure to sun and gradual exposure to normal day light 2-3 days after TPCS2a 
administration. Through this dose-escalating study, 1 mg/kg was established as 
maximum tolerated dose, based on adversities reported in patients who had been 
administered with the highest dose (1.5 mg/kg). Surprisingly, even the lowest dose 
(0.25 mg/kg) resulted in a promising treatment response in tumours, observing no dose 
response effect above this dose and concluding a better therapeutic effect. The 
success of PCI treatment was described by the authors of the study as a combination 
of greater therapeutic depth in tumours and complete response outcome (38 mm 
tumour depth). In addition, this PS exhibited selectivity towards tumour tissue as 
opposed to healthy surroundings. As for bleomycin, its single administration limits the 
side effects associated to this antibiotic, described in Chapter 2. Moreover, the fact that 
it acts on highly proliferating cells might enhance the effect in cancerous cells.  This 
preliminary clinical study has served as a basis for further PCI approaches and 
additional clinical trials in cancer treatment are being carried out, mentioned briefly in 
Background and Introduction.  
4.1.4 AlPcS2a as photosensitiser  
As with the above photosensitiser, the amphiphilic nature of AlPcS2a’s structure which 
favours uptake by adsorptive endocytosis, explains the PS’s suitability to cause 
photooxidative damage not just in PDT, but also for PCI.  
AlPcS2a-PDT was compared to 5-ALA in the evaluation of the resulting oedema 
following light and ultimately its capacity to open the blood-brain-barrier (BBB). 
Different PS concentrations and light fluences were used, demonstrating a higher 
potency of AlPcS2a based on the higher mortality rates and oedema formed. A 4/5-hr or 
18 hr DLI were followed for 5-ALA or AlPcS2a light treatment respectively. It was 
indicated by the authors that due to the photosensitiser’s amphiphilicity, it accumulated 
in the membrane of endothelial cells present in the BBB and was capable of directly 
affecting this structure (Mathews et al., 2011).  
In a different study, AlPcS2a was combined with bleomycin to treat human colorectal 
and sarcoma tumour xenografts implanted in mice (Berg et al., 2005). The authors of 
the study confirmed the complete eradication of 60% of tumours 200 days after light 
treatment in PCI-treated animals, while only 10% of PDT-treated mice were cured by 
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this time. A 2-day DLI was used in this study. Importantly, no pneumonitis or fibrosis 
(characteristic effects of bleomycin) were found upon histological analysis of the 
samples and loss weight observed in the animal subjects after administration of the 
drug was recovered soon after treatment (Berg et al., 2005).  
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4.2 Aims 
The present chapter focuses on the application of the minimally invasive focal light-
based therapies PDT and PCI in the treatment of prostate cancer tumours in vivo.  
Copenhagen rats were used as the in vivo model from the present chapter of the thesis 
onwards. Specifically, among the above-described Dunning cell lines, MatLyLu were 
selected based on their similarities with advanced hormone-independent human 
prostate cancer and their commercial availability. Tumours were initially grown 
subcutaneously and all light treatments were performed on heterotopic tumours. 
However, an orthotopic tumour model has also been developed and will be additionally 
reported. Different photosensitisers (TPCS2a –Amphinex–, BPD-MA –Visudyne– or 
AlPcS2a) were independently used to evaluate the potential of light-based therapies to 
treat highly aggressive prostate cancer tumours, as is the case of our chosen model. 
BPD-MA is a PDT photosensitiser, while TPCS2a and AlPcS2a have been selected 
primarily due to their application for PCI, although TPCS2a could only be used at UCL 
owing to a prearranged material transfer agreement between PCI biotech A.S., as the 
owner of the drug, and UCL. As performed in vitro in Chapter 2 and Chapter 3, early 
studies in vivo involve PDT procedures as a starting point to establish the optimal 
conditions for an effective light-based treatment. Hereafter, we also briefly performed a 
preliminary investigation combining PS and the chemotherapy agent saporin, following 
PCI in tumour-bearing rats.  
Due to the greater complexity of in vivo models, administration of therapeutic agents 
systemically follows a more intricate “journey” until these reach diseased areas, where 
there is a continuous interplay between drugs and biological systems. Therefore, in 
vivo experiments require a more thorough consideration as opposed to cells in a 
laboratory plate in vitro. On this basis, before performing light treatments, 
biodistribution and pharmacokinetic studies of photosensitisers were also evaluated in 
the above-mentioned rat model.  
Overall, the therapeutic outcome of PDT and PCI was assessed and reported in the 
present chapter through the observation of tumour samples and survival curves. We 
directly relate the length of time required to reach a pre-established endpoint, to the 
delay of tumour growth after light treatment. Additionally, the mechanisms behind cell 
death in light-based treatments were evaluated through immunohistochemistry 
staining. 
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4.3 Materials & Methods 
Animals and tumour models 
Experiments were carried out using a subcutaneous syngeneic rat prostate 
adenocarcinoma tumour model (MatLyLu subline - Dunning R3327, purchased from 
ECACC Cat. 94101454). Copenhagen rats were used throughout (100-300 g).  All 
animal experiments were performed in compliance with UKCCCR guidelines (under the 
authority of both project (70/7666) and personal licences (IC01B2571) granted by the 
Home Office) or the subcommittee on Research Animal Care (IACUC) of 
Massachusetts General Hospital in accordance with NIH guidelines (2015N000120).  
 Subcutaneous model  
106 or 4x105 MatLyLu cells prepared in 100 µl RPMI 1640 media were implanted 
subcutaneously into the right flank of syngeneic Copenhagen rats (approximately 100 
g), previously shaved. A state of general anaesthesia was maintained using inhaled 
isoflurane throughout the procedure.  
 Orthotopic tumour model 
Under general anaesthesia, Copenhagen rats (approximately 250 g, n=4) were shaved 
in their abdominal region and a 2 cm longitudinal incision was performed from the pubic 
bone in a cranial direction. The prostate was exposed upon retraction of the bladder. 
104, 2x104, 2.5x104 or 5x104 MatLyLu cells prepared in 100 µl RPMI 1640 media were 
injected into the stroma of the ventral lobe of the prostate. PBS was used with 
frequency to avoid dehydration during surgery. A solution of 10% povidone-iodine was 
used towards the end of the procedure to irrigate the surgical field in order to avoid 
growth of tumour cells which could have been unintentionally spilled in the surrounding 
areas. A 6-0 absorbable (Polyglactin 910) suture was used to repair the muscle layers 
and a 4-0 suture was used to close the incision in the skin. A state of general 
anaesthesia was maintained using inhaled isoflurane throughout the procedure. A 
combination of analgesics, Vetergesic (0.05-0.1 mg/kg) and Rimadyl (5 mg/kg) were 
administered subcutaneously 30 minutes prior to the procedure and in days following if 
the animals were found in pain or distress.  
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Figure 53. Orthotopic tumour implant procedure.  
Copenhagen rats were shaved in their abdominal region (A) and a 2 cm longitudinal incision was 
performed from the pubic bone in a cranial direction (B). The prostate was exposed upon retraction of the 
bladder (C). 104, 2x104, 2.5x104 or 5x104 MatLyLu cells were injected into the stroma of the ventral lobe of 
the prostate (D). Incision 3 days after surgery (E) 
Chemicals and photosensitisers 
TPCS2a (Amphinex®) was kindly donated by PCI Biotech AS, Oslo, Norway. The 30 
mg/ml stock in Cremophor was diluted in PBS to a final concentration of 0.25-2.5 
mg/ml for intravenous (i.v.) injection, sterile filtered and kept at 4ºC. 
BPD-MA (Visudyne®) was purchased from Novartis. 15 mg of lyophilised powder were 
dissolved in 1 ml 5% dextrose and stored at -80ºC. Working solutions were prepared at 
0.5 mg/ml and kept at 4ºC. 
AlPcS2a was purchased from Frontier Scientific Inc., U.S. The stock solution was 
prepared by dissolving powder in sodium hydroxide, and neutralising with 0.1 M 
hydrochloric acid to a 1-2 mg/ml final concentration. Working AlPcS2a solutions were 
kept at 4°C and experimental concentrations were obtained diluting a 1-2 mg/ml 
solution in cell media to reach desirable concentrations. 
Saporin (Sigma Aldrich, S9896) was dissolved in PBS to a final concentration of 0.25 
mg/ml for intravenous (i.v.) injection and kept at 4ºC. 
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Qualitative biodistribution of TPCS2a using fluorescence microscopy 
2.5 mg/ml TPCS2a was administered intravenously to 15 Copenhagen rats via tail vein. 
Liver, spleen, skin, tumour, distal colon, prostate, urethra and bladder samples were 
collected 6 hr, 24 hr, 48 hr and 72 hr after administration and 3 animals were used per 
group, including control group. Fresh tissue samples were snap-cooled in isopentane 
for 10 s upon removal. Excess liquid was dried placing the specimen on paper tissue 
and these were then immersed in liquid nitrogen and kept frozen at -80ºC after 
collection until sectioning.  
OCT Embedding Medium (Raymond A. Lamb, UK) was used to mount samples for 
cryosectioning. Samples were sectioned at 10 µm and collected on polylysine-coated 
slides and kept in -20 ºC after collection until imaging. Minimal environmental light was 
used during sectioning to avoid bleaching of TPCS2a. 
Fluorescence emission of TPCS2a in tissues was imaged using an Olympus IMT-2 epi-
fluorescence microscope with a low power (2 mW) 405 nm blue diode laser coupled to 
a liquid light guide. A PIXIS 521 charge-coupled device (CCD) camera (Princeton 
Instruments) was attached to the microscope, using a 10X magnification objective 
giving 500 x 500 – micron scale images. A 660 nm bandpass detection filter was used. 
Image analysis was performed using Image J software. Control animal samples without 
TPCS2a, showed insignificant levels of autofluorescence, yet, these were taken into 
consideration and subtracted when examining the samples under investigation. 
Accordingly, a baseline for TPCS2a-based fluorescence was obtained. After imaging, 
sections were stained following a standard haematoxylin eosin (H&E) protocol and 
examined on a Hamamatsu Nanozoomer Digital Pathology (NDP) scanner 
(Hamamatsu Photonics K.K., UK), which recorded whole sections producing high 
resolution images. 
Quantitative biodistribution of TPCS2a using chemical extraction 
2.5 mg/ml TPCS2a was administered intravenously to 15 Copenhagen rats via tail vein. 
Liver, blood, spleen, skin, tumour and distal colon samples were collected 6 hr, 24 hr, 
48 hr and 72 hr after administration and 3 animals were used per group, including 
control subjects. Tissue samples were kept frozen at -80 ºC after collection. 
Solvable™, was purchased from PerkinElmer to perform chemical extraction. Prior to 
use, samples were completely defrosted and 0.1 g (in triplicate) were cut from each 
organ sample and immersed in tubes containing 2 ml of Solvable™. Due to expected 
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higher fluorescence in blood samples, 3 ml Solvable™ were used. Tubes were then 
placed in a shaking water bath at 50ºC during 2 hours until the samples had completely 
dissolved. 0.15 ml of these tissue solutions were diluted in 3 ml Solvable™ prior to 
measurement of fluorescence, again, performed in triplicate. Right before measuring 
fluorescence, samples were cooled to room temperature and each solution was plated 
in 4 wells of a black 96-well plate.  
Standard curves of TPCS2a were obtained for each organ by making up a TPCS2a 
series of known concentrations of control tissue and solvable mixtures. Fluorescence 
was measured at 652 nm, and hereafter used to calculate unknown concentrations in 
the different groups. The displacement factor of each organ in solvable was taken into 
account.  
Qualitative biodistribution of BPD-MA and AlPcS2a using a fluorescent in vivo imaging 
system (IVIS)  
1 mg/ml BPD-MA or 2 mg/ml AlPcS2a were administered intravenously to Copenhagen 
rats via tail vein. Images were taken immediately, 15 min or 6 hr (for BPD-MA and 
AlPcS2a respectively) and 24 hr after administration.  
Fluorescence emission of both photosenstisers was imaged using an IVIS® Lumina 
Series III (PerkinElmer, Inc., Waltham, MA, USA). Before imaging, a state of general 
anaesthesia was induced using inhaled isoflurane in the subjects. Rats were then 
placed in the imaging chamber on an adjustable stage. Optimal excitation/emission 
filters for the phtalocyanine-based PS (AlPcs2a) were not available in the existing IVIS 
equipment. Therefore, for both BPD-MA and AlPcs2a, fluorescence emission was 
measured at 670 nm, setting excitation at 420 nm.  
Light sources 
Different devices were used to tailor light treatment to each photosensitiser: 
 A diode laser emitting at 652 nm was used for Amphinex® treatment groups 
(Diomed Ltd., UK) 
 A LumaCare lamp LC-122 (LumaCare, USA) was used for BPD-MA and 
AlPcS2a treatment groups.  A fibreoptic probe was attached to the lamp emitting 
in the spectral region 670-700 and 635-670 nm for each photosensitiser 
respectively.  
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TPCS2a - PDT treatment on subcutaneously grown tumours  
For PDT treatments with TPCS2a, a 0.25 mg/ml solution was injected 24 hr prior to light 
delivery via a tail vein administering different PS dosages: 0.5, 1 or 2.5 mg/kg. Before 
light treatment, the skin above subcutaneously growing tumours was shaved and a 
small incision was made, exposing these tumours. Two different light treatments were 
performed hereafter. At least 3 animals were used per combination of PS and light 
(PDT group - n≥3) 
 
Figure 54. Timeline for TPCS2a treatments in vivo. 
TPCS2a solutions were administered i.v. via tail vein, allowing either a 16 hr or 24 hr DLI. After light 
treatment, animals were monitored regularly and sacrificed when tumour volume reached a humane end 
point (volume = 1.8 cm3).   
 Interstitial illumination 
A 400 µm laser fibre was used to deliver light interstitially. The bare cleaved tip of the 
fibre was used to penetrate the tumour capsule, inserting it perpendicular to the tumour 
surface (see Figure 55). Laser power was set to 0.1 W at a light irradiance of 10 J or 20 
J. 
Figure 55. Interstitial illumination of 
previously exposed subcutaneous 
tumours.  
The area of skin above the growing tumour 
was shaved and a small incision was made 
to expose the tumours (0.6-1 cm diameter 7 
days after implantation - depending on the 
cell number injected).  A cleaved tip 400 µm 
laser fibre was used to penetrate the tumour 
capsule and deliver light in a perpendicular 
manner into the top of the tumour. 
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 Surface illumination 
A 400 µm microlens fibre was placed above the tumour, generating a 2 cm uniform 
spot of light. Laser power was set to 0.1 W/cm2 at a light irradiance of 75 J/cm2. To 
avoid undesired skin toxicity, the area surrounding the tumour was covered in 
previously sterilised opaque thick drapes during light delivery as shown in Figure 
56. 
 
Figure 56. Surface illumination of 
previously exposed subcutaneous tumours. 
The area of skin above the growing tumour 
was shaved and a small incision was made to 
expose the tumours (0.6-1 cm diameter 7 days 
after implantation - depending on the cell 
number injected). A microlens fibre was used 
to deliver a 2cm spot of light on top of the 
exposed tumour surface. 
 
 
 
During light treatments a state of general anaesthesia was maintained using inhaled 
isoflurane throughout the procedure. A combination of analgesics - Vetergesic (0.05-
0.1 mg/kg) and Rimadyl (5 mg/kg), was administered subcutaneously 30 minutes prior 
to the procedure and the days following if the animals were found in pain or distress. 
Animals were monitored regularly and sacrificed when tumour volume reached a 
humane end point (volume = 1.8 cm3). Tumour samples were cleaned in PBS and 
immersed in formalin for 24 hr – 48 hr based on their size. These were then processed 
and stained following a standard H&E protocol.   
BPD-MA PDT treatment on subcutaneously grown tumours 
1 mg/kg of BPD-MA was injected i.v. via tail vein 15 minutes before light treatment. No 
surgical procedure was carried out during BPD-MA PDT procedures. The fibreoptic 
attached to the lamp was placed above the skin covering the tumour, which had been 
previously shaved. Laser power was set to 0.1 W/cm2 at a light irradiance of 120 J/cm2. 
During light treatments a state of general anaesthesia was maintained using inhaled 
isoflurane throughout the procedure. Buprenex (0.05-0.1 mg/kg) was administered 
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subcutaneously prior to the procedure and the days following if the animals were found 
in pain or distress. At least 3 animals were used per combination of PS and light (PDT 
group - n≥3) 
 
Figure 57. Timeline for BPD-MA PDT treatments in vivo.  
BPD-MA solutions were administered i.v. via tail vein, allowing a 15-minute DLI. After light treatment, 
animals were monitored regularly and euthanised when tumour volume reached a humane end point 
(volume = 1.8 cm3).   
AlPcS2a PDT and PCI treatments on subcutaneously grown tumours 
2 mg/kg of AlPcS2a was injected i.v. via tail vein 6 or 24 hr before light treatment. No 
surgical procedure was carried out during AlPcS2a PDT or PCI procedures. The 
fibreoptic attached to the lamp was placed above the skin covering the tumour, which 
had been previously shaved. Laser power was set to 0.1 W/cm2 at a light irradiance of 
100 J/cm2. During light treatments a state of general anaesthesia was maintained using 
inhaled isoflurane throughout the procedure. Buprenex (0.05-0.1 mg/kg) was 
administered subcutaneously prior to the procedure and the days following if the 
animals were found in pain or distress. In animals belonging to PCI groups, 250 µg/kg 
saporin was administered 1 hr prior to light. As reviewed previously, photooxidative 
damage has a vascular effect in vivo. Founded on this, saporin was administered 
before light: this would ensure the systemic delivery of saporin, i.e. tumour area, in the 
event of a later vascular shut down. At least 3 animals were used per combination of 
PS and light (PDT group) or PS, light and saporin (PCI group) (n≥3). 
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Figure 58. Timeline for AlPcS2a PDT/PCI treatments in vivo.  
AlPcS2a solutions were administered i.v. via tail vein, allowing either a 6 hr or 24 hr DLI. 1 hr before light 
treatment, 250 µg/kg saporin was administered i.v. via tail vein to animal subjects belonging to the PCI 
group. After light treatment, animals were monitored regularly and euthanised when tumour volume 
reached a humane end point (volume = 1.8 cm3).   
Standard histological analysis of tumour samples  
Tissue samples removed from Copenhagen rats were washed in PBS directly after 
sampling and immersed in 10% formalin during 24-48 hr depending on the size of the 
specimen. Samples were then processed following a standard tissue processing 
protocol and embedded in paraffin. Paraffin blocks were trimmed and once the whole 
sample was accessible section collection was started. 4-5 µm thick sections were cut 
from each sample. H&E staining was performed following a standard protocol. Sections 
were then examined on a Hamamatsu Nanozoomer Digital Pathology (NDP) scanner 
(Hamamatsu Photonics K.K., UK), which recorded whole section high resolution 
images. 
Immunohistochemistry staining  
Immunohistochemistry staining was performed by UCL Advanced Diagnostics. Briefly, 
for cleaved caspase-3 staining, a primary antibody was purchased from Cell Signaling 
Technology® (Cat. 9661). This is a rabbit polyclonal antibody which detects the 
endogenous fragment of activated caspase-3 enzyme, resulting from its cleavage 
adjacent to D175. Antigen retrieval was achieved at pH 6 during 30 minutes at 99°C. 
An epitope retrieval solution from Leica Biosystems (AR9961) was used. Staining was 
performed on a Leica Bond III automated immunostainer and detection was carried out 
using Leica Bond Polymer Refine DAB detection system (Leica DS9800) as follows: 
incubation with the primary antibody was allowed during 15 minutes at room 
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temperature (1/300 dilution). Slides were then blocked with hydrogen peroxide and an 
additional anti-mouse post-primary antibody was applied for 8 minutes. Finally, an 8-
minute incubation with an anti-rabbit secondary antibody was completed. 
Statistical analysis 
Statistical analysis was performed using GraphPad Prism 6.  
For tumour growth rate analysis, at least 3 animal subjects were used in each group (n 
≥ 3) but for light only controls and AlPcS2a-PDT. In the latter group, 2 animals died 
during light treatment due to anaesthesia overdose. Therefore, n = 2 was used for 
these. A two-way ANOVA followed by Bonferroni post hoc multiple testing correction 
was used to in those cases where at least 3 animals were used (n ≥ 3). In comparative 
analysis involving n = 2 groups, a one-way ANOVA between matched groups followed 
by Bonferroni post hoc was performed.  
Significance level of p < 0.05 (*p = 0.05 to 0.01; **p = 0.01 to 0.001; ***p = 0.001 to 
0.0001)  
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4.4 Results 
4.4.1 Prostate tumours in Copenhagen rats 
All PDT and PCI light treatments were performed on subcutaneous tumours due to the 
relatively easy generation and growth monitoring of this tumour model. Despite the 
greater accuracy and reliability in the evaluation of tumour treatment when tumour 
masses are found in their natural physiological environment (prostate in this specific 
project), the anatomical localisation of the prostatic gland hinders the accurate 
monitoring of tumour growth. Hence, reproducibility between animal subjects and 
assessment of tumour evolution can be hampered. In addition, tumour implantation in 
this case requires an additional surgical procedure (as described in the Materials & 
Methods section) with the associated risk and comorbidity in the animals this entails. 
Finally, the reduced size of rat prostate hampers the exclusive injection of cancer cells 
in this organ, jeopardising surrounding tissues, which may accommodate possible 
spillage of malignant cells. Consequently, the use of subcutaneous tumours in this 
case enables the faster generation of a larger number of tumours to perform studies 
on.  
As reported in the in vitro study in Chapter 2, MatLyLu is a very metabolically active 
and rapidly growing cell line. Throughout the in vivo study, we observed that tumour 
growth was gradual up to around 0.8 cm diameter, from which point an exponential 
growth occurred. This would accelerate the period of time for animals to reach the 
humane pre-established endpoint based on tumour size and burden. Therefore, the 
aim during tumour generation was to determine an adequate cell number during 
implantation that would be large enough to result in tumour formation, yet in a 
controlled manner, since cells require a sufficient amount of time to form “organised” 
tumour masses. Additionally, this should be achieved within reasonable periods of 
time, which would suit our experimental timeline and enable reproducibility.  
So as to determine this optimal cell number to generate tumours in vivo, different cell 
concentrations were tested. Initial experiments in tumour generation were performed 
using 106 cells/implantation, which resulted in 1 cm diameter tumours in 7 days. We 
then attempted 4x105 cells, which lead to a delay of 1 day in tumour growth, reaching 
the 1 cm diameter after 8-9 days. The first interstitial-light treatments described below 
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were performed with 1 cm diameter tumours after a 106-cell implantation. Due to the 
sudden exponential tumour growth stated in the lines above, treatment was initiated on 
0.5-0.7 cm tumours resulting from the implantation of 4x105 cells.  
  
Figure 59. Orthotopic prostate tumour.  
5x104 MatLyLu cells were implanted into the ventral lobe of the prostate in Copenhagen rats through 
surgical procedure. (A) tumour removed 8 days post implantation; (B) H&E staining, top red arrow 
indicates the remaining glandular prostate tissue, bottom red arrow indicates an affected tumour area; (C), 
(D) tumour prior to removal – both show highly vascularised tumours; (E), (F) detail of H&E staining at 
2.5X magnification. Scale bars shown as 1 cm for tumour shown in (A), (C), (D); 2 mm for H&E tumour 
staining (B), (E), (F). “A” and “V” in (E), (F), indicate affected prostate tumour and viable tumour regions 
respectively.  
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Even though we did not perform treatment on orthotopic tumours for the reasons stated 
above, we attempted the orthotopic implantation of MatLyLu cells for potential future 
experiments. In this case, rats bearing tumours in the prostate gland were regularly 
monitored to assess tumour growth through abdominal palpitation. No tumour mass 
was detected by this mean; however, based on previous in vitro knowledge regarding 
the fast growth rate of MatLyLu cells, animal subjects were euthanised 8 days post 
surgery.  
Only the rat that had been injected with the largest cell number (5x104 cells) developed 
a tumour of large dimensions - 1.4 cm3 (Figure 59A, Figure 59C, Figure 59D). This 
tumour invaded the whole prostate (Figure 59A), which consequently lost its 
characteristic anatomical glandular structure, being detectable only in a small region of 
the periphery as indicated with a red arrow in Figure 59B. In addition, the highly 
vascularised nature of the tumour under investigation was observed in this specimen. 
Interestingly, despite this tumour had not received treatment, an affected area in the 
central region of the tumour was found (Figure 59D). This is a common feature of large 
tumours, generally spontaneous necrosis due to fast growth. 
Briefly, we observed throughout our study that MatLyLu tumours were very fast 
growing and frequently resulted in multi-nodular tumours. This correlates with previous 
observations of cells cultured in vitro during the present project as well as in preceding 
studies, where doubling time was 19.7 hr, contact inhibition was lost and clumps were 
found even at low confluence (Wenger et al., 1984). 
4.4.2 Amphinex PDT in rat subcutaneous prostate carcinoma 
Amphinex® was the first photosensitiser to be employed in our in vivo study since it 
was being used at the same time in the first-in-man PCI clinical for cancer treatment 
trial at UCLH (University College London Hospital). As stated in the Introduction section 
above, the success of this study has been recently reported (Sultan et al., 2016).  
In the present project, initial experiments involved the evaluation of pharmacokinetics 
and biodistribution in the rat model described, prior to the conduction of PDT and PCI 
light treatments. These investigations were carried out following two different 
techniques as will be reported in the sections below: quantification by chemical 
extraction and qualitative observation through fluorescence microscopy.  
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4.4.2.1 Quantitative biodistribution of TPCS2a 
(Amphinex) in Copenhagen rats – Chemical 
extraction  
In order to evaluate pharmacokinetics of TPCS2a in our animal model as well as to 
determine the optimal drug light interval for light treatments, chemical extraction of 
certain organs was carried out. An optimal DLI is important to maximise the amount of 
photosensitiser present in the tumour mass whilst keeping levels in surrounding healthy 
tissues under certain limits to avoid undesired phototoxicity in the event of unavoidable 
normal tissue illumination. 
 
Figure 60. Biodistribution of TPCS2a in liver, blood, spleen, skin, tumour and distal colon.  
2.5 mg/kg TPCS2a were administered i.v. via tail vein to 15 Copenhagen rats (n=3, including control). 
Samples were obtained 6 hr, 24 hr, 48 hr and 72 hr after injection. Solvable™ was used to dissolve tissue 
samples. Fluorescence of the samples was measured at 652 nm. To quantify, standard curves of known 
concentrations of TPCS2a were obtained for each of the studied organs. Concentration is shown as mean 
µg per gram of tissue ± SEM. 
Liver and spleen were chosen due to their intrinsic nature as filtration organs. Blood is 
the vehicle responsible for the systemic distribution throughout the body and for this 
reason it was also investigated. As for skin, when using light-based therapies, it is 
important to consider side phototoxicity that might emerge as a consequence of the 
exposure to natural sunlight and visible light in the environment. Finally, it is also 
important to consider levels of PS in tissues located in the proximities of the prostate 
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such as bladder or distal colon. Therefore, the amount of TPCS2a in distal colon was 
quantified through chemical extraction; while levels in bladder and prostate, were 
assessed through fluorescence microscopy (reported in the following section) due to 
their reduced size.   
As shown in Figure 60, the earliest time point (6 hr) resulted in the largest amount of 
photosensitiser in all organs sampled. Not surprisingly, liver was the organ exhibiting 
the greatest presence of TPCS2a at all time points evaluated. However, it was quickly 
cleared, being present at 24.3 µg/g, 6.3 µg/g and 2.3 µg/g at 6 hr, 24 hr or 72 hr 
respectively. In blood and spleen similar amounts were found 6 hr after administration, 
5.6 µg/g and 6.4 µg/g correspondingly. Both of these tissues also exhibited analogous 
clearance of the photosensitive compound, being levels significantly lower at 24 hr and 
negligible at 72 hr. In distal colon TPCS2a was not retained at remarkable 
concentrations in any of the time points investigated (0.99 µg/g - 0.58 µg/g). Skin 
exhibited a similar accumulation and clearance profile as described for distal colon, 
with a slightly higher accumulation at the 6 hr time point (1.6 µg/g). Regarding the 
tumour tissue of interest, 6 hr was also the time point exhibiting the largest amount of 
TPCS2a (2.9 µg/g) and then gradually decreased, showing only insignificant traces 72 
hr after administration (0.6 µg/g).  
4.4.2.2 Qualitative biodistribution of Amphinex in 
Copenhagen rats – Fluorescence microscopy  
Fluorescence microscopy was used to assess biodistribution in liver, spleen, skin, 
tumour, distal colon in a qualitative manner in addition to the quantification reported 
above. In addition, this was an additional verification of the accumulation of the 
photosensitiser under study and later clearance from the mentioned tissues. Prostate, 
urethra and bladder were not subject to chemical extraction given their reduced size 
(the amount of existing tissue would have been insufficient to follow the chemical 
extraction protocol as described in the Materials & Methods section). However, a 
qualitative assessment of the accumulation of TPCS2a in these tissues was carried out 
through fluorescence imaging 6 hr, 24 hr, 48 hr and 72 hr after injection of 
photosensitiser solution. These fluorescence images are dis played in Figure 61, 
Figure 62 and Figure 63. 
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Figure 61. 
Distribution of 
TPCS2a in liver, 
spleen and skin.  
2.5 mg/kg 
TPCS2a were 
administered i.v. 
via tail vein in 15 
Copenhagen rats 
(n=3, including 
control). 
Fluorescence 
images were 
taken from liver 
(A, B, C, D); 
spleen (F, G, H, 
I); skin (K, L, M, 
N). Tissues were 
sampled 6 hr, 24 
hr, 48 hr and 72 
hr after injection 
of 2.5 mg/kg 
TPCS2a. (E), (J), 
(O) H&E staining 
from each tissue 
shown at 10X 
magnification. 
Scale bars shown 
as 200 µm. 
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Figure 62. 
Distribution of 
TPCS2a in 
urethra, bladder 
and distal colon.  
2.5 mg/kg 
TPCS2a were 
administered i.v. 
via tail vein in 15 
Copenhagen rats 
(n=3, including 
control). 
Fluorescence 
images were 
taken from 
urethra (A, B, C, 
D); bladder (F, G, 
H, I); distal colon 
(K, L, M, N). 
Tissues were 
sampled 6 hr, 24 
hr, 48 hr and 72 
hr after injection 
of 2.5 mg/kg 
TPCS2a. (E), (J), 
(O) H&E staining 
from each tissue 
shown at 10X 
magnification.  
Scale bars shown 
as 200 µm. 
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Figure 63. Distribution of TPCS2a in subcutaneous prostate tumour and prostate. 
2.5 mg/kg TPCS2a were administered i.v. via tail vein in 15 Copenhagen rats (n=3, including control). Fluorescence images were taken from subcutaneously grown 
tumour (A, B, C, D); prostate (F, G, H, I). Tissues were sampled 6 hr, 24 hr, 48 hr and 72 hr after injection of 2.5 mg/kg TPCS2a. (E), (J), (K) H&E staining from each 
tissue shown at 10X magnification.  Scale bars shown as 200 µm. 
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Similarly to chemical extraction findings, images 6 hr after administration of 
photosensitiser resulted in the highest intensity of fluorescence, thus accumulation of 
TPCS2a in all tissues (Figure 61A, Figure 61F, Figure 61K, Figure 62A, Figure 62F, 
Figure 62K, Figure 63A, Figure 63F, Figure 63K), which was then significantly reduced 
by 24 hr (Figure 61B, Figure 61G, Figure 61L, Figure 62B, Figure 62G, Figure 62L, 
Figure 63B, Figure 63G, Figure 63L). Liver (Figure 61A) displayed the greatest 
emission of fluorescence out of all sampled tissues, followed by spleen (Figure 61F). 
Similar fluorescence levels were found between the rest of the tissues 6 hr after 
injection. 24 hr after injection negligible fluorescence was detected in liver (Figure 61B), 
spleen (Figure 61F), skin (Figure 61L) and distal colon (Figure 62L); which were kept 
constant hereafter up to micrographs taken at 72 hr (Figure 61B-Figure 61D; Figure 
61G-Figure 61I; Figure 61L-Figure 61N; Figure 62L- Figure 62N respectively). Although 
emission of fluorescence at 24 hr was also reduced in urethra (Figure 62B), bladder 
(Figure 62G), tumour (Figure 63B) and prostate (Figure 63G) compared to 6 hr, this fall 
was not as drastic as in liver, spleen and skin. 
Fluorescence in urethra seemed to be quite similar 6 hr – 48 hr after injection, as 
shown in Figure 62A-Figure 62C, being significantly reduced by 72 hr (Figure 62D). As 
for bladder, emission of fluorescence was reduced by 24 hr (Figure 62G), followed by 
similar levels 24 hr – 72 hr (Figure 62G- Figure 62I). 
Tumour tissue seemed to retain TPCS2a up to 48 hr post administration (Figure 63B- 
Figure 63C), although a higher fluorescence resulted from micrographs taken at 6 hr 
(Figure 63A). Importantly, this fluorescence was uniformly distributed and located 
within cells, not restricted to vascular structures within the tumour mass, which is a 
particularly important observation regarding light treatment in PCI procedures. Healthy 
prostate exhibited a similar accumulation pattern of photosensitiser throughout the 
study, although levels were slightly higher at the earliest imaged time point (Figure 
63F). No significant fluorescence was detected in control samples.  
4.4.2.3 TPCS2a light treatment (PDT) 
Although the earliest time point (6 hr) in the distribution and pharmacokinetic study 
(Figure 60) showed the greatest accumulation of TPCS2a (Amphinex®) in tumours, we 
started performing light treatments following a 24 hr drug light interval. This would 
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ensure a more subcellular effect as opposed to high dose PDT, enabling the 
comparison with PCI in further experiments.  
 
Figure 64. Evaluation of affected tumour area 24 hr after TPCS2a-PDT interstitial light treatment to 
subcutaneous prostate tumours.  
2.5 mg/kg TPCS2a was injected i.v. via tail vein to Copenhagen rats bearing subcutaneously grown 
prostate tumours (i, ii, iii). 24 hr after administration, light treatments were carried out at a fluence rate of 
20 J and 0.1 W power and animals were euthanised 24 hr after light treatment. Once sampled, tumours 
were H&E stained and examined on a Hamamatsu Nanozoomer Digital Pathology (NDP) scanner, 1.25X 
magnification. A: affected tumour area; V: viable tumour area; scale bars shown as 2 mm. 
We initiated PDT treatment to subcutaneous tumours using interstitial illumination. An 
early assessment of photooxidative damage was carried out 24 hr after a 20 J light 
treatment of tumours in animals previously injected with TPCS2a. As indicated as “A” in 
Figure 64, the combination of TPCS2a and light resulted in large affected regions in 
these tumours. The additional staining against cleaved caspase-3, marker for apoptotic 
cell death, revealed a major participation of apoptosis resulting from PDT 
photooxidative damage, as observed in Figure 65, one of the tumour samples 
belonging to this first group of treated animal subjects also analysed through H&E 
staining in Figure 64i.  
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Figure 65. Evaluation of apoptosis 24 hr after TPCS2a-PDT interstitial light treatment to 
subcutaneous prostate tumours.  
2.5 mg/kg TPCS2a was injected i.v. via tail vein to Copenhagen rats bearing subcutaneously grown 
prostate tumours. 24 hr after administration, light treatments were carried out at a fluence rate of 20 J and 
0.1 W power and animals were euthanised 24 hr after light treatment. Once sampled, tumours were 
stained with anti-cleaved caspase-3 (D175) and examined on a Hamamatsu Nanozoomer Digital 
Pathology (NDP) scanner.  (i), (ii) and (iii) are different ROIs within the tumour sample; shown at 20X, 40X 
and 80X magnification. Same tumour sample as shown in Figure 64i. Different stages of the apoptotic 
process are indicated with black (earlier stages), green (later stages) and red (final stages) arrows. Scale 
bars shown as 2 mm. 
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During early stages of apoptosis thecleavage of pro-caspase-3 results in an active form 
of the enzyme in the cell cytosol, that then participates in the apoptotic pathway. In the 
tumour sample under investigation, this is indicated with black arrows in Figure 65, 
where a brown stain is consistent throughout the cell cytosol. As apoptosis occurs, 
nuclear chromatin is condensed in the nuclear fraction, specifically at the nuclear 
membrane, and the cytoplasm shrinks, hence the nucleus appears to occupy the 
totality of the cell structure. This is a significant observation during apoptotic cell death. 
In Figure 65, this stage is indicated with green arrows, pointing at dark brown-stained 
cells. Finally, the fragmentation of cells in late stages of apoptosis and appearance of 
apoptotic bodies is highlighted with red arrows. The three different ROIs indicated in 
Figure 65 show: largely affected areas based on the number of apoptotic cells (Figure 
65i), areas affected to a lower extent (Figure 65ii), or negligible apoptosis (Figure 65iii). 
Staining of the tumour periphery was particularly noteworthy. 
Interestingly, control untreated tumours (Figure 66) and tumours exposed to light alone 
in the absence of photosensitiser (Figure 68, Figure 71), also exhibited a large affected 
area, alike TPCS2a and 20 J-treated tumours (Figure 64). Nevertheless, distribution of 
these areas was different in control tumours and those treated shown above: TPCS2a 
and 20J light resulted in a more homogeneous and uniformly affected area while 
controls exhibited disorganised affected regions throughout the tumour tissue.  
 
Figure 66. Control subcutaneous prostate tumour in Copenhagen rats.  
6-7 days after implantation of tumour cells subcutaneously, a standard H&E staining was performed in 
untreated tumours and these were then examined on a Hamamatsu Nanozoomer Digital Pathology (NDP) 
scanner, 1.25X magnification. A: affected tumour area; V: viable tumour area; scale bars shown as 2 mm. 
In vivo studies of PDT and PCI in Prostate Cancer  
 
185 
The observation of magnified H&E tumour images revealed clear differences in 
morphological features of cells in viable and affected ROIs. With the assistance of a 
pathologist’s expertise, we became acquainted with different morphological features of 
infiltrating leucocytes and were able to identify these in the tumour samples H&E-
stained in the present chapter. For instance, polymorphonuclear leucocytes (i.e. 
neutrophils) are small cells, with granular cytoplasm and highly lobed nuclei. These 
cells can be mistaken by apoptotic cells, which display large intracellular spaces 
(suggesting inexistent connexions between cells), enlarged nuclear compartment, more 
condensed chromatin and shrunk cytoplasm. For these reason, tumour samples were 
stained with anti-cleaved caspase-3, apoptotic marker.  
 
Figure 67. Extravasation of leucocytes and tumour infiltration.  
Highlighted with black arrows: (i) circulating leucocytes shown inside a blood vessel in the tumour mass; 
(ii) leucocytes being release from circulating vessels due to possible endothelial cell damage resulting in 
leaky vasculature. Shown at 20X magnification.  
Some of these infiltrating cells also exhibited disparities in their affinity for haematoxylin 
and eosin: a more eosinophilic cytoplasm is observed in cells within the affected area 
in the tumour sample, based on the pink shade acquired by these, as opposed to the 
purple-blue shade observed in the cytosol of cells within the viable tumour area. Along 
these lines, leucocytes being released from blood vessels and then infiltrating tumour 
tissue are shown in Figure 67. We also determined the presence of infiltrating 
leucocytes, indicated as IC and with red or green arrows in Figure 68i.  
As opposed to the tumour sample displayed in Figure 65, apoptotic cells were found in 
interstitial light-control tumours to a significantly lesser extent, as indicated with black 
arrows in Figure 68ii. This was also applicable to images shown below (Figure 70, 
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Figure 73), observing no clear differences between treatment groups. In addition to 
apoptotic cells in Figure 68, observation of cells which appear to be losing their natural 
structure (“disintegrating”), suggest the presence of necrotic regions (circled in black in 
Figure 68i).  
 
Figure 68. Interstitial light only-control tumour.  
6-7 days after tumour cell implantation, tumours were exposed to light at a fluence rate of 20 J and 0.1 W 
power. Once sampled, tumours were stained and examined on a Hamamatsu Nanozoomer Digital 
Pathology (NDP) scanner. (i) H&E staining, (ii) cleaved caspase-3 (D175) staining. 20X, 40X and 80X 
magnification shown. A: affected tumour area; V: viable tumour area. TC: tumour cells; IC: infiltrating cells. 
Black arrows indicate apoptotic cells; red and green arrows indicate different infiltrating leucocytes; 
necrotic cells highlighted within a black circle. Scale bars shown as 2 mm. 
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Despite causing significant damage to tumours, the combination of 2.5 mg/kg of 
photosensitiser and 20 J light, would have been excessive for PCI approaches, in 
which therapeutic outcome does not only rely on the photooxidative component. 
Therefore, aiming to compare PDT and PCI in later experiments, light dose was 
reduced to 10 J (Figure 69i).  
Nonetheless, a 10 J light fluence rate did not result in a sufficient photooxidative effect 
in tumours as observed after H&E staining (Figure 69i) and light dose was increased 
again to 20 J. Yet, to avoid an excessive photooxidation as shown earlier in Figure 64, 
the concentration of photosensitiser was reduced and two different doses of TPCS2a 
were assayed (see Figure 69ii and Figure 69iii).  
 
Figure 69. TPCS2a-PDT interstitial light treatment to subcutaneous prostate tumours.  
Different concentrations of TPCS2a [(i) 2.5 mg/kg; (ii) 0.5 mg/kg; (iii) 1 mg/kg)]  was injected i.v. via tail vein 
to Copenhagen rats bearing subcutaneously grown prostate tumours. 24 hr after administration, light 
treatments were carried out at a fluence rate of 10 J or 20 J and 0.1 W power. Once sampled, tumours 
were H&E stained and examined on a Hamamatsu Nanozoomer Digital Pathology (NDP) scanner, at 
1.25X magnification. A: affected tumour area; V: viable tumour area; scale bars shown as 2 mm. 
Regardless of the TPCS2a concentration used, 20 J resulted in a greater phototoxicity 
compared to 10 J, Figure 69ii and Figure 69iii as opposed to Figure 69i. Despite 
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observing large affected areas in these tumour samples, growth rate was unaffected, 
rapidly reaching the endpoint and having to euthanise these animals only 5-7 days 
after light treatment as displayed in Figure 75. There was great disparity in the overall 
affected surface area between tumours within the same treatment group: the affected 
area on sections was not reproducible and presented significant variability (labelled as 
“A” in the figures). Consequently, no quantitative evaluation was performed on these 
damaged regions.  
 
Figure 70. Detail of H&E staining of control and subcutaneous prostate tumours treated with 
TPCS2a-PDT interstitial illumination.  
Once sampled, tumours were H&E stained and examined on a Hamamatsu Nanozoomer Digital Pathology 
(NDP) scanner. 20X, 40X and 80X magnification shown. A: affected tumour area; V: viable tumour area. 
Green arrows indicate infiltrating leucocytes; necrotic cells highlighted within a black circle.  
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The investigation of these samples to a greater detail (Figure 70), also revealed 
morphological features of infiltrating leukocytes as described above. These are 
indicated with green arrows in the figure. In addition, some necrotic cells were also 
identified.  
 
Figure 71. TPCS2a-PDT surface-light treatment to subcutaneous prostate tumours (24 hr DLI).  
(i) Surface light control. Different concentrations of TPCS2a [(ii) 0.5 mg/kg; (iii) 1 mg/kg]  were injected i.v. 
via tail vein to Copenhagen rats bearing subcutaneously grown prostate tumours. 24 hr after 
administration, light treatments were carried out at a fluence rate of 75 J/cm2 and 0.1 W power. Once 
sampled, tumours were H&E stained and examined on a Hamamatsu Nanozoomer Digital Pathology 
(NDP) scanner, at 1.25X magnification. A: affected tumour area; V: viable tumour area. Scale bars shown 
as 2 mm. 
During interstitial treatments, we encountered an added challenge: difficulty in piercing 
the tumour capsule effectively due to the size of tumours before illumination, thereby 
the delivery of light throughout the entire structure of the tumour could be 
compromised. As a consequence, we then moved on to carry out surface instead of 
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interstitial light delivery so as to compare the outcome and assess whether this could 
result in an enhancement of light treatment.  
 
Figure 72. TPCS2a-PDT surface-light treatment to subcutaneous prostate tumours (16 hr DLI). 
Different concentrations of TPCS2a [(i) 0.5 mg/kg; (ii) 1 mg/kg - 3 different tumour samples for each group]  
were injected i.v. via tail vein to Copenhagen rats bearing subcutaneously grown prostate tumours. 16 hr 
after administration, light treatments were carried out at a fluence rate of 75 J/cm2 and 0.1 W power. Once 
sampled, tumours were H&E stained and examined on a Hamamatsu Nanozoomer Digital Pathology 
(NDP) scanner, at 1.25X magnification.  A: affected tumour area, V: viable tumour area; scale bars shown 
as 2 mm. 
Similar findings to those stated after interstitial light delivery were observed in these 
surface-light groups of treatments (Figure 71). Briefly, no consistency was found within 
the same light/PS group. For example, no damaged areas were observed in some of 
the tumours treated with 1 mg/kg PS and light as opposed to large regions in a different 
sample belonging to the same group. In addition, the affected area of tumours treated 
with the highest photosensitiser dose (Figure 71iii) was smaller compared to the lowest 
PS dose (Figure 71ii). Moreover, similarly to the interstitial light control group (Figure 
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68), surface-light alone also resulted in largely affected tumours as shown in Figure 
71i. 
 
Figure 73. Detail of H&E staining of TPCS2a-PDT surface illumination to subcutaneous prostate 
tumours.  
Once sampled, tumours were H&E stained and examined on a Hamamatsu Nanozoomer Digital Pathology 
(NDP) scanner. (i) Surface light control. (ii, iii) 0.5 mg/kg TPCS2a was injected i.v. via tail vein to 
Copenhagen rats bearing subcutaneously grown prostate tumours. 16 hr (ii) or 24 hr (iii) after 
administration light treatments were carried out at a fluence rate of 75 J/cm2 and 0.1 W power. Green 
arrows indicate infiltrating leucocytes. A: affected tumour area; V: viable tumour area. 
Finally, we decided to carry out a last study shortening the drug light interval from 24 hr 
to 16 hr so as to take advantage of the increased amount of photosensitiser present in 
the tumour region during light treatment, as observed in 4.4.2.1 Quantitative 
biodistribution of TPCS2a (Amphinex) in Copenhagen rats – Chemical extraction. This 
group of light treatments, shown in Figure 72, resulted in a more uniformly affected 
area in the tumours, and samples also displayed greater similarity between them. In 
addition, growth rate of these was delayed by an average of 2 days (Figure 75).  
As in the interstitial light delivery groups, similar observations resulted from the 
magnification of H&E surface light tumour samples (Figure 73).  
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Figure 74. Evaluation of apoptosis 16 hr and 24 hr after TPCS2a-PDT surface light treatment to 
subcutaneous prostate tumours.  
1 mg/kg TPCS2a was injected i.v. via tail vein to Copenhagen rats bearing subcutaneously grown prostate 
tumours. 16 hr and 24 hr after administration, light treatments were carried out at a fluence rate of 75 
J/cm2 and 0.1 W power. Once sampled, tumours were stained with anti cleaved caspase-3 (D175) and 
examined on a Hamamatsu Nanozoomer Digital Pathology (NDP) scanner. 20X, 40X and 80X 
magnifications are shown. Same tumour samples as shown in Figure 71iii and Figure 72ii. TC: tumour 
cells; IC: infiltrating cells. Scale bars shown as 2 mm. 
Surface-light tumour samples were also stained with anti cleaved caspase-3 (Figure 
74). These were not as heavily stained as the interstitial light treated tumour sample 
removed 24 hours after illumination (Figure 65). Stained cells were found dispersed 
throughout the tumour tissue, being more relevant in the 16 hr DLI group. 
Morphological variations of cells within affected tumour areas reported in the H&E 
stained samples shown in Figure 71 and Figure 72, were also detected in the same 
ROIs in cleaved caspase-3 stained samples (Figure 74). Yet, cleaved caspase-3 
staining was not particularly noteworthy in these cells with morphological features 
different to healthy tumour. Again, this took us to consider the presence of different cell 
types within tumour cells in Figure 74 - IC (infiltrating cells). 
An evaluation of the delay of tumour growth after TPCS2a-PDT is shown in Figure 75. 
No significant differences were found overall. Both light- and PS- alone controls 
showed no delay in tumour growth rate, these continued growing at the same pace and 
consequently animal subjects had to be euthanised 5-7 days after injection of 
photosenstiser in the PS-alone control or after light delivery in the light-alone controls 
(both interstitial and surface illumination). Similarly to these controls, PDT treatments 
10 J / 2.5 mg/kg and 20 J / 0.5 mg/kg (both TPCS2a and interstitial light) did not affect 
tumour growth. When the photosensitiser dose was increased to 1 mg/kg a weak 
improvement was observed, being tumours removed 7 days after light. Similar 
observations resulted from all surface light treatments at a 24 hr DLI. However, 
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although still not significantly different to the above, growth of tumours treated through 
surface illumination after a 16 hr-DLI seemed to be slightly delayed and most subjects 
were euthanised 10 days after light (Figure 75).  
 
Figure 75. Tumour growth after TPCS2a-based treatment until end point.  
Scatterplot of days between light delivery to tumours and euthanasia of animal subjects based on tumour 
size/burden endpoint. Each symbol represents an independent animal subject. Data shown as mean ± 
SEM. 
4.4.3  BPD-MA and AlPcS2a PDT in rat subcutaneous 
prostate carcinoma 
As will be later reported in Chapter 5, BPD-MA and AlPcS2a were the photosensitisers 
used to evaluate the generation of an immune response after light-based therapies. 
Therefore, a preliminary assessment on the tumour eradication capacity of both was 
carried out. 
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4.4.3.1 Biodistribution of BPD-MA  
BPD-MA is a widely used photosensitiser in PDT approaches, as reviewed in 4.1 
Introduction. Due to its main vascular effect, shorter DLI are generally used.  
 
Figure 76. BPD-MA biodistribution in Copenhagen rats.  
1 mg/kg BPD-MA was administered i.v. via tail vein. Fluorescence images were taken immediately after 
injection and 15 min, 24 hr post administration. (A) – Dorsal, (B) – Lateral view. White arrow indicates s.c. 
growing tumour, green arrows indicate the abdominal region where liver is located. 
Before performing light treatments on tumour-bearing rats, we evaluated the 
distribution of this photosensitiser at different time points including 15 minutes, which 
was the drug light interval chosen for PDT procedures in our study. This was carried 
out by performing live imaging to anesthetised animal subjects using an in vivo imaging 
system (IVIS). Due to the limited sensitivity of the system through the skin and the 
intrinsic autofluorescence of tissues, this enabled only a qualitative evaluation, allowing 
the determination of particularly outstanding events, as displayed in Figure 76.  
As with most exogenous substances entering an organism, the greatest accumulation 
of BPD-MA was found in liver from the earliest imaging time point, immediately after 
administration. This liver uptake increased over time as observed 24 hr after injection 
(indicated with green arrow). No significant fluorescence was detected around the 
tumour area, specified with a white arrow in Figure 76. 
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4.4.3.2 Biodistribution of AlPcS2a  
Alike above described for BPD-MA, distribution studies were also performed with 
AlPcS2a using the same imaging system, shown in Figure 77. Due to differences in 
photophysical properties between BPD-MA and AlPcS2a, in vivo biodistribution was not 
compared between compounds in a quantitative manner.  
As opposed to BPD-MA, AlPcS2a’s amphiphilic properties make this photosensitiser 
suitable not just for PDT but more importantly for PCI. Therefore, longer DLI were 
considered before exposure to light and imaging was performed at later time points, i.e. 
6 hr is the earliest imaging time point as opposed to the 15 minutes imaging conducted 
with BPD-MA. Regarding this phtalocyanine compound, accumulation in the abdominal 
region increased as soon as it was administered, suggesting presence in the liver. This 
further increased 6 hr later, and even more at the 24 hr time point (Figure 77). 
Importantly, an increase in fluorescence in the tumour-bearing region was found 24 hr 
after administration (indicated with a white arrow in Figure 77). 
 
Figure 77. AlPcS2a biodistribution in Copenhagen rats.  
2 mg/kg AlPcS2a was administered i.v. via tail vein. Fluorescence images were taken immediately after 
injection and 6 hr, 24 hr post administration. (A) – Dorsal, (B) – Lateral view. White arrow indicates s.c. 
growing tumour, green arrows indicate the abdominal region where liver is located. 
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4.4.3.3 BPD-MA-based light treatment (PDT) 
As stated for TPCS2a, 7 days after s.c. implantation of 4x105 cells, BPD-MA was 
administered i.v. and tumours were surface-illuminated when they had reached a 0.5-
0.7 cm diameter. Subcutaneously grown tumours were completely eradicated in 18% 
(4/22) of the animal subjects treated with BPD-MA following PDT procedures. An 
example of the evolution of these tumours after light treatment is displayed in Figure 
78. Light treatment induced the formation of black eschars in the skin directly above 
tumours, sign of necrosis after PDT. It then became a scab with progressively reduced 
size and finally the wound was completely healed (i.e. 35 days after light).   
 
Figure 78. Tumour evolution after treatment with BPD-MA following PDT procedures until complete 
eradication. 
1 mg/kg BPD-MA was administered via tail vein to Copenhagen rats bearing subcutaneously grown 
prostate tumours. Light treatment was performed after a 15-minute drug light interval at a fluence rate of 
120 J/cm2 and 0.06-0.1 W power. Images shown 72 hr, 7 days, 11 days, 15 days, 22 days and 35 days 
after surface illumination of tumours.  
Moreover, tumour growth in non-cured animals was delayed compared to the 
previously observed TPCS2a-based PDT (Figure 75). Specifically, the endpoint was 
delayed from 7-10 days, as seen in TPCS2a groups, up to 13 days after light treatment 
on average (Figure 85). 
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As for the histological analysis of these tumour samples (Figure 79), observations were 
similar to those above described for TPCS2a PDT-treated (Figure 68 - Figure 73). 
Affected regions in tumour samples were large and more homogeneously distributed 
than above described, although there were still differences in the magnitude of these 
areas between samples within the same treatment group (Figure 79). Again, based on 
their morphological features, a mixture of different cell types was likewise found in 
these tumours, highlighted with red and green arrows in Figure 79. 
 
Figure 79. BPD-MA-PDT surface-light treatment to subcutaneous prostate tumours (15 min DLI) 
and detail of H&E staining.  
1 mg/kg BPD-MA was injected i.v. via tail vein to Copenhagen rats bearing subcutaneously grown prostate 
tumours (i, ii, iii). 15 min after administration, light treatments were carried out at a fluence rate of 120 
J/cm2 and 0.06-0.1 W power. Once sampled, tumours were H&E stained and examined on a Hamamatsu 
Nanozoomer Digital Pathology (NDP) scanner. 20X and 40X magnifications are shown. A: affected tumour 
area, V: viable tumour area. Green and red arrows indicate different cell types among tumour cells. Scale 
bars shown as 2 mm. 
The analysis of cleaved caspase-3 in these samples, revealed disperse apoptotic cells 
as occuring in the above-reported cases (Figure 74). In addition, affected areas shown 
in H&E also corresponded in this treatment group with lightly caspase-3-stained 
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regions. As described in Figure 74 for TPCS2a-PDT, phenotipical features different to 
healthy tumour cells, were noteworthy. These regions were considered and indicated in 
magnified images in Figure 80 as infiltrating cells (IC). 
 
Figure 80. Evaluation of apoptosis after BPD-MA -PDT surface light treatment to subcutaneous 
prostate tumours.  
1 mg/kg BPD-MA was injected i.v. via tail vein to Copenhagen rats bearing subcutaneously grown prostate 
tumours. 15 min after administration, light treatments were carried out at a fluence rate of 120 J/cm2 and 
0.06-0.1 W power. Once sampled, tumours were stained with anti cleaved caspase-3 (D175) and 
examined on a Hamamatsu Nanozoomer Digital Pathology (NDP) scanner. Same tumour sample as 
shown in Figure 79i. 20X, 40X and 80X magnifications are shown. TC: tumour cells; IC: infiltrating cells. 
Green arrows indicate infiltrating leucocytes, disintegrating necrotic tumour cells are circled in red. Scale 
bars shown as 2 mm. 
4.4.3.4 AlPcS2a-based light treatment (PDT & PCI) 
Prior to combining AlPcS2a with saporin in PCI approaches, we evaluated the 
phototoxicity resulting from PDT.  
 
Figure 81. Damage to animal subjects' hind leg after surface light treatment with AlPcS2a-PDT (6 hr 
DLI).  
2 mg/kg AlPcS2a was injected i.v. via tail vein to Copenhagen rats bearing subcutaneously grown prostate 
tumours. 6 hr after administration, light treatments were carried out at a fluence rate of 100 J/cm2 and 
0.06-0.1 W power. (A) Immediately after light and (B) 24 hr after light animals retracted and dragged the 
illuminated hind leg; (B), (C) 24 hr after light, the illuminated area of the skin appeared bruised (indicated 
with white arrow).  
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A 6 hr-DLI was used in the first PDT experiments of the study. However, this resulted in 
severe damage to the animal’s legs (see Figure 81): the area above the tumour bruised 
and stiffened, animals then walked dragging their illuminated hind leg as soon as they 
woke up from anaesthesia. Despite some mobility being restored, they never recovered 
the full condition exhibited prior to light delivery. Furthermore, pain and distress 
symptoms were recognised in these subjects and only these received additional 
analgesics beyond the dose given before light treatment.  
Therefore, so as to enable clearance of PS and reduce phototoxicity, DLI was 
increased from 6 hr to 24 hr. Following this light treatment, large damaged areas were 
seen in tumours, indicated as “A” in Figure 82. 
 
Figure 82. AlPcS2a-PDT surface-light treatment to subcutaneous prostate tumours (24 hr DLI) and 
detail of H&E staining.  
2 mg/kg AlPcS2a was injected i.v. via tail vein to Copenhagen rats bearing subcutaneously grown prostate 
tumours (i, ii). 24 hr after administration, light treatments were carried out at a fluence rate of 100 J/cm2 
and 0.06-0.1 W power. Once sampled, tumours were H&E stained and examined on a Hamamatsu 
Nanozoomer Digital Pathology (NDP) scanner. 20X and 40X magnifications are shown. A: affected tumour 
area, V: viable tumour area. Green arrows indicate infiltrating leucocytes, scale bars shown as 2 mm. 
Similar findings resulted from staining PCI-treated samples, as shown below in Figure 
83. Again, H&E revealed a similar observations to the above reported for TPCS2a 
(Figure 69-Figure 73) and BPD-MA (Figure 79) regarding cellular morphology. This is 
detailed with green and red arrows in Figure 82 and Figure 83.  
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Figure 83. AlPcS2a & saporin-PCI surface-light treatment to subcutaneous prostate tumours (24 hr 
DLI) and detail of H&E staining. 
2 mg/kg AlPcS2a was injected i.v. via tail vein to Copenhagen rats bearing subcutaneously grown prostate 
tumours (i, ii). 250 µg/kg saporin was injected i.v. via tail vein 1 hr prior to light delivery. 24 hr after 
administration of AlPcS2a, light treatments were carried out at a fluence rate of 100 J/cm2 and 0.06-0.1 W 
power. Once sampled, tumours were H&E stained and examined on a Hamamatsu Nanozoomer Digital 
Pathology (NDP) scanner. 20X and 40X magnifications are shown. A: affected tumour area, V: viable 
tumour area. Green and red arrows indicate different infiltrating cell types. Scale bars shown as 2 mm. 
AlPcS2a-based phototoxicity also led to apoptotic cell death based on the positively 
stained cells shown in Figure 84 in both PDT and PCI (indicated with black arrows). 
Again, as reported above for TPCS2a and BPD-MA (Figure 74 and Figure 80 
respectively) those regions which appear differentially stained in H&E, indicated as “A” 
in Figure 82 and Figure 83, correspond to tumour areas with large infiltration of 
leucocytes. These cells exhibiting characteristic morphologies are pointed with red and 
green arrows in Figure 84.  
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Figure 84. Evaluation of apoptosis after AlPcS2a-PDT/PCI surface light treatment to subcutaneous 
prostate tumours.  
(i,ii) PDT, (iii) PCI samples. 2 mg/kg AlPcS2a was injected i.v. via tail vein to Copenhagen rats bearing 
subcutaneously grown prostate tumours. 24 hr after administration, light treatments were carried out at a 
fluence rate of 100 J/cm2 and 0.06-0.1 W power. In PCI groups 250 µg/kg saporin was injected i.v. via tail 
vein 1 hr prior to light delivery. Once sampled, tumours were stained with anti cleaved caspase-3 (D175) 
and examined on a Hamamatsu Nanozoomer Digital Pathology (NDP) scanner. Same tumour samples as 
shown in Figure 82ii and Figure 83i. 20X, 40X and 80X magnifications are shown. TC: tumour cells; IC: 
infiltrating cells. Green and red arrows indicate different infiltrating leucocytes; black arrows indicate 
apoptotic cells. Scale bars shown as 2 mm. 
Combination of AlPcS2a with saporin did not result in different observations of that 
described for PDT with AlPcS2a or any other of the previously examined PS nor did it 
enhance delay in tumour growth as shown in Figure 85, which revealed the endpoint 
was reached at the same time for both group of treatments, around 10 days after light. 
No significant differences between treatment groups were detected. However, 
compared to TPCS2a, there was a tendency to delay the end point by 3 days with 
AlPcS2a compared to the 24 hr-DLI observations after TPCS2a-PDT shown in Figure 75. 
AlPcS2a also slightly improved the mean outcome after TPCS2a-PDT in the 16 hr DLI 
group. As for BPD-MA, it surpassed the outcome shown by both AlPcS2a and TPCS2a, 
delaying the endpoint at least 3 days, compared to AlPcS2a (Figure 85). 
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Figure 85. Tumour growth after BPD-MA or AlPcS2a-based treatment until end point.  
Scatterplot of days between PDT/PCI treatment to tumours and euthanasia of animal subjects based on 
tumour size endpoint. Data shown as mean ± SEM. 
4.4.4 Survival curves after light treatment  
Despite the overall comparison of all light treatments reported in the sections above 
concluded no significant variances as regards tumour growth, survival of animal 
subjects displayed in Kaplan-Maier curves, did result in significant differences after light 
treatment. As a matter of fact, increasing PS and light doses led to a general increase 
in survival, irrespective of whether light delivery was performed interstitially (Figure 
86A) or superficially (Figure 86B, Figure 86C and Figure 86D).  
The shortest survival resulted from interstitial-PDT using TPCS2a as photosentiser (1 
week after treatment at best with the highest light dose assayed, 20 J and 1 mg/kg PS - 
Figure 86A). The maximum survival resulted from surface-PDT using BPD-MA 
(greatest survival of animals seen 19 days after post treatment at the highest 
concentration assayed, 1 mg/kg - Figure 86C). BPD-MA survival was followed by 
AlPcS2a-PDT/PCI (both of which displayed the greatest survival of animal subjects up 
to 12 days post light - Figure 86D). TPCS2a surface-PDT following a 16-hr DLI was next 
in maximal survival of animals at 10 days post light at most Figure 86B, while the same 
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treatment following a 24-hr DLI only slightly improved survival to that displayed after 
interstitial-PDT of the same PS by 1 day (8 days after light as opposed to 7), although a 
lower PS dose was used (0.5 mg/kg rather than 1 mg/kg respectively).  
Most of the animals treated with light alone survived 4-5 days after light at best and 
none of these exceeded survival over 1 week after illumination, displayed with black 
lines in Figure 86. Surprisingly, the surface light-alone group resulted in a better 
outcome than the TPCS2a-based surface PDT group of animals (maximal survival of 7 
and 6 days respectively - Figure 86B). 
Overall, significant observations in survival curves were only found in BPD-MA – 4/22 
(Figure 86C) and AlPcS2a-PCI (Figure 86D) groups compared to untreated (p = 0.0005 
and p = 0.0455 respectively). Conversely, the other two treatments exhibiting a 
noticeable delay in tumour endpoint, AlPcS2a-PDT (Figure 86D) and TPCS2a-surface 
light following a 16 hr DLI (Figure 86B),  showed p values = 0.0833 and 0.256 
respectively. 
 
Figure 86. Summary of survival proportions for different light treatments performed with TPCS2a, 
BPD-MA and AlPcS2a.  
Survival curves were plotted for the different light treatments reported in the sections above.  (A) TPCS2a-
PDT following interstitial light treatment. (B) TPCS2a-PDT following surface light treatment. (C) BPD-MA-
PDT following surface light treatment. (D) AlPcS2a-PDT/PCI following surface light treatment. 
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4.5 Discussion  
Throughout the present chapter, we have reported the effect of light-based 
treatments in a highly aggressive prostate cancer tumour model. These tumours were 
generated implanting MatLyLu cells in syngeneic Copenhagen rats. As repeatedly 
commented, this cell line divides rapidly, which has shown evidence to lead to a 
disorganised tumour structure forming clumps in vitro and often resulting in 
multinodular tumours in vivo. In addition, MatLyLu tumours grew gradually up to a 
certain threshold, then growth became exponential. The above posed a difficulty during 
the generation of tumours of reproducible properties to compare treatment groups of 
PDT and PCI.  
Cells were implanted subcutaneously in most cases, although an orthotopic tumour 
model was also developed for future experiments, since implantation of cells in the 
prostate preserves the natural host environment surrounding tumours, hence resulting 
in more realistic studies. This was performed following a protocol described in previous 
studies based on the same model (Momma et al., 1998). Out of all the cell 
concentrations we assayed, only the highest cell number (5x104) resulted in tumour 
formation. Moreover, despite we could not notice tumour formation by abdominal 
palpitation and no pain or unrecoverable loss weight were observed in the tumour-
bearing rat, animal euthanasia revealed that the tumour formed had reached an 
excessive size in only 8 days after cell injection. The fact that lower cell concentrations 
did not form tumour could be due to an insufficient initial cell challenge or a possible 
human error during the injection of cells. This last hypothesis seems more likely based 
on the growth potential of MatLyLu cells experienced in vitro stated in Chapter 2. 
Regardless, we confirmed the potential to generate orthotopic prostate tumours 
surgically through mini-laparotomy. Importantly, this procedure did not cause major 
stress to animals and it was performed in a safe and aseptic manner: no deaths 
caused by the procedure itself nor infection in any of the animals were reported.  
Other authors have concluded faster tumour growth rate in orthotopically as opposed to 
subcutaneously implanted tumours (Chen et al., 2005). Higher levels of endothelial-
growth related proteins have been also observed in orthotopic tumours, which 
translated in a denser vasculature. This was important during the BPD-based light 
treatment performed, after which a greater photooxidative damage was reported in 
orthotopic tumours especially following a cellular-targeted rather than vascular-targeted 
PDT approach. Importantly, the effect of the tumour microenviroment in the overall 
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outcome of PDT was determined (Chen et al., 2005). Similarly, images shown in Figure 
59 confirm that the orthotopic tumour model under investigation is highly vascularised. 
In our examinations, light treatment was only performed on subcutaneous tumours 
using several photosensitisers of diverse nature and thereby photophysical properties, 
namely TPCS2a, AlPcS2a and BPD-MA. PDT was the light-based treatment performed 
the most, while PCI was conducted on fewer occasions combining saporin exclusively 
with AlPcS2a. An early assessment of pharmacokinetics and biodistribution of 
photosensitisers was conducted before performing PDT or PCI. This was measured 
quantitatively through chemical extraction in the case of TPCS2a (Figure 60), as well as 
qualitatively through fluorescence imaging of frozen tissue sections (TPCS2a, Figure 
61- Figure 63) or by live imaging using an “IVIS” system (BPD-MA or AlPcS2a, Figure 
76, Figure 77 respectively). In all cases, the liver resulted in the highest accumulation 
of all photosensitive compounds irrespective of the technique used (chemical extraction 
or fluorescence imaging) and whether the earliest time point was immediately after 
injection (IVIS images shown in Figure 76, Figure 77) or 6 hr after administration of PS 
solutions (chemical extraction displayed in Figure 60 or fluorescence imaging or 
cryosections shown in Figure 61- Figure 63). Regarding TPCS2a, observations upon 
quantification via chemical extraction (Figure 60) correlated with fluorescence imaging 
(Figure 61- Figure 63). The former revealed that 6 hr after administration most of the 
compound had already been cleared from circulation as concluded by the higher 
presence in liver (24.3 µg/g) and lower levels in blood (5.6 µg/g) (Figure 60). Not 
surprisingly and to a lesser degree, the spleen displayed a similar 
accumulation/clearance profile.  
As reported above, accumulation in skin had an irrelevant impact overall (1.6 µg/g 
tissue at best), this would result in minimal skin phototoxicity if taken to a clinical 
context. In our studies, no side skin photosensitivity was reported in animals 
administered with TPCS2a. However, animal subjects were never exposed to direct light 
and always kept under subdued light conditions and housed in amber-tinted cages, 
which reduce the overall penetration of light. In contrast, in the recently published 
clinical trial in humans using this same photosensitiser, greater sensitivity was 
reported. Precautionary measures were followed by patients to avoid skin phototoxicity 
as stated previously (Sultan et al., 2016).  
Pharmacokinetics of TPCS2a in organs located in close proximity to the prostate (i.e. 
bladder, urethra, distal colon) revealed insignificant accumulation from 24 hr, despite 
some fluorescence being detected at 6 hr (Figure 62). This is important during light 
In vivo studies of PDT and PCI in Prostate Cancer  
 
206 
treatment, since the welfare of healthy surrounding tissues could potentially be ensured 
with the optimal TPCS2a and light doses, as well as DLI.  
In our subcutaneous prostate tumours, accumulation of TPCS2a was notable 6 hr after 
injection (2.9 µg/g), was then cleared and only traces were seen by 72 hr (Figure 60, 
Figure 63). The fact that fluorescence was located intracellularly rather than in 
extracellular compartments within tumours suggests this photosensitiser could 
potentially result in a valuable PCI effect. In addition, as suggested by the study 
performed by Chen et al., the denser vasculature in orthotopically implanted prostate 
tumours would have resulted in a larger accumulation of photosensitser than shown in 
subcutaneous findings (Chen et al., 2005).  
Importantly, photosensitiser levels in the normal prostate were similar to those seen in 
subcutaneous tumours (Figure 63). In addition, it was the only tissue where 
fluorescence was reduced 6-24 hr but remained constant from then up to 72 hr (Figure 
63). This could act as a “double-edged sword”: on the one hand, presence of TPCS2a in 
the event of a prostate-located tumour would be ensured; on the other hand, this could 
result in side photooxidative damage to healthy areas of the prostate gland. 
Distribution of BPD-MA and AlPcS2a was carried out exclusively in a qualitative 
manner using an in vivo imaging system. Differences in the intensity of fluorescence 
resulting between both photosensitisers could be due to differences in their quantum 
yields as well as the fact that excitation/emission settings were only optimal for BPD-
MA, since we were limited by filters existing in the equipment. For all of the above, no 
comparison in accumulation and distribution between both compounds is possible, 
since the IVIS system cannot detect reliably internal fluorescence within the animal’s 
body due to tissue autofluorescence, particularly in the overlying skin. Accordingly, it 
was used to determine significant events, such as abdominal accumulation in the case 
of both photosensitisers (Figure 76, Figure 77). Founded on the known accumulation of 
photosensitisers and other foreign bodies in the liver when entering an organism 
especially via intravenous administration, we concluded it is likely the organ 
responsible to a major extent for the accumulation of fluorescence in the abdominal 
region. Potentially, the spleen could have also resulted in some significant 
accumulation of both photosensitisers.  
Previous investigations confirm the targeting of vascular structures soon after 
administration of BPD-MA (explained by its intrinsic hydrophobic structure) and 
determine that, transport rate from the vascular space into the parenchyma will define 
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the transition between vascular and cellular PDT (Zhou et al., 2004). Similarly, 
vasculature density was directly correlated with the intensity of fluorescence in tumours 
in a different study, also concluding differences between subcutaneous and orthotopic 
tumours (Zhou et al., 2006). Available published reports suggest an early accumulation 
of BPD-MA in vascular structures in tumours followed by transport to tumour 
parenchyma.  
As for AlPcS2a (a more amphiphilic PS) Dietze et al. recognised the rapid elimination of 
PS from the blood stream as early as 24 hr, while presence in tumours was maintained 
2-48 hr. However, while 2 hr after administration fluorescence was found within 
proximities of the tumour vasculature as well as stromal compartments, a higher 
emission of fluorescence was confirmed in tumour cells at the later 48 hr time point 
(Dietze et al., 2005). In this study, a large accumulation in the liver was also reported. 
Our own observations, as stated above, are supported by these previous findings, 
since we found a slight increase in fluorescence emission in the area bearing the 
subcutaneously grown tumour (Figure 77). This was not observed with BPD-MA 
(Figure 76). As a matter of fact, had there been more adequate excitation/emission 
settings IVIS available, we think this observation would have been more noticeable.  
Once we had studied the in vivo distribution of photosensitisers, we moved on 
to evaluate the outcome of light treatment to tumours, as described in the Results 
section. The first set of light treatments were carried out in 1 cm diameter tumours, 
which were formed only 7 days after implantation of 106 cells. We considered that the 
exceedingly fast growth of these would be unrealistic in vivo in human patients and 
consequently reduced the cell burden during tumour implantation to 4x105. In addition, 
to widen the available window of tumour progression prior to exponential tumour 
growth, tumours were treated at a smaller size hereafter (0.5-0.7 cm diameter).  
All photosensitisers were assayed in PDT applications, aiming to optimise these as a 
base for later PCI experiments. In an attempt to replicate the conditions that would be 
applied in PCI in the clinic, Amphinex® (TPCS2a) was the first photosensitiser used and 
light was delivered interstitially based on the current clinical prostate PDT: placing 
fibres in the gland within needles (Moore et al., 2009; Svanberg et al., 2010). Interstitial 
and surface illumination have been compared in their application for different PDT 
approaches. For instance, the former led to an enhancement in therapeutic outcome 
over the latter for intramuscular squamous cell carcinoma treatment (Sajisevi et al., 
2015). 24 hr after PDT, necrotic cell death observed was more significant in interstitial-
PDT than transcutaneous-PDT. During interstitial PDT, light distribution is a complex 
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process where intensity and dose are higher in areas immediately adjacent to the fibre, 
being the base of the tumour less exposed to light. Based on the heterogeneity and 
high vascularisation observed in MatLyLu tumours, added to difficulties encountered 
while piercing the tumour capsule to insert the fibre, light treatment was later on 
performed superficially on exposed tumours. In line with this, inserting the fibre in the 
centre of tumours could have caused bleeding and this might have affected light 
distribution. 
Along these lines, the importance of a good PDT-planning in large-volume tumours 
regarding dosimetry of light was addressed in the study carried out by Davidson et al. 
(Davidson et al., 2009). This study describes the use of software to tailor light 
treatments to each specific prostate cancer patient in terms of number, position and 
length of fibres required as well as energy delivered. Generally, the use of interstitial 
illumination is accepted for deeper lesions (Svanberg et al., 2010). Likewise, the 
deeper penetration in PCI commented in the Background and Introduction, would 
further enhance the treatment of deeply located tumours. 
A 24 hr DLI was selected for the first groups of treatments using TPCS2a, based 
on previous investigations carried out by other members of the research group together 
with findings from the biodistribution study (1.37 µg/g tissue), verifying the presence of 
photosensitiser in tumour tissue at this specific time point. Following interstitial 
illumination, nearly the entire surface of the tumour sample resulted in PDT-based 
damage 24 hr after light when combining TPCS2a 2.5 mg/kg and 20 J interstitial light 
(Figure 64). As a matter of fact, apoptosis seemed to be the main cause of cell death 
as revealed upon staining against cleaved caspase-3 in Figure 65, finding a largely 
noteworthy caspase-3 positive area 1 day after light treatment. Briefly, the comparison 
of H&E and caspase-3 staining of the same tumour sample indicated that those regions 
with a healthy appearance in H&E staining only had a few apoptotic cells; whereas 
areas which were differentially H&E-stained, were heavily stained for caspase-3.  
As reviewed in the Background and Introduction, apoptosis is the cell death 
mechanism reported in many studies previously as the most relevant induced by PDT 
(Agostinis et al., 2011). This may vary depending on the target cells, photosensitiser 
and light radiance used (Rodríguez et al., 2016). In an attempt to identify the optimal 
PDT conditions which maximise apoptotic cell death using Foslip as a photosensitiser 
in a squamous carcinoma mouse model, it was recently concluded that reduction of 
photosensitiser dose could successfully result in apoptosis in vivo under specific light 
conditions. In their study, probably assisted by the liposomal encapsulation of mTHPC, 
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a reduction of Foslip’s dose to 40 mg/kg enabled the observation of apoptosis in 
tumours when illuminating at 100 mW/cm2 (Haedicke et al., 2016). Detection of 
apoptotic cell death was achieved at early time points in their investigations. Moreover, 
the use of low PS doses would limit unwanted phototoxicity. The authors of the study 
made an additional important consideration regarding the outcome observed: available 
ground-state oxygen is essential to ensure the success of the treatment. As a matter of 
fact, the consumption of this oxygen in tumours during PDT is dependent on a 
combination of photosensitiser levels in the tumour area, absorption coefficient of such 
and light fluence employed (Foster and Gao, 1992).  
Rather than euthanising animals 24 hr after light delivery, animal subjects 
treated hereafter were monitored regularly and tumours were not removed until these 
reached a pre-established end point (1.8 cm3). Regardless of whether light delivery 
was performed interstitially or via surface illumination, no consistency was observed in 
any of the TPCS2a-based light treatments and each tumour sample seemed to behave 
in a particular manner in terms of phootoxidative-induced affected tumour area (Figure 
69, Figure 71). Uncured BPD-MA-based (Figure 79) and AlPcS2a-based (Figure 82, 
Figure 83) light treatments on tumours, showed a similar pattern of affected areas. In 
relation to this, heterogeneity and irreproducibility reported in a different PDT study 
carried out on Dunning R3327-AT2 prostate carcinoma, were attributed to the intrinsic 
hypoxic characteristics of the model (Bozzini et al., 2013a). Other investigations 
combining PDT with agents such as misonidazole (cytotoxic to hypoxic cells), resulted 
in an enhancement over PDT alone in tumour eradication rate and growth delay 
(Gonzalez et al., 1986).  
Based on our observations after interstitial illumination, we conclude that higher PS 
doses (2.5 mg/kg) combined with lower light irradiance (10 J) as shown in Figure 69i 
did not result in as much photooxidative damage as lower PS doses (0.5-1 mg/kg) 
combined with higher light irradiance (20 J). In the recent clinical application of PCI 
(Sultan et al., 2016), 0.25 mg/kg TPCS2a represented a dose threshold, above which 
no dose-response was noticed using the same light dose, hence concluding light dose 
was a limiting factor. This therefore supports our above-stated findings.  
The use of a shorter DLI, such as 16 hr in surface illumination, showed an 
improvement over the treatments just stated (Figure 72). In this case, tumour size was 
controlled to some extent and affected areas were more homogeneous. This translated 
to a broader time frame between light treatment and sacrifice of the animals, as 
represented in Figure 75. Although 24 hr DLI successfully induced cell apoptosis 
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(Figure 65), a rapid breakdown of PS due to the extraordinarily fast growth of MatLyLu 
cells (as already suggested in vitro), could have been responsible for an insufficient 
PDT effect. In vivo, this translates in a greater photochemical damage when 
illuminating tumours earlier by ensuring larger accumulation of PS in tissue. Based on 
the above, we consider 16 hr DLI improves the therapeutic outcome exhibited after a 
24 hr DLI and will further optimise PDT treatment so as to then conduct PCI 
experiments in combination with saporin in future work.  
Untreated and light-only controls in the study also revealed affected areas, as 
shown in the H&E stained tumour samples in Figure 66, Figure 68, Figure 70 and 
Figure 71 (stained in a light pink colour, rather than the characteristic dark purple of 
healthy tumour cells). The fact that these were also shown in the untreated control 
indicate an intrinsic “source of damage”. These regions were even more 
heterogeneous than in PDT-treated tumours, scattered throughout the tumour and 
appeared to emerge from central regions of the tumour. As a consequence, we 
hypothesise these are spontaneous necrotic regions induced by hypoxia in the centre 
of tumours, which probably became accentuated due to the fast growth and thereby 
oxygen consumption in these tumours. In addition to a rapid growth-related 
spontaneous necrosis, the surgical procedure itself could have caused distress during 
both orthotopic and subcutaneous implantation, as suggested by the histological 
evaluation of the orthotopic tumour in Figure 59, which also revealed an affected 
central region of the tumour-invaded prostate gland.  
The above has been observed in previous studies, for example secretion of tumour 
necrosis factor β (TNF-β) by myeloma cells has been confirmed (Bataille et al., 1989) 
and an inversely proportional correlation between necrosis pre-treatment and 
prognosis has been reported in osteosarcomas (Björnsson et al., 1993). In this last 
publication, the authors concluded that tumours presenting a significant spontaneous 
necrosis were more likely to grow faster and displayed a more significant migratory 
phenotype. It is unlikely that there was any light-alone induced cell death in our 
investigations, founded on the previously conducted in vitro experiments (commented 
in Chapter 2 and Chapter 3), and supported by the fact that untreated control tumours 
also exhibited these affected areas.  
 Overall, we consider the enhancement of the therapeutic outcome and success 
rate of BPD-MA PDT in this investigation, that successfully eradicated tumours in 18% 
of the treated animals, was based on the vascular effect caused by this PS (Fingar et 
al., 1999; Kawczyk-Krupka et al., 2015b). Soon after light treatment, these tumours 
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developed a black eschar in the area of the skin which had been directly exposed to 
light, as shown in Figure 81. Described as tissue necrosis, this has been reported 
previously in BPD-MA vascular-PDT studies, for instance for the treatment of 
squamous cell carcinoma in mice (Marcus et al., 1994) or ovarian adenocarcinoma 
grown on a chorioallantoic membrane (Ismail et al., 1999). We have previously 
described a dense vascular structure and blood supply in MatLyLu tumours as 
indicated in Figure 59. Therefore, the use of short DLI (such as the followed 15 min) 
would ensure a vascular shutdown in these. This seems to have a major implication in 
the cure of animal subjects, observation additionally reinforced by the delayed endpoint 
found in the non-eradicated BPD-MA treated tumours compared to the outcome 
exhibited by the other light treatments (Figure 75, Figure 85). 
As for AlPcS2a, damage caused to tumour-bearing legs after light treatment 
following a 6 hr DLI (described in Figure 81) could be due to neurotoxicity induced by 
accumulation of PS in the peripheral nerves. Although there are no previous AlPcS2a-
related neurotoxicity reports in the literature, it has been observed with other PS, such 
as mTHPC, where cells of the peripheral nervous system were seen to be susceptible 
to mTHPC PDT-mediated necrosis (Wright et al., 2007). In contrast, nerve sparing was 
noted post PDT in neck cancer in human patients and in vitro cell death was reduced 
compared to satellite glia and cancer cells (Wright et al., 2009).  
In our present investigation, no improvement of PCI over PDT was confirmed. Based 
on the preceding success of PCI in vitro and in vivo with different PS (AlPcS2a among 
others) (Berg et al., 2005; Martinez de Pinillos Bayona et al., 2016), we consider that 
the procedure we followed still requires further optimisation and will be addressed in 
future work.  
The comparison of caspase-3 staining between tumours sampled 24 hr after light as 
commented above, and those removed at a later time point (i.e. from 5-10 days after 
light, based on the volume endpoint), concluded a drastic reduction of the number of 
apoptotic cells. These cells appeared disperse throughout the whole structure of 
tumours (including control), with a higher prevalence in peripheral regions and 
surrounded by infiltrating leukocytes (Figure 68, Figure 73, Figure 80 and Figure 84) 
This, together with the low cure rate achieved in of our animal subjects, could be 
explained as follows:  
- PDT did cause apoptotic cell death after delivery of light, since the cytotoxic 
potential of all 3 photosensitisers used has been previously reported in 
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Chapter 2, and there is no evidence of lack of photooxidative-based 
cytotoxicity in vivo.  
- By the time tumours were removed, infiltrating leukocytes had been 
released from circulation, as indicated in Figure 67 showing extravasation 
from vessels located in tumours. Hereafter, these infiltrating cells would 
have initiated their phagocytic activity, engulfing dying tumour cells. 
- Likewise, infiltrating leukocytes could have been released in control 
tumours, engulfing spontaneous necrotic and apoptotic dying cells.  
- In parallel, tumours cells remaining viable after light treatment would have 
surpassed the number of affected cells (based on the doubling rate of 
MatLyLu cells), overtaking the tumour mass and in the end leading to 
uncontrollable tumour growth. Had the samples been removed at an earlier 
time point, the number of dead tumour cells could have been larger. 
On the whole, we conclude that light-based treatment for tumour eradication is 
largely dependent on features of each particular tumour and these should be 
considered while designing PDT or PCI procedures. Specifically, the tumour described 
in the present thesis, is fast growing and highly vascularised. Based on these, the 
complete cure of tumour-bearing subjects requires complete eradication of tumour 
cells: should viable cells be noted post treatment, tumour regrowth would be almost 
inevitable; on the other hand, vascular-targeted procedures are more likely to result in 
a beneficial therapeutic outcome (as seen with BPD-MA). Along this same line of 
thought, PCI could have a better chance of succeeding if vascular components were 
targeted. For instance exploiting the potential of vascular targeted toxins such as 
VEGF-saporin in a similar manner to performed with VEGF-gelonin for colorectal 
cancer treatment (Weyergang et al., 2014). In addition, as indicated in our in vitro 
findings, PCI is a challenging technique to optimise due to the number of different 
variables involved (PS dose, light irradiance, DLI, etc.). Therefore, taking the present 
investigations as a basis, further work is required in the optimisation of such for the 
currently investigated prostate cancer model. 
Importantly, cell death resulting from these treatments trigger systemic processes 
which result in infiltrating circulating cells such as leukocytes, macrophages and 
neutrophils (associated with inflammation). This lays the foundation for investigations 
reported in the following chapter of the present thesis, regarding the activation of the 
immune system post PDT. 
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Chapter 5 Stimulation of the immune system 
following PDT and PCI in Prostate Cancer 
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5.1 Introduction  
The importance of the immune system during cancer treatment dates back a long way, 
even though its importance has not been realised until recently. Already in Egyptian 
times it was noted that wound infection during surgical procedures leads to tumour 
regression due to the activation of the immune system (Castano et al., 2006; Mroz et 
al., 2011a). This was actively studied and pursued by Dr William Coley back in the 
nineteenth century. Dr Coley observed how a sarcoma tumour kept recurring in the left 
cheek of a patient until the extensive wound got severely infected by S. pyogenes. The 
patient then developed strong febrile reactions, identified as “key” in the treatment, in 
the end leading to tumour shrinkage (Hoption Cann et al., 2003). Dr. Coley developed 
a vaccine composed of  S. pyogenes and S. marcescens, which he widely and 
successfully used not only for sarcoma treatment but also carcinoma, melanoma, 
lymphoma and myeloma, even when these had been considered inoperable and 
incurable (Hoption Cann et al., 2003). Overall, it was hypothesised back then that 
tumour regression depended on the generation of an innate immune response in a 
non-specific manner, observing regrowth in those cases where the febrile phase had 
disappeared. In the same way, regression was resumed if the infection was 
reintroduced, as concluded when injections were given on a regular basis.  
Since then, the importance of significantly activating the immune response for cancer 
treatment is now firmly established, including focal therapies (Korbelik and Dougherty, 
1999). However, some of the current gold standards for cancer treatment 
(chemotherapy or radiotherapy for example) can also induce an immunosuppressive 
effect which could negatively affect tumour regression (Hoption Cann et al., 2003). An 
effective cancer treatment nowadays should involve both, the elimination of tumour 
cells as well as the activation of the immune system. Moreover, this should not only 
enhance tumour regression triggering an innate immune response (as described in Dr. 
Coley’s observations), but also induce systemic anti-tumour long-term protection that 
could potentially avoid formation of a distant secondary deposit of tumour cells or even 
individual circulating cancer cells. Accordingly, we will review previous reports on the 
use of light-based therapies combining these two “arms” of cancer treatment. 
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5.1.1 The immune response 
The immune system has the potential of generating protection against exogenous 
molecules whilst avoiding damage to endogenous self-tissues. This is possible due to 
the existence of specific features present in foreign bodies, which enable the 
preservation of self-tolerance. This is a critical step based on the highly toxic 
mechanisms T cells can exert on strange infiltrating bodies (Chaplin, 2010).  
The immune response is composed of two major arms: 
 Innate immunity: these are the very primary protective mechanisms 
which a foreign body encounters upon entrance in the organism, 
encoded in germ-line genes. It comprises physical barriers (skin, 
mucosa, cell-cell interactions), soluble proteins and molecules 
constitutively present in biological fluids (for instance complement 
proteins), molecules released by cells during activation (i.e. cytokines, 
chemokines, lipid mediators, active amines and enzymes, etc.), surface 
receptors and cytosolic proteins capable of recognising motifs in the 
surface of the invading foreign body. 
 Adaptive immunity: this is mainly based on the antigen-specificity 
displayed by T and B lymphocyte receptors. This specificity is generated 
by somatic rearrangement and reassembly of gene elements encoded 
by the germ-line (rather than being directly encoded by these genes 
without further processing). During this process, several many 
combinations of genes exhibiting different specificities towards the 
antigen of interest are assayed. By the end of the somatic 
rearrangement a unique receptor, displaying the highest specificity 
against a particular antigen, will be selected and will in turn lead to the 
clonal expansion of T and B lymphocytes. This process becomes 
outstanding 7 days after the immunological challenge. The antigens that 
are not selected for, will have their apoptotic pathway activated through 
the NFB pathway. 
These two parts of the immune response act in a synergistic manner to bring about an 
optimal response: the innate response will be the earliest line of defence activated in a 
host organism followed by the stimulation of an adaptive immune response (Chaplin, 
2010). Based on the aim of the present chapter, namely to investigate the elucidation 
of tumour-specific immunoprotection in our prostate cancer tumour model, a greater 
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focus will be given to the cellular adaptive arm of the immune response, specifically T 
cells.  
5.1.1.1 The role of NF-B pathway in the immune 
response  
Extracellular events during immune stimulation result in signal transduction, most of 
which involves the transcription factor Nuclear Factor (NF)-B, in the end causing 
changes in gene expression. As a matter of fact, it has a wide range of crucial functions 
in the innate and adaptive immune response and we will comment hereupon the more 
relevant roles of NF-B, to our present project  (Hayden et al., 2006).  
Five related transcription factors have been identified belonging to the NF-B family of 
proteins, namely p50, p52, RelA/p65, c-Rel and RelB which shuttle between cytoplasm 
and nucleus and bind DNA sequences known as KB regulating changes in gene 
expression. While RelA, c-Rel and RelB can activate gene expression due to the 
presence of transcription activation domains in their C-terminal, p50 and p52 lack these 
regions and therefore will only be able to inhibit transcription. In order to achieve this 
however, they need to be released from their interaction with the protein Bcl-3 (Hayden 
et al., 2006). 
This pathway tends to remain inactive under resting conditions, being all the 
constituents in the cytoplasm bound to their corresponding inhibitory from the IB 
protein family (IBα, IBβ, IBε, IBγ, IBNS, IBη, IBζ, Bcl-3, and precursors p105 
and p100). During activation, these inhibitory proteins are phosphorylated by IB 
kinases (IKK) and consequently degraded, then triggering the signalling cascade that 
will result in changes in gene expression within the nucleus. These IKK proteins are 
IKKα and IKKβ, which in addition require the regulatory scaffold NEMO. Two important 
routes for the activation of this pathway have been described, either canonical or non-
canonical, and the requirement of each IKK will be different depending on which of both 
pathways is initiated. 
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Figure 87. NF-B pathway in the immune response.  
Schematic representation of signalling transduction upon cellular stimulation in relation to the NF-B 
pathway effectors. Under resting conditions, the five transcription factors identified to date (p50, p52, RelA, 
cRel, RelB) remain bound to their respective inhibitory proteins, known as IB. These inhibitory proteins 
are phosphorylated by IKK proteins and degraded during activation, triggering the signalling cascade that 
will result in regulation of gene expression in the nucleus of the cell. Bcl-3 acts as an inhibitory protein of 
p50 and p52, regulating the transcription of a wide rage of genes involved in survival (i.e. Bcl-2), 
proliferation, inflammation or immune regulation.  
Among IKB proteins, Bcl-3 (initially identified as a proto-oncogene) has been widely 
studied. It is known to interact with p50 and p52 regulating both canonical and non-
canonical gene transcription. For instance, association between Bcl-3 and p50 or p52 
in DNA promoters activates transcription of genes. Nonetheless, it can also have an 
inhibitory effect in gene transcription binding repressive p50 to DNA. Some studies 
have demonstrated the stabilisation of p50 binding to DNA, inhibiting its degradation or 
preventing other active transcription factors from exerting their activity. An example of 
this stabilisation occurs in response to TNF and TLR (toll like receptor signalling) 
(Carmody et al., 2007; Wessells et al., 2004), where Bcl-3 helps maintain homeostasis 
of the innate immune response by limiting the excessive activation of TLR. An 
excessive signalling could result in an overload and in the end lack of responding 
capacity in the presence of stimuli. Phosphorylation in Bcl-3 might be essential for its 
activity, for example limiting its capacity to promote the interaction between p50 and 
DNA binding sites. Bcl-3 is mainly found in the nuclear compartment although 
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cytoplasmic accumulation has also been seen in certain cells and localisation in either 
could have a major influence in its function.  
Among genes regulated by Bcl-3, it promotes T cell survival inhibiting the activation of 
Bim protein (member of the pro-apoptotic Bcl-2 family) although the mechanism is not 
fully understood (Herrington and Nibbs, 2016). Bcl-2, was initially recognised as anti-
apoptotic (even anti-necrotic in some cases), but several more proteins belonging to 
this family have been identified to date, exhibiting both anti- and pro- apoptotic 
functions (Tsujimoto, 1998). In fact, subcellular localisation of Bcl-2 has been related to 
opposite roles: its anti-apoptotic role has been associated to mitochondria, where it is 
transported from the default localisation in the ER- and nuclear- membrane assisted by 
chaperones, thereby blocking the apoptotic pathway (i.e. inhibiting pore formation, 
cytochrome c release or caspase cascade among others). Studies by Portier and 
Taglialatela showed that localisation of Bcl-2 in the nuclear compartment unavoidably 
ends in cell death (Portier and Taglialatela, 2006). As for its relation to NF-KB,  as an 
example, during the clonal selection of B and T cells in the thymus and bone marrow 
there is a high apoptotic rate and NF-B has important anti-apoptotic functions, via the 
anti-apoptotic Bcl-2 factor among others (Heckman et al., 2002).  
5.1.1.2 Cellular constituents of the immune 
response 
There are many different types of leukocytes involved in the cellular immune response, 
each subset being featured by the expression of specific surface markers, assigned as 
cluster of differentiation (CD). All cells described in the current section are generated 
from a single progenitor, “pluripotent hematopoietic stem cell” that will either lead to a 
lymphoid progenitor or myeloid progenitor, as displayed in Figure 88.  
Relevant to our present study, granulocytes (also known as polymorphonuclear 
leukocytes) emerge from a common myeloid progenitor and have an important 
interface role between the innate and adaptive immune response. Some of these 
granulocytes have been identified in tumour samples described in Chapter 4. Briefly, 
neutrophils and macrophages have a key phagocytic role engulfing foreign “suspicious” 
bodies during the innate phase. Neutrophils are additionally involved in the secretion of 
cytokines in early stages of the immune response, while the latter can also act as 
APCs in an adaptive phase. Compared to neutrophils, macrophages persist longer in 
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the site of inflammation and are frequently associated with chronic inflammatory 
processes, acquiring different phenotypes based on the cytokines involved during their 
activation (i.e. pro-inflammatory as opposed to anti-inflammatory), and play an 
important role in tumour progression/regression. Immature dendritic cells exhibit a 
similar phagocytic function during the innate response and are the most relevant 
antigen presenting cells, interacting with T cells during the initiation of the adaptive 
response. The other granulocytes, namely eosinophils, basophils and mast cells will 
play an major role releasing the content in their cytoplasmic granules during the 
adaptive the immune response once they are activated by an antibody (Charles A 
Janeway et al., 2001).  
 
Figure 88. Differentiation of myeloid cells and lymphocytes from a common hematopoietic stem-
cell progenitor.  
Image taken from [(Chaplin, 2010)] 
As for the lymphoid progenitor, it will differentiate into four major populations cells: B-
cells, Natural killer cells (NK), T-cells and NK-T cells (sharing features present in both 
NK and T cells). Shortly, B-cells are defined by the presence of a surface B-cell 
receptor which will recognise antigens and produce antibodies accordingly (humoral 
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immune response). NK cells on their side can recognise tumour cells or virus infected 
cells via a complex variety of surface receptors, while T-cells are featured by the 
expression of a surface T cell receptor (TCR) that will interact with surface receptors in 
antigen presenting cells (APCs). The TCR is a transmembrane heterodimer protein 
complex with additional side chains involved in signal transduction, for example the 
CD3 complex (CD3ε among other constituents). As a matter of fact, different T cell 
subtypes exhibiting disparities in their phenotypical features have been described (see 
Table 9).  
Name Surface Receptors 
Naïve  CD3, TCR, IL-7R, CD62L, CCR7 
Cytotoxic CD3, TCR, CD8 
Exhausted CD3,CD8, PD1, TIM3, 1B11, LAG3 
Anergic CD3, TCR, BTLA 
Helper 
CD3, TCR, Cytokine receptor, CD4, Chemokine 
receptor 
Regulatory CD3, TCR, CD4, GITR, CTL4, CD25, FoxP3 
Memory CD3, TCR, CD44, IL-7R, CCR7 
NKT TCR, NK1.1, SLAMF1, SLAMF6, TGFβR  
γδ CD3, γδTCR, 
CD8αα CD3, TCR, CD8αα, B220 
Table 9. T cell subsets and their respective surface receptors. 
Adapted from [(Dong and Martinez, 2015)] 
5.1.1.3 Antigen presentation and generation of a 
T-cell specific immune response 
Whether antigens are from pathogen- or tumour- origin, these will be recognised by 
APCs via cell surface glycoproteins known as major histocompatibility (MHC) 
molecules also called human leukocyte-associated (HLA) antigens. Two major MHC 
molecule types have been identified on the surface of APCs:  class I presents antigens 
synthesised by the cell, while class II presents ingested and processed antigens. T 
cells will only be capable of antigen recognition when these have been incorporated in 
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MHC molecules on APCs’ surface. Specifically, MHC I molecules will present antigens 
to CD8+ T cells contrary to MHC II molecules, which present antigens to CD4+ T cells. 
Upon recognition of MHC molecules by either the CD8 or CD4 domain in T cells, with 
the added participation of co-stimulatory molecules present on the surface of APCs 
(CD80, CD86) or T cells (CD28), the acquisition of a fully active phenotype in 
previously naïve T cells occurs. In fact, when antigens are taken up, the expression of 
MHC, CD80, CD86 is increased. Therefore, an effective T-cell immunotherapeutic 
pursues loading cytosolically processed antigens on MHC I molecules in order to 
exploit CD8 T cell responses. 
Among all T cell subsets (CD3+), we would like to highlight in our current study 
cytotoxic T cells and regulatory T cells. 
 CD3+CD4+ - Helper T cells, participate mediating both the cellular and the humoral 
immune response. However, these will not be covered in the present chapter. 
 CD3+CD4-CD8+ - Cytotoxic T cells (Tcs), recognise specific antigens and directly 
kill pathogen-infected or mutated cells through the secretion of effector molecules 
such as perforin and granzyme, inducers of apoptosis in target cells. In addition, 
these cells can limit regulatory cells responsible for immunosuppression.   
 CD3+CD4+CD8- - Regulatory T cells (Tregs), promote tolerance and 
immunosuppression.  
o CD3+CD4+CD8-FoxP3+ - Natural Regulatory T cells present a nuclear 
forkhead box P3 transcription factor key in their development. These cells 
mainly exert their regulatory function through secretion of anti-inflammatory 
cytokines: TGFβ and IL-10. 
o CD3+CD4+CD8-FoxP3+/- - Induced/Adaptive T cells developed via antigen-
specific stimulation, hence the variable expression of FoxP3 (often 
dependant on IL10). Rather than being developed in the thymus (as natural 
Treg), this Treg subset is induced in peripheral regions from naïve CD4+ 
cells. As noted above in natural regulatory T cells, induced T cells also exert 
their regulatory function through secretion of anti-inflammatory TGFβ and 
IL-10. 
Antigen presentation takes place in secondary lymphoid tissues, i.e. lymph nodes, 
which exhibit distinguishable regions characterised by B or T cell accumulation. In 
these, circulating antigen-loaded APC will interact with naïve cells undergoing somatic 
mutation to select the cell clone showing the highest affinity for a specific antigen. 
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Mature B and T cells then receive specific signals indicating their egress out of the 
lymph nodes and release into the blood stream (Chaplin, 2010).  
5.1.1.4 Immune inhibitory checkpoints: PD1 and 
PD-L1 
Antigen presentation is a regulated process whereby the interaction between T cell 
receptor and MHC molecules present in the surface of APCs involves additional 
molecules which in the end will determine whether a stimulatory or inhibitory signal is 
transduced. These are known as immune checkpoints.  
CD28 present in the surface of T cells has a major role as stimulator of the immune 
response, enhancing the activation of T cells against a particular antigen. In contrast, 
immune checkpoint inhibitors which interfere with this activation process have been 
described: PD1 (programmed cell death protein 1) and CTLA-4 (cytotoxic T 
lymphocyte-associated antigen 4, which will be further commented below). Both of 
these are present on the surface of activated T cells and participate in the blockage of 
an anti-tumour response upon interaction with receptors in the surface of APCs or 
tumour cells, in the case of CTLA-4 and PD1 respectively. This has resulted in a great 
interest to develop therapeutic strategies that can overcome this inhibition, and hence 
favour potent anti-tumour protection as is the case of the antibodies ipilimumab (anti-
CTLA-4) or Nivolumab (anti-PD-1) (Philips and Atkins, 2015). 
Focusing on PD1, it is a transmembrane protein belonging to the CD28 family, 
expressed CD4+ and CD8+ T cells, B cells, NK cells, monocytes DCs; yet not present 
on resting T cells unless induced by prolonged exposure to antigens. Its expression 
was first identified as a consequence of the apoptotic pathway (Ishida et al., 1992). 
PD1 binds to two main ligands, PD-L1 or PD-L2, resulting in a down-regulation of 
effector-T cell activation: inhibiting proliferation, causing cytolysis, interfering in the 
expression of anti-apoptotic molecules, cytokines and other biochemical pathways 
(Philips and Atkins, 2015). In addition, it has been related to the promotion of Treg-
development, assisting the maintenance of FoxP3 and their suppressive effect. In the 
anti-tumour context, expression of PD-L1 has been shown in many different tumour 
cases, reporting that binding of PD-L1 to PD1 facilitates immune evasion by tumours. 
Tumours exhibiting high PD-L1 levels have been associated to poor prognosis (Jin et 
al., 2010). Conversely a direct relationship between high expression of PD1 and a 
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favourable prognosis was noted in follicular lymphoma patients (Carreras et al., 2009). 
Interestingly, an alternative expression between PD1 and FoxP3 was found in this 
study, indicating that the suppressive tumour microenvironment could be determinant 
in the overall outcome of follicular lymphoma.  
In line with this, cancer cells can avoid immune recognition and control through 
immunoediting: diseased cells that escape elimination by the immune system undergo 
an editing procedure after which they go unnoticed by immune system effectors, 
becoming stealth tumour cells.  
5.1.1.5 The interplay between cytotoxic and 
regulatory T cells in cancer  
As previously noted, CD4+CD8-FoxP3+ are a highly immunosuppressive subtype of T 
cells, responsible for the maintenance of immune homeostasis. They play an essential 
role in immune tolerance to self-tissues which in fact appears to be deregulated in 
autoimmune diseases or allergic reactions (Takeuchi and Nishikawa, 2016). As briefly 
mentioned, these cells exert their suppressive role releasing inhibitory cytokines, 
consuming IL-2, degrading ATP, establishing direct contact through inhibitory receptors 
such as CTLA4 or else releasing cytotoxic enzymes such as granzyme-B or perforin 
(Alroqi and Chatila, 2016).  
Treg-induced immunosuppression does not only affect the effector phase of the 
immune response, but in fact Tregs can also interfere during earlier phases, i.e. during 
antigen presentation affecting the generation of Tcs. Briefly, CTLA4 has an important 
role engaging with CD80 and CD86 molecules during this process and can transmit 
inhibitory signals to APCs, blocking the consequent maturation of cells, and thus 
impeding the establishment of an adaptive immune response (Walker and Sansom, 
2011). Moreover, the role of IL-2 is crucial in “tipping” the balance in favour of Tc or 
Tregs, based on the potential to activate both cell subsets. Low IL-2 levels have been 
associated with an increase of Tregs; while higher concentration might assist the 
proliferation of Tcs (Boyman and Sprent, 2012).  
Importantly, the secretion of Treg-recruiting cytokines has been described in tumour 
cells (Takeuchi and Nishikawa, 2016). In this regard, tumour associated macrophages 
(TAM) play a relevant role. These cells are a heterogeneous population in relation to 
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oxygen levels and tumour growth. Two main types have been identified, M1 and M2. It 
is the inflammatory microenvironment created during early stages of tumour 
development that will cause the infiltration of these TAM. In this specific context, M1-
TAM release chemoatractants to bring NK cells among others into play (i.e. IL.6, IL-12, 
TNF-α). In addition, this pro-inflammatory environment will additionally help maintain 
the M1 phenotype. However, tumour progression or the appearance of hypoxic regions 
in the tumour mass, promote polarisation towards the M2 phenotype. This will result in 
the secretion of different cytokines such as IL-10 and TGFβ, which have been indicated 
above as inhibitors of the anti-tumour immune response (Zamarron and Chen, 2011) . 
Therefore, within a tumour environment, the presence of antigen-specific Tcs can be 
compensated by infiltrating Tregs and it is this balance that will determine the efficiency 
of anti-tumour immunity.   
5.1.1.6 Modulation of T cell response by 
cyclophosphamide 
Based on the above summary, it is not surprising that tumours with large infiltration of 
CD4+CD25+FoxP3+ Tregs exhibit poor prognosis. So as to balance the tumour 
microenvironment towards cytotoxic effector T cells rather than regulatory effector T 
cells, different strategies have been investigated. As concerns the present thesis, we 
will highlight the use of cyclophosphamide (CY). CY is a drug widely used as 
chemotherapeutic (Cytoxan®, Neosar®) for the treatment of different cancers as is the 
case of Burkitt’s lymphoma, Hodgkin’s and non-Hodgkin’s lymphoma, t-cell lymphoma, 
neuroblastoma, etc. It induces cytotoxicity by introducing alkyl groups into DNA chains 
causing cross-linking and in the end impeding proliferation of cells. Importantly, a 
similar CY-induced cell damage has been reported in tumour and lymphocytes and has 
been used accordingly both for cancer and to treat immune-related diseases such as 
lupus or chronic transplant rejection (Abu Eid et al., 2016).  
Interestingly, the administered cyclophosphamide dose regime (concentration, 
sequence of repeated administration, timing) will determine whether this drug has a 
direct cytotoxic effect or else it acts mediating the elucidated immune response.  In line 
with this, low doses (administered in single doses or following a metronomic regime) 
have demonstrated potential to selectively deplete Tregs, opposite to high doses, 
which indiscriminately cause death to all cells. As an example,  200 mg/kg CY resulted 
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in cytotoxic effects, reducing cell number in all T cell subsets; whereas 20 mg/kg 
suppressed CD4+CD25+ cells whilst sparing CD8+ (Motoyoshi et al., 2006). Further 
proof of this resulted from observations on immunocompetent and nude animal 
subjects: low doses only had a therapeutic effect in the former individuals, as opposed 
to high doses, which were effective irrespective of the immunological condition 
(Motoyoshi et al., 2006). 
CY has been taken one step further in humans in several clinical trials. These have 
shown the potential of CY in the generation of antigen-specific effector T cells in cancer 
treatment, for example concluding an enhanced survival of patients when CY 
administration was conducted 3 days before vaccination of cancer patients (Walter et 
al., 2012); in a different study, depletion of Tregs as well an increased activity of NK 
and Tcs were confirmed after metronomic administration of CY (Ghiringhelli et al., 
2007).  
However, all these reductions of Tregs seem to be transient and consequently, normal 
levels are recovered overtime, suggesting repeated administration might improve 
overall results (Abu Eid et al., 2016).  
5.1.2 PDT and the immune response 
It has been hypothesised based on previous observations that the oxidative damage 
induced by Photodynamic Therapy can trigger what has been coined as “immunogenic 
cell death” (ICD). Tumour cells killed by PDT release molecules otherwise confined in 
cellular compartments such as the cytosol or nucleus, i.e. damage-associated 
molecular patterns (DAMPs) or tumour-associated antigens (TAAs) (Castano et al., 
2006; Mroz et al., 2011a; Panzarini et al., 2013; Xiaojie Wang et al., 2015). These act 
in a similar way as pathogen-associated molecular patterns (PAMPs) during infection. 
Phagocytic cells, for example macrophages, are largely present in tumours and can 
recognise and phagocyte these molecules, as well as release chemoattractant 
cytokines. The acute inflammatory process induced by PDT will likewise further attract 
host leukocytes to infiltrate in the tumour (monocytes, neutrophils for example). In fact, 
the effect of PDT in the tumour microenvironment appears to be essential in the 
elucidation of an immune response. One example of this is based on the quick 
consumption of oxygen post-PDT in combination with induced vascular shutdown. This 
facilitates the production of hypoxia inducible factor (HIF), identified in several myeloid 
cell responses, i.e. secretion of inflammatory cytokines (TNF-α, nitric oxide, IL-1), 
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expression of toll-like receptors, expression of co-stimulatory molecules in DCs (Garg 
et al., 2010). The above insinuates a connection between the innate and adaptive 
response of the immune system. A summary of the inflammatory process found in the 
tumour microenvironment after light-based treatment is shown in Figure 89. 
 
Figure 89. PDT-induced effects on tumour microenvironment, interaction with the immune system.  
Image from (Garg et al., 2010) illustrating the acute inflammation induced after PDT. The release and 
recognition of DAMPs by phagocytic cells after tumour cell death and later attraction of additional host 
immune-related cells is displayed. This involves the interaction between the innate and adaptive immune 
response.  
In this context, antigen presenting cells (APCs) such as circulating dendritic cells (DCs) 
will bind TAA via receptors present in their surface, then becoming mature and active 
DCs. Mature DCs will be released into in the blood stream reaching the lymph nodes, 
where antigen cross-presentation to naïve T-cells occurs, generating active T-cell 
formation as graphically displayed in Figure 90. 
Despite DAMPs having been traditionally related to necrotic cells (widely considered to 
be pro-inflammatory and immunogenic), recent anti-cancer studies suggest the 
existence of additional forms of immune stimulation after specific forms of programed 
cell death such as apoptosis, necroptosis, etc. (Hernandez et al., 2016). In fact, the 
apoptotic pathway seems to have a more relevant role in the immunogenicity post PDT 
(Mroz et al., 2011a). Whether cell death occurs in an immunogenic manner or not 
seems to rely on the initiating lethal stimulus, which is not a mere correlation with cell 
death levels: not all anti-tumour therapies induce the release of immunogenic factors 
and those that do may act differently in different tumours (Kepp et al., 2009).  
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Figure 90. Release of DAMPs/TAAs by PDT-killed tumour cells, presentation of antigens and 
generation of effector T cells.  
PDT-killed cells release intracellular DAMPs/TAAs that will be recognised by circulating dendritic cells. 
These migrate to the lymph nodes and stimulate naïve T-cells leading to the generation of different types 
of effector T-cells (i.e. helper, cytotoxic, regulatory, etc.). These cells will be released into the blood 
stream, reaching the tumour they are specific against, recognising it and potentially destroying it. 
Among DAMPs, hydrophobicity has been suggested as a key signal capable of 
activating the immune system. Widely common DAMPs frequently contain hydrophobic 
regions, such as heat-shock proteins (HSP), High Mobility Group Box 1 (HMGB1), 
calreticulin, adenosine triphosphate, hyaluronan or S100 proteins. For instance, an 
early exposure of calreticulin in the surface of tumour treated cells has been noted 
before these even show apoptotic death features, which will be recognised by DCs as 
an “eat me” signal. Another case is the natural location of HMGB1 in the cell cytoplasm 
and its release into the cytosol under hypoxia in tumour cells (Hernandez et al., 2016). 
Especially notable is heat-shock protein 70 (HSP70), an intracellular chaperone that 
prevents aggregation of unfolded proteins, thereby inhibiting apoptosis. When released 
under cellular stress, it binds to DCs’ surface receptors, participating in their activation 
and maturation (Castano et al., 2006). This also reveals the double effect DAMPs may 
have in tumour “progression/regression”: if intracellular, these can sometimes avoid 
tumour cell death and even aggregate with tumour associated antigens located in the 
cytosol; when released they mediate T-cell response through the interaction with 
APCs. 
There is evidence of several PDT strategies inducing a similar response as stated 
above. For instance, in vitro studies carried out on HeLa cells, proved the expression of 
the DAMPs calreticulin, HSP70 and HSP90 in a different manner depending on 
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whether cell death occurred via apoptosis or autophagy (larger release in the former) 
(Panzarini et al., 2014). In a similar manner, hypericin-PDT induced the release of 
calreticulin and HSP70 following a different pattern (Garg et al., 2012). In vivo studies 
have also verified the release of HSP70, calreticulin or HMBG1, as reported post ALA-
PDT in a squamous cell carcinoma mouse model (Xiaojie Wang et al., 2015). This 
release of DAMPs and consequent antigen presentation are preliminary steps during 
the generation of immunological memory. Take as an example the observations 
reported back in 1999, in which the transfer of splenocytes from cured EMT6-bearing 
mice (previously PDT-treated) to immunocompromised mice subjects resulted in 
important cure rates (Korbelik and Dougherty, 1999). EMT6 mammary sarcomas are 
highly immunogenic and the generation of tumour-sensitised T lymphocytes has been 
confirmed before. For example after Photofrin-based PDT performed on 
immunocompetent mice, scid (these suffer from a genetic mutation that alters gene 
rearrangement and selection of clones, resulting in a lack of mature T and B cells in 
these animals) and nude (naturally thymus devoid). In this study, cures only resulted 
from the fully immunocompetent mice (Korbelik et al., 1996).  
5.1.3 Enhancement of PDT-induced immunoprotection 
The double-face or dual mechanism of the immune response noted above, has 
resulted in PDT combinatorial studies focusing on both: (i) an enhancement of tumour-
immunogenicity to favour the increase of tumour-antigen release and (ii) recognition by 
antigen presenting cells (cytotoxic T cell response) and depletion of 
immunosuppression (regulatory T cell response) (Panzarini et al., 2013).  
5.1.3.1 PDT-based vaccines 
PDT has lately demonstrated the potential to exploit immunogenic cell death and 
therefore successfully generate protection against specific tumour antigens. For 
instance, DCs acquired an activated phenotype upon exposure in vitro to PDT-induced 
apoptotic tumour cells. This was concluded through the observation of characteristic 
morphological changes, e.g. enlarged dendrites, as well as the increased expression of 
surface markers CD80, CD86 and MHCII (Ji et al., 2016). Moreover, these DCs 
released stimulatory cytokines such as IL-2 and IFN-γ. Interestingly, in this same study 
control necrotic cells released the inhibitory cytokine IL-10. The in vitro generated DC 
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vaccine was used in vivo, showing immunoprotection to tumour challenge (Ji et al., 
2016). 
A different investigation generated antigen-specific CD8+ cells in squamous cell 
carcinoma-bearing mice upon administration of in vitro PDT-treated cancer cells 
(Korbelik et al., 2007). Specifically, the expression and release of TAAs in in vitro PDT-
treated cells was confirmed before vaccination of animal subject. In addition, post 
vaccination, these showed large number of cytotoxic T cells with degranulating 
capacity. Despite the fact that anti-tumour protection in vivo was systemic, the authors 
stated in their report a correlation concerning the therapeutic outcome and the distance 
between vaccination site and tumour. In fact a more efficient antigen presentation was 
suggested in secondary lymphoid organs located closer to the lesion. An important 
consideration about PDT vaccines was raised: tumour growth rate might be decisive in 
the generation of immunological protection post vaccination – a delay in TAA 
presentation after vaccination might a bad prognosis in faster growing tumours 
(Korbelik et al., 2007).   
Overall, there are only a few examples among a wide range of studies proving the 
positive stimulation of APCs (namely DCs), by PDT-killed tumour cells, which in turn 
successfully generate fully effective cytotoxic T cells against tumours. 
5.1.3.2 PDT and cyclophosphamide 
In addition to enhancing antigen presentation, PDT strategies have been performed in 
combination with cyclophosphamide administration to tackle the impairment of T cell 
subsets present in the tumour microenvironment. Following this line of thought, 
Castano et al. performed cyclophosphamide administration before BPD-PDT to J774- 
bearing mice (alike EMT6 it is known to be a highly immunogenic cell line in which a 
specific antigen has been described) (Castano et al., 2008). Cures were only observed 
in animals treated with a combination of low dose CY and PDT (70%). No cures 
resulted from either low (50 mg/kg) or high CY (150 mg/kg) alone; yet, while the former 
resulted in depletion of Tregs, the latter showed a reduction in the number of all 
lymphocyte populations. In fact, low dose CY resulted in an enhanced survival 
compared to the control, as opposed to high dose CY. Furthermore, the authors 
confirmed the cytotoxic potential of lymphocytes removed from mice which had 
rejected the second challenge of tumour cells against specific tumour cells ex vivo 
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(Castano et al., 2008). Similar results were obtained from the treatment of CT26-
tumour. This study also showed an PDT-induced increase in the number of Tregs 
measured in spleens and lymph nodes the first couple of days after light treatment 
(Reginato et al., 2013).  
This immunoregulatory strategy has also been combined to generate PDT-vaccines. 
Accordingly, an in vitro generated vaccine was injected peritumourally in combination 
with cyclophosphamide in some subjects. These showed a significant improvement on 
the vaccine’s therapeutic effect, resulting in permanent cures when injecting the 
immunomodulator twice. No improvement was found with CY alone, indicating it cannot 
be used as treatment alone. In addition to Tregs, this study also looked into the 
immunosuppressive effect caused by myeloid-derived suppressor cells (MDSC). It was 
also concluded that both cell types have an important influence before and after PDT-
vaccination and should be taken into account for combinatorial therapies (Korbelik et 
al., 2015).    
5.1.4 PCI and immunotherapy  
PCI technology has also been used to develop cancer vaccines (Håkerud et al., 2015; 
Waeckerle-Men et al., 2013a). As opposed to PDT vaccines, in which it tumour treated 
cells themselves are used as vaccine, PCI vaccines benefit from PCI’s intrinsic 
cytosolic delivery. Briefly, PCI is used to deliver tumour antigens into the cytosol of 
APCs (antigen presenting cells) and enhance the presentation of antigens via MHC I 
rather than MHC II (which does not require cytosolic processing of peptide-antigens). 
An example of this was the study conducted by Hakerud et al. (Håkerud et al., 2015), in 
which the exogenous antigen ovalbumin and the photosensitiser TPCS2a were 
coadministered in vivo, enabling a sufficient amount of time before illumination to 
ensure the uptake of the antigen in APCs. A successful generation of CD8+ T cells was 
then concluded founded on the release of effector cytokines (IFN-γ). Besides, tumour 
samples revealed large infiltration of these specific cells, compared to the control 
tumours. Importantly, survival of these individuals was significantly enhanced 
compared to untreated subjects, resulting in complete tumour cures (Håkerud et al., 
2015). Similar results had been previously reported by the same group in different 
tumour models (Håkerud et al., 2014; Waeckerle-Men et al., 2013b).   
Moreover, the underlying mechanism of these PCI-vaccines was elucidated in vitro 
(Waeckerle-Men et al., 2013b).  The successful entry of ovalbumin in the cytosol of 
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bone marrow-derived DCs was confirmed through the enhancement in the release of 
IFN-γ after incubating these with purified CD8+ cells. High photosensitiser and light 
doses however seemed to be disadvantageous in the antigen-presentation process, 
suggesting harmful photosensitisation of DCs above a certain threshold. The 
expression of DC surface molecules relating to an activated DC phenotype (CD80, 
CD86, MHCI) was also observed after PCI photosensitisation of immature DCs 
(Waeckerle-Men et al., 2013b).    
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5.2 Aims 
Based on previous reports regarding the elucidation of an immune response after PDT, 
the main aim of the present chapter was to assess such potential in aggressive 
prostate adenocarcinomas, such as the rat model investigated in the current thesis. 
With this main aim, several experimental objectives were addressed: 
 Following the tumour eradication reported in Chapter 4 after BPD-MA-PDT, we 
evaluated whether light treatment had generated specific immunoprotection 
against MatLyLu cells in cured subjects. Accordingly, we observed the capacity 
of rejecting a second challenge of tumour cells in these animals, without giving 
any additional light treatment.  
 Immunostimulants, specifically cyclophosphamide, were used as coadjuvants to 
light treatments so as to investigate the possible enhancement of tumour cure 
rates following these therapies.  
 We conducted a molecular analysis of the immune response generated. Briefly, 
the PDT-induced immunoprotection was measured through quantification of the 
expression of relevant immune-related genes in formalin-fixed, paraffin-
embedded (FFPE) tumour samples. In addition, immunohistochemical (IHC) 
observations were conducted on a subset of proteins. 
The shared mechanism between PDT and PCI suggests that the immune 
stimulatory capacity described after light-induced photooxidation, would be likewise 
triggered by PCI. This, together with the larger therapeutic effect seen in vitro in 
Chapter 2 and Chapter 3 took us to consider whether PCI could lead to a possible 
enhancement of the stimulation of the immune system (should a PCI procedure be 
optimally established and followed). For these purposes, we used the same syngeneic 
rodent model used in Chapter 3, ensuring a fully competent immune system. 
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5.3 Materials & Methods 
Animals and tumour models 
Experiments were carried out using a subcutaneous syngeneic rat prostate 
adenocarcinoma tumour model (MatLyLu subline, Dunning R3327). Copenhagen rats 
were used throughout (100-300 g).  All animal experiments were performed in 
compliance with the subcommittee on Research Animal Care (IACUC) of 
Massachusetts General Hospital in accordance with NIH guidelines (2015N000120).  
As described in Chapter 4 for the generation of the primary subcutaneous tumour, 
4x105 MatLyLu cells prepared in 100 µl RPMI 1640 media were implanted into the right 
flank of syngeneic Copenhagen rats (approximately 100 g), previously shaved. A state 
of general anaesthesia was maintained using inhaled isoflurane throughout the 
procedure.  
Tumour rechallenge in cured animal subjects 
Animal subjects completely cured post BPD-MA PDT (as stated in Chapter 4) were 
given a second challenge of MatLyLu cells, as displayed in Figure 91. 
 
Figure 91. Timeline for tumour rechallenge in previously cured PDT-treated animals.  
Tumours were generated in animal subjects around 7 days before light treatment injecting 4x105 MatLyLu 
cells subcutaneously into the right flank of Copenhagen rats. Following a 15 minute DLI for BPD-PDT, rats 
were subjected to light treatment (λ = 690 nm) and tumour progression was evaluated regularly. Animal 
subjects showing complete tumour regression were given a second challenge of MatLyLu cells (3x105) 
subcutaneously into the left flank.     
3x105 MatLyLu cells prepared in 100 µl RPMI 1640 media were implanted 
subcutaneously into the left flank of syngeneic Copenhagen rats, previously shaved. A 
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state of general anaesthesia was maintained using inhaled isoflurane throughout the 
procedure.  
Chemicals and photosensitisers 
AlPcS2a was purchased from Frontier Scientific. The stock solution was prepared by 
dissolving powder in sodium hydroxide, and neutralising with 0.1 M hydrochloric acid to 
a 1-2 mg/ml final concentration. Working AlPcS2a solutions were kept at 4°C and 
experimental concentrations were obtained diluting the stock solution in cell media to 
reach desirable concentrations. 
Saporin (Sigma Aldrich, S9896) was dissolved in PBS to a final concentration of 0.25 
mg/ml for intravenous (i.v.) injection and kept at 4ºC. 
Cyclophosphamide (Sigma Aldrich, C7397) was dissolved in PBS to a final 
concentration of 10 mg/ml. Solutions were prepared fresh each time immediately 
before intraperitoneal (i.p.) injection. 
Light source 
LumaCare lamp LC-122 (LumaCare, USA) was used attached to a fibreoptic probe 
emitting in the spectral region 635-670 nm. 
AlPcS2a PDT and PCI treatments in combination with cyclophosphamide 
2 mg/kg of AlPcS2a was injected i.v. via tail vein 24 hr before light treatment. No 
surgical procedure was carried out during AlPcS2a PDT or PCI procedures. The 
fibreoptic attached to the lamp was placed above the skin covering the tumour, which 
had been previously shaved. Laser power was set to 0.1 W/cm2 at a light irradiance of 
100 J/cm2. During light treatments a state of general anaesthesia was maintained using 
inhaled isoflurane throughout the procedure. Buprenex (0.05-0.1 mg/kg) was 
administered subcutaneously prior to the procedure and the days following if the 
animals were found in pain or distress.  
In animals belonging to PCI groups, 250 µg/kg saporin was administered 1 hr prior to 
light.   
Early investigations in Copenhagen rats concerning cyclophosphamide (CY) were 
carried out injecting 50 mg/kg CY intraperitoneally (i.p.) four times: twice before light 
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treatment and twice after light treatment. Due to excessive toxicity this was later on 
reduced to two injections: 24 hr and 48 hr before light treatment.  
 
Figure 92. Timeline for AlPcS2a treatments combined with immunostimulants (CY) in vivo.  
AlPcS2a solutions were injected i.v. via tail vein allowing a 24 hr DLI. Administration of cyclophosphamide 
was performed twice: 24 hr and 48 hr before light treatment. 1 hr before light treatment, 250 µg/kg saporin 
was administered i.v. via tail vein to animal subjects belonging to the PCI group. After light treatment, 
animals were monitored regularly and sacrificed when tumour volume reached a humane endpoint 
(volume = 1.8 cm3) 
Measurement of emission of fluorescence in animal subjects displaying “black” draining 
lymph nodes 
A similar procedure to chemical extraction described in Chapter 4 was followed with 
control and black-appearing inguinal lymph nodes removed from rat subjects. Tissue 
was immersed in 3 ml Solvable™ (PerkinElmer) and placed in a water bath at 50°C 
until completely dissolved. Right before measuring fluorescence, samples were allowed 
to cool to room temperature and transferred to a quartz cuvette.  
The emission of fluorescence from black and control lymph node-tissue were 
compared to an AlPcS2a solution of known concentration (all prepared in Solvable™). 
Fluorescence was measured 610-750 nm, setting excitation at 640 nm. Measurements 
were performed using a Horiba Jobin Yvon Fluoromax-3 Fluorescence Spectrometer 
(Horiba Scientific). 
 Figure 93. Example of inguinal lymph nodes upon co-administration 
of AlPcS2a and cyclophosphamide. 
Animals exposed to AlPcS2a and cyclophosphamide presented blackened 
inguinal lymph nodes which were assessed through H&E and emission of 
fluorescence, compared to a control lymph node sampled from a non-
treated animal. 
Timeline
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administration i.v.
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subject and remove 
tumour samples
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administration i.p.           Tumour monitoring
Light treatment 
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Standard histological analysis of tumour samples  
Tissue samples removed from Copenhagen rats were washed in PBS directly after 
sampling and immersed in 10% formalin during 24-48 hr depending on the size of the 
specimen. Samples were then processed following a standard tissue processing 
protocol and embedded in paraffin. Paraffin blocks were trimmed and started collecting 
sections once whole sample was accessible. 4-5 µm thickness sections were cut from 
each sample. H&E staining was performed following a standard protocol. Sections 
were then examined on a Hamamatsu Nanozoomer Digital Pathology (NDP) scanner 
(Hamamatsu Photonics K.K., UK), which recorded whole section high resolution 
images. 
Immunohistochemistry staining  
Immunohistochemistry staining was performed by UCL Advanced Diagnostics.  
 Caspase-3 staining: see detailed description in Chapter 4, 4.3 Materials & 
Methods. 
 CD3 staining: CD3 primary antibody was purchased from Dako (Cat. A0452). 
This is a rabbit polyclonal antibody which detects the CD3ε chain on surface T 
cell receptors. Antigen retrieval was achieved at pH 6 during 30 minutes at 
99°C. An epitope retrieval solution from Leica Biosystems (AR9961) was used. 
Staining was performed on a Leica Bond III automated immunostainer and 
detection was carried out using Leica Bond Polymer Refine DAB detection 
system (Leica DS9800) as follows: incubation with the primary antibody was 
allowed during 15 minutes at room temperature (1/100 dilution) followed by an 
8-minute incubation with an anti-rabbit secondary antibody. 
 Bcl-3 staining: Bcl-3 primary antibody was purchased from Abcam (Cat. 
Ab49470). This is a mouse monoclonal antibody (1E8 clone) which detects A 
200 amino acid truncate of Bcl-3. Antigen retrieval was achieved at pH 9 during 
20 minutes at 99°C. An epitope retrieval solution from Leica Biosystems 
(AR9640) was used. Staining was performed on a Leica Bond III automated 
immunostainer and detection was carried out using Leica Bond Polymer Refine 
DAB detection system (Leica DS9800) as follows: incubation with the primary 
antibody was allowed during 15 minutes at room temperature (1/100 dilution). 
Slides were then blocked with peroxidase and an additional anti-mouse post-
primary antibody was applied for 8 minutes. Finally, an 8-minute incubation with 
an anti-rabbit secondary antibody was completed. 
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 Bcl-2 staining: Bcl-2 primary antibody was purchased from Leica (Cat. NCL-L-
bcl-2). This is a mouse monoclonal antibody (bcl-2/100/D5 clone) which detects 
Bcl-2 oncoprotein. Antigen retrieval was achieved at pH 9 during 30 minutes at 
99°C. An epitope retrieval solution from Leica Biosystems (AR9640) was used. 
Staining was performed on a Leica Bond III automated immunostainer and 
detection was carried out using Leica Bond Polymer Refine DAB detection 
system (Leica DS9800) as follows: incubation with the primary antibody was 
allowed during 15 minutes at room temperature (1/50 dilution). Slides were then 
blocked with peroxidase and an additional anti-mouse post-primary antibody 
was applied for 8 minutes. Finally, an 8-minute incubation with an anti-rabbit 
secondary antibody was completed. 
 PD-L1 staining: PD-L1 primary antibody was purchased from Cell Signaling 
Technology (Cat.13684). This is a rabbit monoclonal antibody (E1L3N clone) 
which detects endogenous levels of PD-LA protein. Antigen retrieval was 
achieved at pH 9 during 30 minutes at 99°C. An epitope retrieval solution from 
Leica Biosystems (AR9640) was used. Staining was performed on a Leica 
Bond III automated immunostainer and detection was carried out using Leica 
Bond Polymer Refine DAB detection system (Leica DS9800) as follows: 
incubation with the primary antibody was allowed during 15 minutes at room 
temperature (1/200 dilution). Slides were then blocked with peroxidase and an 
additional anti-mouse post-primary antibody was applied for 8 minutes. Finally, 
an 8-minute incubation with an anti-rabbit secondary antibody was completed. 
Laser capture microdissection (LCM) of ROIs differentially stained with anti CD3 
Samples were stained with an anti CD3 antibody as detailed above. Differentially CD3-
stained regions were identified on each section and used as reference to dissect a 
sufficient amount of sections (4 - 5 µm) which would produce enough RNA. The size of 
each section would determine the number of sections required (4 – 8). 
Before microdissection, Cresyl Violet staining was conducted so as to facilitate 
observation of slides under the microscope: a 0.1% solution of Cresyl Violet was 
prepared in distilled water and slides were immersed in a Coplin jar containing the dye 
solution for 2 minutes, then allowed to dry. 
Cresyl violet-stained sections were delineated based on the ROIs established in CD3 
staining so as to perform an independent analysis on the samples. This was performed 
on a Zeiss PALM MicroBeam Laser Capture microscope. Laser capturing of ROIs 
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however, was proved inefficient in our research group (resulting in insufficient RNA 
yields) and instead, laser cutting was used to delimit our ROIs by removing 
immediately adjacent unwanted areas and dissecting ROIs manually using a needle 
(see Figure 94). 
 
Figure 94. Microdissection of Cresyl Violet stained slides on a laser capture microscope.  
(A)Tumour samples were stained with anti CD3, identifying on these differentially stained regions of 
interest (ROI). ROI 1 corresponds to areas of the tumour slide appearing with an overall brown stain; ROI 
2 corresponds to areas of the tumour section presenting discretely stained cells. (B) Tumour samples were 
stained with Cresyl Violet and ROI were identified on a conventional visible light microscope. (C) Using a 
laser capture microscope, the areas adjacent to the ROIs identified on the CD3-stained slide, were 
removed to ensure no cross-contamination between differentially stained ROIs would occur during RNA 
extraction carried out next. Images shown at 1.25X magnification. 
RNA extraction from FFPE samples  
RNA extraction was conducted using a RecoverAll™ Total Nucleic Acid Isolation 
(Ambion, Life Technologies, AM1975) from 4-5 µm FFPE tumour sections previously 
microdissected. A modified protocol from Ambion RecoverAll™ kit was followed with 
addition of Turbo DNase step to the extracted RNA at the end. 
Once the extraction had been completed, RNA concentration and purity were 
measured in a DS-11 FX nanodrop spectrophotometer/Fluorometer (DeNovix Inc.). 
Samples resuting in a 260/280 ratio 1.8 – 2.5 together with a 230/260 ratio above 1, 
were considered good enough quality to continue with cDNA synthesis.  
An additional purification step was performed on samples exhibiting large organic 
contamination (not meeting the above 260/280, 230/260 ratio requirements) or 
insufficiently high RNA concentration using RNA Clean & Concentrator 5/25 (Zymo 
Research). A protocol provided by the manufacturer was followed.  
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cDNA synthesis from RNA template 
Single stranded cDNA was synthesised from RNA previously extracted (detailed 
above) using a SuperScript first-strand Synthesis System for RT-PCR (Invitrogen, Cat. 
11904-018). RNA samples were completely defrosted prior to use.  
Two different approaches were followed for cDNA synthesis: 
 Poly-A specific: poly-A tail present in all post transcriptional mRNA can be 
recognised by oligo (dT) primers, resulting in the non-gene specific reverse 
transcription of all mRNA.  
 Gene-specific priming: FFPE samples can present highly degraded RNA due to 
fixation and processing of tissue samples, often resulting in the loss of poly-A 
tails. Therefore, reverse primers whose sequences had been designed to be 
complementary to specific genes were also used to reverse-transcript mRNA 
sequences containing our genes of interest (see Table 10 below for primer 
sequences) 
A mix solution was prepared combining RNA (100 ng), oligo (dT) (50 pmol) or primers 
(1 pmol) in nuclease-free water (NFW), and dNTP (10 nmol).  
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Gene Primers sequence Biological Role 
*18S ribosomal RNA 
(housekeeping) 
AGCGAGGTGGTTGATTCTTG (F) 
TCGCTCCACCAACTAAGAAC (R) 
18S ribosomal RNA. 
Survivin 
GTTCAGACCGAGCAAGAG (F) 
CAAGTCTGGCTCGTTCTC (R) 
Member of the inhibitor of apoptosis family (IOA). It has multiple roles preventing 
apoptosis and promoting proliferation, for example inhibiting members or the caspase 
cascade. 
CD3ε 
AAGGTGCTGTCTGTCTTGAG (F) 
TTCCACGACAGACAGAACTC (R) 
Component of the CD3 complex, part of the T cell receptor. It mediates processes 
occurring during T cell activation 
Lysosomal Associated 
Membrane Protein 1 
(LAMP1) 
TGTCACCCCAAACACCCGTG (F) 
ACAGTGGGGTTTGTGGGCAC (R) 
Transmembrane glycoprotein highly expressed in cytotoxic T cells. Involved in 
signalling transduction for several characteristic functions of this T cell subset.  
Granzyme-A (GzmA) 
CCCAGTATCGTACCTATCCC (F) 
GGGTCATAGCATGGATAGGG (R) 
Highly abundant protease in the cytosol of effector T cells such as cytotoxic T cells 
and NK cells. When released during stimulation of the immune system, it promotes 
target cell death in an apoptosis-independent manner.  
Perforin 
TACTTCACCCACGGCATCAAC (F) 
ATGAAGTGGGTGCCGTAGTTG (R) 
Highly abundant protease in the cytosol of effector lymphocytes. It is involved in 
granule-dependent cell death causing pore formation by integrating in target cell 
membranes. This promotes cytolysis and apoptosis via an enhancement in the uptake 
of granzymes.  
Tumour Necrosis 
Factor Apoptosis-
Inducing Ligand 
Receptor 
(TRAIL R) 
ACTCGTTGCGTCTGAGCGACA (F) 
TGAGCAACGCAGACTCGCTGT (R) 
Surface receptor containing an intracellular death domain. It can be activated by TNF-
related pro-apoptotic ligands, then transducing an apoptotic signal. 
B cell Lymphoma  
3-encoded protein 
(Bcl-3) 
TCGCCGATACAATAAGACCTG (F) 
AGCGGCTATGTTATTCTGGAC (R) 
Transcriptional co-activator that activates associating to NF-KB homodimers. Its 
expression can be induced via an autoregulatory loop induced by NF-KB, mediated by 
the nuclear permanence of p50. 
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B cell CLL/ Lymphoma 
2 
 (Bcl-2) 
GTGTACTGGGGTGGCTTGAGTTTCT 
(F) 
CACATGACCCCACCGAACTCAAAGA 
(R) 
Mitochondrial membrane protein involved in blockage of apoptosis.  
Forkhead Box P3  
(FOXP3) 
CACCTTTGGAGTGAAGAACCAG (F) 
GTGGAAACCTCACTTCTTGGTC (R) 
Transcriptional regulator with an essential role in suppression exerted by T regs. 
Assists the maintenance of homeostasis in the immune response. 
Programmed Cell 
Death Protein 1 
Receptor (PD1) 
CAGGGATCTTCACGGGTTGT (F) 
GTCCCTAGAAGTGCCCAACA (R) 
Immunoglobulin surface protein involved in the regulation of T cell function in 
tolerance and immunity. It can inhibit effector T cell functions binding to its ligand, 
possibly inducing cell death. 
Programmed Cell 
Death Ligand 1 (PDL1) 
TCGAAGAGGAGAGAGAACCT (F) 
AGCTTCTCCTCTCTCTTGGA (R) 
Inhibitory ligand secreted by T or B cells among others, as well as several tumour 
cells. Interaction with its receptor inhibits activation and cytokine production of T cells, 
hence resulting in an escape to the immune response.  
Tumour Necrosis 
Factor Receptor 
Superfamily (FAS) 
CCACGTTCCCAGTGTCACAA (F) 
GGTGCAAGGGTCACAGTGTT (R) 
Surface receptor involved in apoptotic-mediated cell death via the caspase cascade, 
initiated upon caspase-8 proteolytic activation. It has been related to immune 
peripheral tolerance, causing T cell suicide.  
Tumour Necrosis 
Factor Receptor 
Superfamily Ligand 
(FASL) 
GTCTCCAACCTGTCCCTTCTT (F) 
CAGAGGTTGGACAGGGAAGAA (R) 
Cytokine binding to FAS. Possible participation in apoptosis and development of 
cytotoxic T cells.  
 
 Table 10. Sequences of primers used for cDNA synthesis and qRT-PCR.  
(R) Reverse (anti-sense) primer sequence. (F) Forward (sense) primer sequence. 
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Control samples were prepared replacing RNA with NFW. Each RNA sample mix 
above prepared was incubated at 65 ºC for 5 minutes in a 2720 Thermal Cycler 
(Applied biosystems, Life Technologies) covered by a heated lid, and then placed on 
ice for 2 minutes. Meanwhile, a reaction mix was prepared containing: RT buffer (10X), 
MgCl2 (25 mM), DTT (0.1 mM), RnaseOUT and SuperScript retrotranscriptase 
enzyme, as provided by the manufacturer. This reaction mixture was added into each 
RNA sample mix the incubated at 50ºC for 50 minutes and at 85ºC for 15 minutes 
covered by the thermal cycler´s heated lid. Samples were then cooled on ice during 5 
minutes. Finally, RNase H was added and tubes were incubated at 37ºC for 20 minutes 
covered by the thermal cycler´s heated lid. When finished, cDNA was kept at -20ºC 
until use. 
Real time polymerase chain reaction (qRT PCR) for relative quantification of specific 
gene expression  
iTaq™ Universal SYBR® Green Supermix (BioRad Cat. 1725121) was used to quantify 
the expression of specific genes in qRT PCR.  
Reaction mixtures were prepared independently for each gene’s set of primers (reverse 
and forward) in NFW combining: primers (5 pmol of each reverse/forward) for genes 
indicated in Table 10 and SYBR Green Supermix (1X). 1 µl of the previously 
synthesised cDNA solution (including controls) was plated in triplicate for each gene 
and then 9 µl of each primer reaction mixture were added.  
A real time thermal cycler CFX Connect™ Real-Time PCR Detection System (Bio-Rad) 
was used to amplify and detect fluorescence emission from the SYBR® Green probe. 
SYBR® Green is a fluorescent dye binding to double-stranded DNA by intercalating 
between the bases. Fluorescence can be measured at the end of the amplification 
cycles to quantify the relative expression of genes compared to a constitutively 
expressed gene (housekeeping), 18S in our study. This resulted in ΔCt values for each 
gene assessed in every case.  
NOTE: Ct is the threshold cycle or number of amplification cycles after which 
fluorescence emission passes a threshold cycle (SYBR® Green). This baseline was 
set up in our case within the exponential region of the amplification of our house 
keeping gene, 18S. ΔCt is the difference in the number of amplification cycles required 
to detect fluorescence emission between the house keeping gene and the gene of 
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interest. The larger ΔCt value is, the higher number of cycles are required to detect the 
gene of interest, concluding a lower expression in the cell and vice versa.  
Statistical analysis 
Statistical analysis was performed using GraphPad Prism 6.  
For tumour growth rate analysis at least 3 animal subjects were used in each group (n 
≥ 3) but for AlPcS2a-PDT (with and without cyclophosphamide). In these group, 2 
animals died during light treatment due to anaesthesia overdose. Therefore, n = 2 was 
used for these. In RT-qPCR experiments, each data point was the result of 
experiments carried out in triplicate but for AlPcS2a-PDT (with and without 
cyclophosphamide) tumour samples (n = 2 as stated above). Each of these repeats is 
the result of the quantification of gene expression in triplicate from each cDNA sample. 
A two-way ANOVA followed by Bonferroni post hoc multiple testing correction was 
used to in those cases where at least 3 animals were used (n ≥ 3). In comparative 
analysis involving n = 2 groups, a one-way ANOVA between matched groups followed 
by Bonferroni post hoc was performed.  
Significance level of p < 0.05 (*p = 0.05 to 0.01; **p = 0.01 to 0.001; ***p = 0.001 to 
0.0001)  
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5.4 Results 
5.4.1 Cyclophosphamide as a co-adjuvant to AlPcS2a-based 
therapies 
During our early investigations with cyclophosphamide, animals received 4 injections of 
50 mg/kg (i.p.): two were performed before light treatment and two post illumination. 
These resulted in excessive systemic toxicity in the animals. For instance a significant 
loss of weight was noted compared to the initial baseline, which animal subjects did not 
recover as displayed in Figure 95A. These subjects died 9 days after the first injection 
of CY.  
 
Figure 95. Effect of cyclophosphamide in Copenhagen rats’ welfare.  
(A) Weight loss observed in animal subjects after 4 i.p. injections of CY (50 mg/kg each), 2 before light 
treatment and 2 after light treatment (at 24 hr and 48 hr). (B) Weight loss observed in animal subjects after 
2 i.p. injections of CY (50 mg/kg each) before light treatment (24 hr and 48 hr). Each data point in (A) and 
(B) corresponds to individual animal subjects’ weight. (C) Change in fur colour and thickness in animal 
subjects after i.p. injections of CY (50 mg/kg).  
Consequently, only 2 injections (50 mg/kg i.p.) of the immunoadjuvant (CY) were given 
in experiments carried out from then on. Although an initial weight loss was also seen 
in this group of animals soon after the first injection of CY (Figure 95B), this weight was 
recovered in all subjects (data only shown up to 8 days after the first injection). In 
addition, the fur in all animal subjects CY-injected became lighter in colour and thinner 
as can be noticed by the visibly evident differences in the rat’s face shown in Figure 
95C.  
Stimulation of the immune system following PDT and PCI in Prostate Cancer  
 
 
245 
 
Figure 96. Tumour growth after AlPcS2a-based treatment in combination with cyclophosphamide 
until end point.  
Scatterplot of days between light delivery to tumours and euthanasia of animal subjects based on tumour 
size endpoint. Each symbol represents an independent animal subject. Data shown as mean ± SEM (n = 2 
or 3). 
Non-significant differences were found between groups with and without CY. However, 
the administration of cyclophosphamide in combination with AlPcS2a-based light 
treatments (both PDT and PCI) resulted in a delayed tumour growth trend as indicated 
by the average 10-day endpoint after AlPcS2a-PDT/PCI (also shown in Figure 85 in 
Chapter 4) as opposed to the average 15-day endpoint when CY was co-administered 
Figure 96). As noted in Chapter 4, the presence of saporin did not seem to alter tumour 
growth during PCI. In addition, animals subjected to cyclophosphamide injections alone 
did not experience delay in tumour growth and these were removed as soon as 4 days 
after the first CY injection. Again, this was not significantly different to tumour growth 
seen in any of the animals exposed to light-based treatments. Yet, there was a 6-day 
difference on average between tumour removal in CY control animals and the earliest 
euthanasia performed in animals belonging to any light-based treatment.   
As described in Chapter 4 for AlPcS2a-based treatments in the absence of CY, we 
analysed tumour samples removed from animals which had been also injected with 
CY, shown in Figure 97, Figure 99 and Figure 98. H&E staining did not reveal any 
particularly noteworthy events induced by CY neither in PDT (Figure 97) nor PCI 
(Figure 99) tumours. Similarly to previous tumour samples shown in Chapter 4, 
affected areas within viable regions were identified in the tumours we are describing 
now. These regions exhibited different properties (i.e. size and distribution) between 
Stimulation of the immune system following PDT and PCI in Prostate Cancer  
 
 
246 
samples belonging to the same group, showing again the lack of reproducibility when 
analysing samples through standard H&E staining. Evaluating the magnification of 
affected regions, infiltrating leukocytes were also recognised alike reported in section 
4.4.2.3 in Chapter 4. These cells with characteristic morphological features are 
highlighted with red and green arrows in Figure 97 and Figure 98. Necrosis was also 
detected in tumours as suggested by disintegrated cellular membranes and regions 
showing loss of structure in the tumour section. In addition, extended zones lacking an 
intense blue stain characteristic of the nuclear organelle, indicate the remnants of 
cytoplasmic compartments from previously existing cells.  
 
Figure 97. AlPcS2a-PDT surface-light treatment (24 hr DLI) in combination with cyclophosphamide 
to subcutaneous prostate tumours and detail of H&E staining.  
2 mg/kg AlPcS2a was injected i.v. via tail vein to Copenhagen rats bearing subcutaneously grown prostate 
tumours (i, ii). 50 mg/kg cyclophosphamide was injected i.p. 48 hr and 24 hr before light delivery. 24 hr 
after administration of AlPcS2a, light treatments were carried out at a fluence rate of 100 J/cm2 and 0.06-
0.1 W power. Once sampled, tumours were H&E stained and examined on a Hamamatsu Nanozoomer 
Digital Pathology (NDP) scanner. 20X and 40X magnifications are shown. A: affected tumour area, V: 
viable tumour area. Green and red arrows indicate different infiltrating cell types; necrotic cells highlighted 
within a black circle. Scale bars shown as 2 mm. 
An interesting observation was made from Figure 98ii. In this specific tumour sample, 
the affected area appeared in between 2 viable tumour regions in the slide: this area 
area might have been the most damaged region after exposure to light, experiencing 
tumour regrowth sidewise from viable cells located in the edges of the region.   
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Figure 98. AlPcS2a & saporin -PCI surface-light treatment in combination with cyclophosphamide to 
subcutaneous prostate tumours (24 hr DLI) and detail of H&E staining.  
2 mg/kg AlPcS2a was injected i.v. via tail vein to Copenhagen rats bearing subcutaneously grown prostate 
tumours (i, ii). 250 µg/kg saporin was injected i.v. via tail vein 1 hr prior to light delivery. 50 mg/kg 
cyclophosphamide was injected i.p. 48 hr and 24 hr before light delivery. 24 hr after administration of 
AlPcS2a, light treatments were carried out at a fluence rate of 100 J/cm2 and 0.06-0.1 W power. Once 
sampled, tumours were H&E stained and examined on a Hamamatsu Nanozoomer Digital Pathology 
(NDP) scanner. 20X and 40X magnifications are shown. A: affected tumour area, V: viable tumour area. 
Green and red arrows indicate different infiltrating cell types. Scale bars shown as 2 mm. 
Again, like stated in sections in to previous chapters, apoptosis was assessed in 
representative samples of CY groups (see Figure 99). A larger number of apoptotic 
cells were found in these compared to the PDT or PCI alone samples shown in Figure 
84 in Chapter 4. Clumps of dying cells are observed in Figure 99 upon co-
administration of CY, revealed by caspase-3 staining. Infiltrating cells were also found 
in the two tumour samples shown.  
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Figure 99. Evaluation of apoptosis after AlPcS2a-PDT/PCI surface light treatment in combination 
with cyclophosphamide to subcutaneous prostate tumours.  
(i, ii) PDT, (iii, iv) PCI combined with CY samples. 2 mg/kg AlPcS2a was injected i.v. via tail vein to 
Copenhagen rats bearing subcutaneously grown prostate tumours. 50 mg/kg cyclophosphamide was 
injected i.p. 48 hr and 24 hr before light delivery. 24 hr after administration, light treatments were carried 
out at a fluence rate of 100 J/cm2 and 0.06-0.1 W power. In PCI groups 250 µg/kg saporin was injected i.v. 
via tail vein 1 hr prior to light delivery. Once sampled, tumours were stained with anti cleaved caspase-3 
(D175) and examined on a Hamamatsu Nanozoomer Digital Pathology (NDP) scanner. Same tumour 
samples as shown in Figure 97ii and Figure 98ii. 20X, 40X and 80X magnifications are shown. TC: tumour 
cells; IC: infiltrating cells. Green and red arrows indicate different infiltrating leucocytes; black arrows 
indicate apoptotic cells. Scale bars shown as 2 mm. 
5.4.1.1 Blackening of inguinal lymph nodes upon 
combination of AlPcS2a with cyclophosphamide 
During the experiments carried out injecting CY as an immunostimulant to AlPcS2a-
based treatments, we found that draining lymph nodes removed from the inguinal chain 
of animal subjects, had acquired black pigmentation both in the contralateral and 
ipsilateral side to tumour implantation as shown in Figure 100A. This was consistent in 
all animals treated with both AlPcS2a and CY, regardless of the presence of saporin.  
Stimulation of the immune system following PDT and PCI in Prostate Cancer  
 
 
249 
 
Figure 100. Blackening of inguinal lymph nodes upon coadministration of AlPcS2a and 
cyclophosphamide.  
(A)Ipsilateral and contralateral draining inguinal lymph nodes in animals exposed to both AlPcS2a and 
cyclophosphamide. (B) Once sampled, black-appearing and control lymph nodes were H&E stained and 
examined on a Hamamatsu Nanozoomer Digital Pathology (NDP) scanner. 10X and 40X magnifications 
are shown. Red arrows indicate black aggregates within black-appearing lymph node tissue. Scale bars 
shown as 1 mm. (C) Emission of fluorescence of black lymph node sample compared to control lymph 
node sample and AlPcS2a solution of known concentration. Solvable™ was used to dissolve tissue 
samples as well as to prepare the AlPcS2a solution.  
A standard H&E procedure on these lymph node samples revealed the presence of 
black aggregates as indicated with red arrows, which were inexistent in healthy lymph 
nodes removed from control individuals as displayed in Figure 100B.  
In solution, AlPcS2a acquires a blue tonality. Therefore, suspecting that these could be 
AlPcS2a-based aggregates, we dissolved the “blackened” and control lymph nodes in 
solvable and measured the emission of fluorescence of the solution, comparing it to 
AlPcS2a solutions of known concentration. As shown in Figure 100C, the emission of 
fluorescence of black lymph nodes in solution coincided with that exhibited by a 
solution of AlPcS2a of around 0.015 µM, exhibiting an excitation peak around 665 nm. 
5.4.2 Second tumour challenge to BPD-MA-cured 
Copenhagen rats 
As stated in Chapter 4, 18% (4/22) of the animal subjects treated with BPD-MA PDT 
were completely cured from the initial tumour challenge (4 x 105 MatLyLu cells) and 
were then given a second challenge of the same cells. So as to avoid an overwhelming 
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effect on the immune system and thus enable a successful rejection of these tumour 
cells, this second tumour challenge was slightly lower than initially performed (3 x 105 
cells). However, none of the rechallenged individuals successfully rejected their 2nd 
injection of MatLyLu cells and tumour regrowth was noted in all individuals.  
 
Figure 101. Tumour growth after initial tumour challenge or second challenge in cured animals, 
until end point.  
Scatterplot of days between the first injection of tumour cells or the second injection of tumour cells in 
previously cured animal subjects, and euthanasia based on tumour size endpoint. Each symbol represents 
an independent animal subject. Data shown as mean ± SEM; significance p < 0.05 
Figure 101 displays the endpoint delay experienced by rechallenged animal subjects 
compared to untreated controls exposed to the initial MatLyLu tumour challenge. 
Whereas tumours reached the volume endpoint an average of 11 days after injection, 
the implantation of cancer cells in cured animals experienced a delay in 11 days on 
average (22 days overall) to reach the volume endpoint (Figure 101), and this 
difference was significantly different.  
Despite the fact that rechallenged tumours had not been directly exposed to light-
based treatments, the histological analysis of these tumour samples revealed affected 
regions (Figure 102) akin to previous observations arising from light treated tumours 
(Figure 71, Figure 72, Figure 79 and Figure 84). This is especially noteworthy in Figure 
102ii, in which a large surface area appears to be damaged compared to Figure 102i. 
These areas are also largely composed of infiltrating leukocytes, highlighted with 
arrows in the micrographs, as already described for other tumour samples (i.e. Figure 
97 or Figure 98). Moreover, while the affected area seems to be localised in a central 
region in the latter sample, the former seems to be affected from the outside, 
expanding towards the inside of the tumour structure.  
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Figure 102. Non rejected secondary tumour in animals previously cured from the primary tumour 
after BPD-MA PDT treatment, and detail of H&E staining.  
(i, ii) Rat subjects which had been completely cured from the primary MatLyLu subcutaneous tumour after 
light treatment (BPD-MA PDT) were given a second subcutaneous challenge of MatLyLu cells on the 
opposite flank (left side). Secondary tumours were non rejected and once sampled, these were H&E 
stained and examined on a Hamamatsu Nanozoomer Digital Pathology (NDP) scanner. 20X and 40X 
magnifications are shown. A: affected tumour area, V: viable tumour area. Green and red arrows indicate 
different infiltrating cell types. Scale bars shown as 2 mm. 
As for the evaluation of apoptotic cell death displayed in Figure 103, large apoptotic 
tumour regions were found in this tumours in spite of the lack of direct treatment 
performed on these. 
 
Figure 103. Evaluation of apoptosis in non rejected secondary subcutaneous tumours regrown in 
previously cured BPD-MA PDT-treated animal subjects.  
Rat subjects which had been completely cured from the primary MatLyLu subcutaneous tumour after light 
treatment (BPD-MA PDT) were given a second subcutaneous challenge of MatLyLu cells on the opposite 
flank (left side). Secondary tumours were non rejected and once sampled, these were stained with anti 
cleaved caspase-3 (D175) and examined on a Hamamatsu Nanozoomer Digital Pathology (NDP) scanner. 
Same tumour samples as shown in Figure 102. 20X, 40X and 80X magnifications are shown. TC: tumour 
cells; IC: infiltrating cells. Green and red arrows indicate different infiltrating leucocytes; black arrows 
indicate apoptotic cells. Scale bars shown as 2 mm. 
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5.4.3 Evaluation of the in vivo activation of the immune 
system activation  
As highlighted above, a major aim of this thesis, and specifically reported in the current 
chapter, was to assess whether light-based therapies are capable of eliciting an 
immune response during cancer treatment which would confer long term protection 
should formation of secondary tumour deposits occur. In line with this, we now address 
the presence of different immune-related molecules on tumour samples via 
immunohistochemical staining. Then we will comment on the quantification of the 
expression of relevant genes in different treatment groups.  
5.4.3.1 Bcl-2/Bcl-3 in PDT-treated tumour samples 
As briefly pointed out above, Bcl-2 and Bcl-3 have closely related biological roles in the 
immunological response through the NF-B pathway. Staining of two tumour samples, 
untreated and PDT-treated respectively did not result in a particularly noteworthy 
staining against the apoptotic regulator Bcl-2 as displayed in Figure 104. A faint 
positive cytosolic staining was identified in a few disperse cells within the untreated 
control tumour samples (as indicated with a red arrow in Figure 104A), which we could 
not recognise in the treated specimen (Figure 104B).  
 
Figure 104. Evaluation of Bcl-2 and Bcl-3 staining in untreated and PDT-treated tumours.  
Untreated and PDT-treated tumour samples were stained with anti Bcl-2 and Bcl-3 and examined on a 
Hamamatsu Nanozoomer Digital Pathology (NDP) scanner. 80X magnification shown. (A) Bcl-2 staining 
on untreated tumour. (B) Bcl-2 staining on PDT-treated tumour, red arrow highlights cytoplasmic staining. 
(C) Bcl-3 staining on untreated tumour. (D) Bcl-3 staining on PDT-treated tumour.  
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On the other hand, the transcriptional coactivator Bcl-3, displayed a strong nuclear 
presence in untreated tumours (Figure 104C), whilst no expression was detected in the 
PDT-treated sample (Figure 104D).  
5.4.3.2 PD-L1 expression on rechallenged tumour 
samples 
The great focus nowadays on immune checkpoint inhibitors and the use of immune 
checkpoint blockade strategies as therapeutic alternatives in cancer treatment, 
prompted us to evaluate the expression of the relevant programme cell death ligand 1 
(PD-L1) in cured and rechallenged animals.  
 
Figure 105. Evaluation of Programmed Cell Death-1 Ligand (PD-L1) in non rejected secondary 
subcutaneous tumours regrown in previously cured BPD-MA PDT-treated animal subjects.  
Rat subjects which had been completely cured from the primary MatLyLu subcutaneous tumour after light 
treatment (BPD-MA PDT) were given a second subcutaneous challenge of MatLyLu cells on the opposite 
flank (left side). Secondary tumours were not rejected and once sampled, these were stained with anti PD-
L1 and examined on a Hamamatsu Nanozoomer Digital Pathology (NDP) scanner. Same tumour samples 
as shown in Figure 102i and Figure 103i. 20X, 40X and 80X magnifications are shown. (A) Shows stronger 
stained regions. (B) Shows weaker stained regions. Red arrows highlight the stain in the external cell 
membrane. Scale bars shown as 2 mm. 
It was found that nearly the whole surface of a tumour sample belonging to a 
rechallenged animal subject presented positive stain against PD-L1. Within the overall 
staining, lightly and strongly stained regions could be clearly differentiated. Figure 105A 
highlights stronger staining in the tumour sample, whereas Figure 105B shows a 
weaker, although still positive staining on the tumour. As indicated with red arrows in 
Figure 105B, PD-L1 was localised in the external cell membrane. Interestingly, the 
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expression of PD-L1 seemed to be higher in the centre of the tumour, while the 
periphery did not seem to exhibit as strong a signal.  
It was also found that tumour areas where infiltrating leukocytes were spotted, as 
indicated with red arrows in Figure 106, did not show significant presence of the PD-L1 
molecule based on the lack of staining seen in that specific tumour area.  
 
Figure 106. Detail of Programmed Cell Death-1 Ligand (PD-L1) in non rejected 2ary subcutaneous 
tumours regrown in previously cured BPD-MA PDT-treated animal subjects.  
Rat subjects which had been completely cured from the primary MatLyLu subcutaneous tumour after light 
treatment (BPD-MA PDT) were given a second subcutaneous challenge of MatLyLu cells on the opposite 
flank (left side). Secondary tumours were not rejected and once sampled, these were stained with anti PD-
L1and examined on a Hamamatsu Nanozoomer Digital Pathology (NDP) scanner. Same tumour samples 
as shown in Figure 102i and Figure 103i. (A) and (B) show details of different regions in the tumour at 80X 
magnification. Red arrows highlight the presence of infiltrating leukocytes. 
5.4.3.3 CD3+ Lymphocyte infiltration in tumours 
Among the complexity of the immune response, we have mainly focused on the anti-
tumour role exerted by T cells. As noted above, CD3 is a major surface marker on 
these and consequently its expression on tumour samples belonging to the different 
treatment groups described throughout Chapter 4 and Chapter 5 was evaluated.  
After observing all tumours stained for CD3, we concluded that staining was more 
prominent in the peripheral area of tumours. For instance, in tumour samples that 
exhibited a lower number of infiltrating CD3+ cells these were mainly found in the 
periphery whilst in tumours showing a greater infiltration, these cells were in addition 
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found dispersed throughout the tumour. Moreover, tumours composed of several 
nodules also showed greater infiltration in the interface between two nodules. A detail 
of these is shown in Figure 107B and Figure 107A respectively. In both cases 
localisation of CD3 in the external cell membrane was confirmed, highlighted in Figure 
107 with red arrows.    
 
Figure 107. Detail of CD3-staining in tumour samples.  
Representative tumour samples from each treatment group described throughout Chapter 4 and Chapter 5 
were stained with anti CD3ε (chain on surface T cell receptors) and examined on a Hamamatsu 
Nanozoomer Digital Pathology (NDP) scanner. (A) Detail of the high density of positively stained cells in 
the interface between tumour nodules (multinodular samples). (B) Detail of the high density of positively 
stained cells in the tumour periphery. 10X and 80X magnifications are shown. 
Interestingly, a comparison of PD-L1 and CD3 positively stained zones in the 
rechallenged tumour sample showed that both stains were complementary: CD3+ 
regions were PD-L1- and conversely, CD3- were PD-L1+. This is displayed in Figure 
108, where circled areas represent the clear complementarity found between CD3 and 
PD-L1. For example, regions highlighted with red circles exhibit lack of CD3 staining 
yet a strong PD-L1 signal. In contrast, regions highlighted with green circles exhibit 
reduced PD-L1 staining yet a strong CD3 infiltration. 
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Figure 108. Comparison of CD3 and PD-L1 staining in rechallenged tumour samples.  
Rat subjects which had been completely cured from the primary MatLyLu subcutaneous tumour after light 
treatment (BPD-MA PDT) were given a second subcutaneous challenge of MatLyLu cells on the opposite 
flank (left side). Secondary tumours were non rejected and once sampled, these were stained with anti 
CD3 and PD-L1 and examined on a Hamamatsu Nanozoomer Digital Pathology (NDP) scanner. Same 
tumour samples as shown in Figure 102i, Figure 103i and Figure 109E. (A) and (C) show details of CD3 
staining. (B) and (D) show details of PD-L1 staining on the same area. 10X magnification is shown. Red 
and green circles indicate the same region in the tumour stained for the expression of either marker. 
CD3 resulted in differentially stained regions on tumour samples. Two clearly visible 
regions were identified: defined regions displaying a generalised staining (ROI 1) and 
regions displaying discrete positively stained cells scattered throughout the tumour 
(ROI 2). Generally, ROI 1 corresponded to those areas identified as affected in the 
standard H&E staining in which the amount of infiltrating leukocytes was also larger. 
These identified ROIs were then used as a reference to perform an independent 
quantification of gene expression on either ROI through tissue microdissection, as 
explained in detail in 3.3 Materials & Methods. 
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Figure 109. Tumour sample staining against CD3 and identification of differentially stained ROIs.  
Representative tumour samples from each treatment group described throughout Chapter 4 and Chapter 5 
were stained with anti CD3ε (chain on surface T cell receptors) and examined on a Hamamatsu 
Nanozoomer Digital Pathology (NDP) scanner. ROIs were identified on these slides based on whether an 
overall stained region was found (ROI1) or else positively stained cells were found disperse throughout the 
tumour structure (ROI2). 5X magnification of each ROI is shown. (A) Orthotopic untreated control tumour. 
(B) TPCS2a (PDT) surface light treated tumour (24 hr DLI). (C) TPCS2a (PDT) surface light treated tumour 
(16 hr DLI). (D) BPD-MA (PDT) surface light treated tumour (15 min DLI). (E, F) Regrown tumours after 2nd 
injection of tumour cells upon complete tumour regression post BPD-MA PDT. (G) AlPcS2a (PDT) surface 
light treated tumour (24 hr DLI). (H) AlPcS2a (PDT) & CY surface light treated tumour (24 hr DLI). (I) 
AlPcS2a & Saporin (PCI) surface light treated tumour (24 hr DLI). (J) AlPcS2a & Saporin (PCI) & CY surface 
light treated tumour (24 hr DLI). Scale bars shown as 2 mm. 
A representative tumour sample from each treatment group is displayed in Figure 109, 
in which some of the ROIs used for gene expression quantification are defined. 
Features of ROIs in each tumour sample were different regarding both size and pattern 
of distribution. The lack of consistency determined in the differentially stained ROIs 
between tumour samples relates to observations from H&E staining, given the 
correlation between ROI 1 and the affected areas described in the latter along Chapter 
4 and Chapter 5. 
As mentioned above, in general all tumour samples exhibited infiltration of CD3 cells in 
the periphery regions rather than more central regions (Figure 109). We would like to 
highlight particularly the large infiltration of discretely stained CD3+ cells noted in the 
Stimulation of the immune system following PDT and PCI in Prostate Cancer  
 
 
259 
ROI 2 in rechallenged and AlPcS2a-PDT samples (Figure 109E, Figure 109F and 
Figure 109G respectively). 
5.4.3.4 Molecular analysis on tumour samples 
Prior to the analysis of gene expression in ROIs as described above and represented 
in Figure 109, we assessed whether a poly(A)-specific retrotranscription of mRNA 
would result in an efficient recognition of mRNA sequences from FFPE samples, hence 
successfully quantify our genes of interest. We measured 5 genes of the whole panel 
of selected genes in 6 randomly chosen RNA samples from tumours as shown in 
Figure 110. Some of the genes measured showed large deviation between repeats in 
the same sample as indicated by the error bars. Bcl-3 was not recognised in any of the 
cases. Accordingly, despite the fact that cDNA resulting from non-poly(A) specific 
retrotranscription would only be used to assess the expression of specifically selected 
genes and therefore each cDNA sample would require a more time consuming 
process, we decided to follow a gene-specific retrotranscription for our samples of 
interest.  
 
Figure 110. Gene expression based on cDNA reverse-transcribed using poly (A)-specific priming.  
cDNA from 6 tumour samples was obtained using non specific primers, recognising poly(A) tails in mRNA. 
qRT-PCR was then used to quantify the expression of Bcl2, Bcl3, FoxP3, PD1 and PD-L1 genes. 18S was 
used as housekeeping gene to determine ΔCt values. Data shown as mean ΔCt ± SEM. 
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Among the wide range of genes involved in the immune response, selected CD3ε, 
Lamp1, FoxP3, Perforin, Granzyme-A, Bcl-2, Bcl-3, Survivin, TRAIL-R, FAS, FAS-L, 
PD1, PD-L1 based on their relevance in T cell-mediated response and possible cell 
death induced via the apoptotic pathway. This assessment of gene expression is 
displayed in Figure 111, Figure 112 and Figure 113, performed independently in each 
ROI and treatment group as noted above.  
Regarding T cell markers (), CD3ε appeared to be significantly up-regulated mostly in 
the rechallenged yet non-rejected tumour samples (p < 0.0001) compared to the 
untreated tumour. Although not as significant, it also showed up-regulation in treatment 
groups such as BPD-MA PDT (p = 0.0084) and AlPcS2-PDT (p = 0.0056) -both in ROI 
2- and AlPcS2-PCI (p = 0.0157) in ROI 1. Variations were also detected between 
treatment groups, predominantly an up-regulation in rechallenged compared to the rest 
of the treatment groups (see Table 11). No major differences were found in the 
expression of Lamp 1. Conversely, the comparison of FoxP3 between control and 
treated samples resulted in a down-regulation only in BPD-MA treated animals (p = 
0.0014). Moreover, this down-regulation was also significantly different to other 
treatment groups. Briefly, in ROI 2 relevant differences were detected between BPD-
MA treated tumours and those regrown post rechallenge (p < 0.0001), TPCS2a-PDT (16 
hr DLI, p = 0.0408), AlPcS2a-PDT (p = 0.0007), AlPcS2a-PDT & CY (p = 0.0184), and 
AlPcS2a-PCI & CY (p = 0.0065). In ROI 1 differences were not that noticeable, 
concluding only a weak down-regulation in BPD-MA treated compared to rechallenged. 
Overall, these three genes were especially altered in rechallenged tumours and despite 
CD3ε seemed to be likewise altered between both ROIs defined, variations in FoxP3 
were largely found in ROI 2. 
Cytolytic effector molecules such as Perforin and Granzyme-A showed 
differential variations between ROIs. For instance, ROI 1 in untreated samples had 
significantly higher presence of the former compared to TPCS2a-PDT (24 hr DLI), 
AlPcS2a-PDT & CY, AlPcS2a-PCI and AlPcS2a-PCI & CY. As for ROI 2, Granzyme-A 
was considerably up-regulated only in rechallenged tumours, although these alterations 
were not as strong as those noted above for T cell markers (i.e. p = 0.0012 vs. p < 
0.0001). Despite not many significant differences between groups were noted, again 
variations in Perforin seemed to be more present in ROI 1 and Granzyme-A in ROI 2. 
In line with this, an up-regulation of Perforin was observed in AlPcS2a-PDT treated 
samples as opposed to AlPcS2a-PDT & CY or AlPcS2a-PCI. On the other hand, again it 
was only the rechallenged tumour showing an important increase in the expression of 
Granzyme-A compared to AlPcS2a-PDT & CY. 
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With reference to apoptosis, while Bcl-2 was not particularly noticed in any case, 
expression of Bcl-3 was similarly altered in both ROIs (Figure 112). In detail, a 
significant up-regulation was detected in most treated tumours - TPCS2a-PDT (16 hr 
DLI), rechallenged, AlPcS2a-PDT, AlPcS2a-PDT & CY, AlPcS2a-PCI & CY. Particularly 
interesting are the observations from BPD-MA PDT treated and rechallenged samples 
in ROI 2. Compared to the rest of the treatments, a significant down-regulation resulted 
from the former compared to rechallenge (p < 0.0001), AlPcS2a-PDT (p < 0.0001), 
AlPcS2a-PDT & CY (p < 0.0001), AlPcS2a-PCI (p = 0.0017) and AlPcS2a-PCI & CY (p < 
0.0001). Refer to further details in Table 11.  
No major findings resulted from untreated and treated samples regarding PD1, PD-L1, 
TRAIL-R (Figure 112 and Figure 113). Survivin only showed changes in ROI 1, 
specifically a down-regulation in tumours after some of the conducted treatments. 
TRAIL-R was not altered in a major manner, only rechallenged samples showed some 
up-regulation against other treated tumours (see Table 11). Although no treatment 
showed significant variation of TRAIL-R and PD-L1 with the control group, 
rechallenged samples exhibited significantly higher expression levels than those 
treated using some other PS (p = 0.0039 at the most). Finally, a significant up-
regulation of FAS and FAS-L in AlPcS2a-PDT (ROI 1) and FAS-L in rechallenged (ROI 
2) were detected. Further comparison between groups revealed that changes in FAS 
and FAS-L were restricted to ROI 1. Specifically, an up-regulation of both FAS and 
FAS-L was found again in AlPcS2a-PDT over other treatment groups. The most 
significant down-regulation of FAS resulted from the combination of AlPcS2a-PDT with 
CY (p = 0.0008).  
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Figure 111. Expression of CD3ε, 
LAMP1, FoxP3, Perforin and 
Granzyme A in tumour samples.  
RNA was extracted from two ROI (1 
and 2) defined in tumour samples and 
retrotranscribed to cDNA using 
reverse primers for specific genes of 
interest. Gene expression in different 
treatment groups was quantified 
through RT-qPCR using SYBR®. 18S 
was used as housekeeping gene to 
determine ΔCt values. (A) 
Quantification of the expression of 
CD3, Lamp1, FoxP3 in ROI 1 in 
tumours. (B) Quantification of the 
expression of CD3, Lamp1, FoxP3 in 
ROI 2 in tumours. (C) Quantification of 
the expression of Perforin and 
Granzyme A in ROI 1 in tumours. (D) 
Quantification of the expression of 
Perforin and Granzyme A in ROI 2 in 
tumours.  Data shown as mean ΔCt ± 
SEM, significance level of p < 0.05 
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Figure 112. Expression of Bcl-2, 
Bcl-3, Survivin and TRAIL-R in 
tumour samples.  
RNA was extracted from two ROI (1 
and 2) defined in tumour samples 
and retrotranscribed to cDNA using 
reverse primers for specific genes of 
interest. Gene expression in different 
treatment groups was quantified 
through RT-qPCR using SYBR®. 18S 
was used as housekeeping gene to 
determine ΔCt values. (A) 
Quantification of the expression of 
Bcl-2 and Bcl-3 in ROI 1 in tumours. 
(B) Quantification of the expression 
Bcl-2 and Bcl-3 in ROI 2 in tumours. 
(C) Quantification of the expression 
of Survivin and TRAIL-R in ROI 1 in 
tumours. (D) Quantification of the 
expression of Survivin and TRAIL-R 
in ROI 2 in tumours.  Data shown as 
mean ΔCt ± SEM, significance level 
of p < 0.05 
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Figure 113. Expression of FAS, 
FAS-L, PD1, PD-L1 in tumour 
samples.  
RNA was extracted from two ROI (1 
and 2) defined in tumour samples 
and retrotranscribed to cDNA using 
reverse primers for specific genes of 
interest. Gene expression in different 
treatment groups was quantified 
through RT-qPCR using SYBR®. 18S 
was used as house keeping gene to 
determine ΔCt values. (A) 
Quantification of the expression of 
FAS and FAS-L in ROI 1 in tumours. 
(B) Quantification of the expression 
FAS and FAS-L in ROI 2 in tumours. 
(C) Quantification of the expression 
of PD1 and PD-L1 in ROI 1 in 
tumours. (D) Quantification of the 
expression of PD1 and PD-L1 in ROI 
2 in tumours.  Data shown as mean 
ΔCt ± SEM, significance level of p < 
0.05 
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Table 11. Multiple 
comparison of the 
expression of CD3ε, 
Lamp1, FoxP3, 
Perforin, Granzyme-A, 
Bcl-2, Bcl-3, Survivin, 
TRAIL-R, FAS, FAS-L, 
PD1, PD-L1 in tumour 
samples.  
Summary of significant 
differences between 
treatment groups 
displayed in , Error! 
Reference source not 
found. and Error! 
Reference source not 
found.. (↑) Indicates 
gene up-regulation in the 
corresponding treatment 
group; (↓) indicates gene 
down-regulation in the 
corresponding treatment 
group. Significance level 
of p < 0.05 
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5.5 Discussion  
In the present chapter, we have evaluated the potential anti-tumour protection exerted 
by PDT and PCI using different photosensitiers. We have also co-administered light 
treatments with cyclophosphamide, as an immune-adjuvant based on its known 
capacity to eliminate regulatory T cells at low doses (described in detail in 
5.1Introduction).  
Existing MSDS information on cyclophosphamide monohydrate (Cytoxan®, Bristol-
Myers Squibb Company) claim an LD50 (lethal dose 50) in rat of 94 mg/kg and 121 
mg/kg when administered orally or intraperitoneally respectively. Besides, the oral 
LOAEL (lowest observed adverse effect level) stated was 50 mg/kg, resulting in 80-
90% bioavailability and showing an excretion half-life 4-6 hours after administration. 
Based on these, as well as available scientific reports claiming 50 mg/kg to be within 
the low-dose range of the agent, we initiated experiments conducting four i.p. injections 
(daily): two before light treatment and the remaining two in the days following delivery 
of light. The unexpected death of these individuals made us consider whether the 
combination of both treatments (light-based and cyclophosphamide) could have had an 
additive effect and thus resulted in excessive toxicity. We therefore then reduced the 
number of injections of the immune-adjuvant to two 50 mg/kg as has been studied 
before in combination with light therapies (Castano et al., 2008; Reginato et al., 2013). 
Hair loss, skin discoloration and loss weight are some of the reported side effects of 
cytoxan® as chemotherapeutic in humans, which were also experienced by all our 
animals (Figure 95). However, non-recovered weight loss after four injections reflects 
the extreme toxicity caused, opposite to the recovery and even weight gain of animals 
subjected to only two injections. In spite of the side effects reported, cyclophosphamide 
alone did not affect tumour growth, and tumour-bearing animals subjected to this 
treatment were euthanised only 4 days after the first injection of the immunoadjuvant 
was performed as they reached the end point of tumour burden at this point (Figure 
96).  
Based on the hypothesis that a potent immune response would have only been elicited 
after the complete eradication of tumours in 18% of the animal subjects following BPD-
MA PDT (reported in Figure 78 in Chapter 4), we limited the administration of CY to 
AlPcS2a-treated animals either following PDT or PCI to assess whether CY could result 
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in an improved outcome. As a matter of fact, although this combination did not result in 
any complete tumour eradication, the delay in tumour growth suggests that 
optimisation of the treatment procedure could potentially result in complete cures. 
Previous studies have already reported the benefits of combining cyclophosphamide 
with PDT, although in these cases complete survival of animals was observed when 
using low doses – 50 mg/kg (Castano et al., 2008; Reginato et al., 2013). For instance, 
66% of the animals survived more than 90 days after BPD-PDT (2 mg/kg, 150 J/cm2, 
0.1 W/cm2) with CY, contrary to the lack of cures in any case belonging to the BPD-
PDT alone group (Castano et al., 2008). In addition, in their study, CY alone resulted in 
an improved survival, similar to the BPD-PDT only group. 
Regarding the pathological analysis of these AlPcS2a & CY-treated tumours, H&E 
staining did not reveal any significant differences resulting from the co-administration of 
the immunoadjuvant, neither in the absence nor presence of saporin. This indicates 
that no further interaction between these two drugs might be occurring. Again, as 
described in previous tumour samples, the heterogeneity in the resulting affected areas 
was not different when CY was co-administered. An interesting observation was found 
during the evaluation of apoptosis in these samples: there was a larger number of 
apoptotic cells despite the longer period of time existing between light treatment and 
euthanasia (due to the delay in tumour growth). In a previous chapter of the thesis we 
have hypothesised that despite PDT-based treatments induce apoptosis in tumours 
(seen in samples 24 hr after light, Figure 65), should there be any fast-growing 
MatLyLu surviving tumour cells, apoptotic-dead cells would be overtaken by the viable 
tumour. Accordingly, the greater apoptosis shown in Figure 99 leads us to think that CY 
might be contributing to the apoptotic death PDT/PCI- induced, thereby decreasing the 
amount of remaining MatLyLu viable cells and in the end delay being overtaken by 
viable tumour cells. As a matter of fact, it has been previously confirmed that when 
used as chemotherapeutic rather that immune co-adjuvant, CY triggers apoptosis in a 
caspase cascade- dependent manner in different types of tumours (Schwartz and 
Waxman, 2001; Tsai-Turton et al., 2007). Furthermore, CY could have induced 
apoptosis not only in tumour cells but in infiltrating cells to some extent, given the 
caspase-3+ stain present in regions where large infiltration of leukocytes was found 
(Figure 99). This correlates with the effect CY has specifically on immune-related cells.  
Regarding the blackening of the inguinal lymph nodes in rats where co-administration 
of AlPcS2a and CY had been conducted (shown in Figure 100), the coinciding emission 
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of fluorescence between a solution of AlPcS2a-alone and a dissolved “black”-lymph 
node solution, took us to conclude that the abnormal colour exhibited by these nodes 
was due to the formation of aggregates of this specific PS. This accumulation of 
AlPcS2a could be the result of an enhanced phagocytic activity induced by CY. AlPcS2a 
is a stable compound that tends to dimerise forming aggregates in a pH-dependent 
manner which can be disrupted by 0.1 M NaOH (Chen et al., 2014). If under our 
experimental conditions AlPcS2a aggregates, the increased phagocytic activity induced 
by CY could result in the increased uptake of these aggregates by the lymph nodes. 
Although we did not assess any additional lymph nodes, owing to the proximity to CY’s 
injection site (peritoneum), the inguinal chain of lymph nodes would have been the 
most affected location.  
 In line with the hypothesis of an enhanced phagocytosis, a similar conclusion was 
drawn in a recent study investigating how to overcome resistance to antibody-based in 
cancer treatment (Pallasch et al., 2014). Specifically, the authors confirmed that 
cyclophosphamide triggered the secretion of a series of factors by tumour cells (i.e. 
CCL4, IL8, among others) and this would lead to an enhanced macrophage infiltration 
and phagocytosis.  
Moreover, this PS aggregation would lead to a self-quenching effect, hence a reduction 
in AlPcS2a’s photooxidative capacity, giving an additional possible explanation on the 
lesser therapeutic success observed with this PS.  
Parallel to the investigation concerning cyclophosphamide, animals that had been 
completely cured from the first tumour challenge post BPD-MA-PDT treatment (as 
already described in Chapter 4) were given a second challenge of tumour cells. This 
was conducted to evaluate whether the initial curative PDT had provided the animals 
with anti-tumour protection, should an additional exposure to relevant tumour cells 
occur. We aimed to follow an immune response-mounting strategy. In short, we gave a 
second tumour challenge using a lower amount of tumour cells than initially used, yet 
known to cause tumour formation in naïve animal subjects. Had the initial PDT 
treatment elicited an immune response in cured individuals, this injection of MatLyLu 
cells would have been rejected and we would have consequently performed an 
additional, higher-dose, tumour challenge and so on. Rechallenged animals were not 
subjected to any additional treatment after the second challenge of tumour cells. 
Despite no rejection of the second MatLyLu cell injection was observed, these 
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secondary tumours grew at a significantly slower pace than the initially implanted 
tumours in untreated animals (Figure 101). It could be argued whether this significant 
difference in tumour growth is “real” or else it is due to the lower amount of cells used 
for the second implantation. Throughout the present thesis, several tumour cell 
numbers have resulted in tumour formation such as 5 x 104 in the orthotopic tumour, 
4x105 or 106 in subcutaneous tumour. Irrespective of differences in cell number used, 
these only occasioned growth differences of 1 or 2 days. Therefore, we consider the 
11-day delay observed in the rechallenged rats is not a mere cell number effect.  
Studies in J774 and CT26 tumours combining BPD-MA and CY, resulted in complete 
tumour regression and even rejection of tumour rechallenge on cured subjects 
(Castano et al., 2008; Reginato et al., 2013). Importantly, specific antigens in both of 
these tumours have been identified. In the study carried out in 2008, successful 
rejection of the second tumour injection was antigen-specific, as indicated by the non-
rejection of alternative tumour cells - EMT6, also immunogenic (Castano et al., 2008). 
Additionally, in the 2013 study tumour rejection was exclusively observed provided an 
additional injection of CY was performed before rechallenge (Reginato et al., 2013). In 
this last case, the authors hypothesised that the antigen expressed by CT26 cells (gp 
70) could have been behaved like a self-antigen causing reactivation of Tregs, thus 
requiring an additional depletion of these cells so as to achieve a successful tumour 
rejection (Reginato et al., 2013).  
MatLyLu cells have not been reported to be particularly immunogenic and tumour-
specific antigens have not been described to date. Other researchers have conducted 
studies aiming to enhance the immunogenicity of these cells by down-regulating the 
production of TGFβ (Matthews et al., 2000). TGFβ is known to stimulate development 
of Tregs, having an important role in immune suppression (Liu et al., 2008). This, 
together with the known Treg-induced immunosuppression (both during antigen 
presentation and the effector phase) leads us to consider whether if we had 
administered CY before BPD-MA-PDT treatment and tumour rechallenge, the rejection 
of secondary tumour deposits would have occurred. Even more, BPD-MA-PDT 
treatment (as indicated in Chapter 4) could have also resulted in a more successful 
survival rate.  
The large affected tumour areas observed after performing H&E staining as well as the 
presence of apoptotic cells on these regrown tumours (Figure 102 and Figure 103), 
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indicate that even if PDT had not generated complete protection against further tumour 
formation, it would have triggered immune-protection to some extent. Comparing 
damaged areas in the two rechallenged tumour samples displayed, the differences 
recognised (size and location) could be due to intrinsic disparities in the immunological 
potential of the two animal subjects they belong to. However, these disparities might 
not be that significant based on the similar expression of genes measured next.  
We then performed an evaluation on how the immune response was being stimulated 
through IHC and quantification of gene expression in defined ROIs independently. We 
would like to comment briefly that through the initial analysis of gene expression we 
performed using a poly(A)-specific retro-transcription method (Figure 110), we confirm 
previous reports regarding the low quality of RNA in FFPE samples due to the 
degradation of mRNA poly-(A) tails during tissue processing and embedding (Evers et 
al., 2011). For this reason the remaining investigations, were conducted using gene-
specific priming in the reverse transcription step (Figure 111, Figure 112 and Figure 
113). 
Starting with the NF-B inducible genes Bcl-2 and Bcl-3, light treatment seems to be 
affecting the expression of Bcl-3 in the nucleus as shown in Figure 104. Perhaps, the 
inflammatory process elicited after PDT signals the degradation of this protein in order 
to maintain homeostasis in response to a large stimuli (Figure 104D). Contrary, a 
significant expression of Bcl-3 was found localised in the nucleus in the untreated 
control (Figure 104C).  
As for the downstream effect in Bcl-2 expression regulated by Bcl-3, a very weak 
positive cytoplasmic staining was only observed in the untreated control tumour (Figure 
104A). This indicates that in malignancies with no damaging stimuli, the integrity of Bcl-
3 remains, possibly activating (although weakly observed) the expression of Bcl-2, 
hence implying a slim anti-apoptotic signal occurring in the natural environment of 
viable non-treated tumours. On the other hand, the PDT-treated tumour sample 
displayed did not show any presence of Bcl-2, which we could consider as slight pro-
apoptotic signalling after treatment (Figure 104B). However, throughout Chapter 4 and 
Chapter 5, although some apoptotic cells could be distinguished upon caspase-3 
staining in PDT-exposed tumours, overall we did not make significant observations 
compared to controls. One possible explanation is as already discussed previously: 
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owing to the removal of tumours several days after light treatment, apoptosis was no 
longer as significant as immediately after PDT.  
Besides, other studies have previously concluded a PDT-induced damage to Bcl-2 
protein based on the mitochondrial damage exerted after photooxidation (Usuda et al., 
2003; Xue et al., 2001). In general, the Bcl-2 signal observed in our samples not only in 
treated but also in control tumours does not completely correlate with this PDT-based 
damage.  
As regards to findings in the qRT-PCR experiments a correlation with the above 
discussed IHC results was seen: no major changes were detected in either ROI. 
Conversely, the molecular analysis revealed opposite results to IHC staining in Bcl-3. 
The latter displayed down-regulation in PDT-treated samples compared to a positive 
nuclear stain in untreated tumours (Figure 104); while a significant up-regulation in the 
expression of Bcl-3 was measured in nearly all treatments, but for BPD-MA treated 
(Figure 112). This last observation is especially interesting, since BPD-MA has been 
the only PDT treatment resulting in an efficient tumour regression. Although this single 
down-regulation was not significantly different to control samples (p = 0.3890), it 
suggests that degradation/down-regulation of Bcl-3 might only occur in tumours 
subjected to a sufficient damage capable of affecting the downstream repression of 
anti-apoptotic signalling. Furthermore, successful cell death induced in tumours may be 
dependent on a certain threshold under which no tumour eradication is obtained. On 
the other hand, regrown secondary tumours have not received a direct exogenous 
damaging stimuli and thus alterations in the expression of Bcl-3 will rely on immune 
response effectors present in the tumour microenvironment. In line with this, should 
there be immunosuppressive effectors, the transduction of pro-apoptotic signals might 
be surpassed by the pro-survival counterpart.  
Regarding PD-L1, the large positively stained section in rechallenged tumours (Figure 
105), suggests the secretion of this ligand by tumour cells might have had a major role 
in tumour progression and lack of rejection of secondary tumours. This is related to the 
poor prognosis noted in previous studies (Jin et al., 2010). In our study, T cells 
generated post PDT would recognise the existence of a newly formed tumour and 
accordingly, infiltration would commence in the periphery of these tumours, as 
confirmed in Figure 107. However, it is possible that tumour cells receiving “danger 
signals” from infiltrating cells might have undergone an immunoediting process 
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following which the release of PD-L1 occurs, conferring protection against immune 
cells by inducing cell death in PD-1 expressing cells. This correlates with the opposing 
staining found between infiltrating CD3+ cells and the commented PD-L1 (Figure 108): 
regions expressing PD-L1 cause cell death in T cells, resulting in no CD3 staining; 
while no PD-L1 release enables survival and intervention of effector T cells.  
Despite the noticeable positive staining found in immunohistochemistry in the 
rechallenged sample stained with anti PD-L1 (Figure 105), qRT-PCR did not show a 
significant difference in the expression of PD-L1 between control and rechallenged 
tumour. However, an up-regulation trend was found in these particular specimens as 
reflected in the p values: p = 0.1135 (control against rechallenged) as opposed to p > 
0.999 in the rest of the cases. Based on the discrete regions expressing PD-L1, as 
noted in the antagonistic staining between CD3 and such ligand, a more specific 
microdissection might be needed to obtain comparable findings in IHC and qRT-PCR. 
TRAIL-induced apoptosis does not seem to be particularly relevant in the analysed 
tumour specimens. Likewise, at most it appeared to be altered among treatment 
groups but not compared to untreated samples. Briefly, the up-regulation in 
rechallenged samples suggests a major presence of cells susceptible to this induced 
cell death are detected after complete tumour regression, as a result of immunological 
changes arising from the previous light treatment.  
As for CD3-stained tumours, further study with the assistance of a pathologist revealed 
that the repeated generalised brown staining, appearing in regions identified as ROI 1 
could be due to non-specific staining frequently found in infiltrating polymorphonuclear 
cells such as neutrophils (possibly because of their cytoplasmic content reacting with 
the detection system used). This links to the correlation observed between affected 
areas in H&E stained slides and this ROIs 1. These affected areas exhibiting a heavy 
load of infiltrating leukocytes might be the reflection of a focus of inflammation. On the 
other hand, ROI 2 is featured by discrete intense-brown stained cells, and a lack of the 
overall staining as detected in ROI 1. Due to the general stain in ROI 1, these 
discretely stained cells are not as evident as in ROI 2, although still present (Figure 
109).  
Significant alterations in gene expression, especially in the rechallenged samples, 
reveal the previously noted argument that even if no rechallenge was rejected, the 
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immune system had been stimulated to some extent post PDT. As a matter of fact the 
most significant up-regulation of CD3ε (p < 0.0001) was found in ROI 2 in the 
rechallenged tumour, not only against the control, but also against other treatment 
groups (see Table 11). This suggests that a non-rejected secondary tumour grown 
after the eradication of a primary tumour elicits a greater infiltration of CD3 leukocytes 
than non-cured tumours. In addition, CD3 expression in ROI 2 seemed to be higher 
than that found in ROI 1 within each treatment group. We think this is based on the 
major infiltration of other cell types in the former as opposed to a more exclusive T cell 
infiltration in ROI 2. Overall, expression of CD3 in tumour samples could be 
summarised as follows: ROI 2 in rechallenged > ROI 1 in rechallenged > ROI 2 in 
remaining treatments > ROI 1 in remaining treatments > control. 
The measurement of CD3ε through molecular analysis correlates with the observations 
made in IHC staining. In the latter, rechallenged samples were among the ones 
showing the greatest infiltration of positively stained cells, especially in ROI 2 (Figure 
109E and Figure 109F), alike observations in qRT-PCR analysis (). This can be applied 
for other light-based treatments such as that seen after AlPcS2a-PDT (Figure 109G) . 
The lack of major alterations in the expression of Lamp 1 indicates that the infiltrating T 
cells recognised above, correspond to a T cell subset different from CD8+ cytotoxic T 
cells and further investigations are required. As for T regs, characterised by FoxP3 
expression, again the greater changes in gene expression found in ROI 2 correlate with 
the larger infiltration of T cells in these region rather ROI 1, where other infiltrating 
leukocytes have been mainly described. BPD-MA treated animals showed the greatest 
down-regulation in this marker, which could be indicating that this PDT treatment 
results in a reduction of the immunosuppression naturally present in the tumour 
microenvironment. The later increase in these T regs during the rechallenge stage 
suggests that in the absence of PDT, this subset of cells regrows and is present as 
normal, requiring an additional threat to face the new tumour challenge and assist anti-
tumour effector T cells.  
A similar argument can be applied for non-cured tumours subjected to the other 
PDT/PCI regimes described (i.e. TPCS2a and AlPcS2a), which may not be potent 
enough to confront the immunosuppressive tumour MatLyLu. Accordingly, this also 
suggests that the co-administration of cyclophosphamide during tumour rechallenging 
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would enhance the survival rate and possibly secondary tumour rejection in MatLyLu-
based tumours as shown in other tumours (Castano et al., 2008; Reginato et al., 2013).  
Not surprisingly, the significant down-regulation in the expression of perforin was 
observed in ROI 1 in some treatment groups (which appears to be poorer in T cells 
than ROI 2), given that this particular cytolytic protein is found in cytotoxic lymphocytes 
and NK cells. Importantly, this also correlates with the up-regulation of granzyme A in 
ROI 2 in the rechallenged sample (p = 0.0012). Together with the large presence of 
CD3 cells found in this sample in particular, this indicates that infiltrated T cells are 
responsible for the secretion of cytolytic proteases such as granzyme A, regardless of 
the specific subset present. Besides, having in mind the hypothesis noted previously 
which relates ROI 1 to large inflammation and leukocyte infiltration occurring during this 
stage of the innate immune response, it is possible that the lack of attenuation of the 
inflammatory process observed (even 7 days after light treatment) could have been 
occasioned due to the reduced presence of perforin. Following this line of thought, 
previous studies have confirmed the regulatory role of DCs by observing that a 
deficiency in the release of perforin by these cells resulted in a pro-inflammatory effect 
as well as a higher presence of T helper cells (Zlotnikov-Klionsky et al., 2015). As a 
matter of fact, perforin has been previously claimed to exert a role in prevention of 
inflammation and autoimmune disorders through the control of DCs (Mossu et al., 
2016) and eosinophilic-inflammation (Enomoto et al., 2012), release which was 
assigned to CD8+ cytotoxic T cells.  
Additionally, the down-regulation in the expression of perforin observed in AlPcS2a-
treated tumours when combined with CY or saporin (as opposed to PDT alone), could 
be due to the cytotoxic effect exerted by these agents to perforin-secreting cells.  
In relation to the up-regulation of both FAS and FAS-L, in AlPcS2a-PDT tumours, the 
fact that it was observed in ROI 1 rather than ROI 2 indicates a relationship with the 
inflammatory process taking place in the former region of interest (Figure 113). As a 
matter of fact, FAS ligand has been associated to the promotion of neutrophil 
infiltration, blockage of degranulation and pro-inflammatory signalling (Dupont and 
Warrens, 2007). This correlates with the non rejection of secondary tumours: these 
showed an up-regulation of FASL (even higher in ROI 2), which could have been 
responsible for inducing cell death in infiltrating T cells. 
Stimulation of the immune system following PDT and PCI in Prostate Cancer 
 
  
275 
In conclusion, an activation of the immune response following light-based 
treatment to highly immunosuppressive and aggressive MatLyLu tumours was found. 
This was especially noteworthy in tumours that had not been rejected after the second 
implantation of tumour cells in previously cured animals. In addition, this serves as 
proof that a complete elimination of tumours is necessary prior to achieving a protective 
effect to some extent. Based on these results, we hypothesise that a strong enough 
anti-cancer therapy will affect the intrinsic immunosuppression induced by tumour cells, 
for instance reflected in the down-regulation of regulatory T cells and the blockage of 
the inflammatory process elicited by PDT. In relation to inflammation, the NF-B seems 
to be having an important role through Bcl-3, which in this case will attenuate 
inflammation and possibly result in the reduction of anti-apoptotic signalling (i.e. Bcl-2). 
If the treatment results in the elimination of the initial tumour, should a distant tumour 
deposit occur, it will be recognised by previously generated T cells exhibiting a 
degranulating capacity as indicated by the presence of both granzyme-A and perforin. 
Unfortunately, the lack of an additional detrimental anti-tumour treatment impedes the 
elimination of components of the immune response with an important suppressive role 
(for example seen in the up-regulation of T regs). Consequently, despite tumour growth 
is delayed owing to the role of cytotoxic effector T cells, these will be overwhelmed by 
suppressive effector cells and tumours will in the end regrow. Following this line, we 
hypothesise that immunoadjuvants acting on the elimination of immunosuppression 
such as cyclophosphamide enhance the therapeutic outcome. Such is the case of 
AlPcS2a-based treatment regardless of the presence of saporin, where retardation of 
tumour growth was observed. 
Conversely, in those cases where the initial light-based treatment was not strong 
enough, a prolonged inflammation was detected, even more evident in tumour areas 
showing large infiltration of inflammatory cells. The lack of attenuation of this 
inflammatory stage may result in an inefficient protection against tumours, i.e. reduced 
CD3+ infiltration via down-regulation of perforin or Bcl-3 and up-regulation of FAS-L.  
Although we have not proved the existence of specific antigens in MatLyLu cells, we 
postulate that there is an efficient antigen presentation and effector T cell maturation, 
which does not exert its maximum potential due to immunosuppression. Such findings 
are intriguing and worth testing on human prostate tissue. 
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Overall, these results give an idea of how complex the immune response is, featured 
by its compensatory potential whereby blockage of a specific pathway might have an 
effect in a wide range of other routes. Further analysis is required to shed light on 
cytokines and effectors present in the different tumour microenvironments, which might 
provide a key in an effective therapy against prostate cancer. 
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Conclusions and Future Work 
This study on PDT/PCI for prostate cancer treatment focused on the 
hypothetical improvement of the therapeutic outcome PCI would offer as opposed to 
PDT. Interestingly, the course of this PhD project evolved towards a more 
immunological perspective of energy-based therapeutic alternatives, as reflected in the 
structure of this thesis.  
As a starting point, in vitro investigations are always recommended to determine events 
occurring in more complex organisms. In line with this, although findings in the 
experiments we performed in vitro were not directly translatable in the in vivo study, we 
actually found correlations between both. For instance, even though we could not 
determine the optimal DLI for in vivo treatments from those established in vitro, we did 
find that the fast growth and potentially accelerated metabolism of MatLyLu cells 
observed in vitro (thus expected in vivo), would benefit from shorter DLI to ensure the 
sufficient presence of PS in these tumour cells. Moreover, we also conclude from these 
early in vitro investigations that in optimised PCI protocols, higher light/drug doses are 
not necessarily better that lower doses. For example, 96 hr after light, the combination 
of saporin with 0.2 µg/ml PS and 1.26 J light resulted in a similar or even increase of 
cell death over 0.4 µg/ml PS and 2.1 J. Accordingly, we conclude that the application of 
such low doses of PS in PCI to human individuals would further minimise side effects 
(skin photosensitivity and damage to healthy tissue) observed with PDT.  
In vitro investigations also confirmed the impact of physico-chemical properties of 
photosensitisers regarding the design of light therapy protocols and the interaction of 
photosensitive compounds with cells. Briefly, each cell type’s physiological features 
(i.e. growth rate, metabolism, intracellular pathways, location, etc.), will determine the 
fate and photooxidative damage caused by PS. Taking this into consideration, we 
evaluated the benefits of different PS in our prostate cancer cells (namely TPCS2a, 
TPPS2a, AlPcS2a and BPD-MA). Although in vitro the behaviour of PS (at a cellular or 
subcellular level) is mainly dependent on DLI, in vivo bioavailability, hence 
photooxidative damage, is more a complex process that does not only depend on DLI. 
For instance, determining if a better outcome is achieved with PDT or PCI, whether 
DLIs should be directed to induce vascular shutdown or directly affect tumour cells, etc. 
Importantly, in a clinical setting, this implies differences between each cancer type and 
the necessity to know how different tumour cells respond to treatment in order to adapt 
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therapies to each individual case and maximise the therapeutic outcome, thereby 
ensuring success. In our results, despite PCI was successfully optimised in PC3 
human cells, further optimisation will be carried out in the rat cell line MatLyLu.  
Accordingly, in our future work we will conduct this optimisation of light treatment on 
MatLyLu cells in 3D models, where a more controllable environment is created. This 
will potentially facilitate the translation to rodent models and potentially human 
subjects. Moreover, we will investigate the even more biomimetic context described in 
“tumoroids”, 3D models composed of two differentiated collagen matrices: one bearing 
tumour cells, representing the “stroma” of tumours, and a second scaffold seeded with 
non-tumour cells such as fibroblasts or endothelial cells, mimicking the parenchyma of 
tumours (Ricketts et al., 2014).  Furthermore, patient-derived xenografts can be used to 
test whether the cellular effects found in the MatLyLu 3D model play similar role in 
patients (Kohli et al., 2015). 
Overall, the determination of an optimised PCI protocol in the fast growing, aggressive 
and metastatic MatLyLu cells could serve as basis for tumours exhibiting similar 
properties, shedding light on how we could improve the outcome of these. Perhaps in 
our project, optimised PCI in vivo, could improve the limited successful tumour 
regression found after PDT – only 18% overall cures with one BPD-MA PDT. Therefore 
regarding future work to optimise light treatment in vivo, we would like to test TPCS2a 
(given the clinical relevance), at shorter DLI, i.e. 6 hr after i.v. administration. In our 
studies, since shorter DLI (15 minutes for vascular PDT and 16 hr for TPCS2a-PDT) 
have shown a greater therapeutic outcome. Moreover, in addition to saporin, we aim to 
assess the delivery of additional chemotherapeutics already approved for prostate 
cancer, such as docetaxel or cabazitaxel. This would significantly facilitate the 
translation of an optimised PCI procedure to human patients in a prospective clinical 
trial. 
On the other hand, benefits concluded after PCI in vitro led us to consider 
whether further design of treatments could (i) increase the uptake of PS through CPPs, 
hence intracellular concentrations, and (ii) limit the uptake of PS to tumour cells via 
targeting moieties, thereby improving site-specificity of light-based therapies. Following 
this second objective of the project, we found that CPPs do improve the uptake of PS 
conjugates in human cancer cells, and this results in an increased cytotoxicity with 
even lower doses of photosensitive drugs compared to PS alone. Consequently, we 
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aim to further test this in vivo, comparing the accumulation of such compounds in both 
malignant and normal cells when administered systemically.  
In Chapter 3 we have also reported the use of targeting strategies with PS-conjugates 
potentially recognising CXCR4, although we did not confirm specificity against such 
receptor, based on the study with the inhibitor AMD3100. Consequently, we will further 
look into the interaction between CPPs and CXCR4. In line with this, in collaboration 
with the group synthesising the peptide conjugates in University of Bath, we will carry 
out investigations on the spatial structure of vMIP-II-TAT-TPP. This will determine 
whether the association between the targeting moiety (vMIP-II against CXCR4) and 
TPP could be causing steric hindrance that impedes the interaction between CXCR4 
receptor and ligand in prostate cancer cells. Furthermore, we will verify the expression 
of such receptor in our PC3 cells to reject the hypothetical loss of this receptor in our 
cell stock. These studies will clarify the scenarios described in 3.5. 
Should we resolve this in our future experiments, CXCR4 targeting could result in a 
successful active targeting of PS to diseased prostate cancer cells. Undoubtedly, the 
focal treatment of prostate cancer would benefit from an increased site-specificity and 
the consequent reduction of co-morbidity. However, future studies are needed to 
determine whether more focalised treatments render as good a therapeutic outcome as 
more radical approaches in highly aggressive and rapidly proliferating tumours. Briefly, 
the treatment of highly aggressive tumours might be more beneficial through the latter 
to ensure the complete eradication of tumour cells by treating larger regions 
(guaranteeing tumour edges are also “clean”), thus compromising specificity. Again, 
this indicates the importance of becoming aware of each particular tumour’s features. 
Tumour illumination performed superficially (i.e. conducted with BPD-MA, TPCS2a, 
AlPcS2a) as opposed to interstitially (only conducted with TPCS2a) resulted in a greater 
delay of tumour growth, possibly related to difficulties in fibre placement with the 
interstitial approach in small tumours, causing inconsistencies in homogeneous light 
delivery to the whole tumour. Further experiments would have to be carried out to 
determine the optimum light delivery approach for this subcutaneous tumour model. 
From these experiments, evidence suggests that the tumour periphery, if treated 
insufficiently, is highly proliferative resulting in recurrence of tumour growth. It also 
supports the argument above in relation to the treatment of aggressive tumours: 
compromising site-specificity (where treatment extends beyond the tumour boundary) 
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could favour complete tumour cell-killing, hence preventing tumour regression. 
Moreover, even though we have not concluded any improvement in tumour cure 
combining PS and saporin in PCI strategies, the enhanced cytotoxicity found in vitro 
leads us to think that the procedure followed in vivo with the different amphiphilic PS 
needs further optimisation (as challenging as it is for PCI). We consider that optimising 
PCI in the future could have an important effect in this peripheral region as proved 
previously as the main treatment or adjuvant to an alternative therapeutic approach 
(Norum et al., 2009c).  
Overall, vascular-directed PDT resulted in the most successful therapeutic outcome, as 
concluded by the complete tumour regression after BPD-MA. In line with this, a major 
aim for future work is to determine how to increase tumour cure rate, i.e. enhancing 
tumour apoptosis and necrosis after light in a way that would result in the complete 
elimination of tumours in animal subjects. It is possible that the measurement of tumour 
cell death (i.e. apoptosis/necrosis) at earlier time point after light (for example 24 hr 
post treatment) will give us an idea on the success of each therapeutic approach, as 
opposed to euthanising animals once tumour regrowth has already commenced. In 
addition, based on the important vascular component determined in the studied model 
together with the above-mentioned targeting approaches, it would be interesting in the 
future to assess the outcome of PS/drug-conjugates targeted against vascular 
endothelial cells within the tumour. This has been successfully proved in PCI 
approaches previously using VEGF-conjugates (Weyergang et al., 2014). 
Through the investigations presented herein a large inflammatory response triggered 
after light treatment of tumours was confirmed. The significant infiltration of innate-
immune response cells, mainly neutrophils, was verified regardless of the PS or light 
conditions used. It seems that resolution of the inflammatory process will be 
determinant in the progression of the disease after light, and the additional generation 
of a more destructive adaptive response. In fact, the NF-B pathway could be playing 
an important role in the interaction between innate and adaptive response in these 
energy-based therapies. For example, upon exposure of tumours to PDT, a reduction 
of Bcl-3 expression was shown through IHC, subsequent down-regulation of Bcl-2 
(hence pro-apoptotic signalling) and importantly, resolution of inflammation. We aim to 
further investigate this so as to determine an adequate light-based regime which 
favours this scenario.  
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With reference to the involvement of the immune system in light-based therapies, 
important findings in our investigations came accompanied by the complete eradication 
of tumours. This is suggested by differences at the molecular level observed between 
rechallenged animals (which had been cured from the primary tumour) and the rest of 
the treated tumour samples. The most significant finding was noted by the up-
regulation of the T cell marker CD3 in tumours grown in the rechallenged animals. 
Moreover, in the future we will conduct the evaluation of the tumour bed left behind in 
the cured animals, where the primary tumour was located. Through this examination, 
we aim to determine whether there are any viable tumour cells left as well as 
immunological components, which will further help understand tumour progression.  
First, through this molecular analysis we have identified a great immunosuppressive 
factor in MatLyLu tumours, as suggested by the up-regulation of inducers of Tcell death 
such as PD-L1, or the enhanced infiltration of Tregs (FoxP3). An efficient light 
treatment seemed to involve an initial reduction of the expression of FoxP3. However, if 
this down-regulation is not sufficient, light treatment will not result in tumour eradication 
(e.g. non cured BPD-treated primary tumours). In the future, the aim is consequently to 
search for strategies through which this depletion would be achieved. For example, we 
could combine light treatment with PD-L1 inhibitors, as has been conducted in 
metastatic colorectal tumours previously using nanoparticles combining oxaliplatin 
(chemotherapeutic) and pyropheophorphide (PS) (He et al., 2016). In this study, a 
strong specific immune response was concluded against irradiated primary and distant 
secondary tumours.   
Similarly, Treg depletion induced by cyclophosphamide could result in a beneficial 
outcome. Although it did not result in any tumour cure when combined with AlPcS2a- 
PDT or PCI in our experiments, we consider that if combined with a treatment showing 
intrinsic capacity to affect tumours integrity and immunosuppressive environment (i.e. 
BPD-MA), CY could further enhance the therapeutic outcome. Based on this argument, 
in the future, we would like to administer CY prior to and during light treatment to assist 
Treg depletion both during antigen presentation and effector stages. In a similar way, 
we think the administration of such agent before rechallenging would also improve 
tumour rejection, based on the up-regulation of Tregs found in these regrown tumour 
samples. Potentially, we could also investigate the use of other immunoadjuvants, i.e. 
CpG, which instead of reducing immunosuppression, interact with TLR inducing innate 
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immune responses, for example stimulating monocytes, DCs or macrophages 
(Anzengruber et al., 2015; Xia et al., 2014).  
Additionally, a reduced cytotoxic response was determined in the majority of tumours, 
probably influenced by the described immunosuppression. For instance, this is 
suggested by the alternative expression of CD3 and PD-L1 on rechallenged tumours. 
The presence of tumour-destructive T cells seemed to be being controlled by tumour 
cells via PD-L1 secretion. Furthermore, it would be interesting to examine in future 
work whether PD-L1 could also have an effect in B cell response using Omics 
technology.  
Rechallenged tumours also exhibited an increased expression of cytolytic enzymes: 
Granzyme A and Perforin. Given the relation of Perforin with inflammation and antigen 
presentation to dendritic cells (described in Chapter 5), in the future we will further 
investigate the presence of CD4+ T cells / T helper cells in our tumour samples. 
Similarly, we would like to assess in the future whether CD8+ are present in the 
different tumour samples, given the association of these Tcells with specific cell 
recognition and an effector response.  
Overall, the above-stated future investigations will enable a clearer elucidation on how 
the immune response evolves in the event of an inflammatory response (caused by 
light treatments in this case), what triggers the transition from an innate to an adaptive 
immune response, shed additional light on how B and T cell interaction occurs and how 
we could then attempt to direct these to a specific response, e.g. towards the 
increased/reduced presence of specific cell subtypes, etc. In relation to this, in future 
work, we will also perform whole-transcriptome analysis that will clarify alterations in 
the expression of every gene between different groups: untreated tumour cells, 
infiltrating CD3+ cells in rechallenged tumours, PD-L1 secreting tumour cells in 
rechallenged tumours, FoxP3 expressing cells, etc. We think this will provide extremely 
valuable information as regards what causes the infiltration of each immune-related cell 
subtype. 
Regarding the use of CY as immune-adjuvant, we would like to further investigate the 
increased phagocytic activity induced in lymph nodes, which we identified through the 
accumulation of AlPcS2a aggregates. Again following whole-transcriptome sequencing, 
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we will compare the expression of genes in normal lymph nodes and those exhibiting 
an altered activity.   
Throughout our investigations, the molecular characterisation of tumour samples has 
proved to be an essential tool in the elucidation of the effect of light treatment induced 
in our treated tumours and how such treatment influences the resolution of tumour 
progression. It is particularly relevant to determine how we could exploit these 
alterations at the molecular level, to direct light treatments aiming to achieve an optimal 
molecular response in tumours. For example, we could use these discoveries to 
identify molecular “bio-markers” directly associated with positive prognosis so that 
therapies could be designed to pursue the activation of such bio-markers and vice 
versa. This way, prior to light-based therapies, tumour cells could be sensitised through 
adjuvant therapies so that fully successful PDT/PCI could be later performed. 
Importantly, based on the conclusions of the effect of PDT/PCI on the immune 
response, we can decipher the molecular immunological pathways that play a major 
role in autoimmune diseases, age-related autoimmunity (i.e. rheumatoid arthritis) and 
possibly understanding some of the allergies. In contrast to tumour-induced 
immunosuppression, in these cases there is hyper-activated immune response.   
Finally, in prospective work, we would also like to carry out an evaluation using 
the orthotopic tumour model described in Chapter 4, thereby maintaining the gland’s 
microenvironment.  
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Appendix  
Detailed preparation of TPP conjugates 
 General Procedure for the preparation of peptides by solid phase 
peptide synthesis 
The peptides were assembled according to the Fmoc strategy on Rink Amide MBHA 
Resin (Novabiochem, 200-400 mesh, 0.60 mmol/g loading) using an Activo P11 
automated synthesiser fitted with a reactor heating jacket. The synthesis was 
performed on 250 mg of resin (0.15 mmol scale). Removal of the Fmoc group from the 
resin was performed with 20% piperidine/DMF (2.5 mL, 4 x 3 minutes). The first 
residue attachment for peptides starting with a glycine or an arginine was performed 
using 4 eq. of the amino acid, 4 eq. of DIC and 6 eq. of DIPEA (5 min preactivation 
then 1 h coupling), and was followed by an acetylation step (Ac2O/DIPEA/DMF = 1/1/8, 
2.5 mL, 1 x 10 minutes). Subsequent Fmoc deprotection steps were performed using 
25% piperidine/DMF (3 mL, 1x5 minutes, 1x10 minutes), with the chain elongation 
steps being performed using 3 eq. of Fmoc-protected amino acid (Fmoc-Arg(Pmc)-OH, 
Fmoc-Gln(Trt)-OH), Fmoc-Lys(Boc)-OH, or Fmoc-Gly-OH) 3 eq. of PyBOP, and 6 eq. 
of DIPEA in 4.3 mL of DMF (35 minutes, 60°C). The peptide resin was washed 
thoroughly with DMF, DCM and then dried in vacuo. 
For the cleavage and deprotection of the clickable peptides, the acylated peptidyl resin 
was swollen in DCM for 20 minutes, then it was treated with TFA/TIS/H2O (95/2.5/2.5) 
for 4 hours. The resin beads were filtered off, washed with TFA, and the combined 
filtrates were evaporated to a small volume then anhydrous Et2O was added. The 
resulting precipitate was collected by centrifugation and was washed twice more with 
Et2O. The precipitated material was dissolved in 1% aq. TFA, filtered using a 0.2 µm 
syringe filter and the resulting solution was directly purified by semi-preparative HPLC. 
The purified peptides were then freeze-dried. 
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 General procedure for the click chemistry of peptides 
A solution of peptide (1 µmol) and TPP-DBCO (2 µmol) in DMSO (4000 µL) was 
treated with pyridine (200 µL) and stirred at room temperature overnight, shielded from 
light. The mixture was diluted with 1% aq. TFA and directly purified by semi-
preparative. The purified conjugate was freeze-dried to give a dark green solid.
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